Glucagon-like peptide analogues for type 2 diabetes mellitus by Shyangdan, D. (Deepson) et al.
 University of Warwick institutional repository: http://go.warwick.ac.uk/wrap 
 
This paper is made available online in accordance with 
publisher policies. Please scroll down to view the document 
itself. Please refer to the repository record for this item and our 
policy information available from the repository home page for 
further information.  
To see the final version of this paper please visit the publisher’s website. 
Access to the published version may require a subscription. 
Author(s): Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, 
N. and Snaith, A. 
Article Title: Glucagon-like peptide analogues for type 2 diabetes 
mellitus (Review) 
Year of publication: 2011 
Link to published article: 
http://dx.doi.org/10.1002/14651858.CD006423.pub2 
 
Publisher statement: This review is published as a Cochrane Review in 
the Cochrane Database of Systematic Reviews 2011, Issue 10. 
Cochrane Reviews are regularly updated as new evidence emerges 
and in response to comments and criticisms, and the Cochrane 
Database of Systematic Reviews should be consulted for the most 
recent version of the Review.’ Shyangdan, D.S. et al. (2011). 
Glucagon-like peptide analogues for type 2 diabetes mellitus. 
Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: 
CD006423. DOI: 10.1002/14651858.CD006423.pub2 
http://dx.doi.org/10.1002/14651858.CD006423.pub2 
 
Glucagon-like peptide analogues for type 2 diabetes mellitus
(Review)
Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A
This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library
2011, Issue 11
http://www.thecochranelibrary.com
Glucagon-like peptide analogues for type 2 diabetes mellitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
8RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
28DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
30AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
31ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
31REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
37CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
92DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.2. Comparison 1 Albiglutide versus placebo, Outcome 2 HbA1c - with plot. . . . . . . . . . . 103
Analysis 1.5. Comparison 1 Albiglutide versus placebo, Outcome 5 Weight change - with plot. . . . . . . . . 104
Analysis 2.1. Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 1 HbA1c (%). . . . 107
Analysis 2.2. Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 2 HbA1c < 7%. . . . 108
Analysis 2.3. Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 3 Hypoglycaemia (minor). 108
Analysis 2.4. Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 4 Weight change (kg). . 109
Analysis 2.8. Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 8 Fasting plasma glucose
(mmol/L). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
Analysis 3.1. Comparison 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors, Outcome 1 HbA1c (%). . . . 111
Analysis 3.2. Comparison 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors, Outcome 2 HbA1c < 7%. . . . 112
Analysis 3.3. Comparison 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors, Outcome 3 Hypoglycaemia (minor). 112
Analysis 3.4. Comparison 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors, Outcome 4 Weight change (kg). . 113
Analysis 3.8. Comparison 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors, Outcome 8 Fasting plasma glucose
(mmol/L). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
Analysis 4.1. Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 1 HbA1c (%). . . . . 116
Analysis 4.2. Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 2 HbA1c < 7%. . . . . 116
Analysis 4.3. Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 3 Hypoglycaemia (symptoms
only). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
Analysis 4.4. Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 4 Hypoglycaemia (minor). 117
Analysis 4.6. Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 6 Weight change (kg). . 118
Analysis 4.9. Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 9 Fasting plasma glucose
(mmol/L). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Analysis 5.1. Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 1 HbA1c (%). . . . . . . . . 120
Analysis 5.2. Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 2 HbA1c < 7%. . . . . . . . . 121
Analysis 6.1. Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 1 HbA1c (%). . . . . . . . . 123
Analysis 6.2. Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 2 HbA1c < 7%. . . . . . . . . 123
Analysis 7.1. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 1 HbA1c. . . . . . . . . . . . . 126
Analysis 7.2. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 2 HbA1c < 7%. . . . . . . . . . . 126
Analysis 7.3. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 3 Hypoglycaemia. . . . . . . . . . 127
Analysis 7.4. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 4 Weight change. . . . . . . . . . 127
Analysis 7.6. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 6 Systolic blood pressure. . . . . . . 130
Analysis 7.7. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L). . . . 130
Analysis 7.9. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 9 Triglycerides (mmol/L). . . . . . . 131
Analysis 7.10. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 10 Total cholesterol (mmol/L). . . . . 132
Analysis 7.11. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 11 HDL-cholesterol (mmol/L). . . . . 132
iGlucagon-like peptide analogues for type 2 diabetes mellitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.12. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 12 LDL-cholesterol (mmol/L). . . . . 133
Analysis 8.1. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 1 HbA1c. . . . . . . . . . . . . 134
Analysis 8.2. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 2 HbA1c < 7%. . . . . . . . . . . 134
Analysis 8.3. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 3 Hypoglycaemia. . . . . . . . . . 135
Analysis 8.4. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 4 Weight change. . . . . . . . . . 136
Analysis 8.6. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 6 Systolic blood pressure. . . . . . . 139
Analysis 8.7. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L). . . . 139
Analysis 8.9. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 9 Triglycerides (mmol/L). . . . . . . 141
Analysis 8.10. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 10 Total cholesterol (mmol/L). . . . . 141
Analysis 8.11. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 11 HDL-cholesterol (mmol/L). . . . . 142
Analysis 8.12. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 12 LDL-cholesterol (mmol/L). . . . . 142
Analysis 9.1. Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 1 HbA1c. . . . . . . . . . . . . 144
Analysis 9.2. Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 2 Patients reaching HbA1c < 7%. . . . . 145
Analysis 9.3. Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 3 Weight. . . . . . . . . . . . . 146
Analysis 9.4. Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 4 Systolic blood pressure. . . . . . . . 146
Analysis 10.1. Comparison 10 Liraglutide versus insulin glargine, Outcome 1 HbA1c. . . . . . . . . . . . 147
Analysis 10.2. Comparison 10 Liraglutide versus insulin glargine, Outcome 2 HbA1c < 7%. . . . . . . . . . 147
Analysis 10.3. Comparison 10 Liraglutide versus insulin glargine, Outcome 3 Hypoglycaemia. . . . . . . . . 148
Analysis 10.4. Comparison 10 Liraglutide versus insulin glargine, Outcome 4 Weight change. . . . . . . . . 148
Analysis 10.6. Comparison 10 Liraglutide versus insulin glargine, Outcome 6 Systolic blood pressure. . . . . . 149
Analysis 10.7. Comparison 10 Liraglutide versus insulin glargine, Outcome 7 Fasting plasma glucose (mmol/L). . . 150
Analysis 11.1. Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%). . . . . 151
Analysis 11.2. Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 2 HbA1c < 7%. . . . 151
Analysis 11.3. Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia
(mild/moderate/overall). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
Analysis 11.5. Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 5 Weight change. . . . 153
Analysis 11.9. Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose
(mmol/L). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
Analysis 12.1. Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%). . . . . 155
Analysis 12.2. Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 2 HbA1c < 7%. . . . 156
Analysis 12.3. Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia. . . . 156
Analysis 12.5. Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change (kg). . 157
Analysis 12.9. Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma glucose
(mmol/L). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
Analysis 13.1. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 1 HbA1c (%). . . . . 160
Analysis 13.2. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 2 HbA1c < 7%. . . . 160
Analysis 13.3. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 3 Hypoglycaemia
(mild/moderate/overall). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
Analysis 13.5. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 5 Weight change (kg). . 162
Analysis 13.7. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 7 Systolic blood pressure (mm
Hg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
Analysis 13.9. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 9 Fasting plasma glucose
(mmol/L). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164
Analysis 14.1. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 1 HbA1c (%). . . . . 165
Analysis 14.2. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 2 HbA1c < 7%. . . . 166
Analysis 14.3. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 3 Hypoglycaemia. . . . 166
Analysis 14.5. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 5 Weight change (kg). . 167
Analysis 14.7. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 7 Systolic blood pressure (mm
Hg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
Analysis 14.9. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 9 Fasting plasma glucose
(mmol/L). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169
Analysis 15.2. Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c < 7%. . . . . . . . . . . . 170
Analysis 15.3. Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia. . . . . . . 171
iiGlucagon-like peptide analogues for type 2 diabetes mellitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 15.4. Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg). . . . . . . . . . 172
Analysis 15.6. Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L). . . . . 174
Analysis 15.7. Comparison 15 Lixisenatide versus placebo, Outcome 7 Post-prandial glucose (mmol/L). . . . . . 175
Analysis 15.8. Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self-monitored 7-point blood glucose
(mmol/L). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176
Analysis 16.1. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c. . . . . . . . . . . . . 177
Analysis 16.3. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c < 7%. . . . . . . . . . . 177
Analysis 16.4. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia. . . . . . . . . . . 178
Analysis 16.5. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change. . . . . . . . . . . 178
Analysis 16.8. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure. . . . . . . . 180
Analysis 16.10. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L). . . . 181
Analysis 17.1. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%). . . . . . . . . . 183
Analysis 17.3. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c < 7%. . . . . . . . . 183
Analysis 17.4. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia. . . . . . . . . 184
Analysis 17.5. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg). . . . . . . 184
Analysis 17.8. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure (mm Hg). . . 186
Analysis 17.10. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose (mmol/L). . 187
Analysis 18.1. Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%). . . . . . . . . . . . 189
Analysis 18.3. Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c < 7%. . . . . . . . . . . . 190
Analysis 18.5. Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia. . . . . . . . . . . 191
Analysis 18.7. Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg). . . . . . . . . . 192
Analysis 18.11. Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L). . . . 194
Analysis 19.4. Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg). . . . . . . . . . 198
Analysis 19.6. Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg). . . . . 200
Analysis 19.7. Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg). . . . . 200
Analysis 20.1. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 1 HbA1c. . . . . . . . . . . 202
Analysis 20.2. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 2 HbA1c < 7%. . . . . . . . . 203
Analysis 20.3. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 3 Hypoglycaemia. . . . . . . . 204
Analysis 20.5. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 5 Weight change. . . . . . . . 205
Analysis 20.9. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 9 Systolic blood pressure. . . . . 208
Analysis 20.10. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 10 Fasting plasma glucose (mmol/L). 209
Analysis 20.12. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 12 Triglycerides (mmol/L). . . . 210
Analysis 20.13. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 13 Total cholesterol (mmol/L). . . 211
Analysis 20.14. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 14 HDL-cholesterol (mmol/L). . . 212
Analysis 20.15. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 15 LDL-cholesterol (mmol/L). . . 213
213ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
219APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
226WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
226HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
227CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
227DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
227SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
227DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
227INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iiiGlucagon-like peptide analogues for type 2 diabetes mellitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Glucagon-like peptide analogues for type 2 diabetes mellitus
Deepson S. Shyangdan1 , Pamela Royle1, Christine Clar2, Pawana Sharma3, Norman Waugh1 , Ailsa Snaith4
1Warwick Evidence,Health Sciences Research Institute,WarwickMedical School, University ofWarwick, Coventry, UK. 2Researcher in
Systematic Reviews, CochraneMetabolic and Endocrine Disorders Group, Berlin, Germany. 3Health Services ResearchUnit, University
of Aberdeen, Aberdeen, UK. 4Department of Public Health, University of Aberdeen, School of Medicine, Aberdeen, UK
Contact address: Deepson S. Shyangdan, Warwick Evidence, Health Sciences Research Institute, Warwick Medical School, University
of Warwick, Gibbet Hill Campus, Coventry, CV4 7AL, UK. D.S.Shyangdan@warwick.ac.uk.
Editorial group: Cochrane Metabolic and Endocrine Disorders Group.
Publication status and date: Edited (no change to conclusions), published in Issue 11, 2011.
Review content assessed as up-to-date: 28 February 2011.
Citation: Shyangdan DS, Royle P, Clar C, Sharma P,Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus.
Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD006423. DOI: 10.1002/14651858.CD006423.pub2.
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Glucagon-like peptide analogues are a new class of drugs used in the treatment of type 2 diabetes that mimic the endogenous hormone
glucagon-like peptide 1 (GLP-1). GLP-1 is an incretin, a gastrointestinal hormone that is released into the circulation in response
to ingested nutrients. GLP-1 regulates glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis, and by
suppressing glucagon secretion, delayed gastric emptying and promoting satiety.
Objectives
To assess the effects of glucagon-like peptide analogues in patients with type 2 diabetes mellitus.
Search methods
Studies were obtained from electronic searches of The Cochrane Library (last search issue 1, 2011), MEDLINE (last search March
2011), EMBASE (last search March 2011), Web of Science (last search March 2011) and databases of ongoing trials.
Selection criteria
Studies were included if they were randomised controlled trials of a minimum duration of eight weeks comparing a GLP-1 analogue
with placebo, insulin, an oral anti-diabetic agent, or another GLP-1 analogue in people with type 2 diabetes.
Data collection and analysis
Data extraction and quality assessment of studies were done by one reviewer and checked by a second. Data were analysed by type of
GLP-1 agonist and comparison treatment. Where appropriate, data were summarised in a meta-analysis (mean differences and risk
ratios summarised using a random-effects model).
Main results
Seventeen randomised controlled trials including relevant analyses for 6899 participants were included in the analysis. Studies were
mostly of short duration, usually 26 weeks.
In comparison with placebo, all GLP-1 agonists reduced glycosylated haemoglobin A1c (HbA1c) levels by about 1%. Exenatide 2 mg
once weekly and liraglutide 1.8 mg reduced it by 0.20% and 0.24% respectively more than insulin glargine. Exenatide 2 mg once
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weekly reduced HbA1c more than exenatide 10 µg twice daily, sitagliptin and pioglitazone. Liraglutide 1.8 mg reduced HbA1c by
0.33% more than exenatide 10 µg twice daily. Liraglutide led to similar improvements in HbA1c compared to sulphonylureas but
reduced it more than sitagliptin and rosiglitazone.
Both exenatide and liraglutide led to greater weight loss thanmost active comparators, including in participants not experiencing nausea.
Hypoglycaemia occurred more frequently in participants taking concomitant sulphonylurea. GLP-1 agonists caused gastrointestinal
adverse effects, mainly nausea. These adverse events were strongest at the beginning and then subsided. Beta-cell function was improved
with GLP-1 agonists but the effect did not persist after cessation of treatment.
None of the studies was long enough to assess long-term positive or negative effects.
Authors’ conclusions
GLP-1 agonists are effective in improving glycaemic control.
P L A I N L A N G U A G E S U M M A R Y
Glucagon-like peptide analogues for type 2 diabetes
Glucagon-like peptide analogues or agonists are a new kind of drug in the treatment of type 2 diabetes that are given by injection
under the skin. They regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis, and by suppressing
glucagon secretion, delaying gastric emptying and promoting satiety. Various glucagon-like peptide-1 agonists are in use or in the
licensing process, including exenatide, liraglutide, albiglutide, taspoglutide, lixisenatide and LY2189265.
Seventeen randomised controlled trials of mostly moderate to high quality randomised approximately 6899 people with type 2 diabetes
mellitus. Studies were mostly of short duration, usually 26 weeks. The longest duration study was 30 weeks. Of the seventeen studies,
one compared albiglutide with placebo, two compared exenatide 10 µg twice daily against exenatide 2 mg once weekly, one compared
exenatide 2 mg once weekly against insulin glargine, one compared exenatide 2 mg once weekly against pioglitazone and sitagliptin,
five compared liraglutide with placebo, two compared liraglutide with sulphonylurea, one each compared exenatide twice daily with
liraglutide, liraglutide with sitagliptin, liraglutide with rosiglitazone and liraglutide with insulin glargine, two compared taspoglutide
with placebo and one each compared lixisenatide with placebo and LY2189265 with placebo. In people already treated with oral anti-
diabetes drugs, addition of glucagon-like peptide analogues improved blood sugar control in comparison to placebo, rosiglitazone,
pioglitazone or sitagliptin, but not always in comparison to insulin (for exenatide) or glimepiride (a sulphonylurea). Glucagon-like
peptide analogous caused more weight loss than any of the comparison treatments. However, more nausea and other gastrointestinal
effects such as diarrhoea or vomiting were seen, though these tended to wear off and were not seen in all participants. There was slightly
more hypoglycaemia with glucagon-like analogous than with placebo, but generally less than with other anti-diabetic treatments. The
incidence of hypoglycaemia occurred more frequently in participants taking concomitant sulphonylurea. The studies were not long
enough to assess long-term side effects. None of the studies investigated mortality or morbidity.
B A C K G R O U N D
Description of the condition
Type 2 diabetes is characterised by hyperglycaemia, associatedwith
insulin resistance and hyperinsulinaemia, but later by progressively
impaired insulin secretion in response to glucose load (ingestion
of nutrients, i.e. a meal).
A consequence of this is chronic hyperglycaemia (i.e. elevated lev-
els of plasma glucose) with disturbances of carbohydrate, fat and
protein metabolism. Long-term complications of diabetes melli-
tus include retinopathy, nephropathy and neuropathy. The risk
of cardiovascular disease is increased. For a detailed overview of
diabetes mellitus, please see under ’Additional information’ in the
information on the Metabolic and Endocrine Disorders Group in
The Cochrane Library (see ’Cochrane Review Groups (CRGs)’).
For an explanation of methodological terms, see the main glossary
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in The Cochrane Library.
Maintenance of tight glucose control is important in preventing
complications of diabetes. Traditional treatments for type 2 dia-
betes aim to control blood glucose and reduce the development of
diabetes-associated secondary complications (Turner 1996).How-
ever, there is usually a progressive deterioration in blood glucose
control in type 2 diabetes necessitating changes in treatment. Peo-
ple with type 2 diabetes are initially advised on lifestyle changes
(weight loss, more exercise and diet) and offered ongoing patient
education. If the lifestyle changes fail to control blood glucose,
metformin (especially in overweight people) or sulphonylureas (if
metformin is contraindicated or not tolerated, or if the person
is not overweight) are considered (NICE CG87 2009). When
monotherapy with these drugs no longer provides adequate gly-
caemic control, combination therapy is an option (metformin plus
sulphonylurea), but it may only be a matter of time before treat-
ment must be intensified (for example by using insulin therapy
or pioglitazone) to control glucose levels adequately. The UKPDS
(United Kingdom Prospective Diabetes Study) study has shown
that the deterioration in glycaemic controlmay be attributed to the
loss of pancreatic insulin-secreting beta-islet cell function (Turner
1996). In addition some of the oral hypoglycaemic agents lead
to weight gain and hypoglycaemia, which in turn affects person’s
compliance and glycaemic control. A glycosylated haemoglobin
A1c (HbA1c) level of more than 7% has been taken to indicate in-
adequate glycaemic control (Nathan 2009) though targets should
be individualised.
Description of the intervention
Glucagon-like peptide analogues or agonists are a new group of
drugs that mimic the action of an endogenous hormone called
glucagon-like peptide 1 (GLP-1). GLP-1 is an incretin, a gastroin-
testinal hormone that is released into the circulation in response
to ingested nutrients. GLP-1 regulates glucose levels by stimu-
lating glucose-dependent insulin secretion and biosynthesis, and
by suppressing glucagon secretion, delaying gastric emptying and
promoting satiety (Baggio 2004; Nauck 1993). GLP-1 lowers
glucagon secretion in type 2 diabetes in a glucose-dependent man-
ner thus preventing interference in the normal glucagon counter-
regulatory response to hypoglycaemia (Nauck 2002).
Circulating GLP-1 undergoes destruction by an enzyme, dipep-
tidyl-peptidase IV (DPP-IV), resulting in a half-life of 1 to 2 min-
utes. The natural form is therefore not suitable as a treatment.
Adverse effects of the intervention
Weight gain is amajor side effect of some traditional type 2diabetes
therapies such as the sulphonylureas and the glitazones. However,
the GLP-1 analogues have been shown to produce weight loss in
people with type 2 diabetes (Amori 2007; Barnett 2009; Monami
2009; NICE CG87 2009; Norris 2009).
As regards adverse effects, nausea is common but wears off with
time.No serious adverse effects have yet been proven, but there has
been concern about exenatide and liraglutide causing pancreatitis.
The manufacturers argue that there is no evidence to explain the
pathogenesis of pancreatitis with exenatide and also reports that
pancreatitis is common in type 2 diabetes, and therefore is not
related to the drug. Studies on rats and mice with doses exceed-
ing the recommended human dose showed histological changes of
chronic pancreatitis, but the animals appeared healthy with no be-
havioural changes suggestive of pain. In addition, the animals were
taking food normally and growth was also normal (Butler 2010).
The FDA reports that after marketing of exenatide, there have
been some cases of acute pancreatitis but that the incidence was
low (FDA 2009). The main concern is about the prolonged use of
the drug, as there is evidence of chronic low-grade pancreatitis in
rodents and chronic pancreatitis is one of the important causes of
pancreatic adenocarcinoma. In the liraglutide development pro-
gram, it was found that there were more cases of pancreatitis with
liraglutide compared with other oral comparators (EMEA 2009),
but the absolute risk was low. There are no long term data available
to substantiate this. Recently, FDA has issued a warning to remind
all the doctors that liraglutide may cause pancreatitis and thyroid
carcinoma (Journal Watch 2011).
In addition, there have been reports of thyroid carcinoma in ro-
dents. A two year carcinogenicity study was performed on rats and
mice with liraglutide and it was observed that there was prolifer-
ation of C-cells of the thyroid. The changes were dose-dependent
and ranged from mild or moderate hyperplasia to malignancy. Li-
raglutide induced carcinogenic changes by a non-genotoxic, spe-
cific GLP-1 receptor mechanism to which rodents are specifically
sensitive, whereas monkeys and humans are less sensitive (EMEA
2009). Although humans are not sensitive, the chances of carcino-
genic changes with liraglutide cannot be discounted due to lack of
evidence. Similarly, a two year carcinogenicity study on rats and
mice with exenatide reported incidence of benign thyroid C-cell
adenomas among rats whereas no such cases were found in mice
(FDA 2009). The exposure to the drug ranged from5 to 130 times
the recommended maximum human exposure dose.
How the intervention might work
There are currently at least six GLP-1 analogues. Exenatide
(Byetta, Lilly/Amylin) and liraglutide (NN2211, Novo Nordisk)
have reached the market. Albiglutide (GlaxoSmithKline), tas-
poglutide (Ipsen and Roche), lixisenatide (Sanofi-Aventis) and
LY2189265 (Lilly) have been the subject of trials.
Some current glucose lowering treatments cause hypoglycaemia
owing to the glucose-independent effect of the drugs. In contrast,
the action of the GLP-1 analogues is glucose-dependent, i.e. the
higher the plasma glucose level, the greater the effect of GLP-1 on
insulin secretion with the greatest effect in hyperglycaemic condi-
tions, and little or no effect when the blood glucose concentration
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is less than 3.61 mmol/L (65 mg/dL). This should reduce the oc-
currence of hypoglycaemia.
Much interest has been raised by the possibility that the GLP-
1 analogues might reduce the loss of beta-cell mass. Studies in
rodents have shown that GLP-1 increases pancreatic islet beta-cell
mass by enhancing beta-cell proliferation (Xu 1999), increasing
the differentiation of new beta-cells from progenitor cells in the
pancreatic duct epithelium (Abraham 2002) and reducing beta-
cell apoptosis (Farilla 2003; Li 2003). If this applied in humans,
use of GLP-1 analogues may hold the potential to maintain or
enhance beta-cell mass in type 2 diabetes, and prevent progression
of the disease.
Current evidence for effectiveness of glucagon-like
peptide analogues in type 2 diabetes
Recent evidence has been summarised in reviews by Shyang-
dan and colleagues (Shyangdan 2010), Monami and colleagues
(Monami 2009), Barnett (Barnett 2009), Amori (Amori 2007),
Norris and colleagues (Norris 2009) and inHTA reports forNICE
(Shyangdan 2011; Waugh 2010). This Cochrane review is partly
based on, and partly an update of, the review by Shyangdan and
colleagues (Shyangdan 2010). That review concluded that GLP-
1 agonists are effective in improving glycaemic control when used
as third line agents. In contrast to insulin, glitazones and sulpho-
nylureas, GLP-1 agonists cause weight reduction and the occur-
rence of hypoglycaemia is less. The risk of hypoglycaemia increased
when GLP-1 agonists were combined with a sulphonylurea but
not when given with metformin. GLP-1 agonists caused gastroin-
testinal adverse events mainly nausea but this decreased over time.
There have been several other good quality reviews, but these have
tended to include all trials. However not all trials are relevant to
clinical practice. Some were designed to identify the optimum
dosage. Others investigated GLP-1 analogues against placebo in
people on no other glucose lowering drug, whereas in practice,
older cheaper drugs with long safety records, such as metformin,
should be used first. In the UK, the NICE guideline recommends
that the GLP-1 analogues should be used in triple therapy (NICE
CG87 2009; NICE TA203 2010). In the USA, it appears that
they are more frequently used in dual therapy.
A long-acting-release (LAR) formulation of exenatide has been de-
veloped that undergoes slow degradation over a period of weeks
and can therefore be administered as a single injection per week.
Liraglutide is given only once daily. Newer GLP-1 analogues in-
clude albiglutide, taspoglutide, lixisenatide and LY2189265.
Why it is important to do this review
Conventional treatments used to control hyperglycaemia in type
2 diabetes are unsatisfactory due to weight gain, risk of hypogly-
caemia or a decrease in efficacy with disease progression (Pratley
2008). Their glucose-dependent mechanism of action suggests
that the GLP-1 analogues should not cause hypoglycaemia. In ad-
dition it appears that these agents cause weight loss rather than
weight gain. Sincemost people with type 2 diabetes are overweight
or obese, this is potentially very important. At present, when peo-
ple with type 2 diabetes have poor control on a combination of oral
agents, the next step is to start a third oral hypoglycaemic agents
such as a gliptin or pioglitazone, or a GLP-1 agonist or insulin
(NICE CG87 2009)). The guideline states that GLP-1 agonists
should be continued if it leads to reduction of 1% in HbA1c level
and 3% in weight by six months. GLP-1 agonists cause gastroin-
testinal adverse events, mainly nausea, leading to discontinuation
of the drug in some people. However, there is some evidence that
the newer GLP-1 analogues used once weekly or once every two
weeks reduce this adverse event.
O B J E C T I V E S
To assess the effects of glucagon-like peptide analogues in patients
with type 2 diabetes mellitus.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled clinical trials.
Only articles published in full were included, except that meet-
ing abstracts were considered if they contained data on secondary
outcomes from a study already published in full, or if there was a
published protocol (so that information on the design and quality
are available).
Types of participants
Adults (over 18 years of age) with type 2 diabetes.
To be consistent with changes in classification and diagnostic cri-
teria of type 2 diabetes mellitus through the years, the diagnosis
should have been established using the standard criteria valid at the
time of the beginning of the trial (ADA 1997; ADA 1999; WHO
1998). Ideally, diagnostic criteria should have been described. If
necessary, authors’ definition of diabetes mellitus were used.
Types of interventions
Trials with a minimum duration of eight weeks of any glucagon-
like peptide 1 (GLP-1) analogue (exenatide 10 µg twice daily
compared against exenatide 2 mg once weekly, exenatide 2 mg
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once weekly, liraglutide, albiglutide, taspoglutide, lixisenatide and
newer GLP-1 analogues) in combination with metformin or
sulphonylurea or both were considered. Studies were also consid-
ered if they included additional oral antihyperglycaemic agents,
such as thiazolidinediones (TZD). Trials comparing exenatide 10
µg twice daily against placebo or other oral hypoglycaemic agents
were not considered. Exenatide 10 µg twice daily is not consid-
ered in this review, apart from in comparison with the long-acting
form, having been reviewed elsewhere (Shyangdan 2010) and be-
cause it is expected to be replaced by the long-acting, once weekly
form.
Since GLP-1 agonists are not licensed for use as first line therapy
in treatment-naive patients, the inclusion criteria are based on the
comparisonswhich are considered to be relevant to clinical practice
as suggested by the NICE guideline (NICE CG66 2008) and by
the ADA/EASD joint statement (Nathan 2009).
Therefore, the following comparisons were excluded:
1. GLP-1 used as a monotherapy, whether compared with
placebo or another drug.
2. Use of GLP-1 in patients naive to treatment, i.e. patients
need to have been diagnosed with type 2 diabetes for at least a
year and to have been on at least one oral hypoglycaemic drug for
six months; where trials did not give sufficient detail, we accepted
them if the mean duration of diabetes exceeded two years.
3. Trials of a GLP-1 agonists on patients having failed only on
a sulphonylurea or a glitazone without having been tried on
metformin; in practice, some trials included people who have
failed on either metformin or a sulphonylurea, and did not
necessarily give results separately. We accepted any such trials if
70% of patients or more had been on metformin.
4. Trials or arms using non-standard doses. So most of the
data from dose-ranging studies were not relevant.
Dosages
The standard exenatide regimen is to start with 5 µg twice daily
and to increase after a month or so to 10 µg twice daily.
The dose of liraglutide is less clear, with some trials suggesting
starting with 0.6 mg, and then increasing in stages to 1.2 mg or
1.8 mg. There are some trials in Japanes patients where liraglutide
has been used in the dose of 0.9mg (Kaku 2010). Otherwise, trials
or arms with less than 1.2 mg daily (final dose) were excluded.
For newerGLP-1 agonists, we only included dosages that are likely
to be used in routine care - i.e. those with maximal effects while
minimising adverse events.
The following comparisons were included:
1.GLP-1 agonist as a third line agent. There are two questions of
interest to clinicians in this situation. The first is whether theGLP-
1 analogues are effective in improving glycaemic control, without
causing adverse effects. The second is whether GLP-1 analogues
are as good as, or better than other options. Since dual therapy
is usually metformin and a sulphonylurea, the other options are
insulin, a glitazone or a gliptin.
So comparisons are:
1a. Dual therapy + GLP-1 versus dual therapy + placebo
1b. Dual therapy + GLP-1 versus same dual therapy + another
antihyperglycaemic agent
2. GLP-1 agonist as a second line agent
The questions are similar to those for third line use:
2a. Monotherapy + GLP-1 versus same monotherapy + placebo
2b. Monotherapy + GLP-1 versus same monotherapy + any anti-
hyperglycaemic agent
3. GLP-1 agonist versus other GLP-1 agonist
The general principles of inclusion apply here. So, trials were only
included if they compared different GLP-1 analogues as third line
or second line agents.
Types of outcome measures
Primary outcomes
• glycaemic control as measured by glycated haemoglobin
(HbA1c);
• hypoglycaemia: graded as mild (symptoms easily controlled
by individual), moderate (normal activities interrupted but
assistance not required), severe (individual requiring assistance,
and associated with blood glucose level less than 50 mg/dL (4
mmol/L) or with prompt recovery after oral carbohydrate or
glucagons or intravenous glucose), serious (life threatening or
required subject to be admitted to hospital);
• weight gain or loss/change in body mass index.
Secondary outcomes
• health-related quality of life (using a validated instrument);
• adverse effects (for example congestive heart failure,
oedema, pancreatitis, other gastrointestinal effects);
• mortality (all-cause mortality; diabetes-related mortality
(death from myocardial infarction, stroke, peripheral vascular
disease, renal disease, hyper- or hypoglycaemia or sudden death);
• morbidity (both specific to diabetes such as retinopathy or
nephropathy, and cardiovascular morbidity, for example angina
pectoris, myocardial infarction, heart failure, stroke, peripheral
vascular disease);
• blood pressure;
• fasting blood glucose and post-prandial glucose;
• plasma lipids (triglycerides, total cholesterol, HDL and
LDL-cholesterol);
• beta-cell function.
Covariates, effect modifiers and confounders
• age;
• ethnicity;
• body mass index;
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• HbA1c at baseline;
• diabetes duration.
Search methods for identification of studies
See: Cochrane Metabolic and Endocrine Disorders Group meth-
ods.
Electronic searches
We used the following sources for the identification of trials:
• The Cochrane Library (issue 1, 2011);
• MEDLINE (1996 to March 2011);
• EMBASE (1998 to March 2011);
• Web of Science (1980 to March 2011).
We also searched databases of ongoing trials:
• Current Controlled Trials (www.controlled-trials.com) and
ClinicalTrials.gov
See Appendix 1 for details on all search strategies.
Searching other resources
• American Diabetes Association (ADA) and the European
Association for the Study of Diabetes (EASD) web sites were
searched for recent meeting abstracts
• The web sites of the FDA (Food and Drug Administration)
and EMEA were searched for information on efficacy and safety
Reference lists
We also looked for additional studies by searching the reference
lists of included trials and (systematic) reviews, meta-analyses and
health technology assessment reports identified.
Studies published in any language were to be included.
Data collection and analysis
Selection of studies
To determine the studies to be assessed further, three authors (PR,
DS, PS) independently scanned the abstract, titles or both sections
of every record retrieved. All potentially relevant articles were in-
vestigated as full text. Few differences in opinion existed which
were resolved by a third party (NW). There was no article needing
the author’s clarification for selection. An adapted PRISMA (pre-
ferred reporting in systematic review and meta-analysis (Moher
2009)) flow-chart of study selection is attached (Figure 1).
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Figure 1. Study flow diagram.
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Data extraction and management
Two of the three authors (CC, DS, PS) independently extracted
data using a standard data extraction form that was tested, piloted
and modified for the current review. Data extraction was checked
by a second author (CC, PR, DS). Relevant data on study popu-
lation, intervention, study design and outcomes were pulled out
from included studies. See Characteristics of included studies and
Table 1 for details. Few discrepancies were discussed and resolved
between two authors. There was no such disagreements needing
a third reviewer.
Assessment of risk of bias in included studies
One of the three authors (CC, DS, PS) assessed risk of bias of
each trial, the assessment was checked by another author (CC, PR,
DS). Any disagreements were resolved by consensus between the
authors. There was no requirement of a third party to resolve the
problems.
Measures of treatment effect
Dichotomous data were expressed as relative risks with 95% con-
fidence intervals (CI) and continuous data were expressed as mean
differences with 95% CIs. Outcomes published in different scales
were expressed as standardised mean differences (SMD).
Unit of analysis issues
We planned to take into account the level at which randomisation
occurred, such as cross-over trials, cluster-randomised trials and
multiple observations for the same outcome.
Dealing with missing data
Numbers of patients screened, randomised and analysed as inten-
tion-to-treat or per-protocol were recorded, as were descriptions
of withdrawals or losses to follow-up and reasons for withdrawals.
Each study was assessed for risk of bias for the issues of incomplete
outcome data or missing data by investigating drop-outs, losses
to follow-up and withdrawn study participants and issues of last-
observation-carried-forward (LOCF) and was compared to speci-
fication of primary outcome parameters and power calculation.
Assessment of heterogeneity
We identified heterogeneity by visual inspection of the forest plots
and by using a standard Chi2 test with a significance level of α =
0.1, in view of the low power of this test. We specifically examined
heterogeneity employing the I2 statistic which quantifies incon-
sistency across studies to assess the impact of heterogeneity on the
meta-analysis (Higgins 2002; Higgins 2003), where an I2 statistic
of 75% and more indicates a considerable level of inconsistency
(Higgins 2011).
When heterogeneity was found, we planned to determine poten-
tial reasons for it by examining individual study and subgroup
characteristics.
Assessment of reporting biases
Studies were checked for outcome reporting bias.
Data synthesis
Data were summarised statistically if they were available, suffi-
ciently similar and of sufficient quality. Data were summarised us-
ing a random-effects model. Analyses were done separately for the
different drugs and the different comparisons as outlined above.
Subgroup analysis and investigation of heterogeneity
Results for hypoglycaemia were analysed in separate subgroups for
studies including and not including sulphonylurea therapy.
Sensitivity analysis
Due to the limited number of studies in each comparison, sensi-
tivity analyses were not carried out. Relevant sensitivity analyses
would have especially included analysis by risk of bias.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
Seventeen randomised controlled trials fulfilled the inclusion cri-
teria and were included in the review. Four hundred and eighty
six records were screened for eligibility. A total of 449 papers were
excluded on the basis of title and abstract. Thirty seven full-text
articles were assessed for eligibility, out of which 20 articles, details
are shown inCharacteristics of excluded studies, were excluded.Of
the 17 studies included, four examined exenatide, eight liraglutide
(one trial examined exenatide against liraglutide), two taspoglutide
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and one each examined lixisenatide, albiglutide and LY2189265.
Of the exenatide trials, two trials compared exenatide twice daily
against once weekly exenatide, one compared once weekly exe-
natide against insulin glargine and one compared once weekly ex-
enatide against sitagliptin and pioglitazone. The most important
studies with liraglutide were against active comparators. The ac-
tive comparators were exenatide, rosiglitazone, glargine, sitagliptin
and glimepiride. Albiglutide and taspoglutide were compared to
placebo. Some of the trials also included other comparison groups,
as outlined below. For an overview of comparisons please see Table
2.
Included studies
Characteristics of included studies are shownunderCharacteristics
of included studies. Studies were prefixed with the first or first few
letters of the drug so that trials appear in the right order in the
’Characteristics of included studies’ table.
Albiglutide
Design: The trial by A - Rosenstock 2009 assessing the effects of
albiglutide was a multi-centre and multi-national double-blind
placebo controlled trial. The primary aim of the study was to
study the safety, efficacy and tolerability of incremental doses of
albiglutide compared to exenatide or placebo, all in combination
with background antihyperglycaemic therapy.The group receiving
exenatide was open label and was excluded in the present review as
all participants also receivedmetformin, whereas only a proportion
of the patients in the other groups did. Study duration was 16
weeks.
Participants: The study included 361 participants with type 2 di-
abetes with a mean diabetes duration of 4.9 years. Participants
had a mean age of between 51 and 56 years. Baseline glycosylated
haemoglobin A1c (HbA1c) was between 7.9% and 8.0%, and
baseline body mass index (BMI) between 31.2 kg/m2and 33 kg/
m2. About a quarter to a third of participants were drug-naive,
while the remainder were receiving metformin monotherapy. Par-
ticipants were excluded if they had used any other oral antidiabetic
agent before the beginning of the study.
Interventions: The trial compared 10 intervention groups. Eight
different doses of the drug (4mg or 15 mg or 30mg weekly, 15 mg
or 30 mg or 50 mg biweekly, and 50 mg or 100 mgmonthly) were
compared against placebo or exenatide. Only the groups using 30
mg once a week and 30 mg once every two weeks were included
in the review for comparison because the trial was partly a dose
ranging study and some doses are not relevant to clinical practice.
Excluded doses were less effective, caused more adverse effects, or
causedmore fasting plasma glucose (FPG) fluctuation. Metformin
was continued at pre-study doses.
Outcomes: The primary outcome of the study was HbA1c and
FPG changes at the end of the study while the secondary outcomes
included fasting fructosamine, C-peptide, glucagon, insulin, and
lipid levels, beta-cell function and assessment of adverse events.
Occurrence and duration of nausea and vomiting, immunogenic-
ity, level of anti-albiglutide antibodies and pharmacokinetics of al-
biglutide were assessed. Most of these outcomes were also assessed
during the 11 week washout period.
Exenatide
Out of the seventeen trials included, five (one trial (L - LEAD
6 Buse 2009) compared exenatide and liraglutide and therefore
it will be considered under liraglutide) examined the safety and
efficacy of exenatide.
Design: Three trials were open label (E - Blevins 2011; E -
Diamant 2010; E - Drucker 2008) while one was double-blind (E
- Bergenstal 2010). Trial duration ranged from 24 to 30 weeks. All
the trials were conducted in multiple settings. Two of them were
multinational (E - Bergenstal 2010; E - Diamant 2010). A study
by E - Drucker 2008 was carried out in USA and Canada whereas
the study by E - Blevins 2011 was conducted in the USA only.
Participants: The trials included a total of 1525 randomised pa-
tients. Trial participants had a mean age of between 52 and 58
years. Between 40% and 52% of participants in trials were fe-
male. Ethnicity was reported in all the studies and the propor-
tion of Caucasian participants ranged between 30% and 85%. All
studies included participants with type 2 diabetes with a mean
diabetes duration of between 5 years and 8 years, with most tak-
ing oral anti diabetic agents (OADs). Baseline HbA1c was be-
tween 8.3% to 8.6% and baseline BMI was between 32 kg/m
2and 35 kg/m2. Three trials (E - Blevins 2011; E - Diamant 2010;
E - Drucker 2008) gave detailed information on previous treat-
ments. Participants were taking metformin, sulphonylureas or thi-
azolidinediones either on its own or in combination. The studies
by E - Blevins 2011 and E - Drucker 2008 also included between
14% and 21% of participants on diet and exercise only.
Interventions: Two trials (E - Blevins 2011; E - Drucker 2008)
compared long acting exenatide i.e. 2mg once weekly against twice
daily exenatide i.e. 10 µg. Twice daily exenatide regimen would
start with 5 µg twice a day, increasing to 10 µg twice a day after a
fewweeks. The study by E - Bergenstal 2010 compared long acting
exenatide against sitagliptin 100 mg once daily and pioglitazone
45 mg once daily while the study by E - Diamant 2010 compared
long acting exenatide against insulin glargine.
Outcomes: In all the trials, the primary outcome measure was
change in HbA1c value from baseline to end of study. Secondary
outcome measures included changes in FPG, postprandial glu-
cose (PPG), body weight, hypoglycaemia, blood pressure, lipid
profile, beta-cell function, adverse events, and immunogenicity of
exenatide. Quality of life was reported by two trials (E - Blevins
2011; E - Diamant 2010) and none of the trials reported diabetes-
related morbidity (most of them did not last long enough for a
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meaningful assessment of this outcome).
Liraglutide
Eight trials assessed the safety and efficacy of liraglutide.
Design: Two trials (L - LEAD 6 Buse 2009; L - Pratley 2010) were
open label and five trials were double blind (L - Kaku 2010; L
- LEAD 1 Marre 2009; L - LEAD 2 Nauck 2009; L - LEAD 4
Zinman 2009; L - Yang 2010). One trial (L - LEAD 5 Russell-J
2009) included twodouble blind groups and one open label group.
Trial duration was 26 weeks for all trials except one, L - Yang
2010, which was 16 weeks long. All trials were multi-centre and
multi-national trials except L - Kaku 2010 which was carried out
in multiple settings in Japan only. The study by L - Yang 2010
included participants from three Asian countries namely China,
South Korea and India.
Participants: The trials included a total of 5086 randomised par-
ticipants (excluding liraglutide 0.6 mg dose from all other trials
except L - Kaku 2010). Liraglutide doses of 0.6 mg and 0.9 mg
are standard in Japan and hence L - Kaku 2010 was included in
this review. Trial participants had a mean age of between 52.7
years and 61.3 years. Between 33% and 55% of participants in
trials were female. Ethnicity was not reported in three of the eight
trials (L - LEAD 1 Marre 2009; L - LEAD 5 Russell-J 2009; L -
Yang 2010) and the proportion of Caucasian participants ranged
between 81% and 93%. In the study by L - Kaku 2010, all the
participants were Japanese. All studies included participants with
type 2 diabetes with a mean diabetes duration of between 6.0 years
and 11.6 years, with all taking oral antidiabetic medication. Only
one trial (L - LEAD 1 Marre 2009) did not clearly report on pre-
study medication, but it can be assumed that the participants were
tried on metformin because most of them were from Europe and
Asia where metformin is used as a first line medication. Baseline
HbA1c values were between 8.1% and 8.6% and baseline BMI
was between 29.4 kg/m2 and 33.9 kg/m2. Background antihyper-
glycaemic medication included sulphonylureas in four trials (L -
Kaku 2010; L - LEAD 1Marre 2009; L - LEAD 5 Russell-J 2009;
L - LEAD 6 Buse 2009), and thiazolidinediones in one trial (L -
LEAD 4 Zinman 2009).
Interventions: Two trials (L - LEAD 1 Marre 2009, L - LEAD 2
Nauck 2009) compared five intervention groups, five trials (L -
Kaku 2010; L - LEAD 4 Zinman 2009; L - LEAD 5 Russell-J
2009; L - Pratley 2010; L - Yang 2010) compared three different
intervention groups, and L - LEAD 6 Buse 2009 compared two
intervention groups. Liraglutide was dosed at 0.6, 0.9, 1.2 or 1.8
mg/day, however, in this review we only consider 1.2 and 1.8 mg/
day except L - Kaku 2010. The study by L - Kaku 2010 com-
pared 0.6 or 0.9 mg/day of liraglutide against placebo, with all
participants receiving concomitant glimepiride therapy. L - LEAD
1 Marre 2009 compared 1.2 or 1.8 mg/day of liraglutide against
placebo or rosiglitazone (4 mg/day), with all groups receiving con-
comitant glimepiride therapy. L - LEAD 2 Nauck 2009 compared
1.2 or 1.8 mg/day of liraglutide against placebo or glimepiride 4
mg/day, with all groups receiving concomitant therapy with met-
formin. L - LEAD 4Zinman 2009 compared 1.2 or 1.8 mg/day of
liraglutide against placebo, with all groups receiving concomitant
therapy with metformin and rosiglitazone. L - LEAD 5 Russell-J
2009 compared 1.8 mg/day of liraglutide versus insulin glargine
or placebo, with all groups receiving concomitant therapy with
metformin and glimepiride. L - LEAD 6 Buse 2009 compared 1.8
mg/day of liraglutide against 10 µg BID exenatide, with all groups
remaining on their existing sulphonylurea and/or metformin ther-
apy. L - Pratley 2010 compared 1.2 or 1.8 mg/day of liraglutide
against sitagliptin 100 mg/day, with all groups continuing their
existing metformin therapy. L - Yang 2010 compared 1.2 or 1.8
mg/day against glimepiride 4 mg/day, with all participants receiv-
ing metformin 2000 mg/day. Most trials included a run-in period
used for drug titration.
Outcomes: In all the trials the primary outcomemeasurewas change
in HbA1c value from baseline to end of study. Secondary outcome
measures included changes in FPG, postprandial glucose (PPG),
hypoglycaemia, body weight, adverse events, blood pressure, lipid
profile, beta-cell function and liraglutide immunogenicity. Only
one study (L - LEAD 6 Buse 2009) reported health-related quality
of life and none reported about diabetes-related mortality.
Lixisenatide
One trial assessed the safety and efficacy of lixisenatide.
Design:The trial by Lixi - Ratner 2010 assessing the effects of lixise-
natide was a double-blind, multi-national, parallel-group, placebo
controlled trial. Trial duration was 13 weeks.
Participants: The trial included a total of 542 randomised partic-
ipants with type 2 diabetes with a mean duration of diabetes be-
tween 6.0 years and 7.2 years. Trial participants had a mean age
of between 55.4 years and 56.8 years. Between 40.4% and 63%
of participants in the trial were female. The total proportion of
Caucasian participants were between 64.8% and 86.8%. All the
participants were taking metformin. Baseline HbA1c values were
between 7.46% and 7.61% and baseline BMI was between 30.7
kg/m2 and 32.8 kg/m2.
Interventions:The trial compared nine intervention groups. Lixise-
natide was dosed at 5 µg, 10 µg, 20 µg, 30 µg once or twice
daily and compared against placebo twice daily, with all partici-
pants receiving stable dose of metformin. All groups also received
diet and lifestyle counselling according to the American Diabetes
Association guidelines. It also included an initial 2-week screening
phase followed by a 2-week, single blind, placebo run in period.
Outcomes: The primary outcome measure was change in HbA1c
from baseline to end of study. Secondary outcome measures in-
cluded the proportion of participants achievingHbA1c level of less
than 7% or less than 6.5%, changes in body weight, FPG, 2-hour
post-prandial glucose, hypoglycaemia, blood pressure, heart rate,
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electrocardiogram (ECG) and anti-lixisenatide antibodies. Qual-
ity of life and diabetes related morbidity were not reported.
LY2189265
One trial assessed the safety and efficacy of LY2189265.
Design: The trial by LY2189265 -Umpierrez 2011 assessing the
effects of LY2189265 was a double-blind, placebo-controlled ran-
domised trial. It was carried out in multiple settings in US and
Puerto Rico. Trial duration was 16 weeks.
Participants:The trial included a total of 262participants with type
2 diabetes, of which 46% to 56% were female. Mean duration of
diabetes was between 7.5 years and 9.0 years. Trial participants had
a mean age of between 54 years and 59 years. Between 55% and
61% of participants were Caucasians. Majority of the participants
(72.7% to 73.8%) were taking metformin and sulphonylurea in
combination. Mean HbA1c was between 8.05% and 8.43% and
baseline BMI was between 33.7 kg/m2 and 34.2 kg/m2.
Interventions: The trial compared four intervention groups.
LY2189265 (LY) was dosed at 0.5, 1.0 and 2.0 mg. First group
(also referred as LY0.5/1.0mg) received onceweekly subcutaneous
injection of LY 0.5 mg in the first four weeks followed by 1.0 mg
once weekly injection in the next 12 weeks. Second group (also
referred as LY 1.0/1.0 mg) received once weekly subcutaneous in-
jection of LY 1.0 mg for 16 weeks. Third group (also referred as
LY 1.0/2.0 mg) received once weekly injection of LY 1.0 mg in the
first four weeks followed by once weekly injection of LY 2.0 mg
in the next 12 weeks. Placebo was given as weekly injection. All
the participants continued their baseline oral antihyperglycaemic
drugs.
Outcomes: The primary outcome measure was change in HbA1c
from baseline to end of study. Secondary outcome measures in-
cluded change in FPG, blood glucose response following a solid
mixed-meal test, change in body weight, beta-cell function, treat-
ment emergent adverse events, and hypoglycaemia.
Taspoglutide
Two trials (T - Nauck 2009; T- Ratner 2010) assessed the safety
and efficacy of taspoglutide.
Design:Both trials (T -Nauck 2009; T- Ratner 2010) assessing the
effects of taspoglutide were double blind multi-centre and multi-
national placebo controlled.
Participants: The trials included a total of 439 participants with
type 2 diabetes with a mean diabetes duration of between five
years and eight years. Participants had a mean age of between
53 years and 60 years and between 36% and 64% were female.
Ethnicity was not reported. Baseline HbA1c was between 7.8%
and 8.0%, baseline BMI was between 31.5 kg/m2 and 33.3 kg/m
2. All participants had been on metformin monotherapy.
Interventions: T - Nauck 2009 compared six intervention groups.
Five different doses of taspoglutide (5 mg or 10 mg or 20 mg once
weekly or 10 mg or 20 mg once every two weeks) were compared
against placebo. In this review, we only consider 10 mg and 20 mg
once weekly and 20 mg once every two weeks as the other doses
are unlikely to be relevant to clinical practice. The prestudy drugs
were continued at the same dose throughout the study period.
The trial by T- Ratner 2010 compared four intervention groups.
Three different doses of taspoglutide i.e. 20, 30 and 40 mg once
weekly were used in the study. Taspoglutide 20 mg was injected
once every week in the first 4 weeks and then continued in the
same dose for the next four weeks (20/20 mg group) or titrated
to 30 mg (20/30 mg group) or to 40 mg (20/40 mg group). All
the participants continued metformin in their prestudy dose. The
prestudy diet and exercise plan was followed throughout the study.
Some participants also receivedmedications for cardiovascular risk
factors.
Outcomes: The primary outcome measure in T - Nauck 2009 was
change in HbA1c from baseline to end of study while T- Ratner
2010 explored gastrointestinal tolerability. It was assessed by com-
paring the number of participants who withdrew from study be-
cause of gastrointestinal adverse events Secondary outcome mea-
sures in T - Nauck 2009 included changes in FPG, postprandial
glucose, body weight, hypoglycaemia, adverse events, lipid profile,
and beta-cell function. T- Ratner 2010 explored changes in FPG,
HbA1c, body weight and pharmacokinetic parameters. Quality of
life and diabetes-related morbidity were not reported.
Excluded studies
Studieswere excludedbecause theywere not primary trials, because
they did not compare clinically relevant interventions, or because
patients did not fulfil the inclusion criteria (mainly because of
previous medication).
Risk of bias in included studies
Details of risk of bias assessment of the trials are shown in the
Characteristics of included studies section, in Figure 2 and Figure
3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Out of the seventeen trials, randomisation was adequate in nine,
while for the remaining eight (A - Rosenstock 2009; E - Drucker
2008; L - Kaku 2010; L - LEAD 1Marre 2009; L - LEAD 6 Buse
2009; L - Yang 2010; LY2189265 -Umpierrez 2011; T- Ratner
2010) the randomisation procedure was not reported or unclear.
Ten trials had adequate allocation concealment, while the rest of
the trials (A - Rosenstock 2009; E - Drucker 2008; L - Kaku 2010;
L - LEAD 1 Marre 2009; L - Yang 2010; LY2189265 -Umpierrez
2011; T- Ratner 2010) did not report on allocation concealment.
Blinding
Eleven trials were double blind (A - Rosenstock 2009; E -
Bergenstal 2010; L - Kaku 2010; L - LEAD 1 Marre 2009; L -
LEAD 2 Nauck 2009; L - LEAD 4 Zinman 2009; L - Yang 2010;
Lixi - Ratner 2010; LY2189265 -Umpierrez 2011; T - Nauck
2009; T- Ratner 2010) while five trials (E - Blevins 2011; E -
Diamant 2010; E - Drucker 2008; L - LEAD 6 Buse 2009; L -
Pratley 2010) were open label. L - LEAD 5 Russell-J 2009 was
a three-armed placebo controlled blinded study, with liraglutide
and liraglutide placebo, and the glargine arm open label.
Incomplete outcome data
All the trials except three (L - Kaku 2010; L - Pratley 2010; L -
Yang 2010) used intention-to-treat analysis. All the trials reported
on rates and reasons for withdrawal. Rates of withdrawal ranged
between 1% and 42% (often with more withdrawals in the GLP-
1 agonist groups).
Selective reporting
All the pre-specified (both primary and secondary) outcomes were
reported in all the trials. Ethnicity was not reported in five trials (L
- LEAD 1Marre 2009; L - LEAD 5Russell-J 2009; L - Yang 2010;
T -Nauck 2009; T- Ratner 2010) but other baseline characteristics
were reported in the remaining trials.
Other potential sources of bias
A description about the power calculation was unclear in the trial
by L - Kaku 2010. However, all the remaining trials had carried
out a power calculation. Baseline groups were comparable in all
trials.
Effects of interventions




Results for albiglutide are shown inData and analyses, 1.1 to 1.12.
HbA1c
A - Rosenstock 2009 found a significant difference (P < 0.05) for
HbA1c values between albiglutide and placebo at the end of the
study.HbA1c levels decreased by 0.87%(SD0.65) and0.79%(SD
0.98) in the participants receiving albiglutide 30 mg weekly and
30 mg every two weeks respectively, whereas the level of HbA1c
only decreased by 0.17% (SD 1.01) in the placebo group. The
end values of HbA1c were 7.1%, 7.2% and 7.7% for albiglutide
30 mg weekly, albiglutide 30 mg every two weeks and placebo
respectively. Similarly, there was a significant difference in the pro-
portion of participants reaching target HbA1c of less than 7% be-
tween the albiglutide and placebo groups (52% for albiglutide 30
mg weekly, 50% for 30 mg every two weeks and 20% for placebo).
Greater reductions in HbA1c levels were seen in participants with
baseline HbA1c values of 8.5% or more but details were not given.
Hypoglycaemia
A definition of hypoglycaemia was not given in the study. No sig-
nificant difference was found for the incidence of hypoglycaemia
among groups. None of the participants in the albiglutide 30 mg
weekly group reported hypoglycaemia. Only one patient (3.1%)
in the albiglutide 30 mg every two weeks and two patients (3.9%)
in the placebo group reported hypoglycaemia during the study
period.
Weight change
Weight decreased in both albiglutide and placebo groups. At the
end of the study, there was a reduction of 1.4 kg (SD 2.4) in the
30 mg weekly group, of 1.6 kg (SD 2.5) in the 30 mg every two
weeks group and of 0.7 kg (SD 2.9) in the placebo group. There
were no significant differences in weight reduction between the
study groups.
Adverse events
The incidence of adverse events was similar across all groups and
ranged between 66.7% and 84.4%. The majority of the adverse
events were nausea, vomiting and diarrhoea and the incidence of
the first two was more in the participants receiving albiglutide 30
mg once every week while the incidence of diarrhoea was compar-
atively more in the 30 mg biweekly group. Similarly, the number
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of participants with a positive immunogenicity test was also higher
in albiglutide 30 mg once every week group compared with other
groups (6.4% in albiglutide 30 mg weekly versus 3.1% in albiglu-
tide 30 mg every two weeks and 2% with placebo). None of the
participants on albiglutide therapy suffered from pancreatitis or
any cardiac disorders, however the incidence of skin reactions to
the drug was more in the albiglutide group compared to placebo.
Blood pressure
Both albiglutide and placebo groups showed a decrease in systolic
and diastolic blood pressure. However, the reduction of blood
pressure in the albiglutide groupswhen compared toplacebo group
was not significant.
Fasting plasma glucose
Significant reductions (P < 0.05) in fasting plasma glucose were
observed in the albiglutide groups compared toplacebo.Reduction
of 1.44% (SD 2.03) and 1.58% (SD 2.06) were observed with
albiglutide 30 mg weekly and 30 mg every two weeks while the
reduction was 0.10% (SD 2.90) in the placebo group.
Lipid profiles
No significant changes were seen in the lipid profiles of the par-
ticipants treated with either albiglutide or placebo.
Beta-cell function
A significant improvement in beta-cell function (HOMA-B ratio)
was seen in the participants treated with 30 mg albiglutide weekly
(1.4) compared to placebo (1.0) whereas the difference to placebo
was not significant with 30 mg albiglutide every two weeks (1.2).
Exenatide
Exenatide versus thiazolidinedione (pioglitazone)
Results for exenatide versus thiazolidinedione are shown in Data
and analyses, 2.1 to 2.10. Only one study (E - Bergenstal 2010)
compared once weekly exenatide (2 mg) against pioglitazone 45
mg daily.
HbA1c
E - Bergenstal 2010 found a slightly greater reduction in HbA1c
with once weekly exenatide than with pioglitazone 45 mg once
daily (-1.5% versus -1.2%, P = 0.02).
The proportion of participants achieving target HbA1c level of
less 7% was not different between the two treatment groups (60%
versus 52%, P = 0.15).
Hypoglycaemia
In the trial, minor hypoglycaemia was defined as any episode
where a participant experienced symptoms consistent with hypo-
glycaemia and a blood glucose level of less than 3 mmol/L. Ma-
jor hyperglycaemia was defined as any episode resulting in loss of
consciousness, seizure or coma that resolved after administration
with glucagon or glucose, or any episode with blood glucose level
of less than 3.0 mmol/L and a severe impairment that required
third-party assistance to resolve the episode. Incidences of minor
hypoglycaemia were similar between the groups, two participants
in the exenatide group and one in the pioglitazone group. There
were no cases of major hypoglycaemia.
Weight change
Participants taking exenatide once weekly lost weight while those
taking pioglitazone gained weight (-2.3 kg versus + 2.8 kg, P <
0.00001).
Quality of life
In E - Bergenstal 2010, it was found that all the five parameters of
weight-related quality of life and IWQOL total score significantly
improved with exenatide (IWQOL total score 5.15, 95% CI 3.11
to 7.19) and not with pioglitazone (1.20, 95% CI -0.87 to 3.28).
The treatment difference between exenatide and pioglitazone was
significant (3.94, 95% CI 1.28 to 6.61, P = 0.0038). The im-
provement in IWQOL total score with exenatide was consistent
with differences in body weight changes.
Adverse events
Withdrawals due to adverse eventswere increasedwith onceweekly
exenatide than pioglitazone (6.9% versus 3.6%). The most com-
monly reported adverse events with exenatide were nausea and di-
arrhoea. Withdrawals from the trial were mostly because of these
events. Incidences of other adverse events such as headache, uri-
nary tract infection and injection-site pruritus were similar be-
tween the groups. Pioglitazone caused more serious adverse events
than exenatide (6% versus 3%). Two other serious events (one in
exenatide and other in pioglitazone) led to withdrawals. About
half of the participants had low levels of anti-exenatide antibodies
(48%) but in 40% they were not detectable, and there was no
relation to glycaemic control and safety.
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Blood pressure
Reduction in systolic and diastolic blood pressure was not signifi-
cantly different between the two groups.
Fasting plasma glucose
E - Bergenstal 2010 found that the reduction in fasting plasma
glucose level between once weekly exenatide and pioglitazone was
not different (-1.8 mmol/L versus -1.5 mmol/L, P = 0.33).
Post-prandial glucose
Both exenatide 2 mg once weekly and pioglitazone 45 mg daily
led to reduction in post-prandial glucose levels but the difference
was not significant between the two groups.
Lipid profiles
It was found that only pioglitazone led to a significant reduction
in triglycerides level. Exenatide 2 mg once weekly led to reduction
in total cholesterol and LDL levels. In contrast, pioglitazone led to
an increment in these levels. All these changes were not significant.
It was also found that all the drugs led to improvement in HDL
levels.
Exenatide versus DPP-4 inhibitors (sitagliptin)
Results for exenatide versus DPP-4 inhibitors are shown in Data
and analyses, 3.1 to 3.10. Only one study (E - Bergenstal 2010)
compared once weekly exenatide (2 mg) against sitagliptin 100
mg daily.
HbA1c
E - Bergenstal 2010 found a significantly greater reduction in
HbA1c with once weekly exenatide than with sitagliptin 100 mg
daily (-1.5% versus -0.9%, P < 0.00001). Similarly, the proportion
of participants achieving an HbA1c level of less than 7% was sig-
nificantly higher with once weekly exenatide than with sitagliptin
100 mg daily (60% versus 35%, P < 0.0001).
Hypoglycaemia
Please see above for definition of hypoglycaemia. The incidence
of minor hypoglycaemia was slightly more in the sitagliptin group
than the exenatide group (n = 5 versus n = 2). There were no cases
of major hypoglycaemia.
Weight change
In E - Bergenstal 2010, once weekly exenatide led to a significantly
greater weight loss than sitagliptin 100 mg daily (-2.3 versus -0.8
kg, P = 0.0009).
Quality of life
In E - Bergenstal 2010, all five parameters of weight-related qual-
ity of life and IWQOL total score significantly improved with
exenatide (IWQOL total score 5.15, 95% CI 3.11 to 7.19) and
sitagliptin (4.56, 95% CI 2.56 to 6.57). The improvement in
IWQOL total score with exenatide was consistent with differences
in body weight changes.
In E - Bergenstal 2010, overall treatment satisfaction was com-
paratively higher with exenatide than with sitagliptin (3.96 versus
2.35). The treatment difference between the two was 1.61 (95%
CI 0.07 to 3.16, P = 0.0406).
Adverse events
More withdrawals due to adverse events were seen with once
weekly exenatide than sitagliptin (6.9% versus 3%). The most
commonly reported adverse events with exenatide and sitagliptin
were nausea and diarrhoea, while vomiting was more common
with exenatide only. Withdrawals from the trial were mostly be-
cause of these events. Incidences of other adverse events such as
headache, urinary tract infection and injection-site pruritus were
similar between the groups. Incidences of serious adverse events
were similar in the exenatide and sitagliptin groups (3% versus
3%). All these events resolved except one in the sitagliptin group,
that was fatal. About half (48%) of participants had low levels
of anti-exenatide antibodies (48%) while in 40% they were not
detectable, with no relation to glycaemic control and safety.
Blood pressure
At the end of the study, exenatide 2 mg once weekly was found
to cause significantly greater reduction in systolic blood pressure
than with sitagliptin (treatment difference of -4 mm Hg, 95% CI
-6 to -1, P = 0.0055). Reductions in diastolic blood pressure were
not different between the groups.
Fasting plasma glucose
E - Bergenstal 2010 found a significant difference in favour of
once weekly exenatide compared with sitagliptin 100 mg daily (-
0.90 mmol/L, 95% CI -1.50 to -0.30, P = 0.0038).
Post-prandial glucose
Exenatide 2mgonceweekly caused significantly greater reductions
in post-prandial glucose levels at all measurements of the six-point
self-monitored blood glucose profile than with sitagliptin 100 mg
daily (P < 0.05).
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Lipid profiles
Exenatide 2 mg once weekly led to reductions in total cholesterol
and LDL levels. In contrast, sitagliptin led to an increment. All
these changes were not significant. All the drugs led to improve-
ment in HDL levels.
Exenatide versus insulin (glargine)
Results for exenatide versus insulin glargine are shown inData and
analyses, 4.1 to 4.10. The trial by E - Diamant 2010 compared
once weekly exenatide against insulin glargine.
HbA1c
Onceweekly exenatide led to a slightly greater reduction inHbA1c
than with insulin glargine (-1.5% versus -1.3%). The treatment
difference between the two group was -0.20% (95% CI -0.35 to
-0.05, P = 0.03).
Similarly, the proportion of participants achieving a target HbA1c
levels of less than 7% was slightly higher in the once weekly exe-
natide group than in the insulin glargine group (60% versus 48%,
P = 0.03).
Hypoglycaemia
In the study, minor hypoglycaemia was defined as participants ex-
periencing signs or symptoms of hypoglycaemia, with concurrent
blood glucose level of less than 3.0 mmol/L that was either self-
treated or resolved independently. Any episode causing loss of con-
sciousness or seizure that resolved after treatment with glucose or
any episode with documented blood glucose level of less than 3.0
mmol/L requiring third party assistancewas termed asmajor hypo-
glycaemia. The number of participants that experiencedminor hy-
poglycaemia was greater in the group taking insulin glargine than
those taking exenatide (26% versus 8%). Similarly the number
of participants experiencing symptoms of hypoglycaemia but not
confirmed by blood glucose measurement was also higher in the
group taking insulin glargine (31% versus 13%). Hypoglycaemia
occurred most frequently in those taking concomitant sulphony-
lurea. Major hypoglycaemia occurred in three patients (2 in in-
sulin glargine group and 1 in exenatide group). All three cases were
treated with oral carbohydrate administration and did not lead to
study discontinuation.
Weight change
Participants taking once weekly exenatide lost significant amounts
of weight while those taking insulin glargine gained weight (-2.6
kg versus +1.4 kg). The treatment difference was -4.0 kg (95% CI
-4.55 to -3.45, P < 0.00001).
Quality of Life
It was reported in the trial that a significant improvement for
one of the IWQOL-Lite domains (self esteem) and one EQ-5D
dimensions resulted with once weekly exenatide compared with
insulin glargine (no data given). All other domains were similar
between the two groups.
Adverse events
The most frequently reported adverse events with exenatide were
nausea, diarrhoea, nasopharyngitis, injection-site reaction and
headache while nasopharyngitis and headache weremost common
with insulin glargine. Gastrointestinal adverse events were mild to
moderate in intensity.
Withdrawals due to adverse events were greater in the exenatide
group than in the insulin glargine group (4.7% vs. 0.9%). The
incidence of serious adverse events was not different between the
groups (5% in exenatide group vs. 4% in insulin glargine group).
No deaths occurred during the study period. There was one case of
oedematous pancreatitis in the exenatide group. It resolved a day
after onset and the participant fully recovered. It was found that
68% of participants tested positive for anti-exenatide antibodies
however, these had no effect on treatment response and safety.
Fasting plasma glucose
The reduction in fasting plasma glucose was slightly greater with
insulin glargine than with exenatide (-2.8 mmol/L versus -2.1
mmol/L). The treatment difference between the two groups was
0.70 (95% CI 0.14 to 1.26, P = 0.01).
Post-prandial glucose and glucose profiles
Both treatments reduced post-prandial glucose at all eight time
points. Participants taking once weekly exenatide had significantly
lower glucose concentrations after dinner than insulin glargine (P
= 0.004) while those on insulin glargine had lower glucose concen-
trations at 0300 h (P = 0.022) and before breakfast (P < 0.0001).
Once weekly exenatide led to greater reduction in post-prandial
glucose excursions compared to insulin glargine after morning (P
= 0.001) and evening (P = 0.033) meals.
Liraglutide
Liraglutide versus placebo
Results for liraglutide 0.6mg versus placebo are shown inData and
analyses, 5.1 to 5.9. Results for liraglutide 0.9 mg verus placebo
are shown in Data and analyses, 6.1 to 6.9. Results for liraglutide
1.2 mg versus placebo are shown in Data and analyses, 7.1 to
7.13. Results for liraglutide 1.8 mg versus placebo are shown in
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Data and analyses, 8.1 to 8.13. Data and analyses, 9.1 to 9.4 show
comparisons of 1.2 mg with 1.8 mg liraglutide.
HbA1c
One trial reported change inHbA1c level for 0.6 or 0.9mg liraglu-
tide versus placebo (L - Kaku 2010). The reduction in HbA1c
level at end of the study was significantly greater with 0.9 mg
liraglutide than with 0.6 mg liraglutide (-1.56% versus -1.46%)
or placebo (-1.56% versus -0.4%). Similarly, the proportion of
participants achieving a target HbA1c level of less than 7% was
significantly greater with 0.9 mg liraglutide than with 0.6 mg li-
raglutide (71.3% versus 46.5%, P < 0.05) or placebo (71.3% ver-
sus 14.8%, P < 0.0001). Three trials reported HbA1c for 1.2 mg
liraglutide versus placebo (L - LEAD 1 Marre 2009; L - LEAD
2 Nauck 2009; L - LEAD 4 Zinman 2009). HbA1c was signifi-
cantly reduced with 1.2 mg liraglutide compared to placebo. The
overall mean difference was -1.15 (95% CI -1.33 to -0.96, P <
0.00001), with no significant heterogeneity of the results. Reduc-
tions in HbA1c ranged from -1.0% to -1.5% in the 1.2 mg li-
raglutide groups, while HbA1c changes ranged from +0.23% to -
0.5% in the placebo groups.
The reduction of HbA1c with 1.8 mg liraglutide was similar to
that of 1.2 mg liraglutide. Overall, the four studies examining
this comparison (L - LEAD 1 Marre 2009; L - LEAD 2 Nauck
2009; L - LEAD 4 Zinman 2009; L - LEAD 5 Russell-J 2009)
found a difference of -1.15 (95% CI -1.31 to -0.99, P < 0.00001)
between 1.8 mg liraglutide and placebo. There was no substantial
heterogeneity. As with 1.2 mg liraglutide, reductions in HbA1c
with 1.8 mg liraglutide ranged from -1.0% to -1.5%. There was
no significant difference between 1.2 mg and 1.8 mg liraglutide
in reducing HbA1c (see Analysis 9.1).
The proportion of participants achieving an HbA1c level of 7%
or less was also higher with 1.2 mg liraglutide compared with
placebo, with 35% to 57.5% reaching the target in the liraglutide
groups, and 8% to 28% in the placebo groups. The overall risk
ratio for liraglutide 1.2 mg versus placebo was 2.91 (95% CI 1.74
to 4.87, P < 0.0001). There was significant heterogeneity (which
disappeared when excluding L - LEAD 4 Zinman 2009).
After treatment with 1.8 mg liraglutide, 42% to 54% reached an
HbA1c value of 7% or less. The overall risk ratio for liraglutide 1.8
mg compared with placebo was 3.25 (95% CI 1.97 to 5.36, P <
0.00001), with significant heterogeneity (which disappearedwhen
excluding L - LEAD 4 Zinman 2009). There was no significant
difference between 1.2 and 1.8 mg liraglutide (see Analysis 9.2).
Both L - LEAD 5 Russell-J 2009 and L - LEAD 2 Nauck 2009
reported the lowestHbA1c values with liraglutide at week 12, with
a slight increase towards the end of the studies. However, in the L
- LEAD 4 Zinman 2009 study, HbA1c remained steady until the
end of the study after the lowest level was observed at week 12.
In L - LEAD 1 Marre 2009, the largest decrease in HbA1c with
liraglutide was seen in participants previously on monotherapy
compared with those on previous combination therapy.
Hypoglycaemia
In the study by L - Kaku 2010, minor hypoglycaemia was defined
as an episode that could be self-treated while those requiring third-
party assistance was considered as major. It was reported that the
rate of minor hypoglycaemic episodes (events/patient/year) was
higher in the liraglutide groups (2.17 in the 0.6 mg group, 1.96 in
the 0.9mg group) than in the placebo group (1.01). All three trials
of 1.2 mg liraglutide reported hypoglycaemia. L - LEAD 1 Marre
2009 and L - LEAD4Zinman 2009 definedminor hypoglycaemia
as an episode that could be self-treated while those needing third
party assistance ormedical interventionswere categorised asmajor.
In L - LEAD 1 Marre 2009, the proportion of participants with
minor hypoglycaemia was significantly higher (P = 0.048) with
liraglutide 1.2 mg compared with placebo whereas in L - LEAD
4 Zinman 2009 and L - LEAD 2 Nauck 2009 no significant
difference was seen. Overall, there was no significant difference in
minor hypoglycaemia between 1.2mg liraglutide and placebo (risk
ratio 1.54, 95% CI 0.54 to 4.42, P = 0.42), with no significant
heterogeneity. Rates of hypoglycaemia were between 0.8% and
9.2% in the liraglutide groups and between 2.6% and 5.1% in the
placebo groups.
There were no reports of major hypoglycaemic episodes in partici-
pants on either liraglutide 1.2 mg or placebo in any of the studies.
Of the four studies reporting hypoglycaemia with 1.8 mg liraglu-
tide, L - LEAD 1 Marre 2009 found that the incidence of minor
hypoglycaemia was higher with liraglutide 1.8 mg compared with
placebo (P = 0.0065). Similarly, L - LEAD 4 Zinman 2009 found
that the rate of minor hypoglycaemia was significantly higher with
liraglutide 1.8 mg compared with placebo (P = 0.0004). In L -
LEAD 5 Russell-J 2009, hypoglycaemia was categorised as major
(third party assistance), minor (FPG less than 3.1 mmol/L) and
symptoms only. The rate of hypoglycaemia reported was 0.06, 1.2
and 1.0 events/patient-year (major, minor and symptoms only) in
the 1.8mg liraglutide group and 0, 1.0 and 0.5 events/patient-year
in the placebo group. The proportion of participants with hypo-
glycaemia was higher with 1.8 mg liraglutide compared to placebo
(27.4% versus 16.7%). There was no significant difference in mi-
nor hypoglycaemia between 1.8 mg liraglutide and placebo in L
- LEAD 2 Nauck 2009. In the other trials, the rate of hypogly-
caemia was about between 2.5% and 8% with 1.8 mg liraglutide.
Overall, there was significantly more hypoglycaemia with 1.8 mg
liraglutide, risk ratio 1.66 (95% CI 1.15 to 2.40, P = 0.007), with
no significant heterogeneity.
In two of the trials, no cases of major hypoglycaemia were seen (L
- LEAD 2 Nauck 2009; L - LEAD 4 Zinman 2009). In L - LEAD
1 Marre 2009, one major hypoglycaemic episode was reported
in a participant on liraglutide 1.8 mg and glimepiride; this was
considered to be related to glimepiride and not the study drug and
accordingly the dose of glimepiride was reduced. In L - LEAD 5
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Russell-J 2009, five patients had major hypoglycaemic events in
the 1.8mg liraglutide group with only one requiring somemedical
assistance.
Weight change
In L - Kaku 2010, there was no change in mean body weight
with both 0.6 and 0.9 mg dose of liraglutide while a reduction of
1.12 kg in weight was seen with placebo. Two of the three trials
showed significantly more weight loss with 1.2mg liraglutide than
with placebo (L - LEAD 2 Nauck 2009; L - LEAD 4 Zinman
2009), while one showed no significant difference (L - LEAD 1
Marre 2009). No significant weight changes in either the 1.2 mg
liraglutide group of the placebo group were seen in the study using
only sulphonylurea as concomitant antihyperglycaemic therapy
(+0.3 kg SD 3.02 with 1.2 mg liraglutide, -0.1 kg SD 2.88 with
placebo)(L - LEAD 1 Marre 2009). In the other two studies (L
- LEAD 2 Nauck 2009; L - LEAD 4 Zinman 2009) the weight
loss in the 1.2 mg liraglutide groups was between 1.1 and 1.6 kg
greater than in the placebo groups (P < 0.00001 for the combined
effect in the two studies). Weight loss in the 1.2 mg liraglutide
groups was between 1.0 and 2.6 kg, weight change in the placebo
groups ranged between -1.5 and +0.6 kg.
In three of the four studies, the weight reduction with 1.8 mg
liraglutide was significantly greater than with placebo (L - LEAD
2 Nauck 2009; L - LEAD 4 Zinman 2009; L - LEAD 5 Russell-J
2009). There was no difference between the groups in L - LEAD
1Marre 2009. Overall, the mean difference for 1.8 mg liraglutide
versus placebo was -1.33 (95% CI -2.38 to -0.27, P = 0.01) with
significant heterogeneity (P < 0.0001) (probably due to different
co-interventions having different effects on weight). Weight loss
in the 1.8 mg liraglutide groups was between -0.2 and -2.8 kg.
Overall, weight loss with 1.8 mg liraglutide was 0.48 kg (95% CI
0.08 to 0.88) greater than with 1.2 mg liraglutide (P = 0.02), see
Analysis 9.3.
Adverse events
In L - Kaku 2010, the total numbers of adverse events were sim-
ilar across all groups (76.1% in 0.6 mg group, 78.4% in 0.9 mg
group and 75% in placebo). It was reported that the most com-
mon adverse events in the trial were nasopharyngitis, diarrhoea
and constipation. The proportions of participants complaining of
gastrointestinal adverse events in the first four weeks were higher
in the liraglutide groups than the placebo group. The numbers of
participants withdrawing from the study were similar across the
groups (n = 3 in 0.6 mg group, n = 2 in 0.9 mg group and n = 2
in placebo group). Treatment-related serious adverse events were
seen in eight participants (3 in 0.6 mg group, 2 in 0.9 mg group
and 3 in placebo group) but no deaths occurred in the trial.
In all four trials (L - LEAD 1 Marre 2009; L - LEAD 2 Nauck
2009; L - LEAD 4 Zinman 2009; L - LEAD 5 Russell-J 2009),
the most frequently reported adverse events with liraglutide were
gastrointestinal events. Nausea occurred in between 10.5% and
29% of participants in the 1.2 mg liraglutide groups and in be-
tween 14% and 40% in the 1.8 mg liraglutide groups; vomiting
in between 4.5% and 7% with 1.2 mg and between 5% and 17%
with 1.8 mg liraglutide; and diarrhoea in around 8% with 1.2 mg
and between 10% and 15% with 1.8 mg liraglutide. The corre-
sponding rates in the placebo groups were between around 2% to
4% nausea, 1% to 3.5% vomiting, and 4% to 5.3% diarrhoea.
Withdrawals due to adverse events were between 5% and 10%
with 1.2 mg liraglutide, between 4% and 15% with 1.8 mg li-
raglutide and between 1% and 5% in the placebo groups.
Most of the withdrawals were due to gastrointestinal events and
occurred during the first four to eight weeks of the studies. Serious
adverse events occurred in around 4% of participants with 1.2
mg liraglutide, between 4% and 6% of participants on 1.8 mg
liraglutide, and between 3% and 7% of participants on placebo.
Only one trial reported a case of pancreatitis, in L - LEAD2Nauck
2009, one of the participants on 1.2 mg liraglutide withdrew from
the study because of acute pancreatitis. There were two deaths
reported in the study considered unrelated to the study drug.There
were no deaths in L - LEAD 1Marre 2009 or L - LEAD 4Zinman
2009.
None of the studies found any significant differences between
treatment groups for physical examination findings, laboratory
analyses, ECG, ophthalmology and other adverse events. Between
10% and 13% of participants were positive for anti-liraglutide an-
tibodies (nodifference reported between1.2 and1.8mg), however,
this had no effect on the HbA1c response or on adverse events.
Blood pressure
The Japanese study (L - Kaku 2010) reported that neither sys-
tolic and diastolic blood pressure changed in any group (no data
given). Only one trial (L - LEAD 4 Zinman 2009) reported sig-
nificantly more reduction in systolic blood pressure with 1.2 or
1.8 mg liraglutide compared to placebo weighted mean difference
to placebo between -4.5 and -5.6 mm Hg), whereas there was no
significant difference between either 1.2 or 1.8 mg liraglutide and
placebo in systolic blood pressure in L - LEAD 2Nauck 2009, and
a significant difference between 1.8 mg liraglutide and placebo
in L - LEAD 5 Russell-J 2009. Overall, there was no significant
difference in systolic blood pressure for 1.2 mg liraglutide versus
placebo (mean difference -3.26 mmHg (95% CI -7.71 to 1.20, P
= 0.15, significant heterogeneity, possibly due to different co-in-
terventions)), but the results for 1.8 mg liraglutide versus placebo
were marginally significant (-2.42 mmHg, 95% CI -4.90 to 0.05,
P = 0.05, no significant heterogeneity). In L - LEAD 1 Marre
2009, there was a reduction in both systolic and diastolic blood
pressure with 1.2 and 1.8 mg liraglutide and with placebo but
the difference between the groups was not significant (not enough
details given to include the data in the statistical summary). There
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was no reduction in diastolic blood pressure in any of the groups.
There was no significant difference in systolic blood pressure be-
tween 1.2 and 1.8 mg liraglutide, see Analysis 9.4.
Fasting plasma glucose
In L - Kaku 2010, both 0.6 mg (-2.3 mmol/L) and 0.9 mg (-2.28
mmol/L) liraglutide significantly reduced fasting plasma glucose
levels compared with placebo (-0.64mmol/L). Fasting plasma glu-
cose was significantly reduced with liraglutide 1.2 mg or 1.8 mg
compared to placebo. The overall mean difference was -2.13 (95%
CI -2.59 to -1.68, P < 0.0001, no significant heterogeneity) for 1.2
mg liraglutide versus placebo, and -2.21 (95% CI -2.49 to -1.93,
P < 0.00001, no significant heterogeneity) for 1.8 mg liraglutide
versus placebo. Changes in fasting plasma glucose ranged between
-1.6 and -2.2 mmol/L with 1.2 mg liraglutide, between -1.55 and
-2.4 mmol/L with 1.8 mg liraglutide and between -0.4 and +1.01
mmol/L with placebo.
All studies reported that fasting plasma glucose values decreased
within two weeks of commencing liraglutide and remained rela-
tively stable thereafter.
Post-prandial glucose
L - Kaku 2010 found that both doses of liraglutide (0.6 mg and
0.9 mg) led to significant improvement in the self-monitored 7-
point plasma glucose profiles compared to placebo (P < 0.0001).
In L - LEAD 1 Marre 2009, L - LEAD 2 Nauck 2009, L - LEAD
4 Zinman 2009 post-prandial glucose values were significantly
reduced with 1.2 mg liraglutide versus placebo (reductions by 2.3
to 2.6 mmol/L with liraglutide compared to reductions of 0.4 to
0.8 mmol/L with placebo). Similarly, reductions in post-prandial
glucose values with 1.8mg liraglutide were significantly larger than
with placebo (reductions by 1.8 to 2.7 mmol/L with liraglutide
compared to reductions of 0.30 to 0.8mmol/Lwith placebo). In L
- LEAD 4 Zinman 2009, the post-prandial increment (post-meal
minus pre-meal value) was significantly reduced over breakfast in
both liraglutide (1.2 and 1.8 mg) groups, but not at the other
meals. L - LEAD 5 Russell-J 2009 reported that significantly more
participants on 1.8 mg liraglutide achieved the ADA target for
post-prandial glucose (≤ 10 mmol/L) participants on placebo.
Lipid profiles
In L - Kaku 2010, it was reported that no significant changes
occurred in any of the parameters of the lipid profile with any
treatment. No data were reported.
Details of effects on lipid profiles were also reported by L - LEAD
4 Zinman 2009. For both liraglutide groups, there was a decrease
in free fatty acids (-0.03 mmol/L SE 0.02 to -0.05 mmol/L SE
0.02), whereas levels were increased with placebo (+0.02 mmol/
L SE 0.02, P < 0.05). There was significantly more reduction in
triglycerides and LDL cholesterol with 1.2 mg liraglutide than
with placebo (triglycerides: -0.38 mmol/L SE 0.10 versus -0.13
mmol/L SE 0.11 with placebo, P < 0.05; LDL cholesterol: -0.28
mmol/L SE 0.07 versus -0.10 mmol/L SE 0.07 with placebo, P
< 0.05). No significant difference to placebo was seen in the 1.8
mg liraglutide group (reduction in triglycerides: -0.32 mmol/L SE
0.10; LDL cholesterol: -0.23 mmol/L SE 0.07).
Beta-cell function
L - LEAD 1 Marre 2009, L - LEAD 2 Nauck 2009, L - LEAD
4 Zinman 2009 all reported HOMA-B and proinsulin-to-insulin
ratio for 1.2 and 1.8 mg liraglutide versus placebo. All studies
showed a significant improvement in HOMA-B with 1.2 mg li-
raglutide compared to placebo (improvement between +23% and
+28% compared to between -4% and +6% with placebo). In L
- LEAD 1 Marre 2009, HOMA-B improvement with 1.8 mg li-
raglutide was only marginal compared to placebo (P = 0.051), but
the difference was significant in the other two studies. The im-
provement in HOMA-B all three studies was between +27% and
+35%.
All three studies showed a significant improvement in proinsulin-
to-insulin ratio both with 1.2 and 1.8 mg liraglutide compared
to placebo. Changes were between -0.03 and -0.12 with 1.2 mg
liraglutide, between -0.09 and -0.12 with 1.8 mg liraglutide, and
between +0.02 and +0.1 with placebo. There was a significant
improvement in proinsulin-to-C-peptide ratio with 1.2 and 1.8
mg liraglutide in L - LEAD 4 Zinman 2009, and with 1.8 mg
liraglutide in L - LEAD 5 Russell-J 2009.
Liraglutide versus insulin (glargine)
Results for liraglutide 1.8 mg versus insulin glargine are shown in
Data and analyses, 10.1 to 10.9. This comparison was only carried
out by L - LEAD 5 Russell-J 2009.
HbA1c
HbA1c was significantly more reduced with 1.8 mg liraglutide
thanwith insulin glargine (mean difference -0.24%, 95%CI -0.39
to -0.08, P = 0.0015 according to the original analysis). HbA1c
was reduced by 1.33% with liraglutide and by 1.09% with insulin
glargine.
Similarly, the proportion of participants achieving the target
HbA1c level of less than 7% was higher with liraglutide compared
with insulin glargine (53.1% versus 45.8%, P = 0.0139).
Hypoglycaemia
The proportion of participants with minor hypoglycaemia was
similar with liraglutide and insulin glargine.Minor hypoglycaemia
was seen in 27% of patients in the liraglutide group and 29% in
the glargine group. Five patients had major hypoglycaemic events
in the liraglutide group with only one requiringmedical assistance.
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There were no reports of major hypoglycaemic episodes in the
glargine group.
Weight change
There was significant weight reduction in the liraglutide group (-
1.8 kg SE 0.33) while weight increased the insulin glargine group
(+1.6 kg SE 0.33). The mean treatment difference was -3.43 kg
(95% CI -4.00 to -2.86, P < 0.0001, according to the original
analysis).
Adverse events
The most frequently reported adverse events were nausea, vomit-
ing and diarrhoea, which were more frequent with liraglutide than
with insulin glargine (see above). The incidence of gastrointesti-
nal events in the glargine group was similar to that in the placebo
group (or even somewhat lower). No other adverse events were
seen with glargine (for liraglutide results see above).
Blood pressure
There was a significant reduction of systolic blood pressure with
liraglutide (-4.0mmHg) whereas an increase was seen with insulin
glargine (+0.54mmHg) (treatment difference -2.53mmHg (95%
CI -6.82 to -2.20, P = 0.0001, according to the original analysis).
There was no significant effect on diastolic blood pressure in any
of the comparison groups.
Fasting plasma glucose
There was no significant difference in fasting plasma glucose be-
tween liraglutide and insulin glargine. Fasting plasma glucose was
reduced by 1.55 mmol/L in the liraglutide group and by 1.79
mmol/L in the glargine group.
Post-prandial glucose
There was no significant difference in post-prandial glucose be-
tween liraglutide and insulin glargine. Post-prandial glucose was
reduced by 1.8 mmol/L in the liraglutide group and by 1.6 mmol/
L in the glargine group.
Beta-cell function
The proinsulin-to-insulin ratio was significantly improved with
liraglutide compared to insulin glargine (treatment difference -
0.00366, 95% CI -0.0057 to -0.00136, P = 0.0019).
Liraglutide versus thiazolidinedione (rosiglitazone)
Results for liraglutide 1.2 mg versus rosiglitazone are shown in
Data and analyses, 11.1 to 11.11. Results for liraglutide 1.8 mg
versus rosiglitazone are shown inData and analyses, 12.1 to 12.11.
Only oneRCTcompared liraglutide and rosiglitazone, L - LEAD1
Marre 2009 (1.2 and 1.8 mg liraglutide). The dose of rosiglitazone
was 4 mg.
HbA1c
In L - LEAD 1 Marre 2009, both liraglutide and rosiglitazone
reduced HbA1c levels, but the reduction was significantly greater
with liraglutide (P < 0.0001). HbA1c reduction was by 1.08% to
1.13% with liraglutide and by 0.44% with rosiglitazone.
HbA1c equal to or less than 7%
The proportion of participants achieving ADA HbA1c target lev-
els was significantly greater with liraglutide compared with rosigli-
tazone (P ≤ 0.0003). Between 35% and 42% reached an HbA1c
level of less than 7% with liraglutide, while only 22% on rosigli-
tazone did (L - LEAD 1 Marre 2009).
Hypoglycaemia
The incidence of minor hypoglycaemia was significantly higher
with liraglutide (8.1% to 9.2%, 0.51 events/patient-year)
than with rosiglitazone (4.3%, 0.12 events/patient-year) (P =
0.048).There was one report of major hypoglycaemia in a partic-
ipant on 1.8 mg liraglutide and glimepiride. This was considered
to be related to glimepiride and its dose was reduced.
Weight change
There was a significant difference in weight change in favour of
both liraglutide groups compared to rosiglitazone (P < 0.0001).
Participants on liraglutide had weight changes of between -0.2
to +0.3 kg, while weight increased by 2.1 kg in the rosiglitazone
group (L - LEAD 1 Marre 2009).
Adverse events
The most frequently reported adverse event was gastrointestinal
disorders that included nausea, vomiting and diarrhoea, which
was more frequent with liraglutide than with rosiglitazone (see
above). No other adverse events were seen with rosiglitazone (for
liraglutide results see above) (L - LEAD 1 Marre 2009).
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Fasting plasma glucose
The participants on liraglutide had significantly greater reductions
in fasting plasma glucose levels compared to those on rosiglitazone
(-1.6mmol/L for liraglutide versus -0.88mmol/L for rosiglitazone,
P ≤ 0.006). Similarly, at the end of study the proportions of
participants achieving ADA target fasting plasma glucose values
of between 5.0 mmol/L and 7.2 mmol/L were greater with both
doses of liraglutide compared with rosiglitazone (37% to 38%
with liraglutide versus 26% with rosiglitazone, P ≤ 0.01).
Post-prandial glucose
The reduction in mean post-prandial glucose values was signifi-
cantly greater with both doses of liraglutide compared to rosigli-
tazone (-2.5 to -2.7 mmol/L with liraglutide versus -1.8 mmol/L
with rosiglitazone, P < 0.05).
Beta-cell function
The improvement in mean HOMA-B was significantly greater
with both doses of liraglutide compared with rosiglitazone (P <
0.05). Similarly, the reduction in the proinsulin-to-insulin ratio
was also greater with liraglutide compared to rosiglitazone (P ≤
0.02).
Liraglutide versus DPP-4 inhibitors (sitagliptin)
Results for liraglutide 1.2 mg versus sitagliptin are shown in Data
and analyses, 13.1 to 13.11. Results for liraglutide 1.8 mg versus
sitagliptin are shown in Data and analyses, 14.1 to 14.11. The
comparison between liraglutide and sitagliptin was carried out by
L - Pratley 2010. The dose of sitagliptin was 100 mg daily.
HbA1c
In L - Pratley 2010, the reduction in HbA1c with 1.8 mg li-
raglutide was higher than with 1.2 mg liraglutide (-1.5% versus
-1.24%) or sitagliptin 100 mg (-1.5% versus -0.9%). The treat-
ment difference between liraglutide 1.8 mg versus sitagliptin was
-0.6% (95% CI -0.78 to -0.42, P < 0.00001) while the difference
between liraglutide 1.2 mg versus sitagliptin was -0.34% (95% CI
-0.53 to -0.15, P = 0.0006).
HbA1c equal to or less than 7%
L - Pratley 2010 found that the proportion of participants achiev-
ing this target was significantly higher with liraglutide than with
sitagliptin. Fifty six percent of participants taking liraglutide 1.2
mg, 44%taking liraglutide 1.8mg and22%on sitagliptin achieved
this target HbA1c level.
Hypoglycaemia
In L - Pratley 2010, the proportion of participants experiencing
minor hypoglycaemiawas similar in all groups(i.e. 5%). It reported
that one participant on 1.2 mg liraglutide had a major hypogly-
caemic episode, but none on the 1.8 mg dose or on sitagliptin.
Weight change
The weight change with liraglutide was significantly greater com-
pared to sitagliptin (P < 0.00001). The mean weight loss with li-
raglutide was between -2.86 and -3.38 kg, while only a reduction
of 0.96 kg occurred with sitagliptin (L - Pratley 2010).
Adverse events
In L - Pratley 2010, the most frequently reported treatment-emer-
gent adverse events were gastrointestinal related symptoms, that
were more frequent with liraglutide than with sitagliptin. Out of
all gastrointestinal symptoms, nausea was themost common how-
ever, it was transient in nature.The incidence of infections was
not different between liraglutide and sitagliptin. The occurrence
of serious adverse events were similar between the groups and were
thought not to be related to the study drug. Two deaths occurred
(one with pancreatic carcinoma taking 1.8 mg liraglutide and one
with fatal cardiac arrest taking sitagliptin), both regarded not to
be related to the study drug. There were no cases of pancreatitis.
No report on anti-liraglutide antibodies.
Blood pressure
The effect on systolic blood pressure was not different amongst
the groups. The treatment difference between liraglutide 1.2 mg
and sitagliptin was 0.39 mmHg (95% CI -2.08 to 2.86, P = 0.76)
while the difference between liraglutide 1.8 mg and sitagliptin was
0.22 mm Hg (95% CI -2.25 to 2.69, P = 0.86). The effect on
diastolic blood pressure was significantly greater with sitagliptin
compared with liraglutide 1.8 mg (-1.78 versus +0.07 mm Hg)
but not compared with liraglutide 1.2 mg (-1.78 versus -0.71 mm
Hg).
Fasting plasma glucose
Reduction in fasting plasma glucose was significantly greater with
liraglutide than with sitagliptin. The mean treatment difference
between liraglutide 1.2mg and sitagliptinwas -1.04mmol/L (95%
CI -1.46 to -0.62, P < 0.00001) and the difference between li-
raglutide 1.8 mg versus sitagliptin was -1.31 mmol/L (95% CI -
1.73 to -0.89, P < 0.00001).
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Postprandial glucose
It was reported that post-prandial glucose recorded during the
study was highly variable, suggesting that most glucose values were
not post-prandial. The authors also added that meal patterns i.e.
content and time of day were different across different countries.
Beta cell function
In L - Pratley 2010, both doses of liraglutide led to signifi-
cant improvements in HOMA of β-cell function compared with
sitagliptin. Similarly liraglutide also led to significant improve-
ments in C-peptide concentration, and proinsulin-to-insulin ratio
compared to sitagliptin. The improvement in HOMA index for
insulin concentration was not significantly different between the
group. Liraglutide 1.8 mg and sitagliptin led to improvement in
fasting insulin level but the difference between the two groups was
not significant.
Liraglutide versus sulphonylurea (glimepiride)
Results for liraglutide 1.2 and 1.8 mg versus sulphonylurea are
shown in Data and analyses, 16.1 to 16.13 and 17.1 to 17.13
respectively. This comparison was carried out by L - LEAD 2
Nauck 2009 (versus 1.2 and 1.8mg liraglutide) and L - Yang 2010
(versus 1.2 and 1.8 mg liraglutide). The dose of glimepiride was
4 mg daily.
HbA1c
There was no significant difference between 1.2 or 1.8 mg liraglu-
tide and glimepiride. Reductions in HbA1c level with liraglutide
ranged between -0.97% and -1.45% and between -0.98% and -
1.39% with glimepiride.
There was also no significant difference between liraglutide and
glimepiride in the proportion of participants reaching an HbA1c
of 7% or less (range 35% to 45% with liraglutide and 36% to
44% with glimepiride).
Hypoglycaemia
The incidence of hypoglycaemia was significantly lower with li-
raglutide compared with glimepiride (0% to 2% with liraglutide
versus 17% to 19% with glimepiride. The mean treatment differ-
ence between liraglutide 1.2 mg and glimepiride was 0.06 (95%
CI 0.00 to 1.72, P = 0.10 with significant heterogeneity, I2 statistic
= 82%). This may have been because none of the participants in
the study by L - Yang 2010 taking liraglutide 1.2 mg had minor
hypoglycaemia. The mean treatment difference between liraglu-
tide 1.8 mg and glimepiride was 0.13, 95% CI 0.07 to 0.25, P
< 0.00001. No cases of major hypoglycaemia were reported with
either treatment.
Weight change
Participants of the liraglutide groups lost between 2.3 and 2.8 kg,
while participants in the glimepiride group gained between 0.08
and 1 kg. It was reported that nauseawas not responsible for weight
loss in these participants.
Adverse events
The most frequently reported adverse event was gastrointestinal
disorders that included nausea, vomiting and diarrhoea, which
was more frequent with liraglutide than with rosiglitazone (40%
to 44% with liraglutide and 17% with glimepiride reported in L
- LEAD 2 Nauck 2009 whereas no data given by L - Yang 2010).
It was also reported that the gastrointestinal adverse events with
liraglutide was transient and occurred more frequently in the first
four weeks and the incidence decreased overtime. The occurrence
of serious adverse events were similar between the groups and they
were considered not related to the treatment drugs. Withdrawals
due to adverse events ranged between 9.4% and 12.9% with li-
raglutide and 1.3% to 3% with glimepiride.
In L - Yang 2010, anti-liraglutide antibodies did not have any
effect on safety or HbA1c response.
Blood pressure
There was a significant difference in favour of both 1.2 and 1.8mg
liraglutide compared to glimepiride in terms of change in systolic
blood pressure. In L - LEAD2Nauck 2009, systolic blood pressure
was reduced by between 2.3 and 2.8 mm Hg in the liraglutide
groups and increased by 0.4 mm Hg in the glimepiride group (P
= 0.01). Similarly, in L - Yang 2010, the systolic blood pressure
decreased by more than 3 mm Hg in the liraglutide groups while
only decreased by 0.91 mm Hg in the glimepiride group. In L
- LEAD 2 Nauck 2009, diastolic blood pressure did not change
from baseline in any of the intervention groups while in L - Yang
2010 it slightly decreased in all treatment groups
Fasting plasma glucose
There was no significant difference in decrease in fasting plasma
glucose from baseline between liraglutide and glimepiride groups
(-1.6 to -2.12 mmol/L with liraglutide and -1.3 to -2.18 mmol/L
with glimepiride).
Post-prandial glucose
There was a reduction in post-prandial glucose level with all treat-
ment groups (-2.3 to -3.51 mmol/L with liraglutide, -2.5 to -
2.6 mmol/L with glimepiride) but the difference was significant
only between liraglutide 1.8 mg and glimepiride (-3.51 versus -
2.6 mmol/L, P < 0.0001).
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Beta-cell function
L - LEAD 2 Nauck 2009 reported that there was a significant im-
provement inmeanHOMA-B value with all treatment groups and
the difference was not significant between the treatment groups (+
23% to + 28% with liraglutide, + 25% with glimepiride). Similar
reductions in the proinsulin-to-insulin ratio were observed with
liraglutide or glimepiride.
L - Yang 2010 also reported improvements in mean HOMA-B
value with all treatment groups but the difference between the
groups was not significant. Similarly all treatment groups led to
reduction in the proinsulin-to-insulin ratio but the difference be-
tween the groups was not significant.
Lixisenatide
Lixisenatide versus placebo
Results for lixisenatide versus placebo are shown in Data and
analyses, 15.1 to 15.8. The comparison was carried out by only
one study (Lixi - Ratner 2010).
HbA1c
A dose-dependent reduction in HbA1c level was observed with
both once daily and twice daily regimen. Reductions in HbA1c
level ranged between 0.47% and 0.87% with lixisenatide com-
pared to reduction of 0.18% with placebo.
HbA1c equal to or less than 7%
The proportion of participants achieving the target HbA1c level
of 7% or less were significantly (P < 0.05) higher with both once
daily (47% to 69%) and twice daily (51% to 77%) lixisenatide
compared with placebo (32%).
Hypoglycaemia
There was no dose-dependent relationship with symptomatic hy-
poglycaemic episodes. The occurrence of hypoglycaemic episode
ranged between 1 and 3 events per group. There were no cases of
severe hypoglycaemia.
Weight change
There was a dose dependent reduction in weight with both once
daily and twice daily regimen of lixisenatide. Reduction in weight
with the once daily lixisenatide ranged between -1.94 and -3.47 kg
while the reduction with twice daily lixisenatide ranged between -
2.10 and -3.89 kg. Participants in the placebo group lost 1.94 kg
at end of the study.
Adverse events
Withdrawals due to treatment-related adverse events ranged from
1.8%to11.1% in the once daily lixisenatide group and from0%to
14.8% in the twice daily group. Only 1.8% of participants taking
placebo withdrew from the study. The incidence of adverse events
was dose-dependent.Most frequently reported adverse events were
gastrointestinal, mainly nausea. It was mild to moderate in inten-
sity and occurred in most cases during the first five weeks of the
study.None of the participants had pancreatitis. Eight participants
in the lixisenatide group and three in the placebo group experience
serious adverse events. One participant taking lixisenatide 30 µg
once daily experienced few seconds of loss of consciousness thus
withdrew from the study. Another patient taking lixisenatide 10
µg once daily discontinued from the study after experiencing 30
minutes of pruritis all over the body 10 min after the injection
during 3rd week of treatment and a second episode of swollen
lips/tongue and difficulty in breathing within 10 min of injection.
The participant improved after taking oral antihistamine. There
were two more cases of urticaria with lixisenatide and three with
placebo. The changes in laboratory tests and ECG were not clini-
cally significant (data not given). At the end of study, the propor-
tions of participants with anti-lixisenatide antibody ranged from
43.1% in the 10 µg once daily group to 71.2% in the 20 µg twice
daily group.
Blood pressure
Changes in systolic blood pressure ranged from -2 to -9 mm Hg
in the lixisenatide group while it fell by -3 mm Hg in the placebo
group. The reduction in diastolic blood pressure with lixisenatide
group ranged from -2 to -4 mm Hg while it reduced by -2 mm
Hg in the placebo group. In most cases, changes in blood pressure
were seen as early as week one.
Fasting plasma glucose
Adose dependent reduction in fasting plasma glucosewas observed
with both once daily and twice daily regimen of lixisenatide. The
reduction with the once daily regimen ranged from -0.62 to -1.02
mmol/L and ranged from -0.19 to -1.42 mmol/L with the twice
daily regimen. Placebo led to reduction of 0.21 mmol/L.
Post-prandial glucose
Similarly a dose-dependent reductions in daily averaged seven-
point self monitored blood glucose and 2 hour post-prandial
plasma glucose concentration occurred with both once daily and
twice daily lixisenatide.
LY2189265
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LY2189265 versus placebo
Results for LY2189265 versus placebo are shown in Data and
analyses, 19.1 to 19.9. The comparison between LY2189265 ver-
sus placebo was reported by LY2189265 -Umpierrez 2011.
HbA1c
The reduction in HbA1c level with LY2189265 was significantly
higher compared to the reduction with placebo at all time points.
HbA1c decreased by 1.38% in the 0.5/1.0 group, by 1.32% in the
1.0/1.0 group and by 1.59% in the 1.0/2.0 group (no data given
for placebo). There was no significant difference between the LY
groups.
HbA1c equal to or less than 7%
The proportions of participants achieving the target HbA1c level
across all treatment groups ranged from 49% to 54%.
Hypoglycaemia
The incidence of hypoglycaemia was significantly higher in all the
LY groups compared to the placebo group. The numbers of par-
ticipants experiencing hypoglycaemic episodes with all LY groups
were significantly (P <0.05) higher at 8weeks compared toplacebo
but the incidence decreased over time. The difference at end of
the study between all LY groups and placebo was not significant
(P ≥ 0.17). There were no cases of severe hypoglycaemia.
Weight change
There was a significant weight reduction in all the LY groups com-
pared to placebo group. Reduction in weight with LY ranged from
-1.44 to -2.55 kg with the highest reduction occurring in the LY
1.0/2.0 group. With placebo, weight decreased only by 0.12 kg.
Weight reduction was independent of nausea.
Adverse events
The most commonly reported treatment-related adverse events
were gastrointestinal and these events occurred more frequently
in the highest LY dose. The occurrence of nausea, diarrhoea and
abdominal distension was higher than other adverse events. The
proportions of participants experiencing adverse events possibly
related to the study drug were 30.8% to 41.5% for the LY groups
and 22.7% for placebo. Participants discontinuing the study drug
because of adverse events was comparatively greater in the LY
groups compared to placebo (6.1% to 6.2% versus 1.5%).
Seven participants experienced serious adverse events (1 in placebo
group, 3 in LY 0.5/1.0 group, 2 in LY 1.0/1.0 and 1 in LY 1.0/2.0)
and the investigators considered three (hallucination, cryptogenic
organising pneumonia and pancreatitis) to be related to the study
drug. Two participants had pancreatitis, both in the LY 0.5/1.0
group. First case of pancreatitis was reported at week 16 and the
second after week 11. There were no deaths during the study.
Blood pressure
There was reduction in both systolic (-3.5mmHg) and diastolic (-
2.3 mmHg) blood pressure with placebo. All LY groups had dose-
dependent reductions in systolic blood pressure, ranging from -
0.6 to -3.0 mm Hg, There was no reduction in diastolic blood
pressure in any LY group.
Fasting plasma glucose
It was observed that the reduction in fasting plasma glucose level
was significantly greater in the LY groups than in the placebo
group. Reduction with LY ranged from -2.05 to -2.65 mmol/L
while it fell by 0.49 mmol/L in the placebo group.
Beta-cell function
There was a significant improvement in HOMA2-%B in all the
LY groups compared to placebo group. The improvement ranged
from 32.9% to 45.6% in the LY groups while it increased by 1%
in the placebo group. There was no significant change in any LY
group for HOMA2-%S or HOMA2-%IR.
Taspoglutide
Taspoglutide versus placebo
Results for taspoglutide are shown in Data and analyses, 18.1 to
18.16. The comparison of taspoglutide against placebowas carried
out by two trials T - Nauck 2009 and T- Ratner 2010.
HbA1c
T - Nauck 2009 found a significant reduction in the level of
HbA1c in participants on taspoglutide compared to placebo (P
< 0.0001). The reduction was similar in all taspoglutide groups
(10 mg weekly -1.2%; 20 mg weekly -1.2% and 20 mg every
two weeks -1.0%). The reduction in HbA1c was comparatively
larger in participants with higher baseline HbA1c levels (equal to
or greater than 8.0%). Similarly T- Ratner 2010 also found a sig-
nificant reduction in HbA1c level taking taspoglutide compared
to placebo. The titration of the taspoglutide dose to higher dose
did not lead to increased reduction in HbA1c levels (-1.2% in 20/
20 once weekly group; -0.9% in 20/30 once weekly group and -
1.2% in 20/40 once weekly group).
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HbA1c equal to or less than 7%
T - Nauck 2009 found a significant difference in the proportion
of participants achieving target HbA1c level of less than 7% be-
tween intervention groups, with 79%, 81%, and 63% of partici-
pants achieving this target with 10 mg weekly, 20 mg weekly and
20 mg every two weeks taspoglutide, respectively, and 17% with
placebo (P < 0.0001 versus placebo). Similarly, the proportion of
participants achieving the target HbA1c level was higher with tas-
poglutide than with placebo (72% in the 20/20 mg once weekly
group, 53% in the 20/30 mg once weekly group, 70% in the 20/
40 mg once weekly group and 19% in the placebo group).
Hypoglycaemia
InT -Nauck2009, nodefinitionof hypoglycaemiawas given. Also
no data were reported for the separate comparison groups however
it was reported that 6 patients had 7 hypoglycaemic events, 2 of
which were asymptomatic. In addition, it was also reported that
there were no cases of severe hypoglycaemia in the taspoglutide
group.
No definition of hypoglycaemia was given in T- Ratner 2010. In-
cidence of hypoglycaemia was comparatively similarly between all
the treatment groups. There were no cases of severe hypoglycaemia
during the study.
Weight change
The weight reduction was comparatively greater in the taspog-
lutide groups compared with the placebo group. The reduction
was significant in the 10 mg once weekly taspoglutide group (-
2.1 kg, P = 0.02 versus placebo) and the 20 mg every two weekly
taspoglutide group (-1.9 kg, P = 0.01 versus placebo) compared
to placebo group (-0.8 kg). However there was no significant dif-
ference between the 20 mg once weekly taspoglutide group com-
pared against placebo group. The mean difference was -1.07 kg
(95% CI -2.93 to 0.79, P = 0.26) with significant heterogeneity
(I2 statistic = 88%). The titration of 20 mg weekly dose to 30
mg once weekly led to significant weight reduction compared to
placebo (-3 versus -2 kg, P = 0.03) but not when the dose was
titrated to 40 mg weekly (-2.7 versus -2 kg, P = 0.17) (T- Ratner
2010).
Adverse events
In T - Nauck 2009, the most commonly reported adverse events
were gastrointestinal (nausea, vomiting and diarrhoea) which oc-
curred more frequently in the taspoglutide groups than with
placebo. In the taspoglutide groups, nausea occurred in 24% of
patients on 10 mg weekly, in 52% on 20 mg weekly, and in 41%
on 20 mg every two weeks (versus in 6% on placebo). Vomiting
occurred in 4% of patients on 10 mg taspoglutide weekly, in 22%
on 20 mg weekly, and in 24% on 20 mg every two weeks (versus
in 4% on placebo). Diarrhoea occurred in 10% of patients on 10
mg taspoglutide weekly, in 10% on 20 mg weekly, and in 18%
on 20 mg every two weeks (versus in 8% on placebo). Nausea
was commoner at the beginning of treatment and decreased over
the course of the study. Similarly, in T- Ratner 2010, the most
frequently reported adverse events were gastrointestinal events,
mainly nausea, diarrhoea and dyspepsia. The occurrence of these
eventswas higher in the participants taking taspoglutide than those
on placebo. The overall incidence did not change with titration to
higher dose. It was also reported that nausea was mild to moderate
in intensity and occurred more frequently in the first few weeks.
The occurrence of nausea and vomiting reduced over time, with
the greatest reduction seen in participants who remained on the
20 mg taspoglutide throughout the study. Injection site reactions
were higher with taspoglutide than with placebo.
In T - Nauck 2009, six patients experienced serious adverse events
and that led to discontinuation in two of them in the placebo group
however, the investigators considered this not to be related to the
study drug. There were reports of mild to moderate injection site
reactions which did not lead to any discontinuation. There were
no significant differences in headache and no clinically relevant
abnormalities in ECG, vital signs, and laboratory parameters.
In T- Ratner 2010, two serious adverse events were reported how-
ever both of them were considered not to be related to the study
drug.
Fasting plasma glucose
In T - Nauck 2009, fasting plasma glucose was significantly re-
duced in all considered taspoglutide groups compared to placebo
(P = 0.02 to P < 0.0001). The reduction in the 10 mg weekly and
the 20 mg once weekly groups was -2.5 mmol/L, -1.4 mmol/L
in the 20 mg every two weeks group, and -0.78 mmol/L in the
placebo group. Fasting plasma glucose fluctuated more in once
every two week regimens than in the weekly regimens.
Fasting plasma glucose significantly reduced in all the taspoglutide
groups compared to placebo. The reduction in the 20/20 mg,
20/30 mg and 20/40 taspoglutide group was -2.3 mmol/L, -1.6
mmol/L and -2.2 mmol/L respectively while the reduction in the
placebo group was -2.2 mmol/L.
Post-prandial glucose
The mean percent decrease from baseline in plasma glucose 120
min after a mixed meal was larger in the once weekly taspoglutide
groups (-22% with 10 mg weekly, -18% with 20 mg weekly)
compared to 20 mg once every two weeks (-5.5%) and placebo (-
10.5%). Similarly, the percentage change from baseline in glucose
AUC (area under the curve over 240min) was comparatively larger
in the onceweekly taspoglutide groups (-27.5%with 10mgweekly
and -22.2% with 20 mg weekly) compared to 20 mg once every
two weeks (-9.2%) and placebo (-7.2%).
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Themedian percentage change in plasma insulin levels at 120 min
was +44.4% with 20 mg once weekly taspoglutide group, +28.5%
with 10 mg once weekly, -13% with 20 mg every two weeks and -
15.3% with placebo. This outcome was not reported in T- Ratner
2010.
Lipid profiles
There was a decline in triglyceride levels with taspoglutide that
appeared to be dose-related and there was also some decrease in
total cholesterol levels. None of the other lipid parameters showed
any consistent changes. Lipid profile was not reported in T- Ratner
2010.
Beta-cell function
There were statistically significant decreases in the fasting proin-
sulin-to-insulinmolar ratio in the once weekly taspoglutide groups
(-0.12 with 10 mg once weekly, -0.17 with 20 mg once weekly, P
< 0.01) compared to placebo. Changes with 20 mg taspoglutide
every two weeks (-0.055) and placebo (+0.002) were non-signifi-
cant. This outcome was not reported by T- Ratner 2010.
GLP-1 agonist versus GLP-1 agonist
Results for different GLP-1 agonists or different GLP-1 formula-
tions compared with each other are shown in Data and analyses,
20.1 to 20.16. L - LEAD 6 Buse 2009 compared 1.8 mg once
daily liraglutide with 10 µg exenatide twice daily, E - Blevins 2011
and E - Drucker 2008 compared 10 µg exenatide BID with 2 mg
exenatide once weekly.
HbA1c
In the direct comparison of exenatide with liraglutide (L - LEAD
6 Buse 2009), HbA1c was significantly more reduced with liraglu-
tide (-1.22% versus -0.79%, mean difference 0.33 (95% CI 0.11
to 0.55, P < 0.0001). Similarly, the proportion of participants
that reached the target HbA1c level of 7% or less was significantly
higher with liraglutide (54%) than with exenatide (43%).
When comparing 10 µg exenatide twice daily with 2 mg exenatide
once weekly(E - Blevins 2011, E - Drucker 2008), HbA1c was
significantly more reduced with the weekly regimen. The mean
treatment differencewas 0.55%(95%CI0.26 to 0.84, P = 0.0002)
with slight heterogeneity of 55%. Similarly, the proportion of
participants achieving a target HbA1c level of 7% or less was
higher with once weekly exenatide. The mean difference was 0.65
(95% CI 0.42 to 1.01, P = 0.06) with significant heterogeneity (I
2 statistic = 84%).
Hypoglycaemia
The proportion of participants who hadminor hypoglycaemiawas
significantly higher with the exenatide group than with liraglu-
tide (34% versus 26%, P = 0.0131). Participants on metformin as
background therapy had fewer episodes of minor hypoglycaemia
in both the liraglutide (6%) and the exenatide (11%) group com-
pared to the participants taking sulphonylurea with or without
metformin (33% for liraglutide versus 42% for exenatide). Two
participants in the exenatide group receiving sulphonylurea as con-
comitant medication reported major hypoglycaemic episodes but
no major episodes were reported in the liraglutide group.
There was no significant difference in hypoglycaemia between par-
ticipants on exenatide twice daily or exenatide once a week. It was
reported by E - Drucker 2008 that participants on sulphonylurea
background therapy had more episodes of minor hypoglycaemia
compared to the participants without sulphonylurea background
therapy (with SU: 14.5% with exenatide once weekly, 15.4% with
exenatide twice a day; without SU: 0%with exenatide once weekly,
1.1%with exenatide twice a day). Similarly, E -Blevins 2011 found
that the participants taking concomitant sulphonylureas therapy
experienced hypoglycaemia (four in the twice daily group while
five in the once weekly group). No major hypoglycaemic episodes
were reported in both studies.
Weight change
There was no significant difference in weight loss between liraglu-
tide and exenatide. Weight loss with exenatide was -2.87 kg (SE
0.33) and weight loss with liraglutide was -3.24 kg (SE 0.33). The
proportion of participants who lost weight was similar between
the groups (78% with liraglutide versus 76% with exenatide).
Similarly, there was no significant difference inweight loss between
10 µg exenatide BID and 2 mg exenatide QW.Weight loss ranged
from -1.4 to -3.7 kg in the once weekly group and -2.3 to -3.6 kg in
the twice daily group. In E - Drucker 2008, more than 75% of the
participants lost weight in both groups (76% with exenatide once
weekly versus 79% with exenatide twice daily). Weight decreased
in participants who reported no episodes of nausea throughout
the study (70%) .In E - Blevins 2011, 77% of participants in the
exenatide once weekly group and 63% in the twice daily group
lost weight.
Treatment satisfaction / Quality of life
Overall satisfaction was significantly higher with liraglutide than
with exenatide (Diabetes Treatment satisfaction Questionnaire,
15.18 SE 0.58 with liraglutide, 13.30 SE 0.58 with exenatide, P
= 0.0004).
There was no significant difference in treatment satisfaction be-
tween exenatide once a week compared with exenatide twice daily
(Diabetes Treatment Satisfaction Questionnaire); there was also
no significant difference inweight-related quality of life (IWQOL-
Lite).
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Adverse events
The overall rate of adverse events was slightly higher with exenatide
than with liraglutide (79% versus 75%), but there were more seri-
ous and severe adverse events with liraglutide (serious: 5.1% ver-
sus 2.6%; severe: 7.2% versus 4.7%), only one of these (severe
hypoglycaemia with exenatide) was considered treatment-related.
There were slightly more withdrawals due to adverse events with
exenatide than with liraglutide (13% versus 10%). Themost com-
monly reported adverse event was nausea followed by diarrhoea
and vomiting. The rate of gastrointestinal events was similar be-
tween exenatide and liraglutide groups. However, nausea was re-
ported to be less persistent with liraglutide. There were no reports
of acute pancreatitis in either group. One episode of mild chronic
pancreatitis was reported in the liraglutide group but the investi-
gators confirmed it not to be related to the study drug.
When comparing exenatide 10 µg twice daily with exenatide 2 mg
once weekly, there was slightly more nausea (34.5% to 35% versus
14% to 26.4%) and vomiting (8.9% to 18.6% versus 4.7% to
10.8%) with the twice daily regimen. Nausea was predominantly
mild in intensity and there were no cases of severe nausea with ex-
enatide once a week. Participants with nausea lost somewhat more
weight, but weight also decreased in participants with no nausea.
Injection site pruritus occurred in 5.4% to 17.6% of the once
weekly group and 1.4% to 2.4% of the twice daily group, however
injection site bruising was somewhat more frequent with twice
daily exenatide compared with once weekly exenatide (10.3% ver-
sus 4.7%). The proportion of participants with serious adverse
events was low in both groups (2% to 5.4% for once weekly and
3.4% to 4% for twice daily) and none were considered to be re-
lated to the study drug. Withdrawal because of adverse events was
similar between the groups (5% to 6.1% for once weekly versus
5% to 5.4% for twice daily exenatide).
Blood pressure
Systolic and diastolic blood pressure decreasedwith both exenatide
and liraglutide but there was no significant difference between the
treatment groups. There was a reduction of 2 mm Hg SD 17.93
in systolic blood pressure with exenatide and of 2.51 mm Hg SD
17.55 with liraglutide.
Similarly, a reduction in systolic and diastolic blood pressure with
both exenatide 10 µg BID and exenatide 2 mg QW was not sig-
nificantly different between the groups. The reduction in systolic
blood pressure ranged from 2.9 to 4.7mmHgwith exenatide once
weekly and 1.2 to 3.4 mm Hg with exenatide twice daily.
Fasting plasma glucose
Fasting plasma glucose was significantly more reduced with li-
raglutide than with exenatide (-1.61 mmol/L versus -0.60 mmol/
L), with a mean difference between the groups of 1.01 mmol/L
(95% CI 0.46 to 1.56, P < 0.0001).
Fasting plasma glucosewas significantlywas also significantly lower
with 2 mg exenatide once weekly than with 10 µg exenatide BID
(-1.9 to -2.3 mmol/L versus -0.7 to -1.4 mmol/L), with a mean
difference between the groups of 1.18 mmol/L (95% CI 1.02 to
1.33, P < 0.00001).
Post-prandial glucose
Exenatide reduced the post-prandial plasma glucose increment (as
obtained from self-monitored 7-point plasma glucose measure-
ments) more than did liraglutide after breakfast and dinner (treat-
ment difference breakfast: 1.33mmol/L, 95%CI 0.80 to 1.86, P <
0.0001; dinner: 1.01 mmol/L, 95% CI 0.44 to 1.57, P = 0.0005);
treatment difference after lunch was not significant.
Both exenatide once a week and exenatide twice daily led to signif-
icant improvements in 7-point self-monitored blood glucose pro-
files. A meal tolerance test was carried out in 51 participants and
2 h post-prandial values were significantly more reduced with ex-
enatide twice a day than with exenatide once weekly (-6.9 mmol/
L SE 0.5 versus -5.3 mmol/L, P = 0.0124).
Lipid profiles
There were significantly greater reductions in triglycerides and free
fatty acids with liraglutide than with exenatide (triglycerides: -
0.41 mmol/L SE 0.1 versus -0.23 mmol/L SE 0.1, P = 0.0485;
free fatty acids: -0.17 mmol/L SE 0.02 versus -0.10 mmol/L SE
0.02, P = 0.0014), and increases in VLDL cholesterol were sig-
nificantly smaller with liraglutide (+0.20 mmol/L SE 0.04 versus
+0.27 mmol/L SE 0.04, P = 0.0277). There were no significant
differences in any other lipid parameters.
When comparing exenatide twice a day and exenatide once weekly,
there were significantly greater reductions from baseline in total
and LDL-cholesterol with the once a week regimen (The mean
difference between the two groups for total cholesterol was 0.31
mmol/L (95% CI 0.10 to 0.51, P = 0.003) with heterogeneity of
61% and themean difference for LDL cholesterol was 0.20mmol/
L (95% CI 0.09 to 0.30) with no heterogeneity. There were no
significant differences in any other lipid parameters.
Beta-cell function
HOMA-B improved significantly more with liraglutide than with
exenatide (+32.1% versus +2.7% (both different from exenatide
studies), P < 0.0001). There were no significant changes in proin-
sulin-insulin ratiowith either treatment and no difference between
the groups in this parameter.
Beta-cell function was not reported for exenatide twice daily versus
once weekly.
D I S C U S S I O N
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Summary of main results
For overview of results please see Appendix 2. Seventeen ran-
domised controlled trials of mostly low risk of bias including rele-
vant analyses for 6899 participants were included in the analysis.
Of these, one compared albiglutide with placebo, two compared
exenatide twice daily against once weekly exenatide, one com-
pared once weekly exenatide against insulin glargine, one com-
pared exenatide once weekly against sitagliptin and pioglitazone,
five compared liraglutide with placebo, two compared liraglu-
tide with glimepiride (sulphonylurea), and one each compared
exenatide with liraglutide, liraglutide with sitagliptin, liraglutide
with rosiglitazone and liraglutide with insulin glargine, two com-
pared taspoglutide with placebo and one each compared lixisen-
atide with placebo and LY2189265 with placebo. In comparison
with placebo, all glucagon-like peptide-1 (GLP-1) agonists sig-
nificantly reduced glycosylated haemoglobin A1c (HbA1c) (treat-
ment difference between 0.47% and 1.56%) and increased the
proportion of participants reaching an HbA1c of 7% or less. Re-
sults for mild hypoglycaemia were variable, with more patients
on exenatide and concomitant sulphonylurea and more partici-
pants on 1.8mg liraglutide experiencingmild hypoglycaemia than
patients on placebo. There were no differences in severe hypo-
glycaemia. Patients using GLP-1 agonists lost significantly more
weight than patients in the placebo groups. GLP-1 agonists caused
gastrointestinal adverse effects, mainly nausea, as well as vomit-
ing and diarrhoea; however, studies generally reported that these
effects were strongest at the beginning and then subsided, and
that weight loss also occurred in patients not experiencing nausea.
Fasting blood glucose was reduced significantly more with GLP-1
agonists. Where reported, GLP-1 agonists reduced post-prandial
glucose and glucose variability. No significant difference in blood
pressure was seen in comparison with placebo and some improve-
ment in lipid parameters was seen, but this outcome was reported
infrequently and results were inconsistent. Beta-cell function was
improved with GLP-1 agonists (HOMA-B, proinsulin-to-insulin
ratio).
Only one study assessed albiglutide but overall, the effects of this
agent on HbA1c and weight appeared to be slightly less than that
of the other agents. Lixisenatide was found to be superior against
placebo in terms of HbA1c, weight, weight, blood pressure and
FPG. One study that assessed efficacy of LY2189265 and found
that it was superior to placebo with respect to HbA1c, weight,
systolic blood pressure (SBP), fasting plasma glucose (FPG) and
beta-cell function. Taspoglutide was found to be superior than
placebo in terms of HbA1c, weight (with some doses), FPG, post-
prandial glucose (PPG), beta-cell function and some improvement
in triglyceride levels.
Both onceweekly exenatide and liraglutidewere superior to insulin
glargine on most outcomes. There was slightly greater reduction
in HbA1c level with exenatide than with glargine (-1.5% versus -
1.3%) while there was a small but statistically significantly larger
reduction in HbA1c with liraglutide (0.24%). The incidence of
hypoglycaemia was less with once weekly exenatide than with in-
sulin glargine (18% less). No significant difference was seen in
hypoglycaemia between liraglutide and exenatide. Long acting ex-
enatide was superior to insulin glargine in terms of the proportion
of participants achieving HbA1c level < 7%, weight and health-
related quality of life. It was also superior to sitagliptin and piogli-
tazone in terms of HbA1c, weight, FPG, health-related quality of
life, PPG and improvement in some parameters of lipid profile.
Exenatide 2mg weekly was superior to exenatide 10 µg twice daily
with respect to HbA1c, proportion of participants reaching the
targetHbA1c level of 7% or less, fasting plasma glucose, frequency
of gastrointestinal adverse events and improvement of some lipid
parameters; however, post-prandial glucose was significantly more
reduced with the twice daily regimen.
Liraglutide was superior to glimepiride in terms of hypoglycaemia,
weight reduction and systolic blood pressure. Liraglutide was su-
perior to rosiglitazone 4 mg with respect to HbA1c, weight re-
duction, fasting and post-prandial plasma glucose values and beta-
cell function; there was slightly more minor hypoglycaemia with
liraglutide (4%). Liraglutide was superior to sitagliptin in terms
of HbA1c, weight, FPG and beta-cell function. In a head-to-head
comparison of exenatide and liraglutide, liraglutide was superior to
exenatide with respect to HbA1c, hypoglycaemia, patient satisfac-
tion, less persistent nausea, systolic blood pressure, improvement
of some lipid parameters, and improvement in beta-cell function.
None of the studies was long enough to assess long-term positive
or negative effects.
Overall completeness and applicability of
evidence
Most of the studies evaluated exenatide or liraglutide. So far, few
studies on other GLP-1 agonists have been published, although
a number are in progress (see Characteristics of ongoing studies).
Therewere only three head-to-head comparisons of differentGLP-
1 agonists (one study compared liraglutide versus exenatide twice
daily and other two compared exenatide twice daily vs exenatide
once weekly), so no firm conclusions could bemade on the relative
effectiveness of the different agents. Once weekly exenatide was
better than twice daily exenatide with respect to most outcomes
especially HbA1c, FPG and frequency of gastrointestinal adverse
events. The improvement in HbA1c with once weekly exenatide
was 0.4%. In a head to head comparison of twice daily exenatide
and liraglutide, liraglutide was superior to exenatide. This trial was
sponsored by themanufacturer of liraglutide however, the findings
appear plausible given the pharmacodynamics of the two drugs,
with liraglutide having a more prolonged action with less ’peak
and trough effect’. These findings suggest that the once weekly
exenatide may be better than liraglutide. Hence, in future GLP-1
analogues may be given once weekly or once every two weeks.
In our meta-analysis, we found that there was no significant dif-
ference between the 1.2 mg and the 1.8 mg liraglutide in terms
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of HbA1c and systolic blood pressure. However, weight reduction
with the 1.8 mg liraglutide was slightly greater than the 1.2 mg
liraglutide.
Only one exenatide trial and one liraglutide trial carried out com-
parisons with insulin glargine, the most commonly used basal in-
sulin in the UK. In addition, the liraglutide trial used the 1.8 mg
dose. Therefore there is a lack of trials comparing GLP-1 agonists
against insulin glargine. There are also no trials comparing GLP-
1 agonists against NPH insulin, the more cost-effective insulin in
type 2 diabetes (Waugh 2010).
Quality of the evidence
Studies were mainly of good to high quality. However, four studies
had small comparison groups (fewer than 50 participants) (A
- Rosenstock 2009; Lixi - Ratner 2010; T - Nauck 2009; T-
Ratner 2010); six studies had a duration of between eight and 16
weeks (A - Rosenstock 2009; L - Yang 2010; Lixi - Ratner 2010;
LY2189265 -Umpierrez 2011; T - Nauck 2009; T- Ratner 2010),
and the remaining trials were between 24 to 30 weeks long - so
there is insufficient evidence regarding long-term outcomes. The
studies were not long enough to entirely remove concerns about
pancreatitis and renal failure with exenatide (FDA 2008; FDA
2009 (kidney function); FDA 2009 (safety update) or pancreatitis
and thyroid carcinoma with liraglutide (EMEA 2009). The FDA
has recently issued a reminder to physicians that there is a potential
risk of thyroid carcinoma and pancreatitis with liraglutide (Journal
Watch 2011). It is however difficult to prove if exenatide and
liraglutide are responsible for pancreatitis because the incidence of
it is increased in type 2 diabetes (Butler 2010; Girman 2010). One
study followed up a cohort of patients taking exenatide and other
hyperglycaemic drugs and concluded that there was no association
of exenatide use and risk of acute pancreatitis (Dore 2011).
All the studies included in this review had industry connections.
In some studies there were some uncertainties or inequalities re-
garding previous or concomitant anti-diabetic treatment. Patients
in L - LEAD 1 Marre 2009 were assumed to have been on pre-
vious metformin therapy, but this was not reported by the study.
In A - Rosenstock 2009, all patients in a concomitant exenatide
group were on metformin, whereas only a proportion of patients
in the other groups were, so this group could not be included in
the analysis.
A range of studies had substantial losses to follow-up (10% and
more but less than 20%), with more withdrawals often occurring
in the GLP-1 groups (mainly due to adverse events).
Potential biases in the review process
Due to the limited number of studies in each categories no sensitiv-
ity or subgroup analyses were carried out andwhile some outcomes
showed some heterogeneity in the overall results, some sources of
heterogeneity could either not be identified or could only be spec-
ulated on.
Agreements and disagreements with other
studies or reviews
Other published reviews included slightly different studies:
The review by Shyangdan 2010 included a search up to July 2010
and included 28 studies. It however included all the exenatide
studies (including twice daily dosage). This Cochrane review is an
update of that review and excludes all the studies comparing the
twice daily exenatide against placebo or other oral hypoglycaemic
agents, but not the ones against other GLP-1 agonists.
The review by Norris 2009 included a search up to 2008, and
included eight trials, including two excluded by the current re-
view as less than 70% of patients had been on previous metformin
therapy. The authors concluded that exenatide 10 µg twice daily
reduced HbA1c to a similar extent as insulin or oral anti-diabetic
agents and that there was a beneficial effect on weight loss. Hy-
pogycaemia with exenatide occurred mainly in participants also
taking a sulphonylurea.
The review by Amori 2007 included data up to 2007 only, in-
cluding seven studies on exenatide and two on liraglutide. The
review included comparisons that are not clinically relevant (such
as monotherapy versus placebo and 0.6 mg liraglutide). The au-
thors found a moderate effect of GLP-1 analogues on HbA1c (-
1%), a beneficial effect on weight and post-prandial glucose, but
increased gastrointestinal adverse events. In placebo-controlled tri-
als, increased hypoglycaemia with exenatide was seen mainly in
trials using concomitant sulphonylurea.
Twenty-one RCTs were included in the review by Monami 2009,
including six unpublished studies. The search included studies up
to 2008. Again, the authors found that GLP-1 agonists reduced
HbA1c by around 1%, and also reduced post-prandial glucose
and weight. There was no evidence of increased cardiovascular
risk, but gastrointestinal adverse effects were common. Increased
hypoglycaemia with exenatide versus placebo was only seen in
trials using concomitant sulphonylurea.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence to date shows that the glucagon-like peptide 1 (GLP-
1) analogues can provide a useful improvement in glucose control
when added to dual treatment with oral drugs, and that at least
in the short term, they can be an alternative to starting insulin.
How long this effect would last, is not known. If we assume that
the disease will steadily progress, as shown in UKPDS 16, then
some of the benefit will be lost since the beta-cells will no longer
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be there to release insulin. Other benefits such as delayed gastric
emptying may continue, which may help control post-prandial
hyperglycaemia.
The glucose-dependent nature of the insulin release means that
hypoglycaemia should be less of a problem, but the differences in
the trials were not marked. Hypoglycaemia was seen mainly when
GLP-1 analogues were used in combination with sulphonylureas.
Weight loss is a useful feature in the trials, though perhaps seen
less in routine care (Loh and Clement 2007) .
The drawbacks are the need for injections, once a day with liraglu-
tide and twice daily with exenatide, the high rate of side-effects,
especially nausea, and the cost. However, newer GLP-1 agonists
can be given once weekly or once every two weeks.
Injecting of a foreign peptide could lead to antibody formation,
but studies measuring antibody formation noted that although
antibodies were detected, these did not appear to reduce efficacy
or have any safety effects.
Implications for research
More high quality trials are needed that:
• compare one GLP-1 agonist against other GLP-1 agonists,
with the emphasis on long-acting agents;
• measure health-related quality of life and treatment
satisfaction;
• measure long-term outcomes (longer than one year follow-
up) in terms of diabetes-related morbidity and mortality and
adverse events, and to indicate duration of efficacy in a
progressive disease;
• examine diverse populations, including adolescents and
older adults;
• use active controls.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
A - Rosenstock 2009
Methods TRIAL DESIGN: Randomised double-blind, placebo-controlled parallel group phase
II trial, multi-centre (118 sites)
DURATION OF INTERVENTION: 16 weeks
DURATION OF FOLLOW-UP: 11 week washout phase to assess safety and immuno-
geneity
RUN-IN PERIOD: None
SETTING: Not reported (NR)
COUNTRY: US (106 sites), Mexico (9 sites), Chile (2 sites), Dominican Republic (1
site)
Participants INCLUSION CRITERIA: Patients with type 2 diabetes diagnosed ≥ 3 months before
screening, men and women aged 18 to 75 years, drug-naive (diet and exercise) or treated
with metformin monotherapy and stable for > 3 months before prescreening; BMI≥ 20
and ≤ 40 kg/m2, HbA1c at screening ≥ 7 and ≤ 10%; only participants treated with
metformin monotherapy were eligible for the exenatide arm (consistent with labelling)
EXCLUSION CRITERIA: Any oral antidiabetic monotherapy (except metformin) ≤
3 months prior to screening or insulin < 1 month prior to screening and not used for
> 7 days; history of pancreatitis, cardiovascular, cerebrovascular, renal or hepatobiliary
diseases; fasting serum triglycerides≥ 9 mmol/L at screening; or haematological profiles
considered to be clinically significant; use of lipid lowering medications must have been
maintained at same dose for 3 months prior to treatment, no prescription or over the
counter weight loss drugs 3 months prior to enrolment
AGE: mean 54.0 to 55.5 years (SD 9.7 to 10.6)
SEX: 45.1% to 74.2% female (74.2% in ALBI 30 mg weekly group, 50% in ALBI 30
mg every 2 weeks group, 45.1% in placebo group)
DIABETES DURATION: mean 4.9 years [range 3.9 to 5.5 years (SD 3.0 to 5.4)]
ETHNICITY: Caucasian (43.8% to 71%) (87.1% and 12.9% of participants were from
U.S. and Latin American clinics respectively)
HbA1c (%): ALBI Weekly 30 mg: 8.0 (SD 0.9), Placebo: 7.9 (SD 0.9), ALBI every 2
weeks 30 mg: 8.0 (SD 1.0)
BMI (kg/m2): ALBI weekly 30 mg: 33.0 (SD 3.9), ALBI every 2 weeks 30 mg: 31.2
(SD 4.1), Placebo: 31.8 (SD 5.4)
PREVIOUS THERAPY: Diet and exercise only: 29.0% to 34.4%, MET: 65.6% to 71.
0%
NUMBERS: Randomised: 361, received treatment (and included in the safety analysis)
: 356, efficacy analysis: 345; ITT: placebo: 51, exenatide: 35; ALBI weekly 4 mg: 35,
15 mg: 35, 30 mg: 31; ALBI every 2 weeks 15 mg: 33, 30 mg: 32, 50 mg: 35; ALBI
monthly 50 mg: 35, 100 mg: 34
Interventions COMPARISON: Albiglutide (ALBI, 8 doses/schedules) +/- Metformin (MET) VER-
SUS Exenatide (EX) + MET VERSUS Placebo +/- MET
NO. OF COMPARISON GROUPS: 10
For the current review, the following groups were excluded: EX (as this included co-
medication with metformin in all patients, whereas only 65.6% to 74.3% of the patients
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in the other groups received metformin, so this was not really a comparison of exenatide
versus albiglutide); ALBI 4 or 15 mg weekly or 15 mg every two weeks (smaller effect on
HbA1c), and ALBI 50 mg every two weeks or 50 or 100 mg monthly (no improvement
in HbA1c compared to groups with largest effect, significantly more adverse events)
DOSE ALBI: 30 mg weekly or 30 mg every 2 weeks injected subcutaneously to the
abdomen
DOSE PLACEBO: Placebo injections
DOSE MET: Not reported, presumably pre study levels
OTHER TREATMENT: Not reported
Outcomes PRIMARY OUTCOMES: Change from baseline in HbA1c at week 16
SECONDARY OUTCOMES: Fasting plasma glucose (FPG), fasting fructosamine, C-
peptide, glucagon, insulin, lipid profiles, beta-cell function (homeostasis model)
OTHEROUTCOMES: Adverse event assessments and safety analyses (nausea and vom-
iting, immunogenicity), 11 week washout post-intervention (HbA1c, FPG, ALBI con-
centrations, fasting fructosamine, C-peptide, glucagon, insulin, lipid profiles, immuno-
genicity)
Notes AIM: To evaluate the efficacy, safety and tolerability of incremental doses of albiglutide,
administered using three dosing schedules in patients with type 2 diabetes inadequately
controlled with diet and exercise or metformin monotherapy
SOURCE OF FUNDING: GlaxoSmithKline, Middlesex, UK
OTHER: Conflict of interest: One author has received research grants and consulting
honoraria for serving on scientific advisory boards from GlaxoSmithKline. Another au-
thor has received research grants from and acted as a consultant for GlaxoSmithKline,
MB FY, and MS are employees/stockholders of GlaxoSmithKline
SAMPLE SIZE:With 30 participants planned in each arm, a two-sided 95%CI for each
group mean response had a half-width of 0.36% on HbA1c scale, assuming a standard
deviation of 1%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk Insufficient information
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind (study personnel and pa-
tients)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comparisons made on the intent to treat
population, using last observation carried
forward, adequate description of with-
drawals or losses to follow-up (28% with-
drawals or losses to follow-up)
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Selective reporting (reporting bias) Low risk All pre-specified (primary and secondary)
outcomes were reported
E - Bergenstal 2010
Methods TRIAL DESIGN:Randomised, double-blind, double-dummy, superiority trial
DURATION OF INTERVENTION: 26 weeks
DURATION OF FOLLOW-UP: NR
RUN-IN PERIOD: NR
SETTING: 72 hospitals and clinics
COUNTRY: USA, India and Mexico.
Participants INCLUSIONCRITERIA: participants aged between 18 years and older; type 2 diabetes
but otherwise healthy; treated with a stable metformin regimen for at least 2 months
before screening; HbA1c of 7.1% to 11.0%; BMI 25 to 45 kg/m2; FPG < 15.5 mmol/
L; not taking or has been stable on other medications of a minimum of 2 months-hor-
mone replacement therapy, OCPs, antihypertensives, lipid-lowering agents, thyroid re-
placement therapy, antidepressant agents and drugs known to affect body weight includ-
ing prescription medications, sibutramine, topiramate and over-the-counter antiobesity
agents
EXCLUSION CRITERIA: pregnant or lactating women; clinically significant medical
conditions like hepatic disease, renal disease, cardiovascular disease, gastroparesis, malig-
nancy, macular edema or chronic infections; drugs or alcohol abuse; fasting triglycerides
≥ 600 mg/dL; previously exposed to exenatide LAR (long acting release); blood donated
within 60 days of screening or is planning to do during study; major surgery or a blood
transfusion within 2 months of screening; currently taking drugs that are excluded or
is expected to be treated with one; received any investigational drug within 1 month of
screening; known allergies or hypersensitivity to any component of study treatment; pre-
vious experience of clinically significant adverse events with TZD or DPP-4 inhibitors;
immediate family or affiliation with the personnel; employed by Amylin, Eli Lilly or
Alkermes
AGE: 52 to 53 years (SD 10 to 11)
SEX: 44% to 52% female [44% in EX 2 mg group; 48% in sitagliptin (SITA) 100 mg
group; 52% in pioglitazone (PIO) 45 mg group]
DIABETES DURATION: 5 to 6 years (SD 4 to 5)
ETHNICITY: 30% to 39% White; 8% to 12% Black; 27% to 31% Hispanic; 23% to
25% Asian; 0% to 2% Native American; 1% to 2% other
HbA1c (%): EX 2 mg: 8.6 SD 1.2; SITA 100 mg: 8.5 SD 1.2; PIO 45 mg: 8.5 SD 1.1
BMI (kg/m2): EX 2 mg: 32 SD 5; SITA 100 mg: 32 SD 5; PIO 45 mg: 32 SD 6
PREVIOUS THERAPY: NR
NUMBERS: Screened: 958; randomised: 514 (EX 2 mg: 170, SITA 100 mg: 172, PIO
45 mg: 172); evaluable patient: 387 (EX 2 mg: 122, SITA 100 mg: 137, PIO 45 mg:
128); ITT: 491 (EX 2 mg: 160, SITA 100 mg: 166, PIO 45 mg: 165)
Interventions COMPARISON: EX 2 mg once weekly + MET + placebo, versus SITA 100 mg once
daily + MET + placebo, versus PIO 45 mg once daily + MET + placebo
NO. OF COMPARISON GROUPS: 3
DOSE EX: EX 2 mg once weekly injection plus oral placebo once daily
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DOSE SITA: SITA 100 mg orally once daily plus placebo once weekly injection
DOSE PIO: PIO 45 mg orally once daily plus placebo once weekly injection
DOSE MET: Mean oral dose between 1480 to 1583 mg
OTHER TREATMENT: NR
Outcomes PRIMARY OUTCOMES: Change in HbA1c
SECONDARY OUTCOMES: Proportion of participants achieving the HbA1c target
of 6.5% or lower, or 7.0% or lower; FPG ≤ 7 mmol/L; six-point self-monitored blood
glucose profile; body weight; fasting lipid profile; fasting insulin profile; SBP and DBP;
cardiovascular risk markers (urinary albumin-to-creatinine ratio, serum adiponectin, B-
type natriuretic peptide, high-sensitivity C-reactive protein, and plasminogen activator
inhibitor-1); patient-reported outcomes from the Impact of Weight on Quality of Life
Questionnaire-Lite (IWQOL), Psychological General Well-being (PGWB) index, the
Diabetes Treatment Satisfaction Questionnaire (DTSQ), and EuroQol-5 dimensions
(EQ-5D)
OTHER OUTCOMES: Safety and tolerability; exenatide antibodies; hypoglycaemia
Notes AIM: To compare the efficacy, safety, and tolerability of three recommended therapies
for patients not sufficiently controlled on metformin
SOURCE OF FUNDING: Amylin Pharmaceuticals and Eli Lilly
OTHER: Conflict of interest: First author’s institution has received consultancy fees or
research grant support, or both, with receipt of travel and accomodation expenses in some
cases, from different pharmaceutical companies. This author also owns stock in Merck.
Another author is a member of the scientific advisory board for Amylin Pharmaceuticals,
is a consultant for Amylin Pharmaceuticals, Eli Lilly and AstraZeneca, is on the speaker’s
bureau of Amylin Pharmaceuticals, Eli Lilly, Merck, Novo Nordisk, and Sanofi-Aventis
and has received travel and accomodation expenses from Amylin Pharmaceuticals. Some
authors are employees and stockholders of Amylin Pharmaceuticals. One author is an
employee and stockholder of Eli Lilly. All research activity and advisory or consultancy
services were done under contract with the non-profit International Diabetes Center at
Park Nicollet
SAMPLE SIZE: Estimated that 500 participants would provide at least 90% power to
detect a statistically significant difference between exenatide and sitagliptin or pioglita-
zone, and assumptions of a difference of 0.5% between groups, a common SD of 1.2%
and an early withdrawal of 10%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation; done
centrally byUBCClinical Technologies via
an interactive voice response system and
was independent of the sponsor, investiga-
tors, study-site staff and participants; allo-
cated in a 1:1:1 ratio
Allocation concealment (selection bias) Low risk Interactive voice response system to conceal
allocation
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis; missing data
were imputed by last-observation-carried
forward method; adequate description of
withdrawals and losses to follow up
Selective reporting (reporting bias) Low risk All the predefined and prespecified out-
comes were reported
E - Blevins 2011
Methods TRIAL DESIGN: Randomised, open-label, comparator-controlled study
DURATION OF INTERVENTION: 24 weeks




Participants INCLUSION CRITERIA: At least 18 years of age and diagnosed with type 2 diabetes,
otherwise healthy, and treated for at least 2 months with diet and exercise alone or with
a stable, maximally effective regimen of metformin, sulphonylurea (SU), thiazolidine-
dione, or a combination of these medications; HbA1c of 7.1% to 11.0%, FPG less than
280 mg/dL (15.5 mmol/L), BMI from 25 to 45 kg/m2.
EXCLUSION CRITERIA: Patients using concomitant weight loss agents.
AGE: 55 to 56 years (SD 10 to 11)
SEX: 40% to 45% female (40% in EX 2 mg once weekly group; 45% in EX 10 µg twice
daily group)
DIABETES DURATION: 7 SD5 years
ETHNICITY: 55% to 63% Caucasian; 5% to 7% Black; 4% Asian; 29% to 33%
Hispanic
HbA1c (%): EX 10 µg BID: 8.4 SD 1.2; EX 2 mg QW: 8.5 SD 1.1
BMI (kg/m2): EX 10 µg BID: 33.0 SD 5.3; EX 2 mg QW: 33.6 SD 5.5
PREVIOUS THERAPY: Diet and exercise only: 16% to 21%; single oral antidiabetic
therapy: 43% to 50%; combination oral antidiabetic therapy: 28% to 40% (alone or in
combination of: 71% to 80% MET; 28% to 31% SU; 10% to 17% TZD)
NUMBERS: EX 10 µg BID: 123; EX 2 mg QW: 129
Interventions COMPARISON: EX 2 mg QW +/- MET +/- SU +/- TZD or EX 10 µg BID +/- MET
+/- SU +/- TZD
NO. OF COMPARISON GROUPS: 2
DOSE EX QW: Subcutaneous injection of exenatide 2 mg once weekly or exenatide 10
µg twice daily
lead-in for 2 mg EX QW: 2 mg once weekly for 24 weeks
lead-in for 10 µg EX BID: 5 µg EX twice daily for 4 weeks, then 10 µg EX twice daily
for the remainder of the 20 weeks
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OTHER TREATMENT: Patients not allowed to change their oral antidiabetic, lipid-
lowering, and antihypertensive medications during the study, unless instructed otherwise
by the investigator
Outcomes PRIMARY OUTCOMES: Change in HbA1c from baseline to week 24.
SECONDARY OUTCOMES: Body weight, FPG, proportion of subjects achieving
HbA1c targets of less than 7% and 6.5% or less at week 24, proportion of patients
achieving FPG target of 126 mg/dL (7.0 mmol/L) or less at week 24, SBP, DBP, fasting
lipid concentrations,
OTHER OUTCOMES: Safety and tolerability; antibody titres.
Notes AIM: To compare the effects of exenatide once weekly and exenatide twice daily on
glycaemic control, body weight, and safety
SOURCE OF FUNDING: Amylin Pharmaceuticals
OTHER: Two authors have received research grants from Amylin Pharmaceuticals, Inc.
and serve as advisers and speaker’s bureau members for Amylin Pharmaceuticals, Inc.
First author has also served as an adviser and speaker’s bureau member for Eli Lilly &
Co. Some authors are employees and stockholders of Amylin Pharmaceuticals, Inc. One
author is an employee and stockholder of Eli Lilly & Co
SAMPLE SIZE: A sample size of approximately 250 patients (ratio of 1:1) was estimated
to provide 90% power to demonstrate that EX QWwas non-inferior to EX BID by a 0.
4% difference in the HbA1c change from baseline to week 24, using a one-sided, two-
sample t test with a significance level of 0.025 and assuming a greater (0.1%) reduction
in HbA1c by EX QW compared with EX BID, a 15% withdrawal rate, and a common
SD of 1.1%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised 1:1 to treat-
ment with EX BID or EX QW, with ran-
domisation performed centrally via an in-
teractive voice or web response system.
Randomization was stratified according to
concomitant SU use at screening and base-
line HbA1c stratum (< 9.0% or ≥ 9.0%)
Allocation concealment (selection bias) Unclear risk Randomization performed centrally via an
interactive voice or web response system
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label; Sponsor personnel remained
blinded to HbA1c and FPG data through-
out treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk intent-to-treat (ITT) population consisted
of all randomised patients receiving at least
one dose of randomised study medication;
Missing post baseline efficacy datawere im-
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puted using the last observation carried for-
ward (LOCF) approach; adequate descrip-
tion of withdrawals and loss to follow-up
Selective reporting (reporting bias) Low risk All the prespecified and predefined out-
comes were reported.
E - Diamant 2010
Methods TRIAL DESIGN: Phase 3, parallel, open-label, randomised controlled trial
DURATION OF INTERVENTION: 26 weeks
DURATION OF FOLLOW-UP: NR
RUN-IN PERIOD: NR
SETTING: 72 sites
COUNTRY: USA (and Puerto Rico), the European Union, Russia, Australia, Korea,
Taiwan, and Mexico
Participants INCLUSION CRITERIA: Participants with type 2 diabetes aged 18 years or older (no
upper limit specified) with sub optimum glycaemic control despite maximum tolerated
doses of metformin or combined metformin and sulphonylurea treatment for 3 months
or longer; HbA1c between 7.1% and 11.0%, inclusive, BMI between 25 kg/m2 and
45 kg/m2, stable bodyweight for 3 months or more; participants have had to be treated
with a stable dose of metformin of 1500 mg or more per day for 8 or more weeks before
screening
EXCLUSION CRITERIA: more than three episodes of major hypoglycaemia within 6
months of screening; treatment within 4 weeks of screening with systemic glucocorti-
coids; and treatment for longer than 2 weeks with insulin, thiazolidinediones, α-glucosi-
dase inhibitors, meglitinides, exenatide twice-a-day formulation, dipeptidyl peptidase-4
inhibitors or pramlintide acetate within 3 months of screening. Prescription and non-
prescription weight-loss drugs were excluded within 3 months of screening and during
the entire 26-week study
AGE: 58 SD 9 to 10 years
SEX: 45% to 48% female (EX 2 mg: 48%, GLAR: 45%)
DIABETES DURATION: 7.8 to 8.0 years (SD 6.0)
ETHNICITY: < 1% to 1% African American; 82% to 85% White; 6% Asian; 9% to
12% Hispanic
HbA1c (%): EX: 8.3 SD 1.1; GLAR: 8.3 SD 1.0
BMI (kg/m2): 32 SD 5.0 for both groups
PREVIOUS THERAPY: 70% MET; 30% MET + SU
NUMBERS: Screened: 659; randomised: 456 (EX: 233, GLAR: 223)
Interventions COMPARISON: EX 2mg once weekly + 70%MET/30%MET + SUVERSUSGLAR
+ MET/MET + SU
NO. OF COMPARISON GROUPS: 2
DOSE EX: EX 2 mg injected into abdominal subcutaneous tissue at randomisation and
once a week (within 2 days of date of first injection) thereafter
DOSE GLAR:GLAR implemented by INITIATE (Initiate Insulin by Aggressive Titra-
tion and Education) dosing algorithm; GLAR treatment started with 10 IU per day,
measured FBG concentrations every morning and the dose of insulin adjusted to achieve
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a target glucose of 4.0 to 5.5 mmol/L. Participants and investigators were asked to ad-
here to titration targets however there was no central supervision to enforce titration.
Insulin was injected at the same time every day, preferably at bedtime. Mean doses of
GLAR increased from a baseline of 10 IU per day to 31 IU per day at endpoint (last
measurement brought forward)
DOSE MET: MET was continued in their stable dose until week 26. Mean doses of
MET ~ 2000 mg throughout study,
DOSE SU: If a participant taking metformin and sulphonylureas had confirmed hy-
poglycaemia, the dose of sulphonylurea was reduced. 46 (21%) of 223 patients had a
reduction in SU dose
BOTH GROUPS: Specific instructions for eight-point self-monitored blood-glucose
profiles (measured before and 2 hour after morning, midday, and evening meals, at
bedtime, and at 0300 hours) were given to both treatment groups
OTHER TREATMENT: NR
Outcomes PRIMARY OUTCOMES: Change in HbA1c at week 26 compared with baseline.
SECONDARY OUTCOMES: Proportion of participants achieving HbA1c targets (<
7.0% and < 6.5%), fasting serum glucose concentrations, self-monitored blood glucose
concentrations, bodyweight, fasting serum lipid concentrations, urinary albumin-to-cre-
atinine ratio, high-sensitivity C-reactive protein, homeostasis model assessment of β-
cell function and insulin sensitivity, alanine aminotransferase, and 1,5-anhydroglucitol
(a short term marker for glycaemic control). Administered five health outcomes ques-
tionnaires: Impact of weight on quality of life-lite (IWQOL-Lite), EuroQol instrument
(EQ-5D), binge eating scale (BES) and diabetes treatment satisfaction questionnaire
(status version; DTSQs)
OTHER OUTCOMES: Adverse events, clinical laboratory assessments, vital signs, and
hypoglycaemia
Notes AIM: To test the hypothesis that improvement in HbA1c concentration achieved with
once-weekly exenatide is better than that achieved with the existing standard second-
line treatment for patients not responding to oral blood-glucose lowering agents, insulin
glargine titrated to glucose targets
SOURCE OF FUNDING: Amylin and Eli Lilly
OTHER: Conflict of interest: First author is a consultant and speaker for Eli Lilly,
Novo Nordisk, and Merck, Sharp and Dohme; and a consultant of Sanofi-Aventis.
Through this author, the VU University Medical Centre in Amsterdam has received
research grants from Amylin Pharmaceuticals, Eli Lilly, Novo Nordisk, Merck, Sharp
and Dohme, Novartis and Takeda. Another author has served on advisory panels for
Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Novo Nordisk and
Sanofi-Aventis, and has received honoraria as member of the speakers’s bureau for Abbott
Laboratories, AstraZeneca, Bristol-Myers Squibb and Eli Lilly. Another author has served
on an advisory panel for Eli Lilly, has received travel grants fromNovo Nordisk, Eli Lilly,
Merck, Sharp and Dohme and Servier and has received research funding support from
Sanofi-Aventis. Some authors are employees of Eli Lilly. One author is an employees of
Amylin Pharmaceuticals
SAMPLE SIZE: A sample size of 205 patients per treatment was needed to achieve 92%
power to detect a difference of 0.4% in change in HbA1c from baseline
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk One to one allocation and block (size
four) randomisation, stratified according
to country and oral blood glucose lower-
ing treatment (70% metformin only; 30%
metformin plus sulphonylurea). Com-
puter-generated randomisation sequence
administered by the sponsor via an auto-
mated voice-response system
Allocation concealment (selection bias) Low risk Computer-generated randomisation se-
quence administered by the sponsor via an
automated voice-response system
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label (study participants and clinical
investigators were not blinded); investiga-
tors analysing data were blinded to treat-
ment assignment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Modified intention-to-treat analysis, de-
tails of withdrawals and losses to follow up
Selective reporting (reporting bias) Low risk All the predefined and prespecified out-
comes were reported
E - Drucker 2008
Methods TRIAL DESIGN: Randomised comparator-controlled, open label trial, non-inferiority
study
DURATION OF INTERVENTION: 30 weeks
DURATION OF FOLLOW-UP: No post-intervention follow-up
SETTING: Not reported
COUNTRY: Canada/USA
Participants INCLUSIONCRITERIA:Peoplewith type 2diabetes, aged at least 16 years old,HbA1c
between 7% and 11%, FPG < 16 mmol/L, BMI between 25 and 45 kg/m2, therapy
with diet modification and exercise, or pharmacological treatment with MET, a SU, a
TZD, or any combination of two of these agents; weight stable (weight did not vary >
10%) for 6 months prior screening, no abnormal results of clinical significance on blood
testing
EXCLUSION CRITERIA: Patients who had used meglitinides, alpha-glucosidase in-
hibitors, insulin therapy, weight-loss drugs, corticosteroids, drugs known to affect gas-
trointestinal motility, or any investigational drug; any exposure to exenatide or a GLP-
1 analogue; or evidence of clinically significant medical conditions that might preclude
safe participation in the study
AGE: 55 SD 10 years
SEX: 45% to 49% female
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DIABETES DURATION: 6 to 7 years (SD 5 to 6)
ETHNICITY: 73% to 83% White, 6% to 13% Black, 11% to 14% Hispanic, 0% to
1% Asian
HbA1c (%) : EX 2 mg QW: 8.3 SD 1.0; EX 10 µg BID: 8.3 SD 1.0
BMI (kg/m2): EX 2 mg QW: 35 SD 5; EX 10 µg BID: 35 SD 5
PREVIOUS THERAPY: Monotherapy: 43% to 46%, combination therapy: 36% to
39%; all MET: 69% to 77%, all SU: 37%, all TZD: 15% to 17%; diet/exercise only:
14% to 16%
NUMBERS: Randomised: 303, Analysed as ITT: 295 (8 withdrew before lead-in); EX
2 mg QW: 148, EX 10 µg BID: 147
Interventions COMPARISON:EX twice daily + previous therapyVERSUSEXonce weekly + previous
therapy
NO. OF COMPARISON GROUPS: 2
RUN-IN: None
DOSE EX: subcutaneous injection of exenatide 2 mg once a week or 10 µg twice a day
lead-in for 2 mg QW: 3 days 5 µg EX BID, then 2 mg QW
lead-in for 10 µg EX BID: 5 µg EX BID for 28 days, then 10 µg EX BID for the
remainder of the 30 weeks
PREVIOUS THERAPY: Diet/exercise or metformin (MET), sulphonylurea (SU), or
thiazolidinedione (TZD) as monotherapy or combination of any two; see above for com-
binations used, doses of MET, SU and TZD were not reported; to avoid hypoglycaemia,
SU dose was reduced to minimum labelled dose until week 10, then up-titrated to reach
target FPG of ≤ 6 mmol/L
OTHER TREATMENT: Not reported
Outcomes PRIMARYOUTCOMES:Change in HbA1c at the end of the study i.e. 30 weeks (non-
inferiority within 0.4%)
SECONDARY OUTCOMES: Safety and tolerability, body weight, fasting plasma glu-
cose (FPG), postprandial glucose (PPG), fasting glucagon, fasting lipids, blood pressure,
proportion of patients achieving HbA1c concentrations of ≤ 7.0%, ≤ 6.5%, ≤ 6.0%,
overall and by baseline HbA1c strata; HbA1c by antibody titre; bodyweight in the pres-
ence and absence of nausea
OTHEROUTCOMES: Treatment-emergent adverse events (defined as those occurring
on or after receiving the first injection of study medication): patients who lost glucose
control (1.5% increase in HbA1c or HbA1c of ≥11.5% at or after week 14; patients
with loss of glucose control withdrawn from the study); hypoglycaemic episodes: minor
(symptoms of hypoglycaemia and a plasma glucose < 3 mmol/L) and major (loss of
consciousness, seizure, or coma; third party assistance to resolve or administration of
glucose or glucagon; and a plasma glucose < 3 mmol/L); vital signs, ECG reports, or
haematological, chemistry, or urinalysis values
Notes AIM: To compare the efficacy and safety of exenatide once a week to that of exenatide
given twice daily, over 30 weeks, in patients with type 2 diabetes
SOURCE OF FUNDING: Amylin Pharmaceuticals and Eli Lilly and Company.
OTHER: Conflict of interest: One author has been a consultant for and received lecture
honoraria from Amylin, Eli Lilly and Novo Nordisk
SAMPLE SIZE: A sample size of 300 patients was estimated to provide 90% power to
test the hypothesis that the treatments were non-inferior with respect to HbA1c control
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation method not stated; ran-
domisation was stratified according to con-
comitant sulphonylurea use at screening
and HbA1c strata (< 9.0% vs ≥ 9.0%)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label; the investigators, sponsor, pa-
tients, and all personnel involved with the
study were not blinded to the identity of
the study medication; blinding of HbA1c
and FPG results
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missingdatawere imputed as the last obser-
vation carried forward, ITT analysis, ade-
quate description of withdrawals and losses
to follow-up (12% withdrawals, no signif-
icant difference between groups)
Selective reporting (reporting bias) Low risk Included all expected and prespecified out-
comes
L - Kaku 2010
Methods TRIAL DESIGN: Double-blind, multicenter, randomised, parallel-group, three arm
trial
DURATION OF INTERVENTION: 24 weeks
DURATION OF FOLLOW-UP: This trial was part of a 52 week, multicenter, double-
blind, randomised, parallel-group trial in which the initial 24 week double-blind period
was followed by a 28 week open label period
RUN-INPERIOD: 4week preceeded randomisation, after which subjects were stratified
according to their pretrial SU therapy
SETTING: 49 centres
COUNTRY: Japan
Participants INCLUSION CRITERIA: Japanese men and women ≥ 20 years of age with type 2
diabetes mellitus currently treated with an SU [glibenclamide (1.25 to 10 mg), gliclazide
(40 to 160 mg) or glimepiride (1 to 6 mg) for ≥ 8 weeks, HbA1c between 7.0% to <
10%, BMI < 35.0 kg/m2.
EXCLUSION CRITERIA: Treated with insulin within 12 weeks, were receiving or
expecting to receive systemic corticosteroids, or had known hypoglycaemia unawareness
or recurrent major hypoglycaemia, impaired renal or hepatic function, significant car-
diovascular disease (heart failure, coronary artery disease or uncontrolled hypertension)
or non stabilized proliferative retinopathy or maculopathy
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AGE: 58.6 SD 9.7 to 61.3 SD 11.0 years
SEX: 33% to 40% female (LIR 0.6 mg: 40%; LIR 0.9 mg: 33%; Placebo: 35%)
DIABETES DURATION: 9.3 SD 5.8 to 11.6 SD 7.7 years
ETHNICITY: All Japanese patients.
HbA1c (%): LIR 0.6 mg: 8.6 SD 0.91; LIR 0.9 mg: 8.21 SD 0.78; Placebo: 8.45 SD
0.99
BMI (kg/m2): LIR 0.6 mg: 25.3 SD 3.6; LIR 0.9 mg: 24.4 SD 3.4; Placebo: 24.9 SD
4.0
PREVIOUS THERAPY: Treated with SU [glibenclamide (1.25 to 10 mg), gliclazide
(40 to 160 mg) or glimepiride (1 to 6 mg)
NUMBERS: Screened: 308;Randomised: 264 (LIR0.6mg: 88; LIR0.9mg: 88; Placebo:
88); Fully analysis set: 264 (LIR 0.6 mg: 88; LIR 0.9 mg: 88; Placebo: 88); per-protocol
set: 235 (LIR 0.6 mg: 79; LIR 0.9 mg: 83; Placebo: 73)
Interventions COMPARISON: Liraglutide (LIR) 0.6 mg/0.9 mg + SU VERSUS Placebo + SU
NO. OF COMPARISON GROUPS: 3
DOSE LIR: LIR 0.6 mg or 0.9 mg once daily: LIR doses were up titrated from 0.3 mg/
day (50 µl) to 0.6 mg/day (100 µl) after the first week, with an additional increase to 0.
9 mg/day (150 µl) for the 0.9 mg cohort after the second week. LIR was injected once
daily in the morning or evening s.c. into the upper arm, thigh or abdomen
DOSE SU: SU continued in prestudy dose.
OTHER TREATMENT: NR
Outcomes PRIMARY OUTCOMES: HbA1c level at 24 weeks
SECONDARY OUTCOMES: 7-point self-measured PPG profiles, body weight, FPG,
meanPPG, lipid profile and biomarkers for cardiovascular effects, proportions of subjects
reaching HbA1c ≤ 7% or ≤ 6.5%
OTHER OUTCOMES: Incidence of hypoglycaemic episodes (self-treated hypogly-
caemic episodes were classified as minor, while those requiring third party assistance were
considered as major and the remainder as symptoms-only), incidence of adverse events,
vital signs and clinical laboratory assessments
Notes AIM: the efficacy and safety of two doses of liraglutide (0.6 and 0.9 mg/day) over 24
weeks compared with placebo, in each case as add-on to SU monotherapy
SOURCE OF FUNDING: Novo Nordisk
OTHER: Conflict of interest: NR
SAMPLE SIZE: No information.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Subjectswere stratified according to pretrial
SU therapy. Insufficient information
Allocation concealment (selection bias) Unclear risk No information
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Efficacy endpoints: Full analysis set; Per
protocol set; LOCF; adequate description
of adverse events, withdrawals and losses to
follow-up
Selective reporting (reporting bias) Low risk All predefined and prespecified outcomes
were reported
L - LEAD 1 Marre 2009
Methods TRIALDESIGN: Randomised double-blind, double dummy, active control, five armed
parallel trial, multi-centre (116 sites)
DURATION OF INTERVENTION: 26 weeks
DURATION OF FOLLOW-UP: No post-intervention follow-up
RUN-IN PERIOD: 2 weeks
SETTING: NR
COUNTRY: 21 countries (mainly in Europe and Asia)
Participants INCLUSION CRITERIA: Patients with type 2 diabetes, OADs for ≥ 3 months, aged
18 to 80 years old, HbA1c 7% to 11% (previous OAD monotherapy) or 7% to 10%
(previous OAD combination therapy), BMI ≤ 45 kg/m2
EXCLUSION CRITERIA: Using insulin within 3 months, impaired liver or renal
function, uncontrolled hypertension (≥ 180/100 mmHg), cancer, use of any drug apart
from OAD likely to affect glucose concentrations
AGE: 54.7 SD 10.0 to 57.7 SD 9.0 years
SEX: 47% to 55% female
DIABETES DURATION: (median, 25th and 75th percentile) 6.5 (3.7, 10.5) to 6.7 (4.
0, 10.7) years
ETHNICITY: NR
HbA1c (%): LIR 1.2 mg: 8.5 SD 1.1; LIR 1.8 mg: 8.5 SD 0.9; Placebo: 8.4 SD 1.0;
ROS (rosiglitazone): 8.4 SD 1.0
BMI (kg/m2): LIR 1.2 mg: 29.8 SD 5.1; LIR 1.8 mg: 30 SD 5.1; Placebo: 30.3 SD 5.
4; ROS: 29.4 SD 4.8
PREVIOUS THERAPY: Previously on mono-therapy: 27% to 32%, on combination
therapy: 68% to 73%
NUMBERS: 1712 screened; Randomised: 1041 (1 to 37 participants per centre); LIR
0.6 mg: 233; LIR 1.2 mg: 228; LIR 1.8 mg: 234; Placebo: 114; ROS: 232
Interventions COMPARISON: LIR (3 doses) + Glimepiride (SU) VERSUS Placebo + SU VERSUS
ROS (TZD) + SU
NO. OF COMPARISON GROUPS: 5 (LIR 0.6 mg not considered in the present
review)
DOSE LIR: 1.2 mg and 1.8 mg: LIR up-titrated weekly in 0.6 mg increments until the
allocated dose reached; injected subcutaneously once daily
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DOSE SU: Forced glimepiride titration for 2 weeks and then 2 weeks maintenance
period; glimepiride 2 to 4 mg/day
DOSE TZD: 4 mg/day rosiglitazone
OTHER TREATMENT: NR
Outcomes PRIMARY OUTCOMES: HbA1c (change from baseline to end of treatment)
SECONDARY OUTCOMES: Proportion of participants reaching targeted goals of
HbA1c (≤ 7%, ≤ 6.5%), FPG (5 to ≤ 7.2 mmol/L), PPG (10 mmol/L); body weight,
FPG (fasting plasma glucose), PPG (post prandial glucose), beta-cell function, blood
pressure; superiority of liraglutide to placebo and non-inferiority to rosiglitazone was
tested
OTHER OUTCOMES: Hypoglycaemic episodes based on PG levels (< 3.1 mmol/
L) (minor: self-treated; major: requiring third party assistance), liraglutide antibodies
including cross-reacting and neutralizing antibodies, tolerability (gastrointestinal com-
plaints), pulse, adverse events, vital signs, ECG, biochemical and haematological param-
eters, calcitonin
Notes AIM: To compare efficacy and safety of liraglutide and glimepiride combination therapy
with either placebo or rosiglitazone added to glimepiride
SOURCE OF FUNDING: Novo Nordisk
OTHER: Conflict of interest: One author had received lecture fees from Novo Nordisk,
Servier, MSD. The second author had received honoraria, grants and lecture fees from
Novo Nordisk. The remaining authors had no conflict of interest
SAMPLE SIZE: A combined power (calculated as the product of the marginal powers
for HbA1c and body weight) of at least 85% was required
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information; participants were
stratified according to previous treatment
(monotherapy or combination therapy)
Allocation concealment (selection bias) Unclear risk Insufficient information




Incomplete outcome data (attrition bias)
All outcomes
Low risk Comparisons made on the intent to treat
population, missing data imputed using
last observation carried forward, adequate
description of withdrawals and losses to fol-
low-up (overall 14%withdrawals, 9 to 27%
in the individual groups)
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Selective reporting (reporting bias) Low risk All pre-specified (primary and secondary)
outcomes were reported
L - LEAD 2 Nauck 2009
Methods TRIAL DESIGN: RCT, double dummy, active control, parallel group trial (part of a
phase 3 clinical development program for liraglutide), multicenter (170 sites)
DURATION OF INTERVENTION: 26 weeks
DURATION OF FOLLOW-UP: No post-intervention follow-up
RUN-IN PERIOD: 6 weeks
SETTING: Not reported
COUNTRY:Multinational (21 countries)
Participants INCLUSION CRITERIA: People with type 2 diabetes, age 18 to 80 years old, HbA1c
between 7% and 11% (prestudy OAD monotherapy for ≥ 3 months) or between 7%
and 10% (prestudy combination OAD therapy for ≥ 3 months), BMI ≤ 40 kg/m2
EXCLUSIONCRITERIA: Patients who had used insulin during the previous 3months
(except short term treatment)
AGE: mean 56 to 57 years (SD 9)
SEX: 40% to 46% female
DIABETES DURATION: mean 7 to 8 years (SD 5)
ETHNICITY: 88% to 89%White, 2% to 4% Black, 7% to 9% Asian, 1% to 3% other
HbA1c (%): LIR 1.2 mg: 8.3 SD 1, LIR 1.8 mg: 8.4 SD 1, SU: 8.4 SD 1, Placebo: 8.4
SD 1.1
BMI (kg/m2): LIR 1.2 mg: 31.1 SD 4.8, LIR 1.8 mg: 30.9 SD 4.6, SU: 31.2 SD 4.6,
Placebo: 31.6 SD 4.4
PREVIOUS THERAPY: 65% combination therapy, 35% monotherapy (88% met-
formin)
NUMBERS: Randomised: 1091 (4 withdrew consent before treatment), Analysed as
ITT: 1087; LIR 0.6 mg: 242, LIR 1.2 mg: 240, LIR 1.8 mg: 242, SU: 242, Placebo:
121
Interventions COMPARISON: Liraglutide (LIR) (3 doses) + Metformin (MET) VERSUS
Glimepiride (SU) + MET VERSUS Placebo + MET
NO. OF COMPARISON GROUPS: 5
RUN-IN: Forced titration period of metformin for three weeks (dose increased up to
2000 mg/day: 1000 mg in the morning and 1000 mg in the evening) followed by a 3
week metformin maintenance period before randomisation
DOSE LIR: 0.6, 1.2 or 1.8 mg/day injected subcutaneously once daily (0.6 mg not
included in this review). LIR titrated after randomisation for 2 to 3 weeks (increase by
0.6 mg/day per week)
DOSE MET: 1500 to 2000 mg/day
DOSE SU: 4 mg glimepiride OD with the first meal of the day. Glimepiride (SU)
titrated after randomisation for 2 to 3 weeks (1 mg in week 1, 2 mg week 2, 4 mg week
3)
OTHER TREATMENT: not reported
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Outcomes PRIMARY OUTCOMES: Change in HbA1c at the end of the study
SECONDARYOUTCOMES:Bodyweight, fasting plasma glucose (FPG), postprandial
glucose (PPG) (7 point plasma glucose profiles: before each meal, 90 min after breakfast)
, beta cell function (based on fasting insulin, fasting C-peptide, fasting proinsulin-to-
insulin ratio and the homeostasis model assessment index of beta cell function (HOMA-
B))
OTHEROUTCOMES: Adverse events, vital signs, electrocardiogram, biochemical and
hematologymeasures, and subject-reported hypoglycaemic episodes (based on symptoms
and plasma glucose <3.1 mmol/L)
Notes AIM: To study the efficacy and safety of Liraglutide as a combination therapy with
metformin as compared with placebo and glimepiride in addition to metformin
SOURCE OF FUNDING: Novo Nordisk (presumably)
OTHER: Conflict of interest: Some authors are members of advisory board and have
received honoraria from Novo Nordisk, and work for Novo Nordisk
SAMPLE SIZE:The combined power (calculated as the product of the marginal powers
for A1C and weight) was at least 85%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned as 2:2:2:1:2. Telephone
or web based randomisation. Patients ran-
domly assigned to the lowest available
randomisation number and stratified with
respect to their previous use of OAD
monotherapy or combination therapy
Allocation concealment (selection bias) Low risk Telephone or web based randomisation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missingdatawere imputed as the last obser-
vation carried forward, ITT analysis, ade-
quate description of withdrawals and losses
to follow-up (19% withdrawals and losses
to follow-up)
Selective reporting (reporting bias) Low risk Included all expected outcomes, including
those prespecified
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Methods TRIAL DESIGN: RCT (1:1:1), placebo control, parallel group, multicenter (96 sites)
DURATION OF INTERVENTION: 26 weeks
DURATION OF FOLLOW-UP: No post-intervention follow-up
RUN-IN PERIOD: 6 to 9 weeks
SETTING: Not reported
COUNTRY: USA and Canada
Participants INCLUSION CRITERIA: people with type 2 diabetes, 18 to 80 years of age HbA1c
between 7% to 11% (prestudy OAD monotherapy for ≥ 3 months or 7% to 10%
(prestudy OAD combination therapy for ≥ 3 months, BMI ≤ 45kg/m2 ; eligibility
for randomisation: participants tolerating maximum doses of OAD (metformin and
rosiglitazone) and with FPG values of 135 to 230 mg/dL (7.5 to 12.8 mmol/L) after 6
weeks treatment with titrated dose
EXCLUSION CRITERIA: Participants using insulin during the previous 3 months
(except short term treatment)
AGE: mean 55 years (SD 10)
SEX: 38% to 49% female
DIABETES DURATION: mean 9 years (SD 6)
ETHNICITY: 81% to 84%White, 10% to 15% Black, 1% to 3% Asian, 1% American
Indian, 2% to 3% other
HbA1c (%): LIR 1.2 mg: 8.5 SD 1.2, LIR 1.8 mg: 8.6 SD 1.2, Placebo: 8.4 SD 1.2
BMI (kg/m2): LIR 1.2 mg: 33.2 SD 5.4, LIR 1.8 mg: 33.5 SD 5.1, Placebo: 33.9 SD
5.2
PREVIOUS THERAPY: 17% monotherapy, 83% combination therapy
NUMBERS: 533 randomised; LIR 1.2 mg:178; LIR 1.8 mg:178; Placebo:177
Interventions COMPARISON: Liraglutide (LIR) (2 doses) + Metformin (MET) + Rosiglitazone
(TZD) VERSUS Placebo + MET + TZD
NO. OF COMPARISON GROUPS: 3
RUN-IN: Treatment with other OADs except MET and TZD were discontinued prior
to randomisation. MET dose started at 500 mg and was titrated up to 2000 mg/day.
Rosiglitazone (TZD) dose started at 4 mg and was titrated up to 8 mg/day
DOSE LIR: LIR 1.2 mg/day or 1.8 mg/day injected subcutaneously once daily. LIR
started with 0.6 mg/day for a week and increased up to 1.2 mg/day and then to 1.8 mg/
day after an additional week for those randomised to highest dose
DOSE MET: 2000 mg/day (1000 mg in the morning and 1000 mg in the evening)
DOSE TZD: Rosiglitazone 8 mg/day (4 mg in the morning and 4 mg in the evening)
OTHER TREATMENT: None
Outcomes PRIMARY OUTCOMES: HbA1c (change from randomisation to end of study)
SECONDARY OUTCOMES: Change in following parameters: body weight, FPG
(Fasting plasma glucose), PPG (Postprandial glucose) (from 7-point plasma glucose
profiles), beta-cell function (based on fasting insulin, fasting C-peptide, fasting pro-
insulin to insulin ratio, and the homeostasis model assessment (HOMA) for beta cells
(HOMA-B) and insulin resistance (HOMA-IR)), blood pressure, lipids
OTHER OUTCOMES: Safety variables including adverse events, vital signs, ECG,
biochemical and haematology measures, and subject reported hypoglycaemic episodes
(plasma glucose < 3.1 mmol/L)
Superiority of liraglutide tested
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Notes AIM:To study the efficacy and safety of Liraglutide as a combination therapy with
metformin and rosiglitazone in type 2 diabetes
SOURCE OF FUNDING: Novo Nordisk (presumably)
OTHER: Conflict of interest Novo Nordisk, Denmark
SAMPLE SIZE:The combined power (calculated as the product of the marginal powers
for HbA1c and weight) was > 95%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised as 1:1:1. Telephone or
web based randomisation; protocol states:
“Randomisation will be carried out cen-
trally using a randomisation system, IVRS/
IWRS” [Interactive voice (or web) response
system]
Allocation concealment (selection bias) Low risk Telephone or web based randomisation
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missingdatawere imputed as the last obser-
vation carried forward (LOCF), ITT anal-
ysis, adequate description of withdrawals
and losses to follow-up (24% withdrawals
and losses to follow-up)
Selective reporting (reporting bias) Low risk Included all prespecified outcomes
L - LEAD 5 Russell-J 2009
Methods TRIAL DESIGN: RCT (2:1:2), parallel group, placebo-controlled, multicenter (107
sites)
DURATION OF INTERVENTION: 26 weeks
DURATION OF FOLLOW-UP: 1 week post-intervention follow-up (but no data
given)
RUN-IN PERIOD: 6 weeks
SETTING: Not reported
COUNTRY:Multinational (17 countries)
Participants INCLUSIONCRITERIA:Peoplewith type 2diabetes, 18 to 80 years, treatedwithOAD
for at least 3months before screening,HbA1c level between 7.5% to 10% (monotherapy)
or 7% to 10% (combination therapy), BMI ≤ 45kg/m2
EXCLUSION CRITERIA: Patients who had used insulin within 3 months prior to the
trial; patients with impaired renal or hepatic function, cardiovascular disease, cancer, hy-
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pertension, retinopathy, maculopathy; pregnant patients; those with recurrent hypogly-
caemia or hypoglycaemia awareness; those who were seropositive for hepatitis B antigen
or hepatitis C antibody; or who have used any other drugs except OAD that could affect
blood glucose levels
AGE: mean 57.5 years (SD10)
SEX: 40% to 51% female
DIABETES DURATION: mean 9.2 to 9.7 years (SD 6)
ETHNICITY: Not reported
HbA1c (%): LIR: 8.3 SD 0.9, Placebo: 8.3 SD 0.9, GLAR (insulin glargine): 8.2 SD
0.9
BMI (kg/m2): LIR: 30.4 SD5 .3, Placebo: 31.3 SD 5.0, GLAR: 30.3 SD 5.3
EXISTING THERAPY: 5 to 6% monotherapy, 94% to 95% combination treatment
NUMBERS: 581 randomised, ITT population 576; LIR: 230, Placebo: 114, GLAR:
232
Interventions COMPARISON: Liraglutide (LIR) + Metformin (MET) + Glimepiride (SU) VERSUS
Placebo + MET + SU VERSUS GLAR + MET + SU
NO. Of COMPARISON GROUPS: 3
RUN-IN: Forced MET and SU dose escalation over 3 weeks followed by 3 weeks main-
tenance
DOSE LIR: 1.8 mg OD. Dose escalation starting at 0.6 mg and increasing weekly by
0.6 mg over 2 weeks
DOSE MET: 2 gm (1 gm BID)
DOSE SU: Glimepiride 4 mg OD, reduction to 2 mg allowed in case of adverse events
or hypoglycaemia
DOSE GLAR: Insulin glargine (open label). Insulin was titrated according to patient-
driven algorithm (average dose at the end of study was 24 IU/day)
OTHER TREATMENT: None
Outcomes PRIMARY OUTCOMES: HbA1c (change from baseline to end)
SECONDARYOUTCOMES:Change inweight, FPG, eight point plasma glucose (PG)
profiles, beta-cell function, and blood pressure
OTHER OUTCOMES: Safety variables like hypoglycaemic episodes, adverse events
Notes AIM: To compare the efficacy and safety of liraglutide to insulin glargine all as add on
to combination therapy of metformin and glimepiride
SOURCE OF FUNDING: Novo Nordisk (presumably)
OTHER: Conflict of interest: Novo Nordisk, Amylin Pharmaceuticals
SAMPLE SIZE: Study was powered to determine a 3% difference in weight with a
combined power > 85%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised as 2:1:1 using a telephone or
web-based randomisation system
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Allocation concealment (selection bias) Low risk Central randomisation using a telephone
or web-based randomisation system
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Investigators, participants, and study mon-
itors were blinded to liraglutide, open label
glargine
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missingdatawere imputed as the last obser-
vation carried forward (LOCF), ITT anal-
ysis, adequate description of withdrawals
and losses to follow-up (9.4% withdrawals
and losses to follow-up)
Selective reporting (reporting bias) Low risk Included all prespecified outcomes
L - LEAD 6 Buse 2009
Methods TRIALDESIGN:RCT, open label, active comparator, parallel group, multi-centre (132
sites)
DURATION OF INTERVENTION: 26 weeks
DURATION OF FOLLOW-UP: No post-intervention follow-up
RUN-IN PERIOD: None
COUNTRY: 15 countries
Participants INCLUSION CRITERIA: People with type 2 diabetes, 18 to 80 years old, HbA1c
between 7% and 11%, BMI ≤ 45 kg/m2, stable on treatment with maximally tolerated
dose of metformin, sulphonylurea, or both, for 3 months or more
EXCLUSION CRITERIA: Previous insulin treatment (except short term treatment),
previous treatment with exenatide or liraglutide, impaired renal or liver function, diseases
like retinopathy or maculopathy or related to cardiovascular requiring acute treatment,
uncontrolled hypertension, cancer
AGE: mean 56 to 57 years (SD 10)
SEX: 45% to 51% female
DIABETES DURATION: mean 7.9 to 8.5 years (SD 6)
ETHNICITY: 91% to 93% White, 1% to 5% Asian, 12% to 13% Black, 3% to 4%
other
HbA1c (%): LIR: 8.2 SD 1.0, EX: 8.1 SD 1.0
BMI (kg/m2): LIR: 32.9 SD 5.5, EX: 32.9 SD 5.7
PREVIOUS THERAPY: 62% to 64%MET plus SU, 27%MET monotherapy, 9% to
10% SU monotherapy
NUMBERS: 464 randomised; LIR: 233; EX: 231; (exposed LIR: 235; EX: 232)
Interventions COMPARISON: LIR + existing therapyMET and/or SU VERSUS EX + existing MET
and/or SU therapy
NO. OF COMPARSION GROUPS: 2
RUN-IN: None
DOSE LIR: Liraglutide 1.8 mg OD; 2 week dose escalation starting at 0.6 mg/day
increasing weekly by 0.6 mg up to 1.8 mg
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DOSE EX: Exenatide 10µg BID; 4 week dose escalation starting at 5µg BID increasing
to 10 µg BID at 4 weeks
DOSE MET: Prestudy dose
DOSE SU: Prestudy dose, in case of unacceptable hypoglycaemia SU dose could be
reduced to no less than 50% of starting dose
OTHER TREATMENT: None
Outcomes PRIMARY OUTCOMES: Change in HbA1c % from baseline to end point
SECONDARY OUTCOMES: Reduction in FPG levels (mmol/L), % of patients who
achieved a target HbA1c level ≤ 7%, % of patients who achieved a target HbA1c level
≤ 6.5%, mean change in body weight %, mean changes in self measured 7-point plasma
glucose profiles, % change inHOMA-B from baseline, mean changes in glucagon, blood
pressure and lipid profiles, overall treatment satisfaction (Diabetes Treatment Satisfaction
questionnaire) assessed in a subgroup of patients
OTHER OUTCOMES: Safety variables including adverse events, vital signs, electro-
cardiogram, biochemical and haematological measures, and patient reported hypogly-
caemic episodes were assessed
Notes AIM: To compare the effectiveness of liraglutide to exenatide as an add on therapy to
metformin and/or sulphonylurea
SOURCE OF FUNDING: Novo Nordisk
OTHER: Conflict of interest: main author is a member of advisory board and have
received honoraria from Novo Nordisk and various other pharmaceutical companies,
and work as consultant for various other pharmaceutical companies
SAMPLE SIZE: 85% power to detect an HbA1c difference of 0.4% between groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned (1:1) to the lowest
available number of the numbers allocated
to the site
Allocation concealment (selection bias) Low risk Randomisation was done with telephone
based or web based system
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Last observation carried forward data with
repeated measures analysis and multiple
imputation methods, ITT analysis, ade-
quate description of withdrawals and losses
to follow-up (17% withdrawals and losses
to follow-up)
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
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Methods TRIAL DESIGN: Active comparator, parallel-group, open label trial; non-inferiority
and superiority comparison
DURATION OF INTERVENTION: 26 weeks
DURATION OF FOLLOW-UP: After the 26 week study, participants could continue
into a 12 month follow-up trial
RUN-IN PERIOD:
SETTING: 158 office-based sites
COUNTRY: Multinational (11 European countries: Croatia, Germany, Ireland, Italy,
Netherlands, Romania, Serbia, Slovakia, Slovenia, Spain and UK; the USA and Canada)
Participants INCLUSION CRITERIA: Participants aged between 18 to 80 years; type 2 diabetes
mellitus, HbA1c of 7.5% to10.0%; BMI ≤ 45 kg/m2; treated with metformin ≥ 1500
mg daily for 3 months or longer
EXCLUSION CRITERIA: Previous treatment with any antihyperglycaemic drug apart
from metformin within 3 months of the trial; recurrent major hypoglycaemia or hy-
poglycaemia unawareness; present use of any drug except metformin that could affect
glucose; contraindications to trial drugs; impaired renal or hepatic function; clinically
significant cardiovascular disease; or cancer
AGE: 55.0 SD 9.0 to 55.9 SD9.6 years
SEX: 45% to 48% female (LIR 1.2 mg: 48%; LIR 1.8 mg: 48%; SITA: 45%)
DIABETES DURATION: 6.0 SD 4.5 to 6.4 SD 5.4 years
ETHNICITY: 82% to 91% White (15% to 17% Hispanic or Latino); 5% to 10%
Black; 1% to 2% Asian or Pacific Islander; 4% to 5% Other
HbA1c (%): LIR 1.2 mg: 8.4 SD 8.0; LIR 1.8 mg: 8.4 SD 0.7; SITA: 8.5 SD 0.7
BMI (kg/m2): LIR 1.2 mg: 32.6 SD 5.2; LIR 1.8 mg: 33.1 SD 5.1; SITA: 32.6 SD 5.4
PREVIOUS THERAPY: MET
NUMBERS: Assessed: 1302; randomised: 665 (LIR 1.2 mg: 225; LIR 1.8 mg: 221;
SITA: 219); full analysis set: 658 (LIR 1.2 mg: 221; LIR 1.8 mg: 218; SITA: 219); fully
analysis/safety analysis set: 658 (LIR 1.2 mg: 221; LIR 1.8 mg: 218; SITA: 219)
Interventions COMPARISON: LIR 1.2 mg or 1.8 mg once daily + MET VERSUS SITA 100 mg
daily + MET
NO. OF COMPARISON GROUPS: 3
DOSE LIR: LIR started at 0.6 mg/day and escalated by 0.6 mg/week to the allocated
dose; s.c. with a pen device
DOSE SITA: SITA was started and maintained at 100 mg/day.
DOSE MET: Background treatment with MET remained stable.
OTHER TREATMENT: NR
Outcomes PRIMARY OUTCOMES: Change in HbA1c from baseline to week 26
SECONDARY OUTCOMES: Superiority and non-inferiority comparisons; propor-
tions of participants reaching HbA1c targets of less than 7.0% (ADA) or of 6.5% or
lower (AACE, IDF,NICE); FPG; PPG; bodyweight;β-cell function; fasting lipid profile;
cardiovascular risk markers (high sensitivity C-reactive protein, plasminogen activator
inhibitor type 1, N-terminal pro-B-type natriuretic peptide, adiponectin, interleukin-
6, tumour necrosis factor α, and von Willebrand factor); BP; HR; physical measures
(waist circumference, waist-to-hip ratio); treatment satisfaction; and a composite end-
point of proportions of participants with HbA1c < 7% with no hypoglycaemia, and
weight change of 0kg or less
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OTHER OUTCOMES: Adverse events, self-reported hypoglycaemia, and selected
haematological and biochemical measures including calcitonin.
Minor hypoglycaemic episodes (PG < 3.1 mmol/L); Major hypoglycaemic episodes
(third-party assistance irrespective of glucose concentrations)
Notes AIM: To compare the efficacy and safety of treatment with liraglutide or sitagliptin for
26 weeks in individuals with type 2 diabetes who did not achieve adequate glycaemic
control with metformin
SOURCE OF FUNDING: Novo Nordisk
OTHER: Conflict of interest: Authors have received grants and consultancy fees from
different pharmaceutical companies
SAMPLE SIZE: To show that 1.8 mg liraglutide plus metformin was non-inferior to
100 mg sitagliptin with metformin with a margin of 0.4%, 163 participants per group
were needed for 85% power and with a predicted withdrawal of 25%, 217 participants
per group were needed.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated by Novo Nordisk;
participants randomly assigned in a 1:1:1
ratio, stratified by country, to receive 1.2
mg or 1.8 mg s.c. liraglutide once daily or
100 mg oral sitagliptin once daily
Allocation concealment (selection bias) Low risk Computer-generated; consecutive alloca-
tion of the randomisation code to individ-
ual participants was concealed by use of a
telephone-based (interactive voice response
system) or web-based (interactive web re-
sponse system) randomisation system
Blinding (performance bias and detection
bias)
All outcomes
High risk Open label; data were masked from the
statistician until database release
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary efficacy analyses: full analysis set
with missing values imputed by last obser-
vation carried forward; Secondary efficacy
analyses: full analysis set, apart from treat-
ment satisfaction analyses, in which miss-
ing data were no imputed; Superiority: full
analysis set; Non-inferiority: full analysis
and per-protocol sets.
Adequate description of withdrawals and
loss to follow up.
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Selective reporting (reporting bias) Low risk All prespecified outcomes reported
L - Yang 2010
Methods TRIAL DESIGN: Double-blind, double dummy, randomised, four-arm, active control
trial
DURATION OF INTERVENTION: 16 weeks
DURATION OF FOLLOW-UP:
RUN-IN PERIOD: Eligible participants discontinued their pretrial OADs except met-
formin and entered a 3-week run-in with forced escalation of metformin to 2000 mg/
day, followed by another 3-week metformin maintenance period
SETTING: China (17 sites), South Korea (10 sites) and India (24 sites)
COUNTRY: China, South Korea and India
Participants INCLUSIONCRITERIA: Participants diagnosed with type 2 diabetes and treated with
one or more oral antidiabetic drugs (OADs) for at least 3 months, aged 18 to 80 years
(18 to 75 years for Chinese subjects), with HbA1c ≥ 7.0% and≤ 11.0% for subjects on
OADmonotherapy or≥ 7.0% and≤ 10.0% for subjects on OAD combination therapy
and BMI ≤ 45.0 kg/m2.
EXCLUSION CRITERIA: Participants treated with insulin within the last 3 months.
AGE: 52.7 SD 9.1 to 53.6 SD9.7 years
SEX: 41.6% to 46.2% female (LIR 1.2 mg: 45.1%; LIR 1.8 mg: 46.2%; GLIM
(Glimepiride): 41.6%)
DIABETES DURATION: 7.2 SD 5.2 to 7.8 SD 6.1 years
ETHNICITY: NR
HbA1c (%): LIR 1.2 mg: 8.6 SD 1.1; LIR 1.8 mg: 8.6 SD 1.1; GLIM: 8.5 SD 1.1
BMI (kg/m2): LIR 1.2 mg: 25.4 SD 3.7; LIR 1.8 mg: 25.8 SD 3.8; GLIM: 25.3 SD 3.
7
PREVIOUS THERAPY: OAD monotherapy: 29.4% to 32.1%; OAD combination:
67.9% to 70.6%
NUMBERS: Randomised: 926; Exposed: 928 (LIR 1.2 mg: 233; LIR 1.8 mg: 233;
GLIM: 231); per-protocol set: 562 (LIR 1.2 mg: 179; LIR 1.8 mg: 172; GLIM: 211)
Interventions COMPARISON: LIR 0.6mg/1.2mg/1.8mg +MET +GLIM PlaceboVERSUSGLIM
+ MET + LIR placebo
NO. OF COMPARISON GROUPS: 3 (LIR 0.6 mg arm excluded)
DOSE LIR 1.2 mg/ LIR 1.8 mg: dose of LIR was increased from 0.6 mg/day to the
respective target dose level (in steps of 0.6 mg/day per week) LIR was injected once daily
at any time of the day
DOSE GLIM: Subjects were instructed to start dose escalation of GLIM by daily ad-
ministration of a 1 mg capsule. Further dose escalation took place over a 2-week period,
incrementing to a maximum dose of 4 mg/day
DOSE LIR PLACEBO: dose of LIR placebo was increased from 0.6 mg/day to the
respective target dose level (in steps of 0.6 mg/day per week) LIR was injected once daily
at any time of the day
DOSEGLIMPLACEBO: start dose escalation ofGLIMplaceboby daily administration
of a 1 mg capsule. Further dose escalation took place over a 2-week period, incrementing
to a maximum dose of 4 mg/day
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OTHER TREATMENT:
Outcomes PRIMARY OUTCOMES: Change in HbA1c from baseline to the end of the trial
SECONDARY OUTCOMES: Changes in body weight, FPG, 7-point self-measured
plasma glucose profile [before each main meal (breakfast, lunch and dinner), 90 min
after start of each main meal, and at bedtime], blood pressure (BP) and β-cell function
measured by the homeostasis model assessment index of β-cell function and the pro-
insulin to insulin ratio
OTHEROUTCOMES: Safety variables included AEs, physical examination, pulse rate,
electrocardiogram, haematology, biochemistry and urine measures, formation of liraglu-
tide antibodies and subject reported hypoglycaemic events (based on symptoms and
plasma glucose < 3.1 mmol/L). Minor hypoglycaemic events were self-treated; major
events required third-party assistance
Notes AIM: To assess and compare the efficacy and safety of liraglutide with those of
glimepiride, both in combination with metformin for the treatment of type 2 diabetes
in Asian population from China, South Korea and India
SOURCE OF FUNDING: Novo Nordisk
OTHER: Conflict of interest: Two authors are employees of Novo Nordisk. Other
authors have no competing interests
SAMPLE SIZE: In order to be able to show that liraglutide was non-inferior to
glimepiride when using a 1 : 1 : 1 : 1 randomisation and a non-inferiority margin of
0.4% (difference in HbA1c reduction) with a power of at least 85%, the sample size
needed was 168 subjects per group. Assuming a drop out rate of 25%, the total number
of subjects to be randomised was 896 (224 subjects for each dose of the liraglutide +
metformin group and 224 in glimepiride + metformin group)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Inadequate information; participants were
stratified with respect to their pretrial OAD
therapy (monotherapy or combination)
and randomised into 1:1:1:1 ratio
Allocation concealment (selection bias) Unclear risk No information
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Full analysis set (FAS) with LOCF; ade-
quate description of adverse events, with-
drawals and loss to follow-up
Selective reporting (reporting bias) Low risk All the pre-defined and pre-specified out-
comes were reported
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Methods TRIAL DESIGN: Multinational, randomised, double-blind, parallel-group, placebo
controlled trial
DURATION OF INTERVENTION: 13 weeks
DURATION OF FOLLOW-UP:




Participants INCLUSION CRITERIA: Participants with type 2 diabetes at least 1 year’s duration
aged 30 to 75 years and inadequately controlled (HbA1c ≥ 7.0 and < 9.0%) on stable
metformin monotherapy (≥ 1000 mg day) for at least 3 months prior to screening
EXCLUSION CRITERIA: History of gastrointestinal disease with prolonged nausea
and vomiting during the previous 6 months; history of chronic pancreatitis or stomach/
gastric surgery; severe cardiovascular events during the previous 6 months; or hepatic
or renal disease at screening [serum creatinine ≥ 114.4 µmol/L for males and ≥ 106.8
µmol/L for females
AGE: 55.4 SD 9.2 to 56.8 SD 7.8 years
SEX: 40.4% to 63% female
DIABETES DURATION: 6.0 SD 4.8 to 7.2 SD 4.9 years
ETHNICITY: 64.8% to 86.8%Caucasian, 1.8% to 16.7%Black, 9.3% to 21.8%Other
HbA1c (%): LIXI 5 µg QD: 7.58 SD 0.7; LIXI 10 µg QD: 7.52 SD 0.6; LIXI 20 µg
QD: 7.58 SD 0.7; LIXI 30 µg QD: 7.52 SD 0.7; LIXI 5 µg BID: 7.60 SD 0.6; LIXI
10 µg BID: 7.54 SD 0.6; LIXI 20 µg BID: 7.61 SD 0.7; LIXI 30 µg BID: 7.46 SD 0.
5; Placebo: 7.53 SD 0.6
BMI (kg/m2): LIXI 5 µg QD: 30.7 SD 4.6; LIXI 10 µg QD: 31.9 SD 4.0; LIXI 20 µg
QD: 32.0 SD 4.3; LIXI 30 µg QD: 31.6 SD 3.6; LIXI 5 µg BID: 31.6 SD 4.2; LIXI
10 µg BID: 32.8 SD 4.4; LIXI 20 µg BID: 32.7 SD 4.4; LIXI 30 µg BID: 32.3 SD 4.
5; Placebo: 31.7 SD 4.2
PREVIOUS THERAPY: MET
NUMBERS: Screened: 1466; randomised: 542 (LIXI 5 µg QD: 55; LIXI 10 µg QD:
52; LIXI 20 µg QD: 55; LIXI 30 µg QD: 54; LIXI 5 µg BID: 53; LIXI 10 µg BID:
56; LIXI 20 µg BID: 54; LIXI 30 µg BID: 54; Placebo: 55)
Interventions COMPARISON: Lixisenatide (LIXI) 5 µg, 10 µg, 20 µg and 30 µg QD or BID
VERSUS Placebo
NO. OF COMPARISON GROUPS: 9
DOSE LIXI: Subcutaneous injections of LIXI doses of 5, 10, 20 or 30 µg administered
once daily or, twice daily within 1 hour before breakfast
DOSEPLACEBO:One of four volume-matched placebo treatments administered twice
daily
DOSE MET: Stable doses of MET
OTHER TREATMENT: All patients received diet and lifestyle counselling according
to the American Diabetes Association guidelines
Outcomes PRIMARY OUTCOMES: Change in HbA1c from baseline to end of study.
SECONDARY OUTCOMES: Percentage of patients achieving an HbA1c ≤ 7.0 or
≤ 6.5%, changes in body weight, FPG, and 2 h post-prandial plasma glucose after
a standardized breakfast. Measurement of anti-lixisenatide antibody levels; safety and
tolerability
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OTHER OUTCOMES: Assessed by physical examination, adverse event reporting,
blood pressure, heart rate, 12-lead ECG and standard laboratory measurements. Symp-
tomatic hypoglycaemia was defined as symptoms consistent with hypoglycaemia, with
an accompanying blood glucose < 3.3 mmol/L or prompt recovery with carbohydrate
Notes AIM: To evaluate thoroughly the dose-response effect of lixisenatide using once- or
twice-daily regimens (5 to 30 µg once or twice daily) on HbA1c changes over 13 weeks
in metformin-treated patients with Type 2 diabetes
SOURCE OF FUNDING: sanofi-aventis, the manufacturer of lixisenatide.
OTHER: Conflict of interest: First author has received research support from different
pharmaceutical companies and has acted as a consultant for some of the companies.
Another author has served on advisory boards and received honorarium or consult-
ing fees from different pharmaceutical companies. He has also received research grants
fromMerck, Pfizer, sanofi-aventis, Novo Nordisk, Bristol-Myers Squibb, Eli Lilly, Glax-
oSmithKline, Forest, Takeda, Novartis, AstraZeneca, Amylin, Johnson & Johnson, Dai-
ichi Sankyo, Boehringer Ingelheim andMannKind. One author is an employee of sanofi-
aventis
SAMPLE SIZE: Sample sizes of 50 patients in each active treatment group and 100
patients in the placebo group were calculated to provide a statistical power of 81% to
detect a 0.6% (6.6 mmol/mol) difference in HbA1c between an active treatment and
placebo assuming a standard deviation of 1.2% (13.1 mmol/L). Statistical significance
was assumed at the 5% level
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised to one of 12 treatment arms
(2:2:2:2:2:2:2:2:1:1:1:1) using interactive
voice response system
Allocation concealment (selection bias) Low risk Interactive voice response system.
Blinding (performance bias and detection
bias)
All outcomes
Low risk The study drug, added-on to stable met-
formin, was double-blind regarding active
treatment or placebo and open-label re-
garding the treatment volume
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis; adequate description of with-
drawals and losses to follow up
Selective reporting (reporting bias) Low risk All the prespecified and predefined out-
comes were reported.
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Methods TRIAL DESIGN: Randomised, placebo-controlled, double-blind study
DURATION OF INTERVENTION: 16 weeks
DURATION OF FOLLOW-UP:
SETTING: multiple (36 sites in United States and 3 sites in Puerto Rico)
COUNTRY: United States; Puerto Rico
Participants INCLUSION CRITERIA: Participants at least 18 years of age with type 2 diabetes;
BMI between 27 and 40 kg/m2; HbA1c > 7.0% but ≤ 10.5%; stable weight for at
least 3 months at entry; receiving stable therapy for at least 3 months with an oral
antihyperglycaemic medications from each of the two different classes (sulphonylurea,
biguanide, thiazolidinedione or DPP-IV inhibitors)
EXCLUSION CRITERIA: previous use of GLP-1 or a GLP-1 analogue, or current use
of insulin or weight-loss medication; history of clinically significant gastric emptying
abnormality, cardiovascular disorders or uncontrolled diabetes requiring hospitalisation
more than once in the previous 6 months
AGE: 54 SD 11 to 59 SD 12 years
SEX: 46% to 56% of female
DIABETES DURATION: 7.5 SD 5.4 to 9.0 SD 7.6 years
ETHNICITY: 55% to 61% Caucasians; 29% to 39% Hispanic;
HbA1c (%): LY 0.5/1.0 QW: 8.25 SD 0.9; LY 1.0/1.0 QW: 8.25 SD 1.0; LY 1.0/2.0
QW: 8.43 SD 1.0; Placebo: 8.05 SD 0.8
BMI (kg/m2): LY 0.5/1.0 QW: 33.7 SD 4.1; LY 1.0/1.0 QW: 33.9 SD 4.0; LY 1.0/2.0
QW: 34.2 SD 4.1; Placebo: 33.9 SD 4.3
PREVIOUS THERAPY: 72.7% to 73.8%MET + SU; 12.3% to 13.6% MET + TZD;
7.6% to 9.1% MET + DPP-IV: 4.5% to 6.2% other; 9.1% to 13.8% discontinued
NUMBERS: LY 0.5/1.0 QW: 66; LY 1.0/1.0 QW: 65; LY 1.0/2.0 QW: 65; Placebo: 66
Interventions COMPARISON: LY 0.5/1.0 QW or LY 1.0/1.0 QW or LY 1.0/2.0 QW VERSUS
Placebo
NO. OF COMPARISON GROUPS: 4
LEAD- IN PERIOD: All participants under went two weeks lead-in period of placebo
injection
DOSE LY 0.5/1.0: Once weekly subcutaneous injection of LY 0.5 mg for 4 weeks
followed by 1.0 mg for 12 weeks
DOSE LY 1.0/1.0: Once weekly subcutaneous injection of LY 1.0 for 16 weeks
DOSE LY 1.0/2.0: Once weekly subcutaneous injection of LY 1.0 for 4 weeks then 2.0
mg for 12 weeks
DOSE Placebo: Once weekly subcutaneous injection of placebo for 16 weeks
OTHER TREATMENT: Participants continued their baseline oral antihyperglycaemic
medications regimen
Outcomes PRIMARY OUTCOMES: Change in HbA1c
SECONDARY OUTCOMES: Changes in FPG, blood glucose responses following a
solid mixed-meal test, body weight, HOMA-2 algorithm to assess β -cell function (%-
B), insulin sensitivity (%-S) and resistance (%-IR)
OTHEROUTCOMES: Safety and tolerability that includes treatment emergent adverse
events, hypoglycaemia, vital signs and laboratory tests
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Notes AIM: To evaluate the efficacy and tolerability of once-weekly LY2189265 (LY), a GLP-
1 IgG4-Fc fusion protein, in participants with type 2 diabetes failing oral antihypergly-
caemic medications
SOURCE OF FUNDING: Eli Lilly and Company
OTHER: First author has received research support from different pharmaceutical com-
panies and has acted as a consultant for some of the companies. Another author has
served on advisory boards and received honorarium or consulting fees from different
pharmaceutical companies. He has also received research grants from some of these com-
panies. Two authors are employees and shareholders of Eli Lilly and Company. One
author was a shareholder, and during the conduct of the study and preparation of the
paper, an employee, of Eli Lilly and Company
SAMPLE SIZE: Sixty patients per arm were estimated to provide 90% power at a 2-
sided α of 0.05 to detect a 0.9% change from baseline in HbA1c relative to placebo,
assuming a standard deviation of 1.3 and 20% dropout rate
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was carried out using a
computer-generated random sequence and
was stratified according to oral antihyper-
glycaemic medication
Allocation concealment (selection bias) Unclear risk Inadequate information




Incomplete outcome data (attrition bias)
All outcomes
Low risk All efficacy and safety analyses were per-
formed using the intent-to-treat popula-
tion
Adequate description of withdrawals and
losses to follow up
Selective reporting (reporting bias) Low risk All the prespecified and predefined out-
comes were reported.
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T - Nauck 2009
Methods TRIAL DESIGN: RCT, parallel group, placebo controlled, multi-centre, phase 2b trial
DURATION OF INTERVENTION: 8 weeks
DURATION OF FOLLOW-UP: 4 weeks post-intervention
RUN-IN PERIOD: Up to 3 week screening period
COUNTRY: Germany and Switzerland
Participants INCLUSION CRITERIA: Participants with type 2 diabetes, on metformin monother-
apy (≥ 1500 mg/day) for at least 3 months before screening, age 18 to 75 years, HbA1c
between 7.0% and 9.5%, BMI > 25 and ≤ 45 kg/m2 and stable weight (± 10%) for at
least 3 months before screening
EXCLUSIONCRITERIA:Type 1 diabetes; patient on any OAD other than metformin
during the prior three months (except insulin); previous exposure to any GLP-1 ana-
logues; impaired liver or kidney function,GI disease, uncontrolled hypertension or stroke
or myocardial infarction
AGE: mean 53 to 57 years (SD 6 to 11)
SEX: 39% to 64% female
DIABETES DURATION: mean 5 to 6 years (SD 4 to 5)
ETHNICITY: Not reported
HbA1c (%): Placebo: 8.0 SE 0.1, TAS 10 mg QW: 7.9 SE 0.1, TAS 20 mg QW: 7.8
SE 0.1, TAS 20 mg Q2W: 7.9 SE 0.1
BMI (kg/m2): Placebo: 31.8 SE 4.9, TAS 10 mg QW: 32.6 SE 4.7, TAS 20 mg QW:
32.4 SE 5.2, TAS 20 mg Q2W: 33.2 SE 5.1
PREVIOUS THERAPY: Metformin monotherapy (mean 1888 mg to 2019 mg)
NUMBERS: 306 randomised (safety database 297); Placebo: 49, TAS 5 mg QW: 50,
TAS 10 mg QW: 49, TAS 20 mg QW: 50, TAS 10 mg Q2W: 50, TAS 20 mg Q2W: 49
Interventions COMPARISON:Taspoglutide (TAS) (5 dose schedules) +Metformin (MET) VERSUS
Placebo + MET
NO. OF COMPARISON GROUPS: 6
For the current review, the following groups were excluded: 5 mg weekly and 10 mg
every 2 weeks as the effect of those groups were less favourable than those of the other
groups
RUN-IN: Screening only
DOSE TAS: Taspoglutide 10 mg or 20 mg once weekly, or 20 mg once every 2 weeks
DOSE MET: Pre-study MET regimen
OTHER TREATMENT: Patients continued their prestudy diet and exercise plan
throughout the study; patients were on a variety of other medication, such as ACE in-
hibitors, thiazide diuretics, angiotensin receptor blockers, statins, beta-blockers
Outcomes PRIMARYOUTCOMES:Change inHbA1c from baseline to end of the study (assessed
1 week after 8 consecutive weeks of treatment)
SECONDARY OUTCOMES: % of patients achieving HbA1c ≤ 7% and ≤ 6.5%;
changes in following parameters from baseline: FPG, body weight, fructosamine, C-
peptide, fasting insulin, pro-insulin, pro-insulin-to-insulin molar ratio, fasting glucagon,
lipids
OTHER OUTCOMES: Safety variables including adverse events, vital signs, physical
examination, clinical laboratory tests, electrocardiogram, local tolerance at the injection
site, anti-taspoglutide antibodies
67Glucagon-like peptide analogues for type 2 diabetes mellitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T - Nauck 2009 (Continued)
Notes AIM: To assess the efficacy and safety of taspoglutide in patient with type 2 diabetes
inadequately controlled with metformin therapy
SOURCE OF FUNDING: Hoffmann-La Roche, Switzerland.
OTHER: Association of some of the authors with Roche
SAMPLE SIZE: Sample size provided 90% power to detect a 1% difference in HbA1c
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly assigned by central
randomisation system
Allocation concealment (selection bias) Low risk Patients were randomly assigned by inter-
active voice response system




Incomplete outcome data (attrition bias)
All outcomes
Low risk Missingdatawere imputed as the last obser-
vation carried forward, ITT analysis (ITT
population comprised of all patients who
were randomly assigned, received at least
one dose of study medication, and had a
baseline and at least post-baseline HbA1C
assessment), adequate description of with-
drawals and losses to follow-up (6.5%with-
drawals / losses to follow-up)
Selective reporting (reporting bias) Low risk Included all expected outcomes, including
those prespecified
T- Ratner 2010
Methods TRIAL DESIGN: Randomized, double-blind, placebo-controlled phase II trial
DURATION OF INTERVENTION: 8 weeks
DURATION OF FOLLOW-UP: 4 weeks follow up
RUN-IN PERIOD: NR
SETTING: 27 sites
COUNTRY: Australia, France, Germany, Mexico, Peru and USA
Participants INCLUSION CRITERIA: Men and post-menopausal or surgically sterilised women
aged 18 to 75 years with type 2 diabetes mellitus, treated with a stable daily dose of
metformin monotherapy for at least 3 months before screening; dose of metformin not
adjusted during the study; HbA1c between 7.0% and 9.5%; FPG > 7mmol/L and≤ 13.
3 mmol/L; BMI > 25 kg/m2 and ≤ 45.0 kg/m2; weight ≤ ± 10% for at least 3 months
before screening.
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EXCLUSION CRITERIA: Subjects with serious co-morbidities or abnormalities in
laboratory tests; those who had previously been treated with GLP-1 receptor agonists
(including GLP-1 itself ) at any time, or with other glucose-lowering medications (apart
from metformin) or weight-loss medications within 12 to 6 weeks respectively
AGE: 55 SE 2.0 to 60 SE 2.0 years
SEX: 53% to 59% female (TAS 20/20 mg QW: 53%; TAS 20/30 mg QW; 55%; TAS
20/40 mg QW: 59%; Placebo: 59%)
DIABETES DURATION: 6 SE 1.0 to 8 SE 1.0 years
ETHNICITY: NR
HbA1c (%): TAS 20/20 mg QW: 8.0 SE0.1; TAS 20/30 mg QW: 8.0 SE0.1; TAS 20/
40 mg QW: 7.8 SE0.1; Placebo: 7.8 SE0.1
BMI (kg/m2): TAS 20/20 mg QW: 33.3 SE0.9; TAS 20/30 mg QW: 31.6 SE1.0; TAS
20/40 mg QW: 31.5 SE0.9; Plaebo: 33.2 SE1.0
PREVIOUS THERAPY: MET
NUMBERS: Randomised: 133 (TAS 20 mg QW: 32, TAS 20/30 mg QW: 33; TAS 20/
40 QW: 32; Placebo: 32); safety population: 129; ITT population: 125
Interventions COMPARISON: TAS + MET VERSUS Placebo + MET
NO. OF COMPARISON GROUPS: 4
DOSE TAS: 20 mg taspoglutide once weekly s.c. for 4 weeks followed by 4 weeks of 20
mg once weekly (20/20) or titration up to 30 mg once weekly (20/30) or 40 mg once
weekly (20/40) taspoglutide;
DOSE PLACEBO: placebo s.c. once weekly
DOSE MET: pre-study metformin regimen throughout the study
DIET and EXERCISE: pre-study diet and exercise plan throughout the study
OTHER TREATMENT: Some patients received medications for cardiovascular risk
factors: statins (22%); ACE-inhibitors (21%), fibrates (5%). ACE, thiazide diuretics,
thyroid hormones and/or lipid-loweringmedications were permitted but only with doses
stable for at least 6 weeks prior to screening
Outcomes PRIMARYOUTCOMES: GI tolerability, assessed by comparing the number of subjects
who withdrew from study because of GI adverse events
SECONDARY OUTCOMES: FPG, HbA1c, body weight and pharmacokinetic pa-
rameters.
OTHER OUTCOMES: NR
Notes AIM: To investigate the safety and tolerability of up titration to high doses of taspoglutide
in patients with type 2 diabetes mellitus
SOURCE OF FUNDING: Hoffmann-La Roche
OTHER: Conflict of interest: Two authors have received consulting and advisory board
honoraria from F. Hoffmann-La Roche as well as from other pharmaceutical companies
developing incretin-based therapies whose products may be perceived as competitive to
taspoglutide. One author has received consulting and research fees from F. Hoffman-La
Roche and Ispen. Some authors are employees of F. Hoffman-La Roche
SAMPLE SIZE:The paper says ’it was planned to enrol approximately 120 subjects into
the study assigned randomly and equally to each of the treatment groups. This sample
size was determined by practical considerations rather than formal calculations’
Risk of bias
69Glucagon-like peptide analogues for type 2 diabetes mellitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T- Ratner 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central system using a stratified randomi-
sation procedure based on disease severity
(HbA1c < 8.0% or ≥ 8.0%) to avoid im-
balances between treatment groups
Allocation concealment (selection bias) Unclear risk Central system; insufficient information




Incomplete outcome data (attrition bias)
All outcomes
Low risk Descriptive statistics were used to report
the safety results; data on secondary end-
points were analysed for the ITT popula-
tion using the last observation carried for-
ward; description of withdrawals and loss
to follow up given
Selective reporting (reporting bias) Low risk All prespecified and predefined outcomes
reported.
BMI :Bodymassindex,HbA1c:Glycosylatedhaemoglobin,ALBI :Albiglutide,MET :Metf ormin,EX:Exenatide,T ZD:T hiazolidinedione,SU :Sulphonylurea,DPP−4:Dipeptidylpeptid
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Astrup 2009 Participants without type 2 diabetes mellitus
Barnett 2007 Patients failing on either metformin therapy or sulphonylurea treatment were included, but less than 70%
of patients were on metformin therapy (only 55%)
Blonde 2006 Combined analysis of three different trials, so patients included for analysis not actually randomised
Bode 2010 Monotherpay compared to glimepiride only.
Brixner 2009 All patient received exenatide.
Buse 2004 Include patients failing on sulphonylurea only.
Feingloss 2005 Liraglutide doses used in the study are clinically not relevant
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Gallwitz 2010 Combined analysis of 3 LEAD trials (LEAD 1, 2 and 4).
Garber 2009 (LEAD 3) Previous treatment with OADs discontinued at randomisation and compared to monotherapy only
Kapitza 2009 Single-dose administration of taspoglutide with follow up duration of less than 8 weeks
Kim 2007 Patients on diet/exercise or metformin were included, but less than 70%were onmetformin therapy (60%)
Madsbad 2004 Liraglutide doses used in the study are clinically not relevant
Malloy 2009 Participants aged less than 18 years of age.
Moretto 2008 Monotherapy compared to placebo only.
Nauck 2009 Combined analysis of subset of participants from two different trials, so patients included for analysis not
actually randomised
Okerson 2010 Combined analysis of six different trials.
Riddle 2006 Combined analysis of two different trials, so patients included for analysis not actually randomised
Seino 2008 Liraglutide doses used in the study are clinically not relevant
Trescoli-Serrano 2005 Published as abstract only.
Vilsboll 2007 Monotherapy and compared to placebo only.
LEAD:LiraglutideEff ectandActioninDiabetes,OAD:Oralantidiabeticdrug
Characteristics of ongoing studies [ordered by study ID]
Albiglutide NCT00838903
Trial name or title Efficacy and safety of albiglutide in treatment of type 2 diabetes
Methods TRIAL DESIGN: Phase III, randomised, double-blind, placebo- and active-controlled, parallel-group study
DURATION OF INTERVENTION: two years
COUNTRY: USA,Germany, HongKong,Mexico, Peru, Phillipines, Russian Federation, South Africa, Spain,
UK
Participants INCLUSION CRITERIA:
• participants aged 18 years or more
• type 2 diabetes
• BMI 20 to 45 kg/m2 inclusive
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Interventions Albiglutide: Alibiglutide + metformin + placebo sitagliptin + placebo glimepiride
Sitagliptin: sitagliptin + metformin + placebo albiglutide + placebo glimepiride
Glimepiride: glimepiride + metformin + placebo albiglutide + placebo sitagliptin
Metformin: metformin + placebo albiglutide + placebo sitagliptin + placebo glimepiride
Outcomes PRIMARY OUTCOME: change in HbA1c
SECONDARY OUTCOMES: change in FPG and body weight
Starting date February 2009, estimated completion date December 2012 (last updated on June 2, 2011)
Contact information GlaxoSmithKline
Notes ClinicalTrials.gov Identifier: NCT00838903; other study ID number: 112753
Albiglutide NCT00838916
Trial name or title A study to determine the safety and efficacy of albiglutide in patients with type 2 diabetes
Methods TRIAL DESIGN: Phase III, randomised, open-label, parallel-group study
DURATION OF INTERVENTION: one year
COUNTRY: USA, Russian Federation, South Africa, UK
Participants INCLUSION CRITERIA:
• participants aged 18 years or more
• type 2 diabetes
• BMI 20 to 45 kg/m2
Interventions Albiglutide: albiglutide weekly injection
Insulin glargine: insulin glargine
Outcomes PRIMARY OUTCOME: change in HbA1c
SECONDARY OUTCOMES: change in FPG and body weight
Starting date February 2009, estimated completion date December 2012 (last updated on June 9, 2011)
Contact information GlaxoSmithKline
Notes ClinicalTrials.gov identifier: NCT00838916; other study ID number: 112754
Albiglutide NCT00849017
Trial name or title Safety and efficacy study of albiglutide in type 2 diabetes
Methods TRIAL DESIGN: Phase III, randomised, double-blind, placebo-controlled, parallel-group study
DURATION OF INTERVENTION: one year
COUNTRY: USA, Mexico
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Participants INCLUSION CRITERIA:
• participants aged 18 years or more
• type 2 diabetes
• BMI 20 to 45 kg/m2
Interventions Albiglutide: albiglutide weekly injection
Placebo: matching albiglutide placebo weekly injection
Albiglutide uptitration: albiglutide uptitration at week 12
Outcomes PRIMARY OUTCOME: change in HbA1c
SECONDARY OUTCOMES: change in FPG and body weight
Starting date January 2009, estimated completion date October 2012 (last updated on June 9, 2011)
Contact information GlaxoSmithKline
Notes ClinicalTrials.gov identifier: NCT00849017; other study ID number: 112756
Albiglutide NCT00849056
Trial name or title Safety and efficacy of albiglutide in type 2 diabetes
Methods TRIAL DESIGN: Phase III, randomised, double-blind, placebo-controlled, parallel-group trial
DURATION OF INTERVENTION: one year
COUNTRY: USA, India, Peru, South Africa, UK
Participants INCLUSION CRITERIA:
• participants aged 18 years or more
• type 2 diabetes
• BMI 20 to 45 kg/m2
Interventions Albiglutide: albiglutide weekly injection + pioglitazone (with or without metformin)
Placebo: placebo albiglutide weekly injection + pioglitazone (with or without metformin)
Outcomes PRIMARY OUTCOME: change in HbA1c
SECONDARY OUTCOMES: change in FPG and body weight
Starting date January 2009, estimated completion date October 2012 (last updated on June 9, 2011)
Contact information GlaxoSmithKline
Notes ClinicalTrials.gov identifier: NCT00849056; other study ID number: 112755
73Glucagon-like peptide analogues for type 2 diabetes mellitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Albiglutide NCT01098461
Trial name or title Dose ranging study of albiglutide in Japanese subjects
Methods TRIAL DESIGN: Phase II, double-blind, randomised, placebo-controlled, multicenter, 4-parallel-group,
dose ranging study
DURATION OF INTERVENTION: 16 weeks
COUNTRY: Japan
Participants INCLUSION CRITERIA:
• Participants aged between 20 and 75 years with a historical diagnosis of type 2 diabetes mellitus who is
currently treated with diet and exercise only or one OAD
• BMI ≥ 18 kg/m2 and < 35 kg/m2 at Screening
• HbA1c between 7.0% and 10.0%
• Fasting C-peptide ≥ 0.8 ng/mL (≥ 0.26 nmol/L)
• Female subjects of childbearing potential must be practicing adequate contraception .
• Able and willing to monitor his/her own blood glucose concentrations with a home glucose monitor.
• Able and willing to provide written informed consent
Interventions Albiglutide: subcutaneous injection albiglutide 15 mg or 30 mg weekly or 30 mg every two weeks
Placebo: subcutaneous injection of placebo to match albiglutide
Outcomes PRIMARY OUTCOME: change in HbA1c
SECONDARY OUTCOMES: change in HbA1c over time, change in FPG and body weight; Proportion of
subjects who achieve HbA1c treatment goal; pharmacokinetic levels of albiglutide
Starting date April 2010, estimated completion date March 2011 (last updated on November 18, 2010)
Contact information GlaxoSmithKline
Notes ClinicalTrials.gov Identifier: NCT01098461; other study ID number: 110932
Albiglutide NCT01128894
Trial name or title A study to determine the efficacy and safety of albiglutide as compared with liraglutide
Methods TRIAL DESIGN: Phase III, randomised, open-label, parallel-group, multicenter study
DURATION OF INTERVENTION: 32 weeks
COUNTRY: USA, Australia, Israel, Korea, Peru, Phillipines, Spain, UK
Participants INCLUSION CRITERIA:
• Diagnosis of type 2 diabetes mellitus and experiencing inadequate glycaemic control on their current
regimen of metformin, TZD, SU, or any combination of these oral antidiabetic medications
• BMI ≥ 20 kg/m2 and ≤ 45 kg/m2
• Fasting C-peptide ≥ 0.8 ng/mL (≥ 0.26 nmol/L)
• HbA1c between 7.0% and 10.0%, inclusive
• Female subjects of childbearing potential must be practicing adequate contraception.
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Interventions Albiglutide: once weekly injection
Liraglutide: liraglutide daily subcutaneous injection, starting at 0.6 mg, then up-titrating to 1.2 mg then 1.
8 mg in accordance with prescribing information
Outcomes PRIMARY OUTCOME: Evaluation of change from baseline of HbA1c levels of albiglutide as compared
with liraglutide
SECONDARY OUTCOMES: HbA1c change from baseline over time; proportion of subjects at an HbA1c
treatment goal of < 7.0% and/or < 6.5%; FPG, body weight, time for hyperglycaemia rescue
Starting date May 2010, estimated completion date September 2011 (last updated on June 9, 2011)
Contact information GlaxoSmithKline
Notes ClinicalTrials.gov identifier: NCT01128894
Exenatide QW NCT00641056
Trial name or title Efficacy of exenatide once weekly and once-daily insulin glargine in patients with type 2 diabetes treated with
metformin alone or in combination with sulfonylurea (DURATION - 3)
Methods TRIAL DESIGN: Phase III, open label, randomised, parallel assignment study (extension study)
DURATION OF INTERVENTION: 26 weeks
COUNTRY: USA,Australia, Belgium,CzechRepublic,Denmark, France,Germany,Greece,Hungary,Korea,
Mexico, Netherlands, Puerto Rico, Russian Federation, Spain, Taiwan,
Participants INCLUSION CRITERIA:
• Has type 2 diabetes and at least 18 years of age at screening.
• HbA1c of 7.1% to 11.0%, inclusive, at screening.
• BMI of 25 kg/m2 to 45 kg/m2, inclusive, at screening.
• Have a history of stable body weight (not varying by > 5% for at least 3 months prior to screening).
• Have been treated with metformin for at least 3 months and have been taking a stable dose for at least
8 weeks prior to screening or,
• Have been treated with metformin for at least 3 months and have been taking a stable dose for at least
8 weeks prior to screening and have been treated with SU for at least 3 months and have been taking a stable
dose of at least an optimally effective dose of brand of SU for 8 weeks prior to screening.
Interventions Exenatide: exenatide 2 mg once weekly subcutaneous injection
Insulin glargine: variable dose once daily subcutaneous injection,
Outcomes PRIMARY OUTCOME: Estimate the difference in change in HbA1c from baseline to treatment endpoint
between 2.0mg exenatide once weekly and insulin glargineQD in patients with type 2 diabetes and inadequate
glycaemic control using Met alone or in combination with SU
SECONDARY OUTCOMES:
• Compare exenatide once weekly and insulin glargine with respect to the proportion of patients
achieving HbA1c ≤ 7% and ≤ 6.5%; fasting serum glucose; change in body weight; 1,5-anhydroglucitol; 8-
point self-monitored blood glucose profile; serum lipids
• Compare exenatide once weekly and insulin glargine with respect to frequency and rate of
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hypoglycaemic events; patient-reported health outcomes; long-term maintenance of glycaemic control,
safety, and tolerability.
Starting date April 2008, estimated completion date January 2012 (last updated on December 3, 2010)
Contact information Eli Lilly and Company
Notes ClinicalTrials.gov identifier: NCT00641056; other study ID number: H8O-MC-GWBR (DURATION - 3)
Exenatide QW NCT00917267
Trial name or title A study to examine the effects of exenatide once-weekly injection on glucose control and safety in Asian
subjects
Methods TRIAL DESIGN: Phase III, randomised, open-label trial
DURATION OF INTERVENTION: 26 weeks
COUNTRY: China, India, Japan, Korea, Taiwan
Participants INCLUSION CRITERIA:
• Have been diagnosed with type 2 diabetes.
• Have suboptimal glycaemic control as evidenced by an HbA1c between 7.1% and 11.0% inclusive.
• Have a BMI of > 21 kg/m2 and < 35 kg/m2, inclusive.
• Have a history of stable body weight (not varying by > 5% for at least 90 days prior to study start).
• Have been treated with a stable dose regimen of Met, SU, TZD, Met plus SU, Met plus TZD, or SU
plus TZD for at least 90 days prior to study start.
Interventions Exenatide QW: 2 mg once weekly subcutaneous injection
Exenatide BID: 5 µg subcutaneous injection twice a day in the first four weeks then, 10 µg subcutaneous
injection twice a day (22 weeks)
Outcomes PRIMARY OUTCOME: change in HbA1c
SECONDARY OUTCOMES: proportion of patients achieving HbA1c ≤ 7% and ≤ 6.5%; fasting serum
glucose; bodyweight; parameters related to glycaemic control, including fasting&postprandial plasma glucose
& 6-point SMBG profiles; serum lipids; incidence and rate of hypoglycaemic events; safety, tolerability, and
treatment-emergent events; beta-cell function (HOMA-B) and insulin sensitivity (HOMA-S)
Starting date July 2009, estimated completion date June 2011 (last updated on December 16, 2010)
Contact information Eli Lilly and Company
Notes ClinicalTrials.gov Identifier: NCT00917267; other study ID number: H8O-MC-GWCK
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Trial name or title Study to evaluate the efficacy and safety of exenatide once-weekly injection compared to once-daily insulin
in type 2 diabetes mellitus
Methods TRIAL DESIGN: Phase III, randomised, open-label study
DURATION OF INTERVENTION: 26 weeks
COUNTRY: Japan
Participants INCLUSION CRITERIA:
• present with type 2 diabetes mellitus
• HbA1c between 7.1% and 11.0% inclusive
• BMI of > 18 kg/m2 and < 35kg/m2, inclusive
• treated with a stable dose regimen of either of biguanide (BG) alone, BG + thiazolidinedione (TZD),
BG + sulphonylurea (SU), or BG + TZD + SU for 90 days prior to study start
Interventions Exenatide: 2 mg once weekly subcutaneous injection
Insulin glargine: subcutaneous injection, titrated to achieve fasting serum glucose target, once a day
Outcomes PRIMARY OUTCOME: change in HbA1c
SECONDARY OUTCOMES: proportion of subjects achieving HBA1c ≤ 7% or ≤ 6.5%; fasting serum
glucose; body weight; 1,5-anhydroglucitol; self-monitored blood glucose profile at 7 time points; serum lipids;
hypoglycaemia; vital signs; waist & hip circumference; waist-hip ratio; safety & tolerability; patient-reported
health outcomes
Starting date July 2009, estimated completion date June 2011 (last updated on February 28, 2011)
Contact information Eli Lilly and Company
Notes ClinicalTrials.gov Identifier: NCT00935532; other study ID number: H8O-JE-GWBX
Exenatide QW NCT01003184
Trial name or title Efficacy of once-weekly exenatide versus once or twice daily insulin detemir in patients with type 2 diabetes
Methods TRIAL DESIGN: Phase III, randomised, open-label trial
DURATION OF INTERVENTION: 26 weeks
COUNTRY: Ireland, UK,
Participants INCLUSION CRITERIA:
• Have suboptimal glycaemic control as evidenced by an HbA1c 7.1% to 10.0%, inclusive
• Have a BMI of 25 kg/m2 to 45 kg/m2, inclusive
• Are receiving metformin at a stable dose (consistent with country specific requirements) of a minimum
of 1000mg for at least 3 months prior to start or are receiving metformin at a minimum dose (consistent
with country specific requirements) of 1000 mg and sulphonylurea (as separate medications not as a fixed
dose combination) at stable doses for 3 months prior to study start
Interventions Exenatide: 2 mg once weekly subcutaneous injection
Insulin detemir: subcutaneous injection, with dosage titrated according to the detemir label and published
titration schedule, once or twice a day
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Outcomes PRIMARY OUTCOME: To test the hypothesis that exenatide given once weekly is superior to a titration of
insulin detemir given once or twice daily assessed by the proportion of patients who have achieved HbA1c
concentration ≤ 7.0% with weight loss (≥ 1.0 kg) at endpoint
SECONDARY OUTCOMES: Proportion of patients who have achieved HbA1c ≤ 7.0% with weight loss
(≥ 1.0 kg) at 12 weeks; proportion of patients who have achieved HbA1c≤ 7.4% with weight loss (≥ 1.0 kg)
at endpoint; proportion of patients who have achieved HbA1c ≤ 7.0% and ≤ 7.4%, with minimal weight
gain (≤ 1 kg) at endpoint; change in HbA1c and body weight; proportion of patients achieving HbA1c
≤ 7.4%, ≤ 7.0% and ≤ 6.5% at endpoint; change in fasting serum glucose; 7-point self-monitored blood
glucose (SMBG) profile; changes in CV risk parameters; incidence and rate of hypoglycaemic events; safety
and tolerability
Starting date October 2009, estimated completion date September 2011 (last updated on January 13, 2011)
Contact information Eli Lilly and Company
Notes ClinicalTrials.gov Identifier: NCT01003184; other study ID number: H8O-EW-GWDL
Exenatide QW NCT01029886
Trial name or title Safety and efficacy of exenatide once weekly versus liraglutide in subjects with type 2 diabetes
Methods TRIAL DESIGN: Phase III, randomised, parallel assignment, open-label trial
DURATION OF INTERVENTION: 26 weeks
COUNTRY: Argentina, Austria, Australia, Belgium, Canada, Czech Republic, France, Germany, Greece,
Hungary, India, Israel, Italy, Korea, Mexico, Poland, Romania, Slovakia, South Africa, Spain, Taiwan
Participants INCLUSION CRITERIA:
• Diagnosed with type 2 diabetes
• Have suboptimal glycaemic control as evidenced by an HbA1c measurement at study start between 7.
1% and 11.0%, inclusive
• Have a BMI of ≤ 45 kg/m2
• Have been treated with lifestyle modification (diet and exercise) and with one of the following single
OADs or combinations of OADs administered at maximum tolerated dose:metformin, SU, metformin plus
an SU’ metformin plus pioglitazone
Interventions Exenatide: 2 mg once weekly subcutaneous injection
Liraglutide: subcutaneous injection, forced titration to 1.8 mg, once daily
Outcomes PRIMARY OUTCOME: change in HbA1c from baseline to treatment endpoint
SECONDARY OUTCOMES: proportion of subjects achieving HbA1c < 7%; FPG, body weight, lipid
profile, safety and tolerability, hypoglycaemia and blood pressure
Starting date January 2010, estimation completion date January 2011 (last updated on January 18, 2011)
Contact information Amylin Pharmaceuticals, Inc. and Eli Lilly and Company
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Notes ClinicalTrials.gov Identifier: NCT01029886 ; other study ID number: H8O-MC-GWDE
Exenatide QW NCT01144338
Trial name or title Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes
after treatment with exenatide once weekly in patients with type 2 diabetes mellitus
Methods TRIAL DESIGN:Phase III, randomised, double-blind, placebo-controlled trial
DURATION OF INTERVENTION: 5.5 years
COUNTRY: USA, Argentina, Australia, Austria, Brazil, Bulgaria, Chile, Colombia, Czech Republic, France,
Germany,HongKong, Hungary, India, Israel, Italy, Korea, Latvia, Lithuania, Malaysia,Mexico, NewZealand,
Peru, Phillipines, Poland, Romania, Russian Federation, Slovakia, Taiwan, Ukraine, UK
Participants INCLUSION CRITERIA:
• Patient has type 2 diabetes mellitus
• Patient has an HbA1c of ≥ 7.0 % and ≤ 10.0% on stable doses of up to three oral antihyperglycaemic
agents for at least 3 months (i.e. no oral antihyperglycaemic agent adjustments in the past 3 months)
• Female patients must not be breast feeding and agree to use an effective method of contraception or
must not otherwise be at risk of becoming pregnant.
Interventions Exenatide: 2 mg once weekly subcutaneous injection
Placebo: matching volume of placebo, once weekly subcutaneous injection
Outcomes PRIMARY OUTCOME: Time to first confirmed cardiovascular event in the primary composite cardiovas-
cular endpoint
SECONDARY OUTCOMES: Time to all-cause mortality; time to first confirmed cardiovascular event for
each component of the primary composite endpoint; time to hospitalisation for acute coronary syndrome;
time to hospitalisation for heart failure
Starting date June 2010; estimation completion date March 2017 (last updated on June 3, 2011)
Contact information Amylin Pharmaceuticals, Inc.
Notes ClinicalTrials.gov Identifier: NCT01144338; other study ID number: BCB109
Liraglutide NCT00856986
Trial name or title The effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and
metformin in participants with type 2 diabetes. A 26 week, randomised, open-label, parallel-group, multi-
center, multinational trial with a 26 week extension
Methods TRIAL DESIGN: Randomised, open label, active control, parallel group, phase III trial, multicenter and
multinational
DURATION OF INTERVENTION: 26 weeks with a 26 week extension
COUNTRY: Europe and North America
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Liraglutide NCT00856986 (Continued)
Participants INCLUSION CRITERIA:
• Patients (18 years to 80 years of both sexes) with type 2 diabetes, insulin naive and treated with
metformin as monotherapy for at least 3 months prior to screening.
• For at least 3 months: treatment with a stable dose of metformin ≥ 1.5 g/day or a combination of
metformin (≥ 1.5 g/day) and a sulphonylureas (≤ half of the maximum approved dose)
• previous history of short term use of insulin during intercurrent illness is allowed
• Level of HbA1c 7.0 to 10.0% on metformin monotherapy and HbA1c of 7.0% to 8.5% in
participants on combination therapy of metformin and sulphonylureas
Interventions Insulin detemir: Liraglutide 1.8 mg/day and insulin detemir (dose titrated based on fasting plasma glucose)
both as injection subcutaneously and metformin at least 1.5 g every day
Liraglutide: Liraglutide 1.8 mg/day subcutaneous injection and metformin at least 1.5 g every day (ran-
domised treatment arm without intensification with insulin detemir despite HbA1c equal to or greater than
7.0%)
Liraglutide: Liraglutide 1.8 mg/day subcutaneous injection and metformin at least 1.5 g every day (non-
randomised trial armwith participants continuing liraglutide andmetformin treatmentwithout intensification
with insulin detemir. Participants with HbA1c less than 7.0% after 12 weeks of run-in will continue in the
trial in this arm)
Outcomes PRIMARY OUTCOME:Change in HbA1c from baseline at 26 weeks.
SECONDARY OUTCOMES:All these outcomes measured at weeks 26 and 52. Change in fasting plasma
glucose concentrations, 7 point plasma glucose profile, fasting insulin, fasting proinsulin, fasting C-peptide,
lipids, body weight, waist and hip circumference, adverse events and hypoglycaemic events
Starting date March 2010, completed (last updated April 2011)
Contact information Novo Nordisk
Notes Study ID number: NN2211-1842, EudraCT No: 2007-005317-19, ClinicalTrials.gov Identifier:
NCT00856986
Liraglutide NCT01117350
Trial name or title Efficacy assessment of insulin glargine versus liraglutide after oral agent failure (EAGLE)
Methods TRIAL DESIGN: Multicenter, international, randomised (1:1), parallel-group, open-label, comparative,
phase IV study
DURATION OF INTERVENTION: 24 weeks comparative period; 24 weeks extension period
COUNTRY:USA, Austria, Brazil, Canada, Czech Republic, Finland, France, Ireland, Mexico, Netherlands,
Slovakia, Spain, Sweden
Participants INCLUSION CRITERIA (comparative period):
• Patients with type 2 diabetes diagnosed for at least 1 year,
• Treated with lifestyle interventions and metformin at the maximum tolerated dosage (with a minimum
daily dosage of 1g), either alone or in combination with an oral insulin secretagogue (sulphonylurea, glinide
or DPP-IV inhibitor), for more than 3 months,
• HbA1c < 7.5% to ≤ 12%,
• BMI between 25 and 40 kg/m2 inclusively,
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Liraglutide NCT01117350 (Continued)
• Ability and willingness to perform PG self monitoring using the sponsor-provided glucose meter and
to complete the patient diary,
• Willingness and ability to comply with the study protocol,
• Signed informed consent obtained prior to any study procedure.
INCLUSION CRITERIA (extension period):Patients treated with liraglutide (at the maximal tolerated
dosage), having a mean FPG ≥ 250 mg/dL at visit 10 (Week 12) or visit 11 (Week 18), or a HbA1c ≥ 7%
at visit 12 (Week 24). Dosage of metformin compliant with the inclusion criteria of visit 1 (i.e. maximum
tolerated dosage, with a minimum daily dosage of 1g), and maintained stable during the comparative period
Interventions Liralutide: 1.8 mg once a day
Insulin glargine: 100 U/mL once a day
Outcomes PRIMARY OUTCOME: percentage of patients reaching HbA1c < 7 %
SECONDARY OUTCOMES: Percentage of patients whose HbA1c has decreased but remains ≥ 7%; per-
centage of patients whose HbA1c has increased; HbA1c change; PPG; FPG, vital signs; hypoglycaemia; dose
of insulin glargine or liraglutide
Starting date July 2010, estimated completion date June 2012 (Last Updated on June 14, 2011)
Contact information Contact-us@sanofi-aventis.com
Notes ClinicalTrials.gov Identifier: NCT01117350; other study ID numbers: LANTU C 03680, 2010-018437-
21, U1111-1116-9684
Liraglutide NCT01296412
Trial name or title Comparison of two treatment regimens (sitagliptin versus liraglutide) on participants who failed to achieve
good glucose control on metformin alone (MK-0431-403)
Methods TRIAL DESIGN: Phase III, multicenter, randomised, open-label clinical trial
DURATION OF INTERVENTION: 26 weeks
COUNTRY: USA, Canada, France, Hungary, Italy, Lithuania, Puerto Rico, Slovenia, Sweden, UK
Participants INCLUSION CRITERIA:
• Type 2 diabetes mellitus.
• On stable dose of metformin monotherapy at a dose of at least 1500 mg per day for at least 12 weeks
and a HbA1c ≥ 7.0% and ≤ 11.0%.
• Capable of using a liraglutide pen device.
Interventions Liraglutide: 0.6 mg by subcutaneous (pen) injection, once daily, on days 1 to 7; in subsequent weeks, the
dose may be up-titrated to 1.8 mg once daily
Sitagliptin: 100 mg tablet, orally, once daily.
Glimepiride: starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after week 12 therapy
Metformin: metformin tablets at a dose of ≥ 1500 mg per day
Outcomes PRIMARY OUTCOME: Glycaemic control
SECONDARY OUTCOMES: Percentage of patients reaching haemoglobin A1C goals (< 7.0% and < 6.
5%); FPG
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Starting date March 2011, estimated completion date May 2012 (last updated on May 3, 2011)
Contact information Toll Free Number 1-888-577-8839 (Merck)
Notes ClinicalTrials.gov identifier: NCT01296412
Liraglutide NCT01336023
Trial name or title Dual action of liraglutide and insulin degludec in type 2 diabetes: a trial comparing the efficacy and safety of
insulin degludec/liraglutide, insulin degludec and liraglutide in subjects with type 2 diabetes (DUAL™ I)
Methods TRIAL DESIGN: Phase III, randomised, parallel three-arm, open-label, multi-centre, multinational treat-
to-target trial
DURATION OF INTERVENTION: 26 weeks
COUNTRY: USA, Australia, Canada, Finland, Germany, Hungary, India, Ireland, Italy, Malaysia, Mexico,
Puerto Rico, Russian Federation, Singapore, Slovakia, South Africa, Spain, Taiwan, Thailand, UK
Participants INCLUSION CRITERIA:
• For certain countries the minimum age is 20 or 21, according to local legislation
• Subjects with type 2 diabetes
• HbA1c (glycosylated haemoglobin) 7.0 to 10.0% (both inclusive)
• Subjects on stable dose of 1 to 2 OADs (metformin or metformin + pioglitazone for at least 90 days
prior to trial start)
• BMI below or equal to 40 kg/m2
Interventions Insulin degludec/liraglutide: insulin degludec/liraglutide treatment will be initiated and titrated (individ-
ually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec/liraglutide is injected
subcutaneously (under the skin) once daily
Insulin degludec: insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted)
twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the
skin) once daily
Liraglutide: liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg.
Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected
subcutaneously (under the skin) once daily
Subjects should continue their pre-trial treatment with metformin or metformin + pioglitazone throughout
the entire trial
Outcomes PRIMARY OUTCOME: Change from baseline in HbA1c
SECONDARY OUTCOMES: body weight, hypoglycaemia, meal test, daily insulin dose
Starting date May 2011, estimated completion date October 2012 (last updated on May 23, 2011)
Contact information Klaus Kjær Laigaard (Novo Nordisk)
Notes ClinicalTrials.gov Identifier: NCT01336023; other study ID numbers: NN9068-3697, U1111-1119-1174,
2010-021560-15
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Lixisenatide NCT00707031
Trial name or title GLP-1 agonist AVE0010 versus exenatide in patients with type 2 diabetes for glycaemic control and safety
evaluation, on top of metformin (GETGOAL-X)
Methods TRIAL DESIGN: Phase III, randomised, open-label, active-controlled, 2-arm parallel-group, multicenter
study
DURATION OF INTERVENTION: 24 weeks
COUNTRY:
Participants INCLUSION CRITERIA:
• Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled
with metformin
Interventions Lixisenatide (AVE0010) at least 24 weeks of treatment, extension period of variable duration
Exenatide: at least 24 weeks of treatment extension period of variable duration
Outcomes PRIMARY OUTCOME: Absolute change from baseline in HbA1c
SECONDARY OUTCOMES: body weight, FPG, treatment satisfaction
Starting date June 2008, completed (last updated on November 25, 2010)
Contact information Sanofi-Aventis
Notes ClinicalTrials.gov identifier: NCT00707031 other study ID numbers: EFC6019, EudraCT 2007-005883-
28
Lixisenatide NCT00713830
Trial name or title GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycaemic control and safety evaluation, on top
of sulphonylurea (GETGOAL-S)
Methods TRIALDESIGN: Phase III, randomised, double-blind, placebo-controlled, 2-armparallel-group,multicenter
study
DURATION OF INTERVENTION: 24 weeks
COUNTRY: USA, Bulgaria, Czech Republic, Egypt, Germany, India, Israel, Japan, Korea, Netherlands,
Romania, Russian Federation, Taiwan, Thailand, Tunisia, Turkey
Participants INCLUSION CRITERIA:
• Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled
with a sulphonylurea alone or a sulphonylurea in association with metformin
Interventions Lixisenatide (AVE0010) at least 24 weeks of treatment, extension period of variable duration
Placebo: at least 24 weeks of treatment, extension period of variable duration
Outcomes PRIMARY OUTCOME: Absolute change from baseline in HbA1c
SECONDARY OUTCOMES: body weight, FPG, 2-hours post-prandial plasma glucose, glucagon, insulin,
pro-insulin, C-peptide
Starting date July 2008, completed (last updated on January 25, 2011)
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Lixisenatide NCT00713830 (Continued)
Contact information Sanofi-Aventis
Notes ClinicalTrials.gov Identifier: NCT00713830, other study ID numbers: EFC6015, EudraCT 2007-005881-
11
Lixisenatide NCT00763815
Trial name or title GLP-1 agonist AVE0010 in patients with type 2 diabetes for glycaemic control and safety evaluation, on top
of pioglitazone (GETGOAL-P)
Methods TRIALDESIGN: Phase III, randomised, double-blind, placebo-controlled, 2-armparallel-group,multicenter
study
DURATION OF INTERVENTION:24 weeks
COUNTRY:USA, Austria, Canada, France, Germany, Greece, Guatemala, India, Mexico, Peru, Puerto Rico,
Romania, Turkey
Participants INCLUSION CRITERIA:
• Type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit, insufficiently controlled
with pioglitazone with or without metformin
Interventions Lixisenatide: AVE0010
Placebo:
Outcomes PRIMARY OUTCOME: Glycaemic control
SECONDARY OUTCOMES: body weight, FPG, fasting insulin levels
Starting date September 2008, estimated completion date June 2011 (last updated on June 22, 2010)
Contact information Sanofi-Aventis
Notes ClinicalTrials.gov Identifier: NCT00763815
Lixisenatide NCT00975286
Trial name or title A randomised, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week double-blind
treatment period assessing the efficacy and safety of lixisenatide in patients with type 2 diabetes insufficiently
controlled with insulin glargine and metformin
Methods TRIAL DESIGN: Randomised, placebo-controlled parallel group phase III trial, multi-centre
DURATION OF INTERVENTION: 24 weeks
COUNTRY: USA, Canada, Sweden, Estonia
Participants INCLUSION CRITERIA:
At screening:
• Patients (18 years or older) with type 2 diabetes mellitus, as defined by WHO (fasting plasma glucose
≥ 7 mmol/L (126 mg/dL) or 2 hours postprandial plasma glucose ≥ 11.1 mmol/L (200 mg/dL), diagnosed
at least 1 year before the screening visit
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Lixisenatide NCT00975286 (Continued)
• For at least 3 months: treatment with a stable dose of metformin ≥ 1.5 g/day or combination of stable
doses of metformin ≥ 1.5 g/day with SUs (to be stopped at visit 1) and/or TZDs
• HbA1c of ≥ 7.0 and ≤ 10%
At the end of the run in phase and before randomisation:
• HbA1c ≥ 7.0 and ≤ 9%
• Mean fasting SMPG calculated from the self measurements for the 7 days prior to visit 12 (week -1) is
less than or equal to 126 mg/dL (7.0 mmol/L)
Interventions Lixisenatide: Lixisenatide once daily on top of insulin glargine (both injected in the morning within 1 hour
prior to breakfast) and metformin (at least 1.5 g/day)
Placebo: Placebo once daily on top of insulin glargine (both injected in the morning within 1 hour prior to
breakfast) and metformin (at least 1.5 g/day)
Outcomes PRIMARY OUTCOME: Glycaemic control
SECONDARY OUTCOMES: percentage of patients reaching HbA1c < 7% and ≤ 6.5 %, on plasma
glucose (fasting, post-prandial during a standardisedmeal challenge test, 7-point self monitored profiles), body
weight, insulin glargine doses; safety and tolerability, treatment satisfaction (diabetes treatment satisfaction
questionnaire)
Starting date October 2009, estimated completion August 2011
Contact information GV-Contact-us@sanofi-aventis.com
Notes Study ID Numbers: EFC10781, EudraCT: 2008-007335-40; ClinicalTrials.gov identifier: NCT00975286
Lixisenatide NCT00976937
Trial name or title A randomised, double-blind, double-dummy, 2-arm parallel-group, multicenter 24-week study comparing
the efficacy and safety of ave0010 to sitagliptin as add-on to metformin in obese type 2 diabetic patients
younger than 50 and not adequately controlled with metformin
Methods TRIAL DESIGN: Randomised double-blind, placebo-controlled parallel group phase III trial, multi-centre
DURATION OF INTERVENTION: 24 weeks
COUNTRY: USA, Australia, Canada, Chile, Mexico, Russian Federation
Participants INCLUSION CRITERIA:
• Patients with type 2 diabetes mellitus, age 18 to 49 years, as defined by WHO, diagnosed for at least 1
year at the time of screening visit, insufficiently controlled with metformin at a stable dose of at least 1.5 g/
day (1.0 g/day for patients from South Korea) for at least 3 months prior to the screening visit.
• Patients with obesity (BMI ≥ 30 kg/m2)
Interventions Lixisenatide: Injection of lixisenatide once a day in the morning within 1 hour prior to breakfast (first 2
weeks of double-blind period: titration 10 to 15 µg, then 15 to 20 µg) and one capsule of sitagliptin placebo
intake in the morning with or without food. On top of metformin background therapy
Sitagliptin: One capsule of sitagliptin intake in the morning with or without food and lixisenatide matched
placebo injection once a day in themorningwithin 1 hour prior to breakfast. On top ofmetformin background
therapy
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Outcomes PRIMARY OUTCOME: Percentage of patients with HbA1c values < 7% and a weight loss of at least 5% of
baseline body weight
SECONDARY OUTCOMES: Absolute change in HbA1c values, percentage of patients with HbA1c values
≤ 6.5%, absolute change in body weight, change in fasting plasma glucose, change in plasma glucose and in
beta-cell function during a test meal, change in insulin resistance assessed by HOMA-IR, change in beta-cell
function assessed by HOMA-beta, percentage of patients requiring rescue therapy during the double-blind
treatment period; safety and tolerability
Starting date August 2009, completed (last updated on May 6, 20 2011)
Contact information GV-Contact-us@sanofi-aventis.com
Notes Study ID Numbers: EFC10780, EudraCT: 2008-007 334-22
Semaglutide NCT00696657
Trial name or title A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide
Methods TRIALDESIGN: Phase II, multi-centre, multi national, double-blind, placebo-controlled, randomised, nine
armed parallel group, dose finding trial
DURATION OF INTERVENTION: 12 weeks
COUNTRY: Austria, Bulgaria, Finland, Former Serbia and Montenegro, France, Germany, Hungary, India,
Italy, South Africa, Spain, Switzerland, Turkey, UK
Participants INCLUSION CRITERIA:
• Men and women-not-of-childbearing potential diagnosed with type 2 diabetes for at least three months
• Stable treatment regimen with either metformin (at least 1500 mg) or diet and exercise alone for at
least three months
• HbA1c: 7.0 to 10.0% (both inclusive)
• Body weight between 60 kg and 110 kg
Interventions Semaglutide: 0.1 or 0.2 or 0.4 or 0.8 mg once weekly s.c. injection; 0.8 mg or 1.6 mg with titration, once
weekly s.c. injection
Placebo: 0.1 or 0.2 or 0.4 mg once weekly s.c. injection; 0.8 mg or 1.6 mg with titration, once weekly s.c.
injection
Liraglutide: 1.2 or 1.8 mg with titration, once daily, s.c. injection
Outcomes PRIMARY OUTCOME: Change in HbA1c
SECONDARY OUTCOMES: Percentage of subjects with an adverse events; percentage of subjects with
hypoglycaemic episode; ECG, vital signs; safety laboratory parameters; percentage of subjects developing anti-
semaglutide antibodies and calcitonin
Starting date June 2008, Final data collection date for primary outcome measure February 2009 (last updated on March
16, 2011)
Contact information Novo Nordisk
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Notes ClinicalTrials.gov Identifier: NCT00696657; other study ID numbers: NN9535-1821, 2007-003956-12
Taspoglutide NCT00717457
Trial name or title Randomised, active controlled, open label study to compare taspoglutide with exenatide as add-on treatment
to metformin and/or thiazolidinediones in patients with type 2 diabetes mellitus
Methods TRIAL DESIGN: Randomised, open label, active controlled, parallel assigned, phase III trial, multi centre,
multinational, safety and efficacy study
DURATION OF INTERVENTION: 3+ years
COUNTRY: USA, Europe, America, South Africa, Asia
Participants INCLUSION CRITERIA:
• Patients (18 years to 75 years of age and both sexes) with type 2 diabetes treated with metformin and/
or pioglitazone or rosiglitazone for at least 12 weeks
• HbA1c ≥ 7.0% and ≤ 10% at screening
• BMI ≥ 25 kg/m2 (> 23 kg/m2 for Asians) and ≤ 45 kg/m2 at screening
• stable weight ± 5% for at least 12 weeks prior to screening
Interventions Taspoglutide: 10 mg subcutaneous injection once weekly
Taspoglutide: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once
weekly
Exenatide: Exenatide 5 mg twice daily for 4 weeks followed by 10 mg twice daily [should presumably read
“µg”?]
Outcomes PRIMARY OUTCOME: Change in HbA1c at 24 weeks
SECONDARY OUTCOMES: All the outcomes measured at 24 weeks. Fasting body weight, proportion
of participants reaching target HbA1c ≤ 7.0%, ≤ 6.5%, relative change in glucose, insulin, C-peptide and
glucagon values during a meal tolerance test in a subset of patients, beta cell function (proinsulin/insulin
ratio)
Starting date July 2008, estimated completion April 2012 (last updated on March 15, 2011)
Contact information Hoffmann-La Roche
Notes Study ID numbers:BC21625, 2008-001856-36, ClinicalTrials.gov Identifier: NCT00717457
Taspoglutide NCT00744367
Trial name or title Amulticenter, randomised, double-blind, placebo-controlled study to assess the safety, tolerability and effect of
taspoglutide on glycaemic control compared to placebo in patients with type 2 diabetes mellitus inadequately
controlled with metformin plus pioglitazone
Methods TRIALDESIGN: Randomised, double-blind, placebo-controlled, phase III trial, multicenter, multinational,
safety and efficacy study
DURATION OF INTERVENTION: 1 to 2 years
COUNTRY: USA, Europe and America
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Participants INCLUSION CRITERIA:
• Patients (18 years to 75 years of age and both sexes) with type 2 diabetes receiving pioglitazone (≥ 30
mg/day) and metformin (≥ 1500 mg/day) for at least 12 weeks prior to screening
• HbA1c ≥ 7.0% and ≤ 10.0% at screening
• BMI ≥ 25 (> 23 for Asians) and ≤ 45 kg/m2 at screening
• stable weight ± 5% for at least 12 weeks prior to screening
Interventions Taspoglutide: 10 mg subcutaneous injection once weekly, metformin > 1.5 g/day, pioglitazone ≥ 30 mg/day
Taspoglutide: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once
weekly, metformin as prescribed and placebo orally once daily, metformin > 1.5 g/day, pioglitazone ≥ 30 mg/
day
Placebo: Placebo subcutaneous once weekly, metformin > 1.5 g/day, pioglitazone ≥ 30 mg/day
Outcomes PRIMARY OUTCOME: Absolute change from baseline in HbA1c at 24 weeks
SECONDARYOUTCOMES: Change from baseline in fasting plasma glucose, change from baseline in body
weight, responder rates for HbA1c (target ≤ 7.0%, ≤ 6.5%), responder rates for body weight and beta cell
function at 24 weeks; safety: adverse events, vital signs, physical examination, clinical laboratory tests, ECG
and anti-taspoglutide antibodies throughout the study
Starting date October 2008, estimated completion September 2010 (last updated on March 15, 2011)
Contact information Hoffmann-La Roche
Notes Study ID numbers: BC20963, 2008-001744-39, ClinicalTrials.gov Identifier: NCT00744367
Taspoglutide NCT00754988
Trial name or title Amulticenter, randomised, double-dummy, placebo and active-controlled study to assess the safety, tolerability
and effect of taspoglutide on glycaemic control compared to sitagliptin and placebo in patients with type 2
diabetes mellitus inadequately controlled with metformin
Methods TRIAL DESIGN: Randomised, double blind, placebo and active controlled, phase III trial, multicenter,
multinational, safety and efficacy study
DURATION OF INTERVENTION: 2+ years
COUNTRY: USA, Europe, Asia, America, Australia
Participants INCLUSION CRITERIA:
• Patients (18 years to 75 years of age and both sexes) with type 2 diabetes receiving metformin ≥ 1.5 g/
day for at least 12 weeks
• HbA1c ≥ 7.0% and ≤ 10.0% at screening
• BMI ≥ 25 (> 23 for Asians) and ≤ 45 kg/m2 at screening
• stable weight ± 5% for at least 12 weeks prior to screening
Interventions Taspoglutide: 10 mg subcutaneous injection once weekly, metformin as prescribed and placebo per orally
once daily
Taspoglutide: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once
weekly, metformin as prescribed and placebo per orally once daily
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Sitagliptin: Sitagliptin 100 mg per orally once daily, placebo subcutaneous once weekly and metformin as
prescribed
Placebo: Placebo subcutaneous once daily, metformin as prescribed and placebo per orally once daily
Outcomes PRIMARY OUTCOME:Mean changes in HbA1c at 24 weeks
SECONDARY OUTCOMES:Change from baseline in fasting plasma glucose, change from baseline in
body weight, responder rates for HbA1c (target ≤ 7.0%, ≤ 6.5%), responder rates for body weight, change
from baseline in lipid profile and beta cell function at 24 weeks; safety: adverse events, vital signs, physical
examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies throughout study
Starting date October 2008, estimated completion May 2012 (last updated on March 15, 2011)
Contact information Hoffmann-La Roche
Notes Study ID numbers: BC21713, 2008-001854-42, ClinicalTrials.gov Identifier: NCT00754988
Taspoglutide NCT00755287
Trial name or title Amulticenter, randomised, open-label, active-controlled study to compare the safety, tolerability and effect on
glycaemic control of taspoglutide versus insulin glargine in insulin-naïve type 2 diabetic patients inadequately
controlled with metformin and sulphonylurea combination therapy
Methods TRIALDESIGN: Randomised, open-label, active controlled, parallel assignment,multicenter,multinational,
phase III trial
DURATION OF INTERVENTION: 2+ years
COUNTRY: USA, Australia, Asia, Europe
Participants INCLUSION CRITERIA:
• Patients (18 years to 75 years of age and both sexes) with type 2 diabetes treated with a stable dose of
metformin and sulphonylurea for at least 12 weeks
• C-peptide (fasting) ≥1.0 ng/mL
• HbA1c ≥ 7.0% and ≤ 10.0% at screening
• BMI ≥ 25 (> 23 for Asians) and ≤ 45 kg/m2 at screening
• stable weight ± 5% for at least 12 weeks prior to screening
Interventions Taspoglutide: 10 mg subcutaneous injection once weekly and metformin as prescribed
Taspoglutide: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once
weekly and metformin as prescribed
Insulin glargine: Starting dose at 10 IU daily and metformin as prescribed
Outcomes PRIMARY OUTCOME: Absolute change from baseline in HbA1c at 24 weeks
SECONDARYOUTCOMES: Change from baseline in fasting plasma glucose, change from baseline in body
weight, responder rates for HbA1c (target ≤ 7.0%, ≤ 6.5%), incidence of hypoglycaemia and change from
baseline in lipid profile at 24 weeks; relative change in glucose, insulin, C-peptide and glucagon during a meal
tolerance test at 24 weeks; safety: adverse events, vital signs, physical examination, clinical laboratory tests,
ECG and anti-taspoglutide antibodies measured throughout study
Starting date October 2008, estimated completion June 2012 (last updated on March 15, 2011)
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Taspoglutide NCT00755287 (Continued)
Contact information Hoffmann-La Roche
Notes Study ID numbers: BC20965, 2008-001855-23, ClinicalTrials.gov Identifier: NCT00755287
Taspoglutide NCT00823992
Trial name or title A randomised, double-blind, placebo-controlled study to assess the effect of taspoglutide on glycaemic control,
and its safety and tolerability, in obese patients with type 2 diabetes mellitus inadequately controlled with
metformin monotherapy
Methods TRIAL DESIGN: Randomised, double-blind, placebo-controlled, parallel assigned, phase III trial, multi-
center, multinational, safety and efficacy study
DURATION OF INTERVENTION: 52 weeks (12 months)
COUNTRY: USA, Europe
Participants INCLUSION CRITERIA:
• Patients (18 years to 75 years of age and both sexes) with type 2 diabetes treated with stable dose of
metformin of ≥ 1.5 g/day for at least 12 weeks
• HbA1c ≥ 6.5% and ≤ 9.5% at screening
• BMI ≥ 30 and ≤ 50 kg/m2 at screening
• Stable weight ± 5% for at least 12 weeks prior to screening
Interventions Taspoglutide: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once
weekly
Placebo: Subcutaneous once weekly
Outcomes PRIMARY OUTCOME: Absolute change from baseline in HbA1c at 24 weeks
SECONDARY OUTCOMES: Change from baseline in body weight, % of patients achieving ≥ 5% weight
loss atweeks 24;%of patients achieving targetHbA1c≤ 6.5%,≤ 7.0%, change frombaseline in fasting plasma
glucose, change from baseline in lipid profile, relative change in glucose, insulin, C-peptide and glucagon
during a meal tolerance test and beta cell function at 24 weeks; safety: adverse events,clinical laboratory tests,
vital signs, physical examination, ECG, anti-taspoglutide antibodies at planned clinical visits for 12 months
Starting date January 2009, completed (last updated on April 18, 2011)
Contact information Hoffmann-La Roche
Notes Study ID numbers: BC22092, 2008-005809-20, ClinicalTrials.gov Identifier: NCT00823992
Taspoglutide NCT00909597
Trial name or title A multicenter, randomised, double blind (double dummy), active controlled study to compare the safety,
tolerability and effect on glycaemic control of taspoglutide versus pioglitazone in type 2 diabetes patients
inadequately controlled on therapy with sulphonylurea or metformin plus sulphonylurea
90Glucagon-like peptide analogues for type 2 diabetes mellitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Taspoglutide NCT00909597 (Continued)
Methods TRIAL DESIGN: Randomised, double blind (participant, investigator), three arm, phase III trial, parallel
assignment, multi centre, multinational, safety and efficacy study
DURATION OF INTERVENTION: 104 weeks (24 months)
COUNTRY: USA, Europe, North and South America
Participants INCLUSION CRITERIA:
• Patients (18 years to 75 years of age and both sexes) with type 2 diabetes treated with stable dose of
sulphonylurea monotherapy or metformin plus sulphonylurea for ≥ 12 weeks prior to screening.
• HbA1c ≥ 7.0% and ≤ 10.0% at screening
• stable weight ± 5% for ≥ 12 weeks prior to screening
Interventions Taspoglutide: 10 mg subcutaneous injection once weekly
Taspoglutide: 10 mg subcutaneous injection once weekly for 4 weeks followed by 20 mg subcutaneous once
weekly
Pioglitazone: 30 mg orally once daily for 4 weeks followed by 45 mg once daily
Outcomes PRIMARY OUTCOME: Absolute change in HbA1c from baseline at 24 weeks
SECONDARY OUTCOMES: Proportion of participants achieving target HbA1c ≤ 6.5%, ≤ 7.0% at
weeks 24, 52 and 104; absolute/percentage change from baseline in body weight, responder rates for body
weight, absolute/percentage change from baseline in waist and hip circumference, absolute/percentage change
from baseline in fasting plasma glucose at weeks 24, 52 and 104; adverse events, laboratory parameters,
cardiovascular events at each clinic visit up to 106 weeks
Starting date May 2009, completed (last updated on June 15, 2011)
Contact information Hoffmann-La Roche
Notes Study ID numbers: BC21893, 2009-009157-24, ClinicalTrials.gov Identifier: NCT00909597
BG:biguanide;BMI :bodymassindex;,CV :cardiovascular;DPP−4:dipeptidylpeptidase−4inhibitor;ECG:electrocardiography;FPG:f astingplasmaglucose;HbA1c:glycosylatedhaemo
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D A T A A N D A N A L Y S E S
Comparison 1. Albiglutide versus placebo




participants Statistical method Effect size
1 HbA1c (%) Other data No numeric data
2 HbA1c - with plot 1 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 ALBI 30 mg weekly 1 79 Mean Difference (IV, Random, 95% CI) -0.7 [-1.07, -0.33]
2.2 ALBI 30 mg every 2 weeks 1 82 Mean Difference (IV, Random, 95% CI) -0.62 [-1.06, -0.18]
3 HbA1c < 7% Other data No numeric data
4 Hypoglycaemia Other data No numeric data
5 Weight change - with plot 1 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 ALBI 30 mg weekly 1 79 Mean Difference (IV, Random, 95% CI) -0.7 [-1.89, 0.49]
5.2 ALBI 30 mg every 2 weeks 1 82 Mean Difference (IV, Random, 95% CI) -0.9 [-2.08, 0.28]
6 Weight change (kg) Other data No numeric data
7 Adverse events Other data No numeric data
8 Blood pressure (mm Hg) Other data No numeric data
9 Fasting plasma glucose (mmol/L) Other data No numeric data
10 Lipid profiles Other data No numeric data
11 Beta-cell function Other data No numeric data
12 Subgroups Other data No numeric data
Comparison 2. Exenatide 2 mg once weekly versus thiazolidinedione




participants Statistical method Effect size
1 HbA1c (%) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
2 HbA1c < 7% 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3 Hypoglycaemia (minor) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4 Weight change (kg) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
5 Quality of life Other data No numeric data
6 Adverse events Other data No numeric data
7 Blood pressure (mm Hg) Other data No numeric data
8 Fasting plasma glucose (mmol/L) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
9 Post-prandial glucose / glucose
profiles
Other data No numeric data
10 Lipid profiles Other data No numeric data
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Comparison 3. Exenatide 2 mg once weekly versus DPP-4 inhibitors




participants Statistical method Effect size
1 HbA1c (%) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
2 HbA1c < 7% 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3 Hypoglycaemia (minor) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4 Weight change (kg) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
5 Quality of life Other data No numeric data
6 Adverse events Other data No numeric data
7 Blood pressure (mm Hg) Other data No numeric data
8 Fasting plasma glucose (mmol/L) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
9 Post-prandial glucose / glucose
profiles
Other data No numeric data
10 Lipid profiles Other data No numeric data
Comparison 4. Exenatide 2 mg once weekly versus insulin glargine




participants Statistical method Effect size
1 HbA1c (%) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2 HbA1c < 7% 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Hypoglycaemia (symptoms only) 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4 Hypoglycaemia (minor) 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5 Severe hypoglycaemia Other data No numeric data
6 Weight change (kg) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7 Adverse events Other data No numeric data
8 Quality of life Other data No numeric data
9 Fasting plasma glucose (mmol/L) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10 Postprandial glucose / glucose
profiles
Other data No numeric data
Comparison 5. Liraglutide 0.6 mg daily versus placebo




participants Statistical method Effect size
1 HbA1c (%) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2 HbA1c < 7% 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Hypoglycaemia rate
(events/patient-year)
Other data No numeric data
4 Severe hypoglycaemia Other data No numeric data
5 Weight change (kg) Other data No numeric data
6 Adverse events Other data No numeric data
93Glucagon-like peptide analogues for type 2 diabetes mellitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
7 Blood pressure (mm Hg) Other data No numeric data
8 Fasting plasma glucose (mmol/L) Other data No numeric data
9 Post-prandial glucose / glucose
profiles
Other data No numeric data
Comparison 6. Liraglutide 0.9 mg daily versus placebo




participants Statistical method Effect size
1 HbA1c (%) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2 HbA1c < 7% 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Hypoglycaemia rate
(events/patient-year)
Other data No numeric data
4 Severe hypoglycaemia Other data No numeric data
5 Weight change (kg) Other data No numeric data
6 Adverse events Other data No numeric data
7 Blood pressure (mm Hg) Other data No numeric data
8 Fasting plasma glucose (mmol/L) Other data No numeric data
9 Postprandial glucose / glucose
profiles
Other data No numeric data
Comparison 7. Liraglutide 1.2 mg versus placebo




participants Statistical method Effect size
1 HbA1c 3 1058 Mean Difference (IV, Random, 95% CI) -1.15 [-1.33, -0.96]
2 HbA1c < 7% 3 1058 Risk Ratio (M-H, Random, 95% CI) 2.91 [1.74, 4.87]
3 Hypoglycaemia 3 1058 Risk Ratio (M-H, Random, 95% CI) 1.54 [0.54, 4.42]
4 Weight change 3 1058 Mean Difference (IV, Random, 95% CI) -0.75 [-1.95, 0.45]
5 Adverse events Other data No numeric data
6 Systolic blood pressure 2 716 Mean Difference (IV, Random, 95% CI) -3.26 [-7.71, 1.20]
7 Fasting plasma glucose (mmol/L) 3 1058 Mean Difference (IV, Random, 95% CI) -2.13 [-2.59, -1.68]
8 Post-prandial glucose (mmol/L) Other data No numeric data
9 Triglycerides (mmol/L) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
10 Total cholesterol (mmol/L) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
11 HDL-cholesterol (mmol/L) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
12 LDL-cholesterol (mmol/L) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
13 Beta-cell function Other data No numeric data
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Comparison 8. Liraglutide 1.8 mg versus placebo




participants Statistical method Effect size
1 HbA1c 4 1410 Mean Difference (IV, Random, 95% CI) -1.15 [-1.31, -0.99]
2 HbA1c < 7% 4 1410 Risk Ratio (M-H, Random, 95% CI) 3.25 [1.97, 5.36]
3 Hypoglycaemia 4 1410 Risk Ratio (M-H, Random, 95% CI) 1.66 [1.15, 2.40]
4 Weight change 4 1410 Mean Difference (IV, Random, 95% CI) -1.33 [-2.38, -0.27]
5 Adverse events Other data No numeric data
6 Systolic blood pressure 3 1062 Mean Difference (IV, Random, 95% CI) -2.42 [-4.90, 0.05]
7 Fasting plasma glucose (mmol/L) 4 1410 Mean Difference (IV, Random, 95% CI) -2.21 [-2.49, -1.93]
8 Post-prandial glucose (mmol/L) Other data No numeric data
9 Triglycerides (mmol/L) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
10 Total cholesterol (mmol/L) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
11 HDL-cholesterol (mmol/L) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
12 LDL-cholesterol (mmol/L) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
13 Beta-cell function Other data No numeric data
Comparison 9. Liraglutide 1.2 mg versus 1.8 mg




participants Statistical method Effect size
1 HbA1c 4 1739 Mean Difference (IV, Random, 95% CI) 0.10 [-0.03, 0.23]
2 Patients reaching HbA1c < 7% 5 2206 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.84, 1.17]
3 Weight 4 1739 Mean Difference (IV, Random, 95% CI) 0.48 [0.16, 0.80]
4 Systolic blood pressure 4 1739 Mean Difference (IV, Random, 95% CI) -0.22 [-1.48, 1.04]
Comparison 10. Liraglutide versus insulin glargine




participants Statistical method Effect size
1 HbA1c 1 Mean Difference (IV, Random, 95% CI) Subtotals only
2 HbA1c < 7% 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3 Hypoglycaemia 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4 Weight change 1 Mean Difference (IV, Random, 95% CI) Subtotals only
5 Adverse events Other data No numeric data
6 Systolic blood pressure 1 Mean Difference (IV, Random, 95% CI) Subtotals only
7 Fasting plasma glucose (mmol/L) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
8 Post-prandial glucose (mmol/L) Other data No numeric data
9 Beta-cell function Other data No numeric data
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Comparison 11. Liraglutide 1.2 mg daily versus thiazolidinedione




participants Statistical method Effect size
1 HbA1c (%) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2 HbA1c < 7% 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3 Hypoglycaemia
(mild/moderate/overall)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4 Severe hypoglycaemia Other data No numeric data
5 Weight change 1 Mean Difference (IV, Random, 95% CI) Subtotals only
6 Adverse events Other data No numeric data
7 Systolic blood pressure (mm Hg) Other data No numeric data
8 Diastolic blood pressure (mm
Hg)
Other data No numeric data
9 Fasting plasma glucose (mmol/L) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
10 Post-prandial glucose (mmol/L) Other data No numeric data
11 Beta-cell function Other data No numeric data
Comparison 12. Liraglutide 1.8 mg daily versus thiazolidinedione




participants Statistical method Effect size
1 HbA1c (%) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2 HbA1c < 7% 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Hypoglycaemia 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4 Severe hypoglycaemia Other data No numeric data
5 Weight change (kg) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6 Adverse events Other data No numeric data
7 Systolic blood pressure (mm Hg) Other data No numeric data
8 Diastolic blood pressure (mm
Hg)
Other data No numeric data
9 Fasting plasma glucose (mmol/L) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10 Post-prandial glucose (mmol/L) Other data No numeric data
11 Beta-cell function Other data No numeric data
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Comparison 13. Liraglutide 1.2 mg daily versus DPP-4 inhibitors




participants Statistical method Effect size
1 HbA1c (%) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
2 HbA1c < 7% 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3 Hypoglycaemia
(mild/moderate/overall)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4 Severe hypoglycaemia Other data No numeric data
5 Weight change (kg) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
6 Adverse events Other data No numeric data
7 Systolic blood pressure (mm Hg) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
8 Diastolic blood pressure (mm
Hg)
Other data No numeric data
9 Fasting plasma glucose (mmol/L) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
10 Post-prandial glucose (mmol/L) Other data No numeric data
11 Beta-cell function Other data No numeric data
Comparison 14. Liraglutide 1.8 mg daily versus DPP-4 inhibitors




participants Statistical method Effect size
1 HbA1c (%) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
2 HbA1c < 7% 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3 Hypoglycaemia 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4 Severe hypoglycaemia Other data No numeric data
5 Weight change (kg) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
6 Adverse events Other data No numeric data
7 Systolic blood pressure (mm Hg) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
8 Diastolic blood pressure (mm
Hg)
Other data No numeric data
9 Fasting plasma glucose (mmol/L) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
10 Post-prandial glucose (mmol/L) Other data No numeric data
11 Beta-cell function Other data No numeric data
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Comparison 15. Lixisenatide versus placebo




participants Statistical method Effect size
1 HbA1c (%) Other data No numeric data
2 HbA1c < 7% 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 LIXI 5 µg QD 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 LIXI 10 µg QD 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 LIXI 20 µg QD 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.4 LIXI 30 µg QD 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.5 LIXI 5 µg BID 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.6 LIXI 10 µg BID 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.7 LIXI 20 µg BID 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.8 LIXI 30 µg BID 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Symptomatic hypoglycaemia 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3.1 LIXI 5 µg QD 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 LIXI 10 µg QD 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.3 LIXI 20 µg QD 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 LIXI 30 µg QD 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.5 LIXI 5 µg BID 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.6 LIXI 10 µg BID 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.7 LIXI 20 µg BID 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.8 LIXI 30 µg BID 1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Weight change (kg) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
4.1 LIXI 5 µg QD 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 LIXi 10 µg QD 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.3 LIXI 20 µg QD 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.4 LIXI 30 µg QD 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.5 LIXI 5 µg BID 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.6 LIXI 10 µg BID 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.7 LIXI 20 µg BID 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.8 LIXI 30 µg BID 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Adverse events Other data No numeric data
6 Fasting plasma glucose (mmol/L) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
6.1 LIXI 5 µg QD 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 LIXI 10 µg QD 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 LIXI 20 µg QD 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.4 LIXI 30 µg QD 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.5 LIXI 5 µg BID 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.6 LIXI 10 µg BID 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.7 LIXI 20 µg BID 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.8 LIXI 30 µg BID 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Post-prandial glucose (mmol/L) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
7.1 LIXI 5µg QD 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 LIXI 10µg QD 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.3 LIXI 20µg QD 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.4 LIXI 30µg QD 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.5 LIXI 5µg BID 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.6 LIXI 10µg BID 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.7 LIXI 20µg BID 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.8 LIXI 30µg BID 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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8 Average self-monitored 7-point
blood glucose (mmol/L)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
8.1 LIXI 5 µg QD 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 LIXI 10 µg QD 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.3 LIXI 20 µg QD 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.4 LIXI 30 µg QD 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.5 LIXI 5 µg BID 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.6 LIXI 10 µg BID 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.7 LIXI 20 µg BID 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.8 LIXI 30 µg BID 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 16. Liraglutide 1.2 mg versus SU




participants Statistical method Effect size
1 HbA1c 1 Mean Difference (IV, Random, 95% CI) Subtotals only
2 HbA1c (%) Other data No numeric data
3 HbA1c < 7% 2 946 Risk Ratio (IV, Random, 95% CI) 0.98 [0.84, 1.14]
4 Hypoglycaemia 2 946 Risk Ratio (M-H, Random, 95% CI) 0.06 [0.00, 1.72]
5 Weight change 1 Mean Difference (IV, Random, 95% CI) Subtotals only
6 Weight change (kg) Other data No numeric data
7 Adverse events Other data No numeric data
8 Systolic blood pressure 1 Mean Difference (IV, Random, 95% CI) Subtotals only
9 Blood pressure (mm Hg) Other data No numeric data
10 Fasting plasma glucose
(mmol/L)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
11 Fasting plasma glucose
(mmol/L)
Other data No numeric data
12 Post-prandial glucose (mmol/L) Other data No numeric data
13 Beta-cell function Other data No numeric data
Comparison 17. Liraglutide 1.8 mg daily versus SU




participants Statistical method Effect size
1 HbA1c (%) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2 HbA1c (%) Other data No numeric data
3 HbA1c < 7% 2 949 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.94, 1.26]
4 Hypoglycaemia 2 949 Risk Ratio (M-H, Random, 95% CI) 0.13 [0.07, 0.25]
5 Weight change (kg) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6 Weight change (kg) Other data No numeric data
7 Adverse events Other data No numeric data
8 Systolic blood pressure (mm Hg) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9 Blood pressure (mm Hg) Other data No numeric data
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10 Fasting plasma glucose
(mmol/L)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11 Fasting plasma glucose
(mmol/L)
Other data No numeric data
12 Post-prandial glucose (mmol/L) Other data No numeric data
13 Beta-cell function Other data No numeric data
Comparison 18. Taspoglutide versus placebo




participants Statistical method Effect size
1 HbA1c (%) 2 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Taspoglutide 10 mg once
weekly verus placebo
1 98 Mean Difference (IV, Random, 95% CI) -1.0 [-1.19, -0.81]
1.2 Taspoglutide 20 mg once
weekly versus placebo
2 163 Mean Difference (IV, Random, 95% CI) -0.87 [-1.16, -0.58]
1.3 Taspoglutide 20 mg once
every 2 weeks versus placebo
1 98 Mean Difference (IV, Random, 95% CI) -0.8 [-0.99, -0.61]
2 HbA1c (%) Other data No numeric data
3 HbA1c < 7% 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Taspoglutide 10 mg once
weekly versus placebo
1 98 Risk Ratio (M-H, Random, 95% CI) 4.88 [2.55, 9.33]
3.2 Taspoglutide 20 mg once
weekly versus placebo
2 163 Risk Ratio (M-H, Random, 95% CI) 4.41 [2.70, 7.22]
3.3 Taspoglutide 20 mg once
every two weeks versus placebo
1 98 Risk Ratio (M-H, Random, 95% CI) 3.88 [1.99, 7.56]
4 HbA1c < 7% Other data No numeric data
5 Hypoglycaemia 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Taspoglutide 20/20 mg
once weekly versus placebo
1 64 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.07, 15.30]
5.2 Taspoglutide 20/30 mg
once weekly versus placebo
1 65 Risk Ratio (M-H, Random, 95% CI) 2.91 [0.32, 26.53]
5.3 Taspoglutide 20/40 mg
once weekly versus placebo
1 64 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.19, 20.97]
6 Hypoglycaemia Other data No numeric data
7 Weight change (kg) 2 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 Taspoglutide 10 mg once
weekly versus placebo
1 88 Mean Difference (IV, Random, 95% CI) -1.3 [-2.13, -0.47]
7.2 Taspoglutide 20 mg once
weekly versus placebo
2 153 Mean Difference (IV, Random, 95% CI) -1.07 [-2.93, 0.79]
7.3 Taspoglutide 20 mg once
every two weeks versus placebo
1 80 Mean Difference (IV, Random, 95% CI) -1.10 [-1.93, -0.27]
8 Weight change Other data No numeric data
9 Adverse events Other data No numeric data
10 Adverse events Other data No numeric data
11 Fasting plasma glucose
(mmol/L)
1 Mean Difference (IV, Random, 95% CI) Subtotals only
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11.1 Taspoglutide 20/20 mg
once weekly versus placebo
1 64 Mean Difference (IV, Random, 95% CI) -1.70 [-2.53, -0.87]
11.2 Taspoglutide 20/30 mg
once weekly versus placebo
1 65 Mean Difference (IV, Random, 95% CI) -1.0 [-1.83, -0.17]
11.3 Taspoglutide 20/40 mg
once weekly versus placebo
1 64 Mean Difference (IV, Random, 95% CI) -1.6 [-2.43, -0.77]
12 Fasting plasma glucose Other data No numeric data
13 Postprandial glucose and
insulin
Other data No numeric data
14 Lipid profiles Other data No numeric data
15 Beta-cell function Other data No numeric data
16 Subgroup Other data No numeric data
16.1 Participants with HbA1c
≥8%
Other data No numeric data
Comparison 19. LY2189265 versus placebo




participants Statistical method Effect size
1 HbA1c Other data No numeric data
2 HbA1c < 7% Other data No numeric data
3 Hypoglycaemia Other data No numeric data
3.1 LY 0.5/1.0 QW Other data No numeric data
4 Weight change (kg) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 LY 0.5/1.0 QW 1 130 Mean Difference (IV, Random, 95% CI) -1.32 [-2.40, -0.24]
4.2 LY 1.0/1.0 QW 1 128 Mean Difference (IV, Random, 95% CI) -1.22 [-2.30, -0.14]
4.3 LY 1.0/2.0 QW 1 128 Mean Difference (IV, Random, 95% CI) -2.43 [-3.52, -1.34]
5 Adverse events Other data No numeric data
6 Systolic blood pressure (mm Hg) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
6.1 LY 0.5/1.0 QW 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.2 LY 1.0/1.0 QW 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6.3 LY 1.0/2.0 QW 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Diastolic blood pressure (mm
Hg)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
7.1 LY 0.5/1.0 QW 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 LY 1.0/1.0 QW 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7.3 LY 1.0/2.0 QW 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Fasting plasma glucose (mmol/L) Other data No numeric data
9 Beta-cell function Other data No numeric data
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Comparison 20. GLP-1 agonist versus GLP-1 agonist




participants Statistical method Effect size
1 HbA1c 3 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 versus Liraglutide 1 464 Mean Difference (IV, Random, 95% CI) 0.33 [0.11, 0.55]
1.2 versus Exenatide 2 mg
once weekly
2 547 Mean Difference (IV, Random, 95% CI) 0.55 [0.26, 0.84]
2 HbA1c < 7% 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 versus Liraglutide 1 464 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.66, 0.96]
2.2 versus Exenatide 2 mg
once weekly
2 511 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.42, 1.01]
3 Hypoglycaemia 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 versus Liraglutide 1 467 Risk Ratio (M-H, Random, 95% CI) 1.32 [0.99, 1.75]
3.2 versus Exenatide 2 mg
once weekly
1 295 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.45, 2.86]
4 Hypoglycaemia Other data No numeric data
5 Weight change 2 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 versus Liraglutide 1 464 Mean Difference (IV, Random, 95% CI) 0.37 [-0.55, 1.29]
5.2 versus Exenatide 2 mg
once weekly
1 295 Mean Difference (IV, Random, 95% CI) 0.10 [-1.29, 1.49]
6 Weight change Other data No numeric data
7 Treatment satisfaction Other data No numeric data
7.1 versus Liraglutide Other data No numeric data
7.2 versus Exenatide 2 mg
once weekly
Other data No numeric data
8 Adverse events Other data No numeric data
8.1 versus Liraglutide Other data No numeric data
8.2 versus Exenatide 2 mg
once weekly
Other data No numeric data
9 Systolic blood pressure 3 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 versus Liraglutide 1 464 Mean Difference (IV, Random, 95% CI) 0.51 [-2.72, 3.74]
9.2 versus Exenatide 2 mg
once weekly
2 547 Mean Difference (IV, Random, 95% CI) 1.49 [-0.71, 3.69]
10 Fasting plasma glucose
(mmol/L)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 versus Liraglutide 1 464 Mean Difference (IV, Random, 95% CI) 1.01 [0.46, 1.56]
10.2 versus Exenatide 2 mg
once weekly
2 547 Mean Difference (IV, Random, 95% CI) 1.18 [1.02, 1.33]
11 Post-prandial glucose (mmol/L) Other data No numeric data
11.1 versus Liraglutide Other data No numeric data
11.2 versus Exenatide 2 mg
once weekly
Other data No numeric data
12 Triglycerides (mmol/L) 3 Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 versus Liraglutide 1 464 Mean Difference (IV, Random, 95% CI) 0.18 [-0.10, 0.46]
12.2 versus Exenatide 2 mg
once weekly
2 547 Mean Difference (IV, Random, 95% CI) 0.01 [-0.04, 0.06]
13 Total cholesterol (mmol/L) 3 Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 versus Liraglutide 1 464 Mean Difference (IV, Random, 95% CI) 0.11 [-0.09, 0.31]
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13.2 versus Exenatide 2 mg
once weekly
2 547 Mean Difference (IV, Random, 95% CI) 0.31 [0.10, 0.51]
14 HDL-cholesterol (mmol/L) 3 Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 versus Liraglutide 1 464 Mean Difference (IV, Random, 95% CI) -0.01 [-0.07, 0.05]
14.2 versus Exenatide 2 mg
once weekly
2 547 Mean Difference (IV, Random, 95% CI) 0.00 [-0.03, 0.04]
15 LDL-cholesterol (mmol/L) 3 Mean Difference (IV, Random, 95% CI) Subtotals only
15.1 versus Liraglutide 1 464 Mean Difference (IV, Random, 95% CI) 0.04 [-0.13, 0.21]
15.2 versus Exenatide 2 mg
once weekly
2 547 Mean Difference (IV, Random, 95% CI) 0.20 [0.09, 0.30]
16 Beta-cell function Other data No numeric data
Analysis 1.1. Comparison 1 Albiglutide versus placebo, Outcome 1 HbA1c (%).
HbA1c (%)
Study ALBI 30 mg weekly ALBI 30 mg every 2 weeks Placebo
A - Rosenstock 2009 -0.87% (SD 0.65)
7.1%
P < 0.05 versus placebo
-0.79% (SD 0.98)
7.2%
P < 0.05 versus placebo
-0.17% (SD 1.01)
7.7%
Analysis 1.2. Comparison 1 Albiglutide versus placebo, Outcome 2 HbA1c - with plot.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 1 Albiglutide versus placebo
Outcome: 2 HbA1c - with plot





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALBI 30 mg weekly
A - Rosenstock 2009 29 -0.87 (0.65) 50 -0.17 (1.01) 100.0 % -0.70 [ -1.07, -0.33 ]
Subtotal (95% CI) 29 50 100.0 % -0.70 [ -1.07, -0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.74 (P = 0.00018)
2 ALBI 30 mg every 2 weeks
A - Rosenstock 2009 32 -0.79 (0.98) 50 -0.17 (1.01) 100.0 % -0.62 [ -1.06, -0.18 ]
Subtotal (95% CI) 32 50 100.0 % -0.62 [ -1.06, -0.18 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.76 (P = 0.0058)
-1 -0.5 0 0.5 1
Favours Albiglutide Favours Placebo
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Analysis 1.3. Comparison 1 Albiglutide versus placebo, Outcome 3 HbA1c < 7%.
HbA1c < 7%
Study ALBI 30 mg weekly ALBI 30 mg every 2 weeks Placebo
A - Rosenstock 2009 52%
(P value not given)
50%
(P value not given)
20%
Analysis 1.4. Comparison 1 Albiglutide versus placebo, Outcome 4 Hypoglycaemia.
Hypoglycaemia
Study Definition ALBI 30 mg weekly ALBI 30 mg every 2 weeks Placebo
A - Rosenstock 2009 not given n = 0, P = NS n=1 (3.1%), P = NS n = 2 (3.9%)
Analysis 1.5. Comparison 1 Albiglutide versus placebo, Outcome 5 Weight change - with plot.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 1 Albiglutide versus placebo
Outcome: 5 Weight change - with plot





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ALBI 30 mg weekly
A - Rosenstock 2009 29 -1.4 (2.4) 50 -0.7 (2.9) 100.0 % -0.70 [ -1.89, 0.49 ]
Subtotal (95% CI) 29 50 100.0 % -0.70 [ -1.89, 0.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
2 ALBI 30 mg every 2 weeks
A - Rosenstock 2009 32 -1.6 (2.5) 50 -0.7 (2.9) 100.0 % -0.90 [ -2.08, 0.28 ]
Subtotal (95% CI) 32 50 100.0 % -0.90 [ -2.08, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
-4 -2 0 2 4
Favours Albiglutide Favours Placebo
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Analysis 1.6. Comparison 1 Albiglutide versus placebo, Outcome 6 Weight change (kg).
Weight change (kg)
Study ALBI 30 mg weekly ALBI 30 mg every 2 weeks Placebo
A - Rosenstock 2009 -1.4 kg (SD 2.4), P = NS -1.6 kg (SD 2.5), P = NS -0.7 kg (SD 2.9)
Analysis 1.7. Comparison 1 Albiglutide versus placebo, Outcome 7 Adverse events.
Adverse events
Study Description ALBI 30 mg weekly ALBI 30 mg every 2
weeks
Placebo
A - Rosenstock 2009 any adverse event 83.9% 84.4% 66.7%
A - Rosenstock 2009 withdrawals 32.2% 42.8% 23.5%
A - Rosenstock 2009 adverse events similar
across groups for:
abdomi-




tory tract infection, back
pain
no systemic allergic reac-
tions to albiglutide
A - Rosenstock 2009 nausea n = 8 (25.8%) n = 8 (25%) n = 6 (11.8%)
A - Rosenstock 2009 vomiting n = 4 (12.9%) n = 3 (9.4%) n = 1 (2%)
A - Rosenstock 2009 diarrhoea n = 5 (16.1%) n = 7 (21.9%) n = 2 (3.9%)
A - Rosenstock 2009 cardiac disorders none none n = 1
A - Rosenstock 2009 pancreatitis none none none
A - Rosenstock 2009 skin reactions 15 events in 7 patients 11 events in 6 patients 3 events in 3 patients
A - Rosenstock 2009 positive immunogenicity
test
2 of 31 (6.4%) 1 of 32 (3.1%) 1 of 51 (2%)
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Analysis 1.8. Comparison 1 Albiglutide versus placebo, Outcome 8 Blood pressure (mm Hg).
Blood pressure (mm Hg)
Study Description ALBI 30 mg weekly ALBI30mgevery 2weeks Placebo
A - Rosenstock 2009 systolic BP (mm Hg) -5.8 (SD 11.2), P = NS -7.4 (SD 14.2), P = NS -0.7 (SD 13.9)
A - Rosenstock 2009 diastolic BP (mm Hg) -1.9 (SD 8.1), P = NS -4.4 (SD 8.9), P = NS -1.0 (SD 8.2)
Analysis 1.9. Comparison 1 Albiglutide versus placebo, Outcome 9 Fasting plasma glucose (mmol/L).
Fasting plasma glucose (mmol/L)
Study ALBI 30 mg weekly ALBI 30 mg every 2
weeks
Placebo FPG fluctuations
A - Rosenstock 2009 -1.44% (SD 2.03), P < 0.
05 versus placebo
-1.58% (SD 2.06), P < 0.
05 versus placebo
-0.10% (SD 2.90) according to figure 1C in the
paper, the once weekly dosing
schedules seemed to cause less
fluctuation in FPG than the less
frequent dosing schedules; how-
ever, data are only shown for 50
mg every 2 weeks and not for 30
mg every 2 weeks
COMMENT: paper says “%”
but should probably be “mmol/
L”??
Analysis 1.10. Comparison 1 Albiglutide versus placebo, Outcome 10 Lipid profiles.
Lipid profiles
Study Description ALBI 30 mg weekly ALBI 30 mg every 2
weeks
Placebo
A - Rosenstock 2009 triglycerides (mmol/L) +0.1 (SD 0.9), P = NS -0.3 (SD 1.0), P = NS -0.4 (SD 1.7)
A - Rosenstock 2009 total cholesterol (mmol/
L)
+0.01 (SD 0.6), P = NS -0.18 (SD 0.45), P = NS +0.1 (SD 0.77)
A - Rosenstock 2009 HDL (mmol/L) -0.05 (SD 0.17), P = NS -0.03 (SD 0.14), P = NS -0.002 (SD 0.13)
A - Rosenstock 2009 LDL (mmol/L) +0.003 (SD 0.6), P = NS -0.06 (SD 0.39), P = NS +0.19 (SD 0.6)
A - Rosenstock 2009 free fatty acids (mmol/L) +0.05 (SD 0.17), P = NS -0.01 (SD 0.25), P = NS +0.08 (SD 0.2)
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Analysis 1.11. Comparison 1 Albiglutide versus placebo, Outcome 11 Beta-cell function.
Beta-cell function
Study Description ALBI 30 mg weekly ALBI 30 mg every 2
weeks
Placebo
A - Rosenstock 2009 HOMA-B endpoint 95.4 74.7 50.4
A - Rosenstock 2009 HOMA-B ratio at end-
point
1.4, P < 0.05 versus
placebo
1.2, P = NS 1.0
Analysis 1.12. Comparison 1 Albiglutide versus placebo, Outcome 12 Subgroups.
Subgroups
Study Outcome Results / comments
A - Rosenstock 2009 HbA1c Numerically greater reductionswere seen in participants with baselineHbA1c≥ 8.5% (no details
given)
Analysis 2.1. Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 1 HbA1c (%).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 2 Exenatide 2 mg once weekly versus thiazolidinedione
Outcome: 1 HbA1c (%)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
E - Bergenstal 2010 160 -1.5 (0.97) 165 -1.2 (1.31) -0.30 [ -0.55, -0.05 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Exenatide 2 mg QW Favours Pioglitazone QD
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Analysis 2.2. Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 2 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 2 Exenatide 2 mg once weekly versus thiazolidinedione
Outcome: 2 HbA1c < 7%
Study or subgroup Exenatide 2 mg QW
Pioglitazone








E - Bergenstal 2010 96/160 86/165 1.15 [ 0.95, 1.40 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 96 (Exenatide 2 mg QW), 86 (Pioglitazone 45 mg QD)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours Pioglitazone QD Favours Exenatide 2 mg QW
Analysis 2.3. Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 3
Hypoglycaemia (minor).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 2 Exenatide 2 mg once weekly versus thiazolidinedione
Outcome: 3 Hypoglycaemia (minor)
Study or subgroup Exenatide 2 mg QW
Pioglitazone








E - Bergenstal 2010 2/160 1/165 2.06 [ 0.19, 22.52 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 2 (Exenatide 2 mg QW), 1 (Pioglitazone 45 mg QD)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Exenatide 2 mg QW Favours Pioglitazone QD
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Analysis 2.4. Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 4 Weight
change (kg).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 2 Exenatide 2 mg once weekly versus thiazolidinedione
Outcome: 4 Weight change (kg)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
E - Bergenstal 2010 160 -2.3 (3.87) 165 2.8 (3.93) -5.10 [ -5.95, -4.25 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-4 -2 0 2 4
Favours Exenatide 2 mg QW Favours Pioglitazone QD
Analysis 2.5. Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 5 Quality of life.
Quality of life
Study Description Exenatide 2 mg QW Pioglitazone 45 mg QD Difference between
groups
E - Bergenstal 2010 IWQOL total score 5.15, 95% CI 3.11 to 7.
19
1.20, 95% CI -0.87 to 3.
28
EX vs PIO: 3.94, 95% CI
1.28 to 6.61, P = 0.0038
E - Bergenstal 2010 Overall treatment satis-
faction
3.96, 95% CI 2.78 to 5.
15
NR NR
Analysis 2.6. Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 6 Adverse
events.
Adverse events
Study Description Exenatide 2 mg QW Pioglitazone 45 mg QD
E - Bergenstal 2010 Withdrawals due to adverse events 6.9% 3.6%
E - Bergenstal 2010 Nausea 24% 5%
E - Bergenstal 2010 Diarrhoea 18% 7%
E - Bergenstal 2010 Vomiting 11% 3%
E - Bergenstal 2010 Urinary tract infection 6% 4%
E - Bergenstal 2010 Headache 9% 4%
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Adverse events (Continued)
E - Bergenstal 2010 Injection-site pruritus 5% 1%
E - Bergenstal 2010 Serious adverse events 3% 6%
E - Bergenstal 2010 Anti-Exenatide antibodies either low (<1/625; n=74, 48%) or
not detectable (n = 61, 40%) titres
-
E - Bergenstal 2010 Severe hypoglycaemia 0 0
Analysis 2.7. Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 7 Blood
pressure (mm Hg).
Blood pressure (mm Hg)
Study Description Exenatide 2 mg QW Pioglitazone 45 mg QD Difference between groups
E - Bergenstal 2010 Systolic blood pressure NR NR EX vs. PIO: P = NS
E - Bergenstal 2010 Diastolic blood pressure NR NR EX vs. PIO: P = NS
Analysis 2.8. Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 8 Fasting
plasma glucose (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 2 Exenatide 2 mg once weekly versus thiazolidinedione
Outcome: 8 Fasting plasma glucose (mmol/L)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
E - Bergenstal 2010 160 -1.8 (2.9) 165 -1.5 (2.62) -0.30 [ -0.90, 0.30 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
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Analysis 2.9. Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 9 Post-prandial
glucose / glucose profiles.
Post-prandial glucose / glucose profiles
Study Description Exenatide 2 mg QW Pioglitazone 45 mg QD Description
E - Bergenstal 2010 Self-monitored blood
glucose
NR NR EX vs PIO: P = NS
Analysis 2.10. Comparison 2 Exenatide 2 mg once weekly versus thiazolidinedione, Outcome 10 Lipid
profiles.
Lipid profiles
Study Description Exenatide 2 mg QW Sitagliptin 100 mg QD Difference between groups
E - Bergenstal 2010 Fasting triglycerides
(mmol/l)
NR NR EX vs. SITA: P = NS; PIO vs.
SITA: P = 0.0062
E - Bergenstal 2010 Total cholesterol (mmol/
l)
NR NR EX vs. SITA: P = NS; PIO vs.
SITA: P = NS
E - Bergenstal 2010 HDL (mmol/l) NR NR EX vs. SITA: P = NS; PIO vs.
SITA: P < 0.0001
E - Bergenstal 2010 LDL (mmol/l) NR NR EX vs. SITA: P = NS; PIO vs.
SITA: P = NS
Analysis 3.1. Comparison 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors, Outcome 1 HbA1c (%).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors
Outcome: 1 HbA1c (%)








N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
E - Bergenstal 2010 160 -1.5 (0.97) 166 -0.9 (1.31) -0.60 [ -0.85, -0.35 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
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Analysis 3.2. Comparison 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors, Outcome 2 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors
Outcome: 2 HbA1c < 7%
Study or subgroup Exenatide 2 mg QW
Sitagliptin
100 mg








E - Bergenstal 2010 96/160 58/166 1.72 [ 1.35, 2.19 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 96 (Exenatide 2 mg QW), 58 (Sitagliptin 100 mg QD)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours Sitagliptin QD Favours Exenatide QW
Analysis 3.3. Comparison 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors, Outcome 3
Hypoglycaemia (minor).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors
Outcome: 3 Hypoglycaemia (minor)
Study or subgroup Exenatide 2 mg QW
Sitagliptin
100 mg








E - Bergenstal 2010 2/160 5/166 0.42 [ 0.08, 2.11 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 2 (Exenatide 2 mg QW), 5 (Sitagliptin 100 mg QD)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Exenatide QW Favours Sitagliptin QD
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Analysis 3.4. Comparison 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors, Outcome 4 Weight
change (kg).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors
Outcome: 4 Weight change (kg)








N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
E - Bergenstal 2010 160 -2.3 (3.87) 166 -0.8 (4.27) -1.50 [ -2.38, -0.62 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Exenatide QW Favours Sitagliptin QD
Analysis 3.5. Comparison 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors, Outcome 5 Quality of life.
Quality of life
Study Description Exenatide 2 mg QW Sitagliptin 100 mg QD Difference between
groups
E - Bergenstal 2010 IWQOL total score 5.15, 95% CI 3.11 to 7.
19
4.56, 95% CI 2.56 to 6.
57
EX vs PIO: 3.94, 95% CI
1.28 to 6.61, P = 0.0038
E - Bergenstal 2010 Overall treatment satis-
faction
3.96, 95% CI 2.78 to 5.
15
2.35, 95% CI 1.19 to 3.
51
EX vs. SITA: 1.61, 95%
CI 0.07 to 3.16, P = 0.
0406
Analysis 3.6. Comparison 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors, Outcome 6 Adverse
events.
Adverse events
Study Description Exenatide 2 mg QW Sitagliptin 100 mg QD
E - Bergenstal 2010 Withdrawals due to adverse events 6.9% 3%
E - Bergenstal 2010 Nausea 24% 10%
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Adverse events (Continued)
E - Bergenstal 2010 Diarrhoea 18% 10%
E - Bergenstal 2010 Vomiting 11% 2%
E - Bergenstal 2010 Urinary tract infection 6% 5%
E - Bergenstal 2010 Headache 9% 9%
E - Bergenstal 2010 Injection-site pruritus 5% 5%
E - Bergenstal 2010 Serious adverse events 3% 3%
E - Bergenstal 2010 Anti-Exenatide antibodies either low (<1/625; n=74, 48%) or
not detectable (n = 61, 40%) titres
-
E - Bergenstal 2010 Severe hypoglycaemia 0 0
Analysis 3.7. Comparison 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors, Outcome 7 Blood
pressure (mm Hg).
Blood pressure (mm Hg)
Study Description Exenatide 2 mg QW Sitagliptin 100 mg QD Difference between groups
E - Bergenstal 2010 Systolic blood pressure NR NR EX vs. SITA: -4mmHg (95%
CI -6 to -1); P = 0.0055
E - Bergenstal 2010 Diastolic blood pressure NR NR EX vs. SITA: P = NS
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Analysis 3.8. Comparison 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors, Outcome 8 Fasting
plasma glucose (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors
Outcome: 8 Fasting plasma glucose (mmol/L)








N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
E - Bergenstal 2010 160 -1.8 (2.9) 166 -0.9 (2.63) -0.90 [ -1.50, -0.30 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors, Outcome 9 Post-prandial
glucose / glucose profiles.
Post-prandial glucose / glucose profiles
Study Description Exenatide 2 mg QW Sitagliptin 100 mg QD Description
E - Bergenstal 2010 Self-monitored blood
glucose
NR NR EX vs SITA: P < 0.05
Analysis 3.10. Comparison 3 Exenatide 2 mg once weekly versus DPP-4 inhibitors, Outcome 10 Lipid
profiles.
Lipid profiles
Study Description Exenatide 2 mg QW Sitagliptin 100 mg QD Difference between groups
E - Bergenstal 2010 Fasting triglycerides
(mmol/l)
NR NR EXvs. SITA: P=0.9718; PIO
vs. SITA: p=0.0062
E - Bergenstal 2010 Total cholesterol (mmol/
l)
NR NR EXvs. SITA: P=0.3424; PIO
vs. SITA: P = 0.3424
E - Bergenstal 2010 HDL (mmol/l) NR NR EXvs. SITA: P=0.9546; PIO
vs. SITA: P < 0.0001
E - Bergenstal 2010 LDL (mmol/l) NR NR EXvs. SITA: P=0.6113; PIO
vs. SITA: P = 0.9965
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Analysis 4.1. Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 1 HbA1c (%).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 4 Exenatide 2 mg once weekly versus insulin glargine
Outcome: 1 HbA1c (%)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
E - Diamant 2010 233 -1.5 (0.76) 223 -1.3 (0.9) -0.20 [ -0.35, -0.05 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Exenatide QW Favours Insulin glargine
Analysis 4.2. Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 2 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 4 Exenatide 2 mg once weekly versus insulin glargine
Outcome: 2 HbA1c < 7%
Study or subgroup Exenatide 2 mg QW Insulin glargine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
E - Diamant 2010 126/216 101/212 1.22 [ 1.02, 1.47 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 126 (Exenatide 2 mg QW), 101 (Insulin glargine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours Insulin glargine Favours Exenatide QW
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Analysis 4.3. Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 3 Hypoglycaemia
(symptoms only).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 4 Exenatide 2 mg once weekly versus insulin glargine
Outcome: 3 Hypoglycaemia (symptoms only)








E - Diamant 2010 28/233 70/223 0.38 [ 0.26, 0.57 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 28 (Exenatide 2 mg QW), 70 (Insulin glargine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Exenatide QW Favours Insulin glargine
Analysis 4.4. Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 4 Hypoglycaemia
(minor).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 4 Exenatide 2 mg once weekly versus insulin glargine
Outcome: 4 Hypoglycaemia (minor)
Study or subgroup Exenatide 2 mg QW Insulin glargine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
E - Diamant 2010 19/233 58/223 0.31 [ 0.19, 0.51 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 19 (Exenatide 2 mg QW), 58 (Insulin glargine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
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117Glucagon-like peptide analogues for type 2 diabetes mellitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.5. Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 5 Severe
hypoglycaemia.
Severe hypoglycaemia
Study Description Exenatide 2 mg QW Insulin glargine
E - Diamant 2010 Taking metformin only 1 (0.4%) 1 (0.4%)
E - Diamant 2010 Takingbothmetformin and sulpho-
nylureas
None 1 (0.4%)
Analysis 4.6. Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 6 Weight change
(kg).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 4 Exenatide 2 mg once weekly versus insulin glargine
Outcome: 6 Weight change (kg)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
E - Diamant 2010 233 -2.6 (3.05) 223 1.4 (2.99) -4.00 [ -4.55, -3.45 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 7 Adverse events.
Adverse events
Study Description Exenatide 2 mg QW Insulin glargine
E - Diamant 2010 withdrawal due to adverse events 11 (4.7%) 2 (0.9%)
E - Diamant 2010 nausea 30 (13%) 3 (1%)
E - Diamant 2010 vomiting 10 (4%) 3 (1%)
E - Diamant 2010 diarrhoea 20 (9%) 8 (4%)
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Adverse events (Continued)
E - Diamant 2010 Nasopharyngitis 30 (13%) 39 (17%)
E - Diamant 2010 Headache 23 (10%) 16 (7%)
E - Diamant 2010 Injection-site reaction 30 (13%) 4 (2%)







E - Diamant 2010 Deaths None None
E - Diamant 2010 Anti-exenatide antibodies 127/233 (54.5%) tested positive for
anti-exenatide antibodies. No effect
on HbA1c
-
Analysis 4.8. Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 8 Quality of life.
Quality of life
Study Description Exenatide 2 mg QW Insulin glargine
E - Diamant 2010 IWQOL-Lite (self-esteem) Significant improvement compared
with insulin glargine; no data given
Analysis 4.9. Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 9 Fasting plasma
glucose (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 4 Exenatide 2 mg once weekly versus insulin glargine
Outcome: 9 Fasting plasma glucose (mmol/L)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
E - Diamant 2010 214 -2.1 (2.93) 207 -2.8 (2.88) 0.70 [ 0.14, 1.26 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.10. Comparison 4 Exenatide 2 mg once weekly versus insulin glargine, Outcome 10 Postprandial
glucose / glucose profiles.
Postprandial glucose / glucose profiles
Study Description Exenatide 2 mg QW Insulin glargine Comment
E - Diamant 2010 8-point SMBG NR NR Both treatments reduced PPG at all eight time-
points (all P < 0.0001)
0300 hour and before breafast: participants re-
ceiving insulin glargine had lower glucose con-
centrations than exenatide at 0300 hour (P = 0.
022) and before breakfast (P < 0.0001)
Dinner, morning and evening meals: partici-
pants receiving exenatide had lower glucose con-
centrations after dinner than insulin glargine (P
= 0.004)
Morning and evening meals: participants receiv-
ing exenatide had lower postprandial glucose ex-
cursions than insulin glargine after morning (P
= 0.001) and evening meals (P = 0.033)
Analysis 5.1. Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 1 HbA1c (%).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 5 Liraglutide 0.6 mg daily versus placebo









N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
L - Kaku 2010 88 -1.46 (0.95) 88 -0.4 (0.93) -1.06 [ -1.34, -0.78 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-100 -50 0 50 100
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Analysis 5.2. Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 2 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 5 Liraglutide 0.6 mg daily versus placebo




daily Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
L - Kaku 2010 41/88 13/88 3.15 [ 1.82, 5.46 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 41 (Liraglutide 0.6 mg daily), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours Placebo Favours Liraglutide
Analysis 5.3. Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 3 Hypoglycaemia rate
(events/patient-year).
Hypoglycaemia rate (events/patient-year)
Study Liraglutide 0.6 mg daily Placebo
L - Kaku 2010 2.17 1.01
Analysis 5.4. Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 4 Severe hypoglycaemia.
Severe hypoglycaemia
Study Liraglutide 0.6 mg daily Placebo
L - Kaku 2010 None None
Analysis 5.5. Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 5 Weight change (kg).
Weight change (kg)
Study Liraglutide 0.6 mg daily Placebo
L - Kaku 2010 +0.06. P < 0.0001 versus placebo -1.12
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Analysis 5.6. Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 6 Adverse events.
Adverse events
Study Description Liraglutide 0.6 mg daily Placebo
L - Kaku 2010 Withdrawals due to adverse events 3 (3%) 2 (2%)
L - Kaku 2010 Overall adverse events 67 (76.1%) 66 (75%)
L - Kaku 2010 Gastrointestinal adverse events More subjects in the two liraglutide
groups reported gastrointestinal ad-
verse events during the first 4 weeks
of the trial than subjects on placebo.
No major differences in gastrointesti-
nal adverse events across groups
L - Kaku 2010 Serious adverse events 3 (3%) 2 (2%)
L - Kaku 2010 Pancreatitis None None
L - Kaku 2010 Deaths None None
Analysis 5.7. Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 7 Blood pressure (mm Hg).
Blood pressure (mm Hg)
Study
L - Kaku 2010 SBP did not change in both groups; P = NS between groups
DBP did not change in both groups; P = NS between groups
Analysis 5.8. Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 8 Fasting plasma glucose
(mmol/L).
Fasting plasma glucose (mmol/L)
Study Liraglutide 0.6 mg daily Placebo
L - Kaku 2010 -2.3, P < 0.0001 versus placebo -0.64
Analysis 5.9. Comparison 5 Liraglutide 0.6 mg daily versus placebo, Outcome 9 Post-prandial glucose /
glucose profiles.
Post-prandial glucose / glucose profiles
Study Description Liraglutide 0.6 mg daily Placebo
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Post-prandial glucose / glucose profiles (Continued)
L - Kaku 2010 7-point SMBG profile -2.66, P < 0.0001 versus placebo -0.35
Analysis 6.1. Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 1 HbA1c (%).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 6 Liraglutide 0.9 mg daily versus placebo









N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
L - Kaku 2010 88 -1.56 (0.84) 88 -0.4 (0.93) -1.16 [ -1.42, -0.90 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 2 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 6 Liraglutide 0.9 mg daily versus placebo




daily Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
L - Kaku 2010 63/88 13/88 4.85 [ 2.88, 8.14 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 63 (Liraglutide 0.9 mg daily), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
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123Glucagon-like peptide analogues for type 2 diabetes mellitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.3. Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 3 Hypoglycaemia rate
(events/patient-year).
Hypoglycaemia rate (events/patient-year)
Study Liraglutide 0.9 mg daily Placebo
L - Kaku 2010 1.96 1.01
Analysis 6.4. Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 4 Severe hypoglycaemia.
Severe hypoglycaemia
Study Liraglutide 0.9 mg daily Placebo
L - Kaku 2010 None None
Analysis 6.5. Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 5 Weight change (kg).
Weight change (kg)
Study Liraglutide 0.9 mg daily Placebo
L - Kaku 2010 -0.37, P = 0.0071 versus placebo -1.12
Analysis 6.6. Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 6 Adverse events.
Adverse events
Study Description Liraglutide 0.9 mg daily Placebo
L - Kaku 2010 Withdrawals due to adverse events 2 (2%) 2 (2%)
L - Kaku 2010 Overall adverse events 69 (78.4%) 66 (75%)
L - Kaku 2010 Gastrointestinal adverse events More subjects in the two liraglutide
groups reported gastrointestinal ad-
verse events during the first 4 weeks
of the trial than subjects on placebo.
No major differences in gastrointesti-
nal adverse events across groups
L - Kaku 2010 Serious adverse events 2 (2%) 2 (2%)
L - Kaku 2010 Pancreatitis None None
L - Kaku 2010 Deaths None None
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Analysis 6.7. Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 7 Blood pressure (mm Hg).
Blood pressure (mm Hg)
Study
L - Kaku 2010 SBP did not change in both groups; P = NS between groups
DBP did not change in both groups; P = NS between groups
Analysis 6.8. Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 8 Fasting plasma glucose
(mmol/L).
Fasting plasma glucose (mmol/L)
Study Liraglutide 0.9 mg daily Placebo
L - Kaku 2010 -2.28, P < 0.0001 versus placebo -0.64
Analysis 6.9. Comparison 6 Liraglutide 0.9 mg daily versus placebo, Outcome 9 Postprandial glucose /
glucose profiles.
Postprandial glucose / glucose profiles
Study Description Liraglutide 0.9 mg daily Placebo
L - Kaku 2010 7-point SMBG profile -2.89, P < 0.0001 versus placebo -0.35
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Analysis 7.1. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 1 HbA1c.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus










N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 1 Marre 2009 228 -1.08 (1.06) 114 0.23 (1.07) 37.7 % -1.31 [ -1.55, -1.07 ]
L - LEAD 2 Nauck 2009 240 -1 (1.55) 121 0.1 (1.1) 31.1 % -1.10 [ -1.38, -0.82 ]
L - LEAD 4 Zinman 2009 178 -1.5 (1.33) 177 -0.5 (1.33) 31.2 % -1.00 [ -1.28, -0.72 ]
Total (95% CI) 646 412 100.0 % -1.15 [ -1.33, -0.96 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.96, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 12.14 (P < 0.00001)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours Liraglutide Favours Placebo
Analysis 7.2. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 2 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 7 Liraglutide 1.2 mg versus placebo












L - LEAD 1 Marre 2009 80/228 9/114 26.9 % 4.44 [ 2.32, 8.53 ]
L - LEAD 2 Nauck 2009 85/240 13/121 31.1 % 3.30 [ 1.92, 5.66 ]
L - LEAD 4 Zinman 2009 102/178 50/177 42.0 % 2.03 [ 1.55, 2.65 ]
Total (95% CI) 646 412 100.0 % 2.91 [ 1.74, 4.87 ]
Total events: 267 (Liraglutide 1.2 mg daily), 72 (Placebo)
Heterogeneity: Tau2 = 0.14; Chi2 = 7.00, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 4.08 (P = 0.000045)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 3 Hypoglycaemia.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus













L - LEAD 1 Marre 2009 21/228 3/114 33.7 % 3.50 [ 1.07, 11.49 ]
L - LEAD 2 Nauck 2009 2/240 3/121 22.0 % 0.34 [ 0.06, 1.98 ]
L - LEAD 4 Zinman 2009 16/178 9/177 44.3 % 1.77 [ 0.80, 3.89 ]
Total (95% CI) 646 412 100.0 % 1.54 [ 0.54, 4.42 ]
Total events: 39 (Liraglutide 1.2 mg daily), 15 (Placebo)
Heterogeneity: Tau2 = 0.49; Chi2 = 4.65, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 7.4. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 4 Weight change.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 7 Liraglutide 1.2 mg versus placebo









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 1 Marre 2009 228 0.3 (3.02) 114 -0.1 (2.88) 34.2 % 0.40 [ -0.26, 1.06 ]
L - LEAD 2 Nauck 2009 240 -2.6 (3.1) 121 -1.5 (3.3) 33.6 % -1.10 [ -1.81, -0.39 ]
L - LEAD 4 Zinman 2009 178 -1 (4) 177 0.6 (3.99) 32.2 % -1.60 [ -2.43, -0.77 ]
Total (95% CI) 646 412 100.0 % -0.75 [ -1.95, 0.45 ]
Heterogeneity: Tau2 = 0.99; Chi2 = 16.34, df = 2 (P = 0.00028); I2 =88%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 7.5. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 5 Adverse events.
Adverse events
Study Description Liraglutide 1.2 mg daily Placebo
L - LEAD 1 Marre 2009 withdrawal due to adverse events 5% 5%
L - LEAD 1 Marre 2009 no significant differences across
groups for: blood pressure; no




L - LEAD 1 Marre 2009 nausea 10.5% (highest) 1.8% (lowest)
L - LEAD 1 Marre 2009 vomiting 4.4%
L - LEAD 1 Marre 2009 diarrhoea 7.9%
L - LEAD 1 Marre 2009 serious adverse events (mostly
judged to be unlikely to be re-
lated to study medication)
4% 3%
L - LEAD 1 Marre 2009 liraglutide auto-antibodies 9 to13%, no effect on HbA1c
L - LEAD 1 Marre 2009
L - LEAD 1 Marre 2009
L - LEAD 1 Marre 2009
L - LEAD 2 Nauck 2009 withdrawal due to adverse events 10% 2%
L - LEAD 2 Nauck 2009 withdrawal due to nausea/vom-
iting/diarrhoea
5% 0
L - LEAD 2 Nauck 2009 no significant differences across
groups for: physical examina-
tion findings, laboratory analy-
ses, ECG, ophthalmoscopy
L - LEAD 2 Nauck 2009 any GI event 40% 17%
L - LEAD 2 Nauck 2009 nausea 16% 3 to 4%
L - LEAD 2 Nauck 2009 vomiting 5 to 7% 1%
L - LEAD 2 Nauck 2009 diarrhoea 8% 4%
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Adverse events (Continued)
L - LEAD 2 Nauck 2009 serious adverse events: 2 deaths
unrelated to liraglutide treat-
ment; 1 participant in 1.2 mg li-
raglutide group withdrawn due
to acute pancreatitis
L - LEAD 2 Nauck 2009 injection site reactions NR NR
L - LEAD 2 Nauck 2009 auto-immune response NR NR
L - LEAD 4 Zinman 2009 withdrawal due to adverse events 6% 3%
L - LEAD 4 Zinman 2009 withdrawal due to nausea/vom-
iting/diarrhoea
3% 0
L - LEAD 4 Zinman 2009 no significant differences across
groups for: physical examina-
tion findings, laboratory analy-
ses, ECG, ophthalmoscopy, car-
diovascular adverse events
L - LEAD 4 Zinman 2009 any GI event 45% 19%
L - LEAD 4 Zinman 2009 nausea 29% NR
L - LEAD 4 Zinman 2009 vomiting 7% NR
L - LEAD 4 Zinman 2009 diarrhoea NR NR
L - LEAD 4 Zinman 2009 serious adverse events 8 events in 8 participants 13 events in 12 participants
L - LEAD 4 Zinman 2009 injection site reactions NR NR
L - LEAD 4 Zinman 2009 auto-immune response 4.1% (no effect on HbA1c)
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Analysis 7.6. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 6 Systolic blood pressure.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 7 Liraglutide 1.2 mg versus placebo









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 2 Nauck 2009 240 -2.81 (13.32) 121 -1.76 (12.54) 51.5 % -1.05 [ -3.85, 1.75 ]
L - LEAD 4 Zinman 2009 178 -6.7 (14.68) 177 -1.1 (15.96) 48.5 % -5.60 [ -8.79, -2.41 ]
Total (95% CI) 418 298 100.0 % -3.26 [ -7.71, 1.20 ]
Heterogeneity: Tau2 = 8.01; Chi2 = 4.42, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 7.7. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 7 Liraglutide 1.2 mg versus placebo









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 1 Marre 2009 228 -1.57 (2.42) 114 1.01 (2.35) 33.9 % -2.58 [ -3.11, -2.05 ]
L - LEAD 2 Nauck 2009 240 -1.6 (2.48) 121 0.4 (2.31) 34.9 % -2.00 [ -2.52, -1.48 ]
L - LEAD 4 Zinman 2009 178 -2.2 (2.8) 177 -0.4 (2.79) 31.2 % -1.80 [ -2.38, -1.22 ]
Total (95% CI) 646 412 100.0 % -2.13 [ -2.59, -1.68 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 4.21, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 9.19 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 7.8. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 8 Post-prandial glucose (mmol/L).
Post-prandial glucose (mmol/L)
Study Description Liraglutide 1.2 mg
daily
Placebo Comments
L - LEAD 1 Marre 2009 average of val-
ues obtained 90 min af-
ter breakfast, lunch and
evening meal
-2.5 mmol/L -0.4 mmol/L Liraglutide 1.2 mg versus placebo:
P < 0.0001
L - LEAD 2Nauck 2009 from self-monitored 7-
point plasma glucose
measurements
-2.3 mmol/L -0.6 mmol/L Liraglutide 1.2 mg versus placebo:
P < 0.001





-2.6 mmol/L -0.8 mmol/L Liraglutide 1.2mg versus placebo: P
< 0.001; the postprandial increment
(postmeal valueminus premeal) was
significantly reduced over breakfast
with liraglutide treatment (-0.9, -0.
8, -0.3 mmol/L respectively; P < 0.
05 for both liraglutide groups ver-
sus placebo) but not for lunch and
dinner
Analysis 7.9. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 9 Triglycerides (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 7 Liraglutide 1.2 mg versus placebo









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 4 Zinman 2009 178 -0.38 (1.33) 177 -0.13 (1.5) -0.25 [ -0.54, 0.04 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 7.10. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 7 Liraglutide 1.2 mg versus placebo









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 4 Zinman 2009 178 -0.21 (1.2) 177 -0.02 (1.3) -0.19 [ -0.45, 0.07 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 7.11. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 11 HDL-cholesterol (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 7 Liraglutide 1.2 mg versus placebo









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 4 Zinman 2009 178 -0.03 (0.27) 177 -0.03 (0.3) 0.0 [ -0.06, 0.06 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 7.12. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 12 LDL-cholesterol (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 7 Liraglutide 1.2 mg versus placebo









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 4 Zinman 2009 178 -0.28 (0.93) 177 -0.1 (0.9) -0.18 [ -0.37, 0.01 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 7.13. Comparison 7 Liraglutide 1.2 mg versus placebo, Outcome 13 Beta-cell function.
Beta-cell function
Study Description Liraglutide 1.2 mg daily Placebo
L - LEAD 1 Marre 2009 HOMA-B (%) 99% SE 184.3 (+28%), P = 0.01
versus placebo
52% SE 107.3 (-4%)
L - LEAD 1 Marre 2009 proinsulin-to-insulin ratio 0.33 SE 0.2 (-0.12), p≤ 0.02 ver-
sus placebo
0.46 SE 0.29 (+0.02)
L - LEAD 1 Marre 2009
L - LEAD 2 Nauck 2009 HOMA-B (%) +23% -2%
L - LEAD 2 Nauck 2009 proinsulin-to-insulin ratio -0.1, P < 0.0001 versus placebo +0.1
L - LEAD 2 Nauck 2009 proinsulin-to-C-peptide ratio
L - LEAD 4 Zinman 2009 HOMA-B (%) +27% SD 59, P < 0.05 vs placebo 6% SD 60
L - LEAD 4 Zinman 2009 proinsulin-to-insulin ratio -0.029 SD 0.35, P < 0.05 vs
placebo
0.036 SD 39
L - LEAD 4 Zinman 2009 proinsulin-to-C-peptide ratio -0.007 SD 0.01, P < 0.05 vs
placebo
-0.002 SD 0.01
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Analysis 8.1. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 1 HbA1c.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus










N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 1 Marre 2009 234 -1.13 (1.06) 114 0.23 (1.07) 28.9 % -1.36 [ -1.60, -1.12 ]
L - LEAD 2 Nauck 2009 242 -1 (1.56) 121 0.1 (1.1) 23.7 % -1.10 [ -1.38, -0.82 ]
L - LEAD 4 Zinman 2009 178 -1.5 (1.33) 177 -0.5 (1.33) 23.8 % -1.00 [ -1.28, -0.72 ]
L - LEAD 5 Russell-J 2009 230 -1.33 (1.36) 114 -0.24 (1.17) 23.7 % -1.09 [ -1.37, -0.81 ]
Total (95% CI) 884 526 100.0 % -1.15 [ -1.31, -0.99 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.40, df = 3 (P = 0.22); I2 =32%
Test for overall effect: Z = 13.95 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 2 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 8 Liraglutide 1.8 mg versus placebo












L - LEAD 1 Marre 2009 98/234 9/114 21.0 % 5.30 [ 2.78, 10.11 ]
L - LEAD 2 Nauck 2009 103/242 13/121 23.6 % 3.96 [ 2.32, 6.76 ]
L - LEAD 4 Zinman 2009 96/178 50/177 29.5 % 1.91 [ 1.46, 2.50 ]
L - LEAD 5 Russell-J 2009 122/230 18/114 25.8 % 3.36 [ 2.16, 5.22 ]
Total (95% CI) 884 526 100.0 % 3.25 [ 1.97, 5.36 ]
Total events: 419 (Liraglutide 1.8 mg daily), 90 (Placebo)
Heterogeneity: Tau2 = 0.20; Chi2 = 14.84, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 4.63 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 3 Hypoglycaemia.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus













L - LEAD 1 Marre 2009 19/234 3/114 9.4 % 3.09 [ 0.93, 10.21 ]
L - LEAD 2 Nauck 2009 6/242 3/121 7.2 % 1.00 [ 0.25, 3.93 ]
L - LEAD 4 Zinman 2009 14/178 9/177 20.4 % 1.55 [ 0.69, 3.48 ]
L - LEAD 5 Russell-J 2009 63/230 19/114 63.1 % 1.64 [ 1.04, 2.61 ]
Total (95% CI) 884 526 100.0 % 1.66 [ 1.15, 2.40 ]
Total events: 102 (Liraglutide 1.8 mg daily), 34 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.60, df = 3 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 2.72 (P = 0.0066)
Test for subgroup differences: Not applicable
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Analysis 8.4. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 4 Weight change.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 8 Liraglutide 1.8 mg versus placebo









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 1 Marre 2009 234 -0.2 (3.06) 114 -0.1 (2.88) 26.2 % -0.10 [ -0.76, 0.56 ]
L - LEAD 2 Nauck 2009 242 -2.8 (3.11) 121 -1.5 (3.3) 25.8 % -1.30 [ -2.01, -0.59 ]
L - LEAD 4 Zinman 2009 178 -2 (4) 177 0.6 (3.99) 24.7 % -2.60 [ -3.43, -1.77 ]
L - LEAD 5 Russell-J 2009 230 -1.8 (5) 114 -0.42 (4.16) 23.2 % -1.38 [ -2.38, -0.38 ]
Total (95% CI) 884 526 100.0 % -1.33 [ -2.38, -0.27 ]
Heterogeneity: Tau2 = 1.00; Chi2 = 21.82, df = 3 (P = 0.00007); I2 =86%
Test for overall effect: Z = 2.46 (P = 0.014)
Test for subgroup differences: Not applicable
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Analysis 8.5. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 5 Adverse events.
Adverse events
Study Description Liraglutide 1.8 mg daily Placebo
L - LEAD 1 Marre 2009 withdrawal due to adverse events 4% 5%
L - LEAD 1 Marre 2009 no significant differences across
groups for: blood pressure; no




L - LEAD 1 Marre 2009 nausea 1.8% (lowest)
L - LEAD 1 Marre 2009 vomiting
L - LEAD 1 Marre 2009 diarrhoea
L - LEAD 1 Marre 2009 serious adverse events (mostly
judged to be unlikely to be re-
lated to study medication)
5% 3%
L - LEAD 1 Marre 2009 liraglutide auto-antibodies 9 to13%, no effect on HbA1c
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Adverse events (Continued)
L - LEAD 1 Marre 2009
L - LEAD 1 Marre 2009
L - LEAD 1 Marre 2009
L - LEAD 2 Nauck 2009 withdrawal due to adverse events 12% 2%
L - LEAD 2 Nauck 2009 withdrawal due to nausea/vom-
iting/diarrhoea
8% 0
L - LEAD 2 Nauck 2009 no significant differences across
groups for: physical examina-
tion findings, laboratory analy-
ses, ECG, ophthalmoscopy
L - LEAD 2 Nauck 2009 any GI event 44% 17%
L - LEAD 2 Nauck 2009 nausea 19% NR
L - LEAD 2 Nauck 2009 vomiting 5 to 7% 1%
L - LEAD 2 Nauck 2009 diarrhoea 15% 4%
L - LEAD 2 Nauck 2009 serious adverse events: 2 deaths
unrelated to liraglutide treat-
ment
L - LEAD 2 Nauck 2009 injection site reactions NR NR
L - LEAD 2 Nauck 2009 anti-liraglutide antibodies NR NR
L - LEAD 4 Zinman 2009 withdrawal due to adverse events 15% 3%
L - LEAD 4 Zinman 2009 withdrawal due to nausea/vom-
iting/diarrhoea
11% 0
L - LEAD 4 Zinman 2009 no significant differences across
groups for: physical examina-
tion findings, laboratory analy-
ses, ECG, ophthalmoscopy, car-
diovascular adverse events
L - LEAD 4 Zinman 2009 any GI event 56% 19%
L - LEAD 4 Zinman 2009 nausea 40% NR
L - LEAD 4 Zinman 2009 vomiting 17% NR
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Adverse events (Continued)
L - LEAD 4 Zinman 2009 diarrhoea NR NR
L - LEAD 4 Zinman 2009 serious adverse events 10 events in 7 participants 13 events in 12 participants
L - LEAD 4 Zinman 2009 injection site reactions NR NR
L - LEAD 4 Zinman 2009 anti-liraglutide antibodies 6.7% (no effect on HbA1c)
L - LEAD 5 Russell-J 2009 withdrawal due to adverse events 5% 0.9%
L - LEAD 5 Russell-J 2009 no significant differences across
groups for: nasopharyngitis,
headache; no pancreatitis
L - LEAD 5 Russell-J 2009 nausea 13.9% 3.5%
L - LEAD 5 Russell-J 2009 diarrhoea 10.% 5.3%
L - LEAD 5 Russell-J 2009 dyspepsia 6.5% 0.9%
L - LEAD 5 Russell-J 2009 vomiting 6.5% 3.5%
L - LEAD 5 Russell-J 2009 serious adverse events 4% 7%
L - LEAD 5 Russell-J 2009 injection site reactions NR NR
L - LEAD 5 Russell-J 2009 anti-liraglutide antibodies 9.8% (no effect on HbA1c)
L - LEAD 5 Russell-J 2009
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Analysis 8.6. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 6 Systolic blood pressure.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 8 Liraglutide 1.8 mg versus placebo









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 2 Nauck 2009 242 -2.29 (12.91) 121 -1.76 (12.54) 40.0 % -0.53 [ -3.29, 2.23 ]
L - LEAD 4 Zinman 2009 178 -5.6 (14.68) 177 -1.1 (15.96) 34.3 % -4.50 [ -7.69, -1.31 ]
L - LEAD 5 Russell-J 2009 230 -4 (19.87) 114 -1.4 (16.76) 25.8 % -2.60 [ -6.61, 1.41 ]
Total (95% CI) 650 412 100.0 % -2.42 [ -4.90, 0.05 ]
Heterogeneity: Tau2 = 1.99; Chi2 = 3.42, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
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Analysis 8.7. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 7 Fasting plasma glucose (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 8 Liraglutide 1.8 mg versus placebo









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 1 Marre 2009 234 -1.59 (2.45) 114 1.01 (2.35) 27.1 % -2.60 [ -3.13, -2.07 ]
L - LEAD 2 Nauck 2009 242 -1.7 (2.33) 121 0.4 (2.31) 30.2 % -2.10 [ -2.61, -1.59 ]
L - LEAD 4 Zinman 2009 178 -2.4 (2.67) 177 -0.4 (2.79) 23.9 % -2.00 [ -2.57, -1.43 ]
L - LEAD 5 Russell-J 2009 230 -1.55 (3.18) 114 0.53 (2.67) 18.8 % -2.08 [ -2.72, -1.44 ]
Total (95% CI) 884 526 100.0 % -2.21 [ -2.49, -1.93 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.92, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 15.58 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.8. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 8 Post-prandial glucose (mmol/L).
Post-prandial glucose (mmol/L)
Study Description Liraglutide 1.8 mg
daily
Placebo Comments
L - LEAD 1 Marre 2009 average of val-
ues obtained 90 min af-
ter breakfast, lunch and
evening meal
-2.7 mmol/L -0.4 mmol/L Liraglutide 1.8 mg versus placebo:
P < 0.0001
L - LEAD 2Nauck 2009 from self-monitored 7-
point plasma glucose
measurements
-2.6 mmol/L -0.6 mmol/L Liraglutide 1.8 mg versus placebo:
P < 0.001





-2.7 mmol/L -0.8 mmol/L Liraglutide 1.8 mg versus placebo:
P < 0.001; the postprandial in-
crement (postmeal value minus
premeal) was significantly reduced
over breakfast with liraglutide
treatment (-0.9, -0.8, -0.3 mmol/
L respectively; P < 0.05 for both
liraglutide groups versus placebo)
but not for lunch and dinner





-1.81 mmol/L -0.03 mmol/L Liraglutide 1.8 mg versus placebo:
P < 0.0001; there was a statistically
significantly higher likelihood of
achieving ADA targets for PPG (≤
10 mmol/l) (P < 0.0001) with li-
raglutide versus placebo
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Analysis 8.9. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 9 Triglycerides (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 8 Liraglutide 1.8 mg versus placebo









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 4 Zinman 2009 178 -0.32 (1.33) 177 -0.13 (1.5) -0.19 [ -0.48, 0.10 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.10. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 10 Total cholesterol (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 8 Liraglutide 1.8 mg versus placebo









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 4 Zinman 2009 178 -0.2 (1.2) 177 -0.02 (1.3) -0.18 [ -0.44, 0.08 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.11. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 11 HDL-cholesterol (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 8 Liraglutide 1.8 mg versus placebo









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 4 Zinman 2009 178 -0.04 (0.27) 177 -0.03 (0.3) -0.01 [ -0.07, 0.05 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.12. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 12 LDL-cholesterol (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 8 Liraglutide 1.8 mg versus placebo









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 4 Zinman 2009 178 -0.23 (0.93) 177 -0.1 (0.9) -0.13 [ -0.32, 0.06 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 8.13. Comparison 8 Liraglutide 1.8 mg versus placebo, Outcome 13 Beta-cell function.
Beta-cell function
Study Description Liraglutide 1.8 mg daily Placebo
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Beta-cell function (Continued)
L - LEAD 1 Marre 2009 HOMA-B (%) 91% SE 108.2 (+35%), P = 0.051
versus placebo
52% SE 107.3 (-4%)
L - LEAD 1 Marre 2009 proinsulin-to-insulin ratio 0.36 SE 0.2 (-0.12), p≤ 0.02 ver-
sus placebo
0.46 SE 0.29 (+0.02)
L - LEAD 1 Marre 2009
L - LEAD 2 Nauck 2009 HOMA-B (%) +28% -2%
L - LEAD 2 Nauck 2009 proinsulin-to-insulin ratio -0.1, P < 0.0001 versus placebo +0.1
L - LEAD 2 Nauck 2009 proinsulin-to-C-peptide ratio
L - LEAD 4 Zinman 2009 HOMA-B (%) +27% SD 56, P < 0.05 vs placebo 6% SD 60
L - LEAD 4 Zinman 2009 proinsulin-to-insulin ratio -0.085 SD 3.47, P < 0.05 vs
placebo
0.036 SD 39
L - LEAD 4 Zinman 2009 proinsulin-to-C-peptide ratio -0.008 SD 0.01, P < 0.05 vs
placebo
-0.002 SD 0.01
L - LEAD 5 Russell-J 2009 proinsulin-to-C-peptide ratio -0.00671 (95% CI: -0.00964, -0.
00377, P <0.0001) versus placebo
L - LEAD 5 Russell-J 2009
L - LEAD 5 Russell-J 2009
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Analysis 9.1. Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 1 HbA1c.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 1 Marre 2009 228 -1.08 (1.06) 234 -1.13 (1.07) 30.4 % 0.05 [ -0.14, 0.24 ]
L - LEAD 2 Nauck 2009 240 -1 (1.55) 242 -1 (1.56) 18.1 % 0.0 [ -0.28, 0.28 ]
L - LEAD 4 Zinman 2009 178 -1.5 (1.33) 178 -1.5 (1.33) 18.3 % 0.0 [ -0.28, 0.28 ]
L - Pratley 2010 221 -1.24 (1.04) 218 -1.5 (0.89) 33.2 % 0.26 [ 0.08, 0.44 ]
Total (95% CI) 867 872 100.0 % 0.10 [ -0.03, 0.23 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.22, df = 3 (P = 0.24); I2 =29%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 9.2. Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 2 Patients reaching HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 9 Liraglutide 1.2 mg versus 1.8 mg














L - LEAD 1 Marre 2009 80/228 98/234 18.5 % 0.84 [ 0.66, 1.06 ]
L - LEAD 2 Nauck 2009 85/240 103/242 18.9 % 0.83 [ 0.66, 1.04 ]
L - LEAD 4 Zinman 2009 102/178 96/178 21.4 % 1.06 [ 0.88, 1.28 ]
L - Pratley 2010 124/221 95/218 21.1 % 1.29 [ 1.06, 1.56 ]
L - Yang 2010 100/233 104/234 20.1 % 0.97 [ 0.79, 1.19 ]
Total (95% CI) 1100 1106 100.0 % 0.99 [ 0.84, 1.17 ]
Total events: 491 (Liraglutide 1.2 mg daily), 496 (Liraglutide 1.8 mg daily)
Heterogeneity: Tau2 = 0.02; Chi2 = 12.11, df = 4 (P = 0.02); I2 =67%
Test for overall effect: Z = 0.10 (P = 0.92)
Test for subgroup differences: Not applicable
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Analysis 9.3. Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 3 Weight.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 1 Marre 2009 228 0.3 (3.02) 234 -0.2 (3.06) 33.4 % 0.50 [ -0.05, 1.05 ]
L - LEAD 2 Nauck 2009 240 -2.6 (3.1) 242 -2.8 (3.11) 33.4 % 0.20 [ -0.35, 0.75 ]
L - LEAD 4 Zinman 2009 178 -1 (4) 178 -2 (4) 14.9 % 1.00 [ 0.17, 1.83 ]
L - Pratley 2010 221 -2.86 (4.01) 218 -3.38 (3.99) 18.3 % 0.52 [ -0.23, 1.27 ]
Total (95% CI) 867 872 100.0 % 0.48 [ 0.16, 0.80 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.50, df = 3 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Not applicable
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Analysis 9.4. Comparison 9 Liraglutide 1.2 mg versus 1.8 mg, Outcome 4 Systolic blood pressure.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 9 Liraglutide 1.2 mg versus 1.8 mg











N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 1 Marre 2009 228 -2.56 (12.83) 234 -2.81 (13.16) 28.2 % 0.25 [ -2.12, 2.62 ]
L - LEAD 2 Nauck 2009 240 -2.81 (13.32) 242 -2.29 (12.91) 28.8 % -0.52 [ -2.86, 1.82 ]
L - LEAD 4 Zinman 2009 178 -6.7 (14.68) 178 -5.6 (14.68) 17.0 % -1.10 [ -4.15, 1.95 ]
L - Pratley 2010 221 -0.55 (13.23) 218 -0.72 (13.14) 26.0 % 0.17 [ -2.30, 2.64 ]
Total (95% CI) 867 872 100.0 % -0.22 [ -1.48, 1.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.63, df = 3 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Liraglutide versus insulin glargine, Outcome 1 HbA1c.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus










N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 5 Russell-J 2009 230 -1.33 (1.36) 232 -1.09 (1.37) -0.24 [ -0.49, 0.01 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.2. Comparison 10 Liraglutide versus insulin glargine, Outcome 2 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 10 Liraglutide versus insulin glargine












L - LEAD 5 Russell-J 2009 122/230 106/232 1.16 [ 0.96, 1.40 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 122 (Liraglutide 1.8 mg daily), 106 (Insulin glargine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.3. Comparison 10 Liraglutide versus insulin glargine, Outcome 3 Hypoglycaemia.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus













L - LEAD 5 Russell-J 2009 63/230 67/232 0.93 [ 0.62, 1.39 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 63 (Liraglutide 1.8 mg daily), 67 (Insulin glargine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.4. Comparison 10 Liraglutide versus insulin glargine, Outcome 4 Weight change.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 10 Liraglutide versus insulin glargine









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 5 Russell-J 2009 230 -1.8 (5) 232 1.6 (5.03) -3.40 [ -4.31, -2.49 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.5. Comparison 10 Liraglutide versus insulin glargine, Outcome 5 Adverse events.
Adverse events
Study Description Liraglutide 1.8 mg daily Insulin glargine
L - LEAD 5 Russell-J 2009 withdrawal due to adverse events 5% 2%
L - LEAD 5 Russell-J 2009 no significant differences across
groups for: nasopharyngitis,
headache; no pancreatitis
L - LEAD 5 Russell-J 2009 nausea 13.9% 1.3%
L - LEAD 5 Russell-J 2009 diarrhoea 10.% 1.3%
L - LEAD 5 Russell-J 2009 dyspepsia 6.5% 1.7%
L - LEAD 5 Russell-J 2009 vomiting 6.5% 0.4%
L - LEAD 5 Russell-J 2009 serious adverse events 4% 7%
L - LEAD 5 Russell-J 2009 injection site reactions NR NR
L - LEAD 5 Russell-J 2009 anti-liraglutide antibodies 9.8% (no effect on HbA1c)
Analysis 10.6. Comparison 10 Liraglutide versus insulin glargine, Outcome 6 Systolic blood pressure.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 10 Liraglutide versus insulin glargine









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 5 Russell-J 2009 230 -4 (19.87) 232 0.54 (19.95) -4.54 [ -8.17, -0.91 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.7. Comparison 10 Liraglutide versus insulin glargine, Outcome 7 Fasting plasma glucose
(mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 10 Liraglutide versus insulin glargine









N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 5 Russell-J 2009 230 -1.55 (3.18) 232 -1.79 (3.2) 0.24 [ -0.34, 0.82 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.8. Comparison 10 Liraglutide versus insulin glargine, Outcome 8 Post-prandial glucose
(mmol/L).
Post-prandial glucose (mmol/L)
Study Description Liraglutide 1.8 mg
daily
Insulin glargine Comments





-1.81 mmol/L -1.61 mmol/L no significant difference
Analysis 10.9. Comparison 10 Liraglutide versus insulin glargine, Outcome 9 Beta-cell function.
Beta-cell function
Study Description Liraglutide 1.8 mg
L - LEAD 5 Russell-J 2009 proinsulin-to-C-peptide ratio -0.00366 (95% CI -0.0057 to -0.00136, P = 0.0019) versus insulin
glargine;
-0.00671 (95% CI -0.00964 to -0.00377, P < 0.0001) versus placebo
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Analysis 11.1. Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 11 Liraglutide 1.2 mg daily versus thiazolidinedione











N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
L - LEAD 1 Marre 2009 228 -1.08 (1.06) 232 -0.44 (1.06) -0.64 [ -0.83, -0.45 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 11.2. Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 2 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 11 Liraglutide 1.2 mg daily versus thiazolidinedione














L - LEAD 1 Marre 2009 80/228 51/232 1.60 [ 1.18, 2.15 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 80 (Liraglutide 1.2 mg daily), 51 (Rosiglitazone 4 mg QD)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 11.3. Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia
(mild/moderate/overall).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 11 Liraglutide 1.2 mg daily versus thiazolidinedione














L - LEAD 1 Marre 2009 21/228 10/232 2.14 [ 1.03, 4.44 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 21 (Liraglutide 1.2 mg daily), 10 (Rosiglitazone 4 mg QD)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 11.4. Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 4 Severe
hypoglycaemia.
Severe hypoglycaemia
Study Liraglutide 1.2 mg daily Rosiglitazone 4 mg QD
L - LEAD 1 Marre 2009 NR NR
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Analysis 11.5. Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 5 Weight change.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 11 Liraglutide 1.2 mg daily versus thiazolidinedione











N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 1 Marre 2009 228 0.3 (3.02) 232 2.1 (3.05) -1.80 [ -2.35, -1.25 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 11.6. Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 6 Adverse events.
Adverse events
Study Description Liraglutide 1.2 mg daily Rosiglitazone 4 mg QD
L - LEAD 1 Marre 2009 withdrawal due to adverse events 11 (5%) 7 (3%)
L - LEAD 1 Marre 2009 overall adverse events NR NR
L - LEAD 1 Marre 2009 nausea 24 (10.5%) NR
L - LEAD 1 Marre 2009 vomiting 10 (4.4%) NR
L - LEAD 1 Marre 2009 diarrhoea 18 (7.9%) NR
L - LEAD 1 Marre 2009 serious adverse events (mostly
judged to be unlikely to be related
to study medication)
9 (4%) 7 (3%)
L - LEAD 1 Marre 2009 liraglutide auto-antibodies 9 to 13%, no effect on HbA1c
L - LEAD 1 Marre 2009 deaths None None
L - LEAD 1 Marre 2009 pancreatitis None None
L - LEAD 1 Marre 2009
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Analysis 11.7. Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 7 Systolic blood
pressure (mm Hg).
Systolic blood pressure (mm Hg)
Study Description Liraglutide 1.2mg daily Rosiglitazone 4 mg QD p values
L - LEAD 1 Marre 2009 Change from baseline -2.6 to -2.8 0.9 to 2.3 P = NS between groups
Analysis 11.8. Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 8 Diastolic blood
pressure (mm Hg).
Diastolic blood pressure (mm Hg)
Study Description Liraglutide 1.2mg daily Rosiglitazone 4 mg QD p values
L - LEAD 1 Marre 2009 Change from baseline -0.7 to -1.4 -0.7 to -1.4 P = NS between groups
Analysis 11.9. Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma
glucose (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 11 Liraglutide 1.2 mg daily versus thiazolidinedione











N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 1 Marre 2009 228 -1.57 (2.42) 232 -0.88 (2.44) -0.69 [ -1.13, -0.25 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 11.10. Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 10 Post-prandial
glucose (mmol/L).
Post-prandial glucose (mmol/L)
Study Description Liraglutide 1.2 mg
daily
Rosiglitazone 4mgQD Comments
L - LEAD 1 Marre 2009 average of val-
ues obtained 90 min af-
ter breakfast, lunch and
evening meal
-2.5 mmol/L -1.8 mmol/L P = 0.043 1.2 mg versus
rosiglitazone
Analysis 11.11. Comparison 11 Liraglutide 1.2 mg daily versus thiazolidinedione, Outcome 11 Beta-cell
function.
Beta-cell function
Study Description Liraglutide 1.2 mg TZD
L - LEAD 1 Marre 2009 HOMA-B (%) 99% SE 184.3 (+28%) 59% SE 63.3 (+13%)
L - LEAD 1 Marre 2009 proinsulin-to-insulin ratio 0.33 SE 0.2 (-0.12) 0.40 SE 0.2 (-0.05)
Analysis 12.1. Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 1 HbA1c (%).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 12 Liraglutide 1.8 mg daily versus thiazolidinedione











N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
L - LEAD 1 Marre 2009 234 -1.13 (1.07) 232 -0.44 (1.06) -0.69 [ -0.88, -0.50 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 12.2. Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 2 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 12 Liraglutide 1.8 mg daily versus thiazolidinedione






4 mg QD Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
L - LEAD 1 Marre 2009 98/234 51/232 1.91 [ 1.43, 2.53 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 98 (Liraglutide 1.8 mg daily), 51 (Rosiglitazone 4 mg QD)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 12.3. Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 3 Hypoglycaemia.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus







4 mg QD Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
L - LEAD 1 Marre 2009 19/234 0/232 38.67 [ 2.35, 636.69 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 19 (Liraglutide 1.8 mg daily), 0 (Rosiglitazone 4 mg QD)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 12.4. Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 4 Severe
hypoglycaemia.
Severe hypoglycaemia
Study Liraglutide 1.8 mg daily Rosiglitazone 4 mg QD
L - LEAD 1 Marre 2009 1 NR
Analysis 12.5. Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 5 Weight change
(kg).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 12 Liraglutide 1.8 mg daily versus thiazolidinedione











N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
L - LEAD 1 Marre 2009 234 -0.2 (3.06) 232 2.1 (3.05) -2.30 [ -2.85, -1.75 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 12.6. Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 6 Adverse events.
Adverse events
Study Description Liraglutide 1.8 mg daily Rosiglitazone 4 mg QD
L - LEAD 1 Marre 2009 withdrawal due to adverse events 9 (4%) 7 (3%)
L - LEAD 1 Marre 2009 overall adverse events NR NR
L - LEAD 1 Marre 2009 nausea NR NR
L - LEAD 1 Marre 2009 vomiting NR NR
L - LEAD 1 Marre 2009 NR NR
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Adverse events (Continued)
L - LEAD 1 Marre 2009 serious adverse events (mostly
judged to be unlikely to be related
to study medication)
12 (5%) 7 (3%)
L - LEAD 1 Marre 2009 liraglutide auto-antibodies 9 to 13%, no effect on HbA1c
L - LEAD 1 Marre 2009 deaths None None
L - LEAD 1 Marre 2009 pancreatitis None None
Analysis 12.7. Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 7 Systolic blood
pressure (mm Hg).
Systolic blood pressure (mm Hg)
Study Description Liraglutide 1.8mg daily Rosiglitazone 4 mg QD p values
L - LEAD 1 Marre 2009 Change from baseline -2.6 to -2.8 0.9 to 2.3 P = NS between groups
Analysis 12.8. Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 8 Diastolic blood
pressure (mm Hg).
Diastolic blood pressure (mm Hg)
Study Description Liraglutide 1.8mg daily Rosiglitazone 4 mg QD p values
L - LEAD 1 Marre 2009 Change from baseline -0.7 to 1.4 -0.7 to -1.4 P = NS between groups
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Analysis 12.9. Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 9 Fasting plasma
glucose (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 12 Liraglutide 1.8 mg daily versus thiazolidinedione











N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
L - LEAD 1 Marre 2009 234 -1.59 (2.45) 232 -0.88 (2.44) -0.71 [ -1.15, -0.27 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 12.10. Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 10 Post-prandial
glucose (mmol/L).
Post-prandial glucose (mmol/L)
Study Description Liraglutide 1.8 mg
daily
Rosiglitazone 4mgQD Comments
L - LEAD 1 Marre 2009 average of val-
ues obtained 90 min af-
ter breakfast, lunch and
evening meal
-2.7 mmol/L -1.8 mmol/L P = 0.0022 1.8mg versus
rosiglitazone
Analysis 12.11. Comparison 12 Liraglutide 1.8 mg daily versus thiazolidinedione, Outcome 11 Beta-cell
function.
Beta-cell function
Study Description Liraglutide 1.8 mg
daily
Rosiglitazone 4mgQD Difference between
groups
L - LEAD 1 Marre 2009 HOMA-B (%) 91% SE 108.2 (+35%) 59% SE 63.3 (+13%) 30, 95% CI 2.00 to 58.
6, p ≤ 0.05
L - LEAD 1 Marre 2009 proinsulin-to-insulin ra-
tio
0.36 SE 0.2 (-0.12) 0.40 SE 0.2 (-0.05) -0.05, 95% CI -0.10 to -
0.01, p ≤ 0.05
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Analysis 13.1. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 1 HbA1c (%).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - Pratley 2010 221 -1.24 (1.04) 219 -0.9 (1.04) -0.34 [ -0.53, -0.15 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 13.2. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 2 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors















L - Pratley 2010 124/221 48/219 2.56 [ 1.94, 3.37 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 124 (Liraglutide 1.2 mg daily), 48 (Sitagliptin 100 mg daily)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 13.3. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 3 Hypoglycaemia
(mild/moderate/overall).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors















L - Pratley 2010 12/221 10/219 1.19 [ 0.52, 2.69 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 12 (Liraglutide 1.2 mg daily), 10 (Sitagliptin 100 mg daily)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 13.4. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 4 Severe
hypoglycaemia.
Severe hypoglycaemia
Study Liraglutide 1.2 mg daily Sitagliptin 100 mg daily
L - Pratley 2010 1 (0.45%) None
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Analysis 13.5. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 5 Weight change
(kg).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - Pratley 2010 221 -2.86 (4.01) 219 -0.96 (4) -1.90 [ -2.65, -1.15 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 13.6. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 6 Adverse events.
Adverse events
Study Description Liraglutide 1.2 mg daily Sitagliptin 100 mg daily
L - Pratley 2010 withdrawal due to adverse events 14 (6.3%) 4 (1.8%)
L - Pratley 2010 overall adverse events 146 (66%) 127 (58%)
L - Pratley 2010 nausea 46 (21%) 10 (5%)
L - Pratley 2010 vomiting 17 (8%) 9 (4%)
L - Pratley 2010 diarrhoea 16 (7%) 10 (5%)
L - Pratley 2010 other gastrointestinal adverse events 17 (8%) 6 (3%)
L - Pratley 2010 serious adverse
events (mostly judged to be unlikely
to be related to study medication)
6 (3%) 4 (2%)
L - Pratley 2010 liraglutide auto-antibodies NR NR
L - Pratley 2010 deaths 0 1 (< 1%) unrelated to drug
L - Pratley 2010 pancreatitis None None
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Analysis 13.7. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 7 Systolic blood
pressure (mm Hg).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - Pratley 2010 221 -0.55 (13.23) 219 -0.94 (13.17) 0.39 [ -2.08, 2.86 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Liraglutide Favours Sitagliptin
Analysis 13.8. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 8 Diastolic blood
pressure (mm Hg).
Diastolic blood pressure (mm Hg)
Study Description Liraglutide 1.2 mg daily Sitagliptin 100 mg daily p values
L - Pratley 2010 Change from baseline -0.71 -1.78 P = NS between groups
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Analysis 13.9. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 9 Fasting plasma
glucose (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - Pratley 2010 221 -1.87 (2.23) 219 -0.83 (2.22) -1.04 [ -1.46, -0.62 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Liraglutide Favours Sitagliptin
Analysis 13.10. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 10 Post-prandial
glucose (mmol/L).
Post-prandial glucose (mmol/L)
Study Description Liraglutide 1.2 mg daily Sitagliptin 100 mg daily Comments
L - Pratley 2010 PPG NR NR Reported in the paper that ’ PPG was
highly variable suggesting that glucose
values were not PPG in many cases
Analysis 13.11. Comparison 13 Liraglutide 1.2 mg daily versus DPP-4 inhibitors, Outcome 11 Beta-cell
function.
Beta-cell function
Study Description Liraglutide 1.2 mg daily Sitagliptin 100 mg daily Difference between
groups
L - Pratley 2010 HOMA-B (%), mean
change from baseline
27.23% (95%CI 19.73 to
34.73)
4.18 % (95% CI -3.27 to
11.62)
23.05% (95% CI 12.95 to
33.15), P < 0.0001
L - Pratley 2010 HOMA-IR (%), mean
change from baseline
-1.06 % (95% CI -1.70 to
-0.42)
-0.94% (95%CI, -1.58 to
-0.30)
-0.12% (95% CI -0.99 to
0.75), P = 0.7834
L - Pratley 2010 Fasting insulin (pmol/L) 5.12 (95% CI -4.34 to 14.
59)
-6.77 (95% CI -16.18 to
2.64)
11.89 (95% CI -0.84 to
24.63), P = 0.0672
L - Pratley 2010 Fasting C-peptide (nmol/
L)
0.09 (95% CI 0.03 to 0.
15)
-0.04 (95% CI -0.10 to 0.
02)
0.13 (95% CI 0.05 to 0.
21), P = 0.0011
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Beta-cell function (Continued)
L - Pratley 2010 Fasting proinsulin-to-in-
sulin ratio
-0.08 (95% CI -0.11 to -0.
05)
-0.03 (95% CI -0.06 to -0.
00)
-0.05 (95% CI -0.09 to -0.
01), P = 0.0121
Analysis 14.1. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 1 HbA1c (%).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - Pratley 2010 218 -1.5 (0.89) 219 -0.9 (1.04) -0.60 [ -0.78, -0.42 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Liraglutide Favours Sitagliptin
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Analysis 14.2. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 2 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors















L - Pratley 2010 95/218 48/219 1.99 [ 1.48, 2.66 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 95 (Liraglutide 1.8 mg daily), 48 (Sitagliptin 100 mg daily)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours Sitagliptin Favours Liraglutide
Analysis 14.3. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 3 Hypoglycaemia.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
















L - Pratley 2010 11/218 10/219 1.11 [ 0.48, 2.55 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 11 (Liraglutide 1.8 mg daily), 10 (Sitagliptin 100 mg daily)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Liraglutide Favours Sitagliptin
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Analysis 14.4. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 4 Severe
hypoglycaemia.
Severe hypoglycaemia
Study Liraglutide 1.8 mg daily Sitagliptin 100 mg daily
L - Pratley 2010 NR, presumably none NR, presumably none
Analysis 14.5. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 5 Weight change
(kg).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - Pratley 2010 218 -3.38 (3.99) 219 -0.96 (4) -2.42 [ -3.17, -1.67 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Liraglutide Favours Sitagliptin
Analysis 14.6. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 6 Adverse events.
Adverse events
Study Description Liraglutide 1.8 mg daily Sitagliptin 100 mg daily
L - Pratley 2010 withdrawal due to adverse events 15 (6.9%) 4 (1.8%)
L - Pratley 2010 overall adverse events 159 (73%) 127 (58%)
L - Pratley 2010 nausea 59 (27%) 10 (5%)
L - Pratley 2010 vomiting 21 (10%) 9 (4%)
L - Pratley 2010 diarrhoea 25 (11%) 10 (5%)
167Glucagon-like peptide analogues for type 2 diabetes mellitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Adverse events (Continued)
L - Pratley 2010 other gastrointestinal adverse events 11 (5%) 6 (3%)
L - Pratley 2010 serious adverse
events (mostly judged to be unlikely
to be related to study medication)
6 (3%) 4 (2%)
L - Pratley 2010 liraglutide auto-antibodies NR NR
L - Pratley 2010 deaths 1 (< 1%) unrelated to drug 1 (< 1%) unrelated to drug
L - Pratley 2010 pancreatitis None None
Analysis 14.7. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 7 Systolic blood
pressure (mm Hg).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors
Outcome: 7 Systolic blood pressure (mm Hg)








N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - Pratley 2010 218 -0.72 (13.14) 219 -0.94 (13.17) 0.22 [ -2.25, 2.69 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Liraglutide Favours Sitagliptin
Analysis 14.8. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 8 Diastolic blood
pressure (mm Hg).
Diastolic blood pressure (mm Hg)
Study Description Liraglutide 1.8 mg daily Sitagliptin 100 mg daily p values
L - Pratley 2010 Change from baseline 0.07 -1.78 P = 0.0210 versus SITA
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Analysis 14.9. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 9 Fasting plasma
glucose (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - Pratley 2010 218 -2.14 (2.21) 219 -0.83 (2.22) -1.31 [ -1.73, -0.89 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Liraglutide Favours Sitagliptin
Analysis 14.10. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 10 Post-prandial
glucose (mmol/L).
Post-prandial glucose (mmol/L)
Study Description Liraglutide 1.8 mg daily Sitagliptin 100 mg daily Comments
L - Pratley 2010 PPG NR NR Reported in the paper that ’ PPG was
highly variable suggesting that glucose
values were not PPG in many cases
Analysis 14.11. Comparison 14 Liraglutide 1.8 mg daily versus DPP-4 inhibitors, Outcome 11 Beta-cell
function.
Beta-cell function
Study Description Liraglutide 1.8 mg daily Sitagliptin 100 mg daily Difference between
groups
L - Pratley 2010 Fasting insulin (pmol/L) 1.29 (95% CI -8.04 to 10.
62)
-6.77 (95%CI -16.18 to 2.
64)
8.06 (95% CI -4.51 to 20.
63), P = 0.2083
L - Pratley 2010 0.09 (95%CI0.03 to 0.15) -0.04 (95% CI -0.10 to 0.
02)
0.14 (95%CI0.06 to 0.21)
, P = 0.0008
L - Pratley 2010 Fasting insulin (pmol/L) 1.29 (95% CI -8.04 to 10.
62)
-6.77 (95%CI -16.18 to 2.
64)
8.06 (95% CI -4.51 to 20.
63), P = 0.2083
L - Pratley 2010 0.09 (95%CI0.03 to 0.15) -0.04 (95% CI -0.10 to 0.
02)
0.14 (95%CI0.06 to 0.21)
, P = 0.0008
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Beta-cell function (Continued)
L - Pratley 2010 -0.10 (95% CI -0.12 to -0.
07)
-0.03 (95% CI -0.06 to -0.
00)
-0.07 (95% CI -0.10 to -0.
03), P = 0.0004




























Analysis 15.2. Comparison 15 Lixisenatide versus placebo, Outcome 2 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 15 Lixisenatide versus placebo
Outcome: 2 HbA1c < 7%








1 LIXI 5 g QD
Lixi - Ratner 2010 26/55 34/107 1.49 [ 1.00, 2.21 ]
2 LIXI 10 g QD
Lixi - Ratner 2010 26/50 34/107 1.64 [ 1.11, 2.40 ]
3 LIXI 20 g QD
Lixi - Ratner 2010 36/53 34/107 2.14 [ 1.53, 2.98 ]
4 LIXI 30 g QD
Lixi - Ratner 2010 35/51 34/107 2.16 [ 1.55, 3.02 ]
5 LIXI 5 g BID
Lixi - Ratner 2010 26/51 34/107 1.60 [ 1.09, 2.36 ]
0.5 0.7 1 1.5 2
Favours Placebo Favours Lixisenatide
(Continued . . . )
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(. . . Continued)








6 LIXI 10 g BID
Lixi - Ratner 2010 35/54 34/107 2.04 [ 1.45, 2.87 ]
7 LIXI 20 g BID
Lixi - Ratner 2010 32/52 34/107 1.94 [ 1.36, 2.75 ]
8 LIXI 30 g BID
Lixi - Ratner 2010 41/53 34/107 2.43 [ 1.78, 3.33 ]
0.5 0.7 1 1.5 2
Favours Placebo Favours Lixisenatide
Analysis 15.3. Comparison 15 Lixisenatide versus placebo, Outcome 3 Symptomatic hypoglycaemia.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 15 Lixisenatide versus placebo
Outcome: 3 Symptomatic hypoglycaemia








1 LIXI 5 g QD
Lixi - Ratner 2010 1/55 1/109 1.98 [ 0.13, 31.09 ]
2 LIXI 10 g QD
Lixi - Ratner 2010 2/52 1/109 4.19 [ 0.39, 45.19 ]
3 LIXI 20 g QD
Lixi - Ratner 2010 1/55 1/109 1.98 [ 0.13, 31.09 ]
4 LIXI 30 g QD
Lixi - Ratner 2010 1/54 1/109 2.02 [ 0.13, 31.66 ]
5 LIXI 5 g BID
Lixi - Ratner 2010 3/53 1/109 6.17 [ 0.66, 57.91 ]
6 LIXI 10 g BID
Lixi - Ratner 2010 1/56 1/109 1.95 [ 0.12, 30.54 ]
7 LIXI 20 g BID
Lixi - Ratner 2010 3/54 1/109 6.06 [ 0.64, 56.86 ]
8 LIXI 30 g BID
Lixi - Ratner 2010 1/54 1/109 2.02 [ 0.13, 31.66 ]
0.01 0.1 1 10 100
Favours Lixisenatide Favours Placebo
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Analysis 15.4. Comparison 15 Lixisenatide versus placebo, Outcome 4 Weight change (kg).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 15 Lixisenatide versus placebo
Outcome: 4 Weight change (kg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LIXI 5 g QD
Lixi - Ratner 2010 55 -2 (2.97) 108 -1.94 (3.33) -0.06 [ -1.07, 0.95 ]
2 LIXi 10 g QD
Lixi - Ratner 2010 51 -2.39 (3) 108 -1.94 (3.33) -0.45 [ -1.49, 0.59 ]
3 LIXI 20 g QD
Lixi - Ratner 2010 53 -3.01 (2.98) 108 -1.94 (3.33) -1.07 [ -2.09, -0.05 ]
4 LIXI 30 g QD
Lixi - Ratner 2010 52 -3.47 (2.96) 108 -1.94 (3.33) -1.53 [ -2.55, -0.51 ]
5 LIXI 5 g BID
Lixi - Ratner 2010 51 -2.1 (2.93) 108 -1.94 (3.33) -0.16 [ -1.18, 0.86 ]
6 LIXI 10 g BID
Lixi - Ratner 2010 54 -2.21 (3.01) 108 -1.94 (3.33) -0.27 [ -1.29, 0.75 ]
7 LIXI 20 g BID
Lixi - Ratner 2010 52 -2.61 (2.96) 108 -1.94 (3.33) -0.67 [ -1.69, 0.35 ]
8 LIXI 30 g BID
Lixi - Ratner 2010 53 -3.89 (2.98) 108 -1.94 (3.33) -1.95 [ -2.97, -0.93 ]
-4 -2 0 2 4
Favours Lixisenatide Favours Placebo




























1 (1.8%) 2 (3.8%) 3 (5.5%) 6 (11.
1%)
0 2 (3.6%) 8 (14.
8%)
5 (9.3%) 2 (1.8%)
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Vomiting 2 (3.6%) 3 (5.8%) 3 (5.5%) 10 (18.
5%)




















5 (8.9%) 6 (11.
1%)




Dizziness 1 (1.8%) 4 (7.7%) 4 (7.3%) 6 (11.
1%)




















0 0 0 0 0 0 0 0 0
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Analysis 15.6. Comparison 15 Lixisenatide versus placebo, Outcome 6 Fasting plasma glucose (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 15 Lixisenatide versus placebo
Outcome: 6 Fasting plasma glucose (mmol/L)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LIXI 5 g QD
Lixi - Ratner 2010 55 -0.62 (1.78) 108 -0.21 (1.97) -0.41 [ -1.01, 0.19 ]
2 LIXI 10 g QD
Lixi - Ratner 2010 51 -0.54 (1.79) 108 -0.21 (1.97) -0.33 [ -0.95, 0.29 ]
3 LIXI 20 g QD
Lixi - Ratner 2010 53 -0.8 (1.82) 108 -0.21 (1.97) -0.59 [ -1.20, 0.02 ]
4 LIXI 30 g QD
Lixi - Ratner 2010 52 -1.02 (1.8) 108 -0.21 (1.97) -0.81 [ -1.42, -0.20 ]
5 LIXI 5 g BID
Lixi - Ratner 2010 51 -0.19 (1.71) 108 -0.21 (1.97) 0.02 [ -0.58, 0.62 ]
6 LIXI 10 g BID
Lixi - Ratner 2010 54 -0.98 (1.76) 108 -0.21 (1.97) -0.77 [ -1.37, -0.17 ]
7 LIXI 20 g BID
Lixi - Ratner 2010 52 -1.13 (1.8) 108 -0.21 (1.97) -0.92 [ -1.53, -0.31 ]
8 LIXI 30 g BID
Lixi - Ratner 2010 53 -1.42 (1.82) 108 -0.21 (1.97) -1.21 [ -1.82, -0.60 ]
-2 -1 0 1 2
Favours Lixisenatide Favours Placebo
174Glucagon-like peptide analogues for type 2 diabetes mellitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 15.7. Comparison 15 Lixisenatide versus placebo, Outcome 7 Post-prandial glucose (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 15 Lixisenatide versus placebo
Outcome: 7 Post-prandial glucose (mmol/L)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LIXI 5g QD
Lixi - Ratner 2010 55 -2.12 (4.97) 108 -0.41 (4.78) -1.71 [ -3.30, -0.12 ]
2 LIXI 10g QD
Lixi - Ratner 2010 51 -3.57 (4.43) 108 -0.41 (4.78) -3.16 [ -4.67, -1.65 ]
3 LIXI 20g QD
Lixi - Ratner 2010 53 -3.65 (4.95) 108 -0.41 (4.78) -3.24 [ -4.85, -1.63 ]
4 LIXI 30g QD
Lixi - Ratner 2010 52 -4.33 (5.12) 108 -0.41 (4.78) -3.92 [ -5.58, -2.26 ]
5 LIXI 5g BID
Lixi - Ratner 2010 51 -2.01 (4.36) 108 -0.41 (4.78) -1.60 [ -3.10, -0.10 ]
6 LIXI 10g BID
Lixi - Ratner 2010 54 -3.51 (4.56) 108 -0.41 (4.78) -3.10 [ -4.61, -1.59 ]
7 LIXI 20g BID
Lixi - Ratner 2010 52 -4.12 (4.9) 108 -0.41 (4.78) -3.71 [ -5.32, -2.10 ]
8 LIXI 30g BID
Lixi - Ratner 2010 53 -4.61 (4.95) 108 -0.41 (4.78) -4.20 [ -5.81, -2.59 ]
-4 -2 0 2 4
Favours Lixisenatide Favours Placebo
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Analysis 15.8. Comparison 15 Lixisenatide versus placebo, Outcome 8 Average self-monitored 7-point
blood glucose (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 15 Lixisenatide versus placebo
Outcome: 8 Average self-monitored 7-point blood glucose (mmol/L)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LIXI 5 g QD
Lixi - Ratner 2010 55 -1.23 (1.78) 108 -0.53 (1.87) -0.70 [ -1.29, -0.11 ]
2 LIXI 10 g QD
Lixi - Ratner 2010 51 -1.27 (1.71) 108 -0.53 (1.87) -0.74 [ -1.33, -0.15 ]
3 LIXI 20 g QD
Lixi - Ratner 2010 53 -1.74 (1.75) 108 -0.53 (1.87) -1.21 [ -1.80, -0.62 ]
4 LIXI 30 g QD
Lixi - Ratner 2010 52 -1.77 (1.8) 108 -0.53 (1.87) -1.24 [ -1.84, -0.64 ]
5 LIXI 5 g BID
Lixi - Ratner 2010 51 -0.88 (1.71) 108 -0.53 (1.87) -0.35 [ -0.94, 0.24 ]
6 LIXI 10 g BID
Lixi - Ratner 2010 54 -1.6 (1.76) 108 -0.53 (1.87) -1.07 [ -1.66, -0.48 ]
7 LIXI 20 g BID
Lixi - Ratner 2010 52 -1.83 (1.73) 108 -0.53 (1.87) -1.30 [ -1.89, -0.71 ]
8 LIXI 30 g BID
Lixi - Ratner 2010 53 -2.08 (1.75) 108 -0.53 (1.87) -1.55 [ -2.14, -0.96 ]
-2 -1 0 1 2
Favours Lixisenatide Favours Placebo
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Analysis 16.1. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 1 HbA1c.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus












N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 2 Nauck 2009 240 -0.97 (1.55) 242 -0.98 (1.56) 0.01 [ -0.27, 0.29 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Liraglutide Favours Glimepiride
Analysis 16.2. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 2 HbA1c (%).
HbA1c (%)
Study Description Liraglutide 1.2 mg daily Glimepiride 4 mg daily Difference between groups
L - Yang 2010 Change in HbA1c -1.36 -1.39 0.03, 95% CI -0.14 to 0.20
Analysis 16.3. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 3 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 16 Liraglutide 1.2 mg versus SU






4 mg daily Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
L - LEAD 2 Nauck 2009 85/240 88/242 43.2 % 0.97 [ 0.77, 1.24 ]
L - Yang 2010 100/233 101/231 56.8 % 0.98 [ 0.80, 1.21 ]
Total (95% CI) 473 473 100.0 % 0.98 [ 0.84, 1.14 ]
Total events: 185 (Liraglutide 1.2 mg daily), 189 (Glimepiride 4 mg daily)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.78)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours Glimepiride Favours Liraglutide
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Analysis 16.4. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 4 Hypoglycaemia.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus















L - LEAD 2 Nauck 2009 8/240 41/242 57.7 % 0.20 [ 0.09, 0.41 ]
L - Yang 2010 0/233 44/231 42.3 % 0.01 [ 0.00, 0.18 ]
Total (95% CI) 473 473 100.0 % 0.06 [ 0.00, 1.72 ]
Total events: 8 (Liraglutide 1.2 mg daily), 85 (Glimepiride 4 mg daily)
Heterogeneity: Tau2 = 5.02; Chi2 = 5.66, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 1.65 (P = 0.10)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Liraglutide Favours Glimepiride
Analysis 16.5. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 5 Weight change.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 16 Liraglutide 1.2 mg versus SU











N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 2 Nauck 2009 240 -2.6 (3.1) 242 1 (3.11) -3.60 [ -4.15, -3.05 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Liraglutide Favours Glimepiride
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Analysis 16.6. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 6 Weight change (kg).
Weight change (kg)
Study Description Liraglutide 1.2 mg daily Glimepiride 4 mg daily p value
L - Yang 2010 Change from baseline -2.35 SD 2.4 0.08 LIR 1.2 vs. GLIM: P < 0.0001
Analysis 16.7. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 7 Adverse events.
Adverse events
Study Description Liraglutide 1.2 mg daily Glimepiride 4 mg daily
L - LEAD 2 Nauck 2009 withdrawal due to adverse events 10% 3%
L - LEAD 2 Nauck 2009 withdrawal due to nausea/vomit-
ing/diarrhoea
5% 0
L - LEAD 2 Nauck 2009 no significant differences across
groups for: physical examina-
tion findings, laboratory analyses,
ECG, ophthalmoscopy
L - LEAD 2 Nauck 2009 any GI event 40% 17%
L - LEAD 2 Nauck 2009 nausea 16% 3 to 4%
L - LEAD 2 Nauck 2009 vomiting 5 to7% 1%
L - LEAD 2 Nauck 2009 diarrhoea 8% 4%
L - LEAD 2 Nauck 2009 serious adverse events: 2 deaths
unrelated to liraglutide treat-
ment; 1 participant each in 1.
2 mg liraglutide group and in
glimepiride groupwithdrawndue
to acute pancreatitis
L - LEAD 2 Nauck 2009 injection site reactions NR NR
L - LEAD 2 Nauck 2009 anti-liraglutide antibodies NR NR
L - Yang 2010 withdrawal due to adverse events 9.4% 1.3%
L - Yang 2010 serious adverse events 1.7 to 3.4% 1.7 to 3.4%
L - Yang 2010 pancreatitis none none
L - Yang 2010 deaths none none
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Adverse events (Continued)
L - Yang 2010 anti-liraglutide antibodies n = 8 from all liraglutide groups -
L - Yang 2010
L - Yang 2010
L - Yang 2010
L - Yang 2010
L - Yang 2010
Analysis 16.8. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 8 Systolic blood pressure.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 16 Liraglutide 1.2 mg versus SU











N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 2 Nauck 2009 240 -2.81 (13.32) 242 0.4 (13.22) -3.21 [ -5.58, -0.84 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 16.9. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 9 Blood pressure (mm Hg).
Blood pressure (mm Hg)
Study Description Liraglutide 1.2 mg
daily
Glimepiride 4 mg daily p values
L - LEAD 2Nauck 2009 Systolic blood pressure,
change from baseline
-2.81 SD 13.32 0.4 SD 13.22 NR
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Blood pressure (mm Hg) (Continued)
L - LEAD 2Nauck 2009 Diastolic blood pressure,
change from baseline
No change No change NR
L - Yang 2010 Systolic blood pressure,
change from baseline
Reduction of more than
3 mm Hg
Reduction of 0.91 mm
Hg
Reduction in the liraglu-
tide 1.2 groupwas signif-
icantly higher than that
in the glimepiride; p
value = NR
L - Yang 2010 Diastolic blood pressure,
change from baseline
A slight decrease inmean
diastolic BP was ob-
served
A slight decrease inmean
diastolic BP was ob-
served
NR
Analysis 16.10. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 10 Fasting plasma glucose (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 16 Liraglutide 1.2 mg versus SU











N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
L - LEAD 2 Nauck 2009 240 -1.6 (2.48) 242 -1.3 (2.49) -0.30 [ -0.74, 0.14 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours Liraglutide Favours Glimepiride
Analysis 16.11. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 11 Fasting plasma glucose (mmol/L).
Fasting plasma glucose (mmol/L)
Study Description Liraglutide 1.2 mg daily Glimepiride 4 mg daily p values
L - Yang 2010 Change from baseline -2.05 -2.18 NR
181Glucagon-like peptide analogues for type 2 diabetes mellitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 16.12. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 12 Post-prandial glucose (mmol/L).
Post-prandial glucose (mmol/L)
Study Description Liraglutide 1.2 mg
daily
Glimepiride 4 mg daily Comments
L - LEAD 2Nauck 2009 Self-monitored 7-point
plasma glucose measure-
ments
-2.3 mmol/L -2.5 mmol/L no significant difference
between groups
L - Yang 2010 Self-monitored 7-point
plasma glucose measure-
ments
-3.03 mmol/L -2.6 mmol/L LIR 1.2 vs. GLIM: P =
NS
Analysis 16.13. Comparison 16 Liraglutide 1.2 mg versus SU, Outcome 13 Beta-cell function.
Beta-cell function
Study Description Liraglutide 1.2 mg
daily
Glimepiride 4 mg daily Difference between
groups
L - LEAD 2Nauck 2009 HOMA-B (%) +23% +25% No significant difference
between liraglutide and
glimepiride groups
L - LEAD 2Nauck 2009 proinsulin-to-insulin ra-
tio
-0.1, P < 0.0001 versus
placebo
similar





L - Yang 2010 HOMA-B Increases between 14
and 21% points ob-
served in all treatment
groups
see previous column No significant difference
between liraglutide and
glimepiride groups
L - Yang 2010 Proinsulin-to-insulin ra-
tio
A slight decrease be-
tween 0.06 and 0.11 ob-
served in all treatment
groups
see previous column No significant difference
between liraglutide and
glimepiride groups
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Analysis 17.1. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 1 HbA1c (%).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 17 Liraglutide 1.8 mg daily versus SU











N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
L - LEAD 2 Nauck 2009 242 -1 (1.56) 242 -0.98 (1.56) -0.02 [ -0.30, 0.26 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours Liraglutide Favours Glimepiride
Analysis 17.2. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 2 HbA1c (%).
HbA1c (%)
Study Description Liraglutide 1.8 mg daily Glimepiride 4 mg daily Difference between groups
L - Yang 2010 Change in HbA1c -1.45 -1.39 -0.06, 95% CI -0.23 to 0.11
Analysis 17.3. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 3 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 17 Liraglutide 1.8 mg daily versus SU






4 mg daily Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
L - LEAD 2 Nauck 2009 103/242 88/242 46.4 % 1.17 [ 0.94, 1.46 ]
L - Yang 2010 104/234 101/231 53.6 % 1.02 [ 0.83, 1.25 ]
Total (95% CI) 476 473 100.0 % 1.09 [ 0.94, 1.26 ]
Total events: 207 (Liraglutide 1.8 mg daily), 189 (Glimepiride 4 mg daily)
Heterogeneity: Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours Glimepiride Favours Liraglutide
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Analysis 17.4. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 4 Hypoglycaemia.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus















L - LEAD 2 Nauck 2009 7/242 41/242 62.4 % 0.17 [ 0.08, 0.37 ]
L - Yang 2010 4/234 44/231 37.6 % 0.09 [ 0.03, 0.25 ]
Total (95% CI) 476 473 100.0 % 0.13 [ 0.07, 0.25 ]
Total events: 11 (Liraglutide 1.8 mg daily), 85 (Glimepiride 4 mg daily)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.99, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 6.38 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Liraglutide Favours Glimepiride
Analysis 17.5. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 5 Weight change (kg).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 17 Liraglutide 1.8 mg daily versus SU











N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
L - LEAD 2 Nauck 2009 242 -2.8 (3.11) 242 1 (3.11) -3.80 [ -4.35, -3.25 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Liraglutide Favours Glimepiride
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Analysis 17.6. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 6 Weight change (kg).
Weight change (kg)
Study Description Liraglutide 1.8 mg daily Glimepiride 4 mg daily p value
L - Yang 2010 Change from baseline -2.44 SD 2.6 0.08 LIR 1.8 vs. GLIM: P < 0.0001
Analysis 17.7. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 7 Adverse events.
Adverse events
Study Description Liraglutide 1.8 mg daily Glimepiride 4 mg daily
L - LEAD 2 Nauck 2009 withdrawal due to adverse events 12% 3%
L - LEAD 2 Nauck 2009 withdrawal due to nausea/vomit-
ing/diarrhoea
8% 0
L - LEAD 2 Nauck 2009 no significant differences across
groups for: physical examina-
tion findings, laboratory analyses,
ECG, ophthalmoscopy
L - LEAD 2 Nauck 2009 any GI event 44% 17%
L - LEAD 2 Nauck 2009 nausea 19% 3 to 4%
L - LEAD 2 Nauck 2009 vomiting 5 to 7% 1%
L - LEAD 2 Nauck 2009 diarrhoea 15% 4%
L - LEAD 2 Nauck 2009 serious adverse events: 2 deaths
unrelated to liraglutide treat-
ment; 1 participant each in 1.
2 mg liraglutide group and in
glimepiride groupwithdrawndue
to acute pancreatitis
L - LEAD 2 Nauck 2009 injection site reactions NR NR
L - LEAD 2 Nauck 2009 anti-liraglutide antibodies NR NR
L - Yang 2010 withdrawal due to adverse events 12.9% 1.3%
L - Yang 2010 serious adverse events 1.7 to 3.4% 1.7 to 3.4%
L - Yang 2010 pancreatitis none none
L - Yang 2010 deaths none none
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Adverse events (Continued)
L - Yang 2010 anti-liraglutide antibodies n = 8 from all liraglutide groups -
L - Yang 2010
L - Yang 2010
L - Yang 2010
L - Yang 2010
L - Yang 2010
Analysis 17.8. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 8 Systolic blood pressure (mm
Hg).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 17 Liraglutide 1.8 mg daily versus SU











N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
L - LEAD 2 Nauck 2009 242 -2.29 (12.91) 242 0.4 (13.22) -2.69 [ -5.02, -0.36 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 17.9. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 9 Blood pressure (mm Hg).
Blood pressure (mm Hg)
Study Description Liraglutide 1.8 mg
daily
Glimepiride 4 mg daily p values
L - LEAD 2Nauck 2009 Systolic blood pressure,
change from baseline
-2.29 SD 12.91 0.4 SD 13.22 NR
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Blood pressure (mm Hg) (Continued)
L - LEAD 2Nauck 2009 Diastolic blood pressure,
change from baseline
No change No change NR
L - Yang 2010 Systolic blood pressure,
change from baseline
Reduction of more than
3 mm Hg
Reduction of 0.91 mm
Hg
Reduction in the liraglu-
tide 1.2 groupwas signif-
icantly higher than that
in the glimepiride; p
value = NR
L - Yang 2010 Diastolic blood pressure,
change from baseline
A slight decrease inmean
diastolic BP was ob-
served
A slight decrease inmean
diastolic BP was ob-
served
NR
Analysis 17.10. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 10 Fasting plasma glucose
(mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 17 Liraglutide 1.8 mg daily versus SU











N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
L - LEAD 2 Nauck 2009 242 -1.7 (2.33) 242 -1.3 (2.49) -0.40 [ -0.83, 0.03 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours Liraglutide Favours Glimepiride
Analysis 17.11. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 11 Fasting plasma glucose
(mmol/L).
Fasting plasma glucose (mmol/L)
Study Description Liraglutide 1.8 mg daily Glimepiride 4 mg daily p values
L - Yang 2010 Change from baseline -2.12 -2.18 NR
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Analysis 17.12. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 12 Post-prandial glucose
(mmol/L).
Post-prandial glucose (mmol/L)
Study Description Liraglutide 1.8 mg
daily
Glimepiride 4 mg daily Comments
L - LEAD 2Nauck 2009 Self-monitored 7-point
plasma glucose measure-
ments
-2.6 mmol/L -2.5 mmol/L no significant difference
between groups
L - Yang 2010 Self-monitored 7-point
plasma glucose measure-
ments
-3.51 mmol/L -2.6 mmol/L LIR 1.8 vs. GLIM: P <
0.0001
Analysis 17.13. Comparison 17 Liraglutide 1.8 mg daily versus SU, Outcome 13 Beta-cell function.
Beta-cell function
Study Description Liraglutide 1.8 mg
daily
Glimepiride 4 mg daily Difference between
groups
L - LEAD 2Nauck 2009 HOMA-B (%) +28% +25% No significant difference
between liraglutide and
glimepiride groups
L - LEAD 2Nauck 2009 Proinsulin-to-insulin ra-
tio
-0.1, P < 0.0001 versus
placebo
similar





L - Yang 2010 HOMA-B Increases between 14%
and 21% points ob-
served in all treatment
groups
see previous column No significant difference
between liraglutide and
glimepiride groups
L - Yang 2010 Proinsulin-to-insulin ra-
tio
A slight decrease be-
tween 0.06 and 0.11 ob-
served in all treatment
groups
see previous column No significant difference
between liraglutide and
glimepiride groups
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Analysis 18.1. Comparison 18 Taspoglutide versus placebo, Outcome 1 HbA1c (%).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 18 Taspoglutide versus placebo
Outcome: 1 HbA1c (%)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Taspoglutide 10 mg once weekly verus placebo
T - Nauck 2009 49 -1.2 (0.49) 49 -0.2 (0.49) 100.0 % -1.00 [ -1.19, -0.81 ]
Subtotal (95% CI) 49 49 100.0 % -1.00 [ -1.19, -0.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.10 (P < 0.00001)
2 Taspoglutide 20 mg once weekly versus placebo
T - Nauck 2009 50 -1.2 (0.49) 49 -0.2 (0.49) 55.9 % -1.00 [ -1.19, -0.81 ]
T- Ratner 2010 32 -1.2 (0.57) 32 -0.5 (0.57) 44.1 % -0.70 [ -0.98, -0.42 ]
Subtotal (95% CI) 82 81 100.0 % -0.87 [ -1.16, -0.58 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 3.00, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 5.83 (P < 0.00001)
3 Taspoglutide 20 mg once every 2 weeks versus placebo
T - Nauck 2009 49 -1 (0.49) 49 -0.2 (0.49) 100.0 % -0.80 [ -0.99, -0.61 ]
Subtotal (95% CI) 49 49 100.0 % -0.80 [ -0.99, -0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.08 (P < 0.00001)
-2 -1 0 1 2
Favours Taspoglutide Favours Placebo
Analysis 18.2. Comparison 18 Taspoglutide versus placebo, Outcome 2 HbA1c (%).
HbA1c (%)
Study 20/30 mg (n = 33) 20/40 mg (n = 32) Placebo (n = 32)
T- Ratner 2010 -0.90 SD 0.57, P < 0.0001 versus
placebo
-1.20 SD 0.57, P < 0.0001 versus
placebo
-0.50 SD 0.57
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Analysis 18.3. Comparison 18 Taspoglutide versus placebo, Outcome 3 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 18 Taspoglutide versus placebo
Outcome: 3 HbA1c < 7%








1 Taspoglutide 10 mg once weekly versus placebo
T - Nauck 2009 39/49 8/49 100.0 % 4.88 [ 2.55, 9.33 ]
Subtotal (95% CI) 49 49 100.0 % 4.88 [ 2.55, 9.33 ]
Total events: 39 (Taspoglutide), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.78 (P < 0.00001)
2 Taspoglutide 20 mg once weekly versus placebo
T - Nauck 2009 40/50 8/49 57.4 % 4.90 [ 2.56, 9.38 ]
T- Ratner 2010 23/32 6/32 42.6 % 3.83 [ 1.81, 8.14 ]
Subtotal (95% CI) 82 81 100.0 % 4.41 [ 2.70, 7.22 ]
Total events: 63 (Taspoglutide), 14 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 5.92 (P < 0.00001)
3 Taspoglutide 20 mg once every two weeks versus placebo
T - Nauck 2009 31/49 8/49 100.0 % 3.88 [ 1.99, 7.56 ]
Subtotal (95% CI) 49 49 100.0 % 3.88 [ 1.99, 7.56 ]
Total events: 31 (Taspoglutide), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.97 (P = 0.000072)
Test for subgroup differences: Chi2 = 0.23, df = 2 (P = 0.89), I2 =0.0%
0.01 0.1 1 10 100
Favours Placebo Favours Taspoglutide
Analysis 18.4. Comparison 18 Taspoglutide versus placebo, Outcome 4 HbA1c < 7%.
HbA1c < 7%
Study 20/30 mg once weekly 20/40 mg once weekly Placebo
T- Ratner 2010 53% 70% 19%
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Analysis 18.5. Comparison 18 Taspoglutide versus placebo, Outcome 5 Hypoglycaemia.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 18 Taspoglutide versus placebo
Outcome: 5 Hypoglycaemia








1 Taspoglutide 20/20 mg once weekly versus placebo
T- Ratner 2010 1/32 1/32 100.0 % 1.00 [ 0.07, 15.30 ]
Subtotal (95% CI) 32 32 100.0 % 1.00 [ 0.07, 15.30 ]
Total events: 1 (Taspoglutide), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Taspoglutide 20/30 mg once weekly versus placebo
T- Ratner 2010 3/33 1/32 100.0 % 2.91 [ 0.32, 26.53 ]
Subtotal (95% CI) 33 32 100.0 % 2.91 [ 0.32, 26.53 ]
Total events: 3 (Taspoglutide), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
3 Taspoglutide 20/40 mg once weekly versus placebo
T- Ratner 2010 2/32 1/32 100.0 % 2.00 [ 0.19, 20.97 ]
Subtotal (95% CI) 32 32 100.0 % 2.00 [ 0.19, 20.97 ]
Total events: 2 (Taspoglutide), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Chi2 = 0.36, df = 2 (P = 0.84), I2 =0.0%
0.02 0.1 1 10 50
Favours Taspoglutide Favours Placebo
Analysis 18.6. Comparison 18 Taspoglutide versus placebo, Outcome 6 Hypoglycaemia.
Hypoglycaemia
Study
T - Nauck 2009 hypoglycaemia not defined; no data reported for the separate comparison groups; overall, there were 7 hypogly-
caemic events in 6 patients, 2 of which were asymptomatic;
there were no cases of severe hypoglycaemia in the taspoglutide group
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Analysis 18.7. Comparison 18 Taspoglutide versus placebo, Outcome 7 Weight change (kg).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 18 Taspoglutide versus placebo
Outcome: 7 Weight change (kg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Taspoglutide 10 mg once weekly versus placebo
T - Nauck 2009 39 -2.1 (1.87) 49 -0.8 (2.1) 100.0 % -1.30 [ -2.13, -0.47 ]
Subtotal (95% CI) 39 49 100.0 % -1.30 [ -2.13, -0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.07 (P = 0.0022)
2 Taspoglutide 20 mg once weekly versus placebo
T - Nauck 2009 40 -2.8 (1.9) 49 -0.8 (2.1) 51.0 % -2.00 [ -2.83, -1.17 ]
T- Ratner 2010 32 -2.1 (2.26) 32 -2 (1.7) 49.0 % -0.10 [ -1.08, 0.88 ]
Subtotal (95% CI) 72 81 100.0 % -1.07 [ -2.93, 0.79 ]
Heterogeneity: Tau2 = 1.59; Chi2 = 8.39, df = 1 (P = 0.004); I2 =88%
Test for overall effect: Z = 1.12 (P = 0.26)
3 Taspoglutide 20 mg once every two weeks versus placebo
T - Nauck 2009 31 -1.9 (1.67) 49 -0.8 (2.1) 100.0 % -1.10 [ -1.93, -0.27 ]
Subtotal (95% CI) 31 49 100.0 % -1.10 [ -1.93, -0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.59 (P = 0.0095)
Test for subgroup differences: Chi2 = 0.13, df = 2 (P = 0.94), I2 =0.0%
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Analysis 18.8. Comparison 18 Taspoglutide versus placebo, Outcome 8 Weight change.
Weight change
Study 20/30 mg once weekly 20/40 mg once weekly Placebo
T- Ratner 2010 -3 SD 1.72, P = 0.03 versus placebo -2.7 SD2.26, P =0.17 versus placebo -2 SD 1.70
Analysis 18.9. Comparison 18 Taspoglutide versus placebo, Outcome 9 Adverse events.
Adverse events







T- Ratner 2010 Withdrawal due to
adverse events
n = 3 n = 6 n = 6 n = 1
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Adverse events (Continued)
T- Ratner 2010 Nausea 38% 52% 34% 13%
T- Ratner 2010 Headache 16% 6% 9% 13%
T- Ratner 2010 Diarrhoea 13% 21% 9% 9%
T- Ratner 2010 Vomiting 13% 27% 13% 0
T- Ratner 2010 Dyspepsia 19% 15% 16% 0
T- Ratner 2010 Abdominal
distension
9% 12% 3% 0
T- Ratner 2010 Injection site reac-
tions
69% 52% 59% 13%
T- Ratner 2010 serious adverse
events
0 0 n = 1, unrelated to
study drug
n = 1, unrelated to
study drug
T- Ratner 2010 severe
hypoglycaemia
0 0 0 0
Analysis 18.10. Comparison 18 Taspoglutide versus placebo, Outcome 10 Adverse events.
Adverse events
Study Description 10 mg weekly 20 mg weekly 20 mg every 2 weeks Placebo
T - Nauck 2009 withdrawal due to
adverse event
n = 2 n = 3 n = 1 n = 0
T - Nauck 2009 adverse events simi-




ECG, vital signs, lab-
oratory parameters
T - Nauck 2009 nausea n = 12 (24%) n = 26 (52%) n = 20 (41%) n = 3 (6%)
T - Nauck 2009 vomiting n = 2 (4%) n = 11 (22%) n = 12 (24%) n = 2 (4%)
T - Nauck 2009 diarrhoea n = 5 (10%) n = 5 (10%) n = 9 (18%) n = 4 (8%)
T - Nauck 2009 serious
adverse events: 6 pa-
tients, 2 of which in
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Adverse events (Continued)
placebo group
considered to be un-
related to study treat-
ment
T - Nauck 2009 mild and moderate
injection site reac-
tions which did not
result in treatment
discontinuation
Analysis 18.11. Comparison 18 Taspoglutide versus placebo, Outcome 11 Fasting plasma glucose (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 18 Taspoglutide versus placebo
Outcome: 11 Fasting plasma glucose (mmol/L)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Taspoglutide 20/20 mg once weekly versus placebo
T- Ratner 2010 32 -2.3 (1.7) 32 -0.6 (1.7) 100.0 % -1.70 [ -2.53, -0.87 ]
Subtotal (95% CI) 32 32 100.0 % -1.70 [ -2.53, -0.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.00 (P = 0.000063)
2 Taspoglutide 20/30 mg once weekly versus placebo
T- Ratner 2010 33 -1.6 (1.72) 32 -0.6 (1.7) 100.0 % -1.00 [ -1.83, -0.17 ]
Subtotal (95% CI) 33 32 100.0 % -1.00 [ -1.83, -0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.36 (P = 0.018)
3 Taspoglutide 20/40 mg once weekly versus placebo
T- Ratner 2010 32 -2.2 (1.7) 32 -0.6 (1.7) 100.0 % -1.60 [ -2.43, -0.77 ]
Subtotal (95% CI) 32 32 100.0 % -1.60 [ -2.43, -0.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.76 (P = 0.00017)
Test for subgroup differences: Chi2 = 1.59, df = 2 (P = 0.45), I2 =0.0%
-4 -2 0 2 4
Favours Taspoglutide Favours Placebo
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Analysis 18.12. Comparison 18 Taspoglutide versus placebo, Outcome 12 Fasting plasma glucose.
Fasting plasma glucose
Study 10 mg once weekly 20 mg once weekly 20 mg every 2
weeks
Placebo FPG fluctuations
T - Nauck 2009 -2.5 mmol/L, P < 0.
0001
-2.5 mmol/L, P < 0.
0001
-1.4 mmol/L, P = 0.
02
-0.78 mmol/L the fluctuation in FPGwas
less for the weekly regi-
mens than for the dosing
once every 2 weeks:
0.6mmol/L amplitude be-
tween week 2 and week 8
for both 10 mg and 20 mg
per week versus 1.3 mmol/
L amplitude betweenweek
2 and week 8 for 20 mg ev-
ery 2 weeks
Analysis 18.13. Comparison 18 Taspoglutide versus placebo, Outcome 13 Postprandial glucose and insulin.
Postprandial glucose and insulin
Study Description 10 mg once weekly 20 mg once weekly 20 mg every 2
weeks
Placebo
T - Nauck 2009 plasma glucose 120
min after a mixed
meal (% change
from baseline)
-22.0% -18.0% -5.5% -10.5%
T - Nauck 2009 glu-
coseAUC(%change
from baseline)
-27.5% (SE 3.2) -22.2% (SE 3.3) -9.2% (SE 5.0) -7.2% (SE3 .5)
T - Nauck 2009 mean
% change in plasma
insulin at 120 min
+28.5% +44.9% -13% -15.3%
Analysis 18.14. Comparison 18 Taspoglutide versus placebo, Outcome 14 Lipid profiles.
Lipid profiles
Study Description 10 mg once weekly 20 mg once weekly 20 mg every 2
weeks
Placebo
T - Nauck 2009 Triglycerides
(mmol/L)
-0.29 mmol/L -0.54 mmol/L -0.30 mmol/L +0.10 mmol/L
195Glucagon-like peptide analogues for type 2 diabetes mellitus (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lipid profiles (Continued)
T - Nauck 2009 Total cholesterol
(mmol/L)
-0.31 mmol/L -0.23 mmol/L -0.31 mmol/L +0.18 mmol/L
T - Nauck 2009 HDL (mmol/L) -0.05 mmol/L -0.03 mmol/L +0 mmol/L +0 mmol/L
T - Nauck 2009 LDL (mmol/L) -0.21 mmol/L +0.03 mmol/L -0.16 mmol/L +0.13 mmol/L
Analysis 18.15. Comparison 18 Taspoglutide versus placebo, Outcome 15 Beta-cell function.
Beta-cell function
Study Description 10 mg once weekly 20 mg once weekly 20 mg every 2
weeks
Placebo
T - Nauck 2009 proinsulin-to-
insulin ratio
-0.12, P = 0.0076 -0.166, P = 0.0003 -0.055, P = NS 0.002
Analysis 18.16. Comparison 18 Taspoglutide versus placebo, Outcome 16 Subgroup.
Subgroup
Study 10 mg once weekly 20 mg once weekly 20 mg every 2 weeks Placebo
Participants with HbA1c ≥8%
T - Nauck 2009 -1.5%, P < 0.0001 versus
placebo
-1.4%, P < 0.0001 versus
placebo
-1.3%, P < 0.0001 versus
placebo
-0.3%
Analysis 19.1. Comparison 19 LY2189265 versus placebo, Outcome 1 HbA1c.
HbA1c





-1.38 SE 0.12 -1.32 SE 0.12 -1.59 SE 0.12 Not reported All LY groups vs.
placebo: P < 0.001;
Between LY groups:
P > 0.05
Analysis 19.2. Comparison 19 LY2189265 versus placebo, Outcome 2 HbA1c < 7%.
HbA1c < 7%
Study Description Result
LY2189265 -Umpierrez 2011 HbA1c < 7% 49 to 54% of participants achieved a target HbA1c level of < 7% at 16 weeks
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Analysis 19.3. Comparison 19 LY2189265 versus placebo, Outcome 3 Hypoglycaemia.
Hypoglycaemia










caemic episodes at 4
weeks




caemic episodes at 8
weeks











0 0 0 0
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Analysis 19.4. Comparison 19 LY2189265 versus placebo, Outcome 4 Weight change (kg).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 19 LY2189265 versus placebo
Outcome: 4 Weight change (kg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LY 0.5/1.0 QW
LY2189265 -Umpierrez 2011 65 -1.44 (3.14) 65 -0.12 (3.14) 100.0 % -1.32 [ -2.40, -0.24 ]
Subtotal (95% CI) 65 65 100.0 % -1.32 [ -2.40, -0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.017)
2 LY 1.0/1.0 QW
LY2189265 -Umpierrez 2011 63 -1.34 (3.1) 65 -0.12 (3.14) 100.0 % -1.22 [ -2.30, -0.14 ]
Subtotal (95% CI) 63 65 100.0 % -1.22 [ -2.30, -0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
3 LY 1.0/2.0 QW
LY2189265 -Umpierrez 2011 63 -2.55 (3.17) 65 -0.12 (3.14) 100.0 % -2.43 [ -3.52, -1.34 ]
Subtotal (95% CI) 63 65 100.0 % -2.43 [ -3.52, -1.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.36 (P = 0.000013)
-4 -2 0 2 4
Favours LY2189265 Favours Placebo
Analysis 19.5. Comparison 19 LY2189265 versus placebo, Outcome 5 Adverse events.
Adverse events





3 (4.5%) 4 (6.2%) 4 (6.2%) 1 (1.5%)
LY2189265 -
Umpierrez 2011






diarrhoea 5 (7.6) 4 (6.2%) 9 (13.8%) 5 (7.6%) Higher LY dosage
was generally associ-
ated with a higher
prevalence of adverse
events
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3 (4.5%) 5 (7.7%) 9 (13.8%) 4 (6.1%) Higher LY dosage
was generally associ-





vomiting 3 (4.5%) 1 (1.5%) 7 (10.8%) 2 (3.0%) Higher LY dosage
was generally associ-





Pancreatitis 2 Both cases related
to study drug. One
participant approxi-
mately 5 months af-
ter last dose of LY 0.5/
1.0, later this was re-
garded as serious. Sec-
ond participant af-
ter the 11th weekly
dose of LY 0.5/1.0
had approximately 1.
5- and 2.5-fold in-
crease in amylase and
lipase levels respec-
tively with no obvi-
ous symptom or ab-






bly LY related ad-
verse events





3 (4.5%) 2 (3.1%) 1 (1.5%) 1 (1.5%) three serious
adverse events related







deaths 0 0 0 0
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Analysis 19.6. Comparison 19 LY2189265 versus placebo, Outcome 6 Systolic blood pressure (mm Hg).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 19 LY2189265 versus placebo
Outcome: 6 Systolic blood pressure (mm Hg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LY 0.5/1.0 QW
LY2189265 -Umpierrez 2011 66 -0.6 (14.62) 66 -3.5 (14.62) 2.90 [ -2.09, 7.89 ]
2 LY 1.0/1.0 QW
LY2189265 -Umpierrez 2011 65 -0.9 (14.51) 66 -3.5 (14.62) 2.60 [ -2.39, 7.59 ]
3 LY 1.0/2.0 QW
LY2189265 -Umpierrez 2011 65 -3 (14.51) 66 -3.5 (14.62) 0.50 [ -4.49, 5.49 ]
-10 -5 0 5 10
Favours LY2189265 Favours Placebo
Analysis 19.7. Comparison 19 LY2189265 versus placebo, Outcome 7 Diastolic blood pressure (mm Hg).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 19 LY2189265 versus placebo
Outcome: 7 Diastolic blood pressure (mm Hg)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LY 0.5/1.0 QW
LY2189265 -Umpierrez 2011 66 1 (9.75) 66 -2.3 (9.75) 3.30 [ -0.03, 6.63 ]
2 LY 1.0/1.0 QW
LY2189265 -Umpierrez 2011 65 1.2 (9.67) 66 -2.3 (9.75) 3.50 [ 0.17, 6.83 ]
3 LY 1.0/2.0 QW
LY2189265 -Umpierrez 2011 65 1.2 (9.67) 66 -2.3 (9.75) 3.50 [ 0.17, 6.83 ]
-4 -2 0 2 4
Favours LY2189265 Favours Placebo
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Analysis 19.8. Comparison 19 LY2189265 versus placebo, Outcome 8 Fasting plasma glucose (mmol/L).
Fasting plasma glucose (mmol/L)
Study Description LY 0.5/1.0 QW LY 1.0/1.0 QW LY 1.0/2.0 QW Placebo p values
LY2189265 -
Umpierrez 2011
Change in FPG -2.10 -2.05 -2.65 -0.49 All LY groups vs. placebo:
P < 0.001;
Between LY groups: P >
0.05
Analysis 19.9. Comparison 19 LY2189265 versus placebo, Outcome 9 Beta-cell function.
Beta-cell function





39.2 SE 45.6% 44.3 SE 93.9% 45.6 SE 55.2% 1.0 SE 41.1% All LY groups vs.














Not reported Not reported Not reported Not reported No statistically sig-
nificant change in
all LY groups
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Analysis 20.1. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 1 HbA1c.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 20 GLP-1 agonist versus GLP-1 agonist
Outcome: 1 HbA1c





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 versus Liraglutide
L - LEAD 6 Buse 2009 231 -0.79 (1.22) 233 -1.12 (1.22) 100.0 % 0.33 [ 0.11, 0.55 ]
Subtotal (95% CI) 231 233 100.0 % 0.33 [ 0.11, 0.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.91 (P = 0.0036)
2 versus Exenatide 2 mg once weekly
E - Blevins 2011 123 -0.9 (1.11) 129 -1.6 (1.14) 50.0 % 0.70 [ 0.42, 0.98 ]
E - Drucker 2008 147 -1.5 (1.21) 148 -1.9 (1.22) 50.0 % 0.40 [ 0.12, 0.68 ]
Subtotal (95% CI) 270 277 100.0 % 0.55 [ 0.26, 0.84 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 2.24, df = 1 (P = 0.13); I2 =55%
Test for overall effect: Z = 3.67 (P = 0.00025)
-1 -0.5 0 0.5 1
Favours exenatide 10 g Favours Other GLP1
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Analysis 20.2. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 2 HbA1c < 7%.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 20 GLP-1 agonist versus GLP-1 agonist
Outcome: 2 HbA1c < 7%









L - LEAD 6 Buse 2009 99/231 126/233 100.0 % 0.79 [ 0.66, 0.96 ]
Subtotal (95% CI) 231 233 100.0 % 0.79 [ 0.66, 0.96 ]
Total events: 99 (Exenatide 10 g BID), 126 (Other GLP1-agonist)
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.017)
2 versus Exenatide 2 mg once weekly
E - Blevins 2011 37/123 75/129 45.8 % 0.52 [ 0.38, 0.70 ]
E - Drucker 2008 79/130 99/129 54.2 % 0.79 [ 0.67, 0.94 ]
Subtotal (95% CI) 253 258 100.0 % 0.65 [ 0.42, 1.01 ]
Total events: 116 (Exenatide 10 g BID), 174 (Other GLP1-agonist)
Heterogeneity: Tau2 = 0.09; Chi2 = 6.36, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 1.91 (P = 0.056)
0.5 0.7 1 1.5 2
Favours Other GLP1 Favours Exenatide 10 g
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Analysis 20.3. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 3 Hypoglycaemia.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 20 GLP-1 agonist versus GLP-1 agonist
Outcome: 3 Hypoglycaemia









L - LEAD 6 Buse 2009 78/232 60/235 100.0 % 1.32 [ 0.99, 1.75 ]
Subtotal (95% CI) 232 235 100.0 % 1.32 [ 0.99, 1.75 ]
Total events: 78 (Exenatide 10 g BID), 60 (Other GLP1-agonist)
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
2 versus Exenatide 2 mg once weekly
E - Drucker 2008 9/147 8/148 100.0 % 1.13 [ 0.45, 2.86 ]
Subtotal (95% CI) 147 148 100.0 % 1.13 [ 0.45, 2.86 ]
Total events: 9 (Exenatide 10 g BID), 8 (Other GLP1-agonist)
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
0.05 0.2 1 5 20
Favours Exenatide 10 g BID Favours Other GLP1
Analysis 20.4. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 4 Hypoglycaemia.
Hypoglycaemia
Study Description Exenatide 10 µg BID Exenatide 2 mg QW
E - Blevins 2011 Minor hypoglycaemia occured only
among participants using a con-
comitant SU (n = 74)
n = 4 n = 5
E - Blevins 2011 Major hypoglycaemia None None
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Analysis 20.5. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 5 Weight change.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 20 GLP-1 agonist versus GLP-1 agonist
Outcome: 5 Weight change





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 versus Liraglutide
L - LEAD 6 Buse 2009 231 -2.87 (5.02) 233 -3.24 (5.04) 100.0 % 0.37 [ -0.55, 1.29 ]
Subtotal (95% CI) 231 233 100.0 % 0.37 [ -0.55, 1.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
2 versus Exenatide 2 mg once weekly
E - Drucker 2008 147 -3.6 (6.1) 148 -3.7 (6.1) 100.0 % 0.10 [ -1.29, 1.49 ]
Subtotal (95% CI) 147 148 100.0 % 0.10 [ -1.29, 1.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
-4 -2 0 2 4
Favours Exenatide 10 g Favours Other GLP1
Analysis 20.6. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 6 Weight change.
Weight change
Study Description Exenatide 10 µg BID Exenatide 2 mg QW Difference between groups
E - Blevins 2011 Change in weight (kg) -1.4 -2.3 -0.95 (95% CI -1.9 to 0.01)
E - Blevins 2011 Proportion of participants
experiencing weight loss
by end of study, n (%)
77 (63) 99 (77) NR
Analysis 20.7. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 7 Treatment satisfaction.
Treatment satisfaction
Study Description Exenatide 10 µg BID Other GLP1 agonist
versus Liraglutide
L - LEAD 6 Buse 2009 Diabetes Treatment Satisfaction
Questionnaire (6 of 8 items)
13.3 SD6.94 15.18 SD 7.36, P = 0.0004 versus exenatide
10 µg BID
versus Exenatide 2 mg once weekly
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Treatment satisfaction (Continued)
E - Drucker 2008 Diabetes Treatment Satisfaction
Questionnaire (8 of 8 items)
29.97 31.17, P = NS versus exenatide 10 µg BID
Analysis 20.8. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 8 Adverse events.
Adverse events
Study Description Exenatide 10 µg BID Other GLP1 agonist
versus Liraglutide
L - LEAD 6 Buse 2009 withdrawal due to adverse events 13% 10%
L - LEAD 6 Buse 2009 overall rate of adverse events 78.9% 74.9%
L - LEAD 6 Buse 2009 no significant differences across
groups for: infections, headache,
back pain, metabolism an nu-
trition disorders, general disor-
ders and administration-site con-
ditions; 1 episode of mild pancre-
atitis in liraglutide group (consid-
ered to be chronic and unrelated
to treatment
L - LEAD 6 Buse 2009 nausea 28.0% 25.5%
L - LEAD 6 Buse 2009 diarrhoea 12.1% 12.3%
L - LEAD 6 Buse 2009 dyspepsia 4.7% 8.9%
L - LEAD 6 Buse 2009 vomiting 9.9% 6.0%
L - LEAD 6 Buse 2009 constipation 2.6% 5.1%
L - LEAD 6 Buse 2009 serious adverse events (only on
event considered to be related to
study medication (exenatide, se-
vere hypoglycaemia))
2.6% 5.1%
L - LEAD 6 Buse 2009 severe adverse events 4.7% 7.2%
versus Exenatide 2 mg once weekly
E - Blevins 2011 withdrawal due to adverse events 5% 5%
E - Blevins 2011 nausea 35%; events: n = 51 14%; events: n = 21
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Adverse events (Continued)
E - Blevins 2011 vomiting 8.9% 4.7%
E - Blevins 2011 diarrhoea 4.1% 9.3%
E - Blevins 2011 headache 8.1% 4.7%
E - Blevins 2011 dizziness 6.5% 2.3%
E - Blevins 2011 upper respiratory tract infection 4.1% 7.0%
E - Blevins 2011 injection site erythema 2.4% 5.4%
E - Blevins 2011 serious adverse events 4%; one fatal myocardial infarc-
tion
2%, one participant with a history
of dyslipidemia was hospitalised
and withdrew due to a diagnosis
of pancreatitis
E - Blevins 2011 anti-exenatide antibody levels 51% participants positive for
treatment-emergent antibodies to
exenatide
73% participants positive for
treatment-emergent antibodies to
exenatide
E - Drucker 2008 withdrawal due to adverse events 5.4% 6.1%
E - Drucker 2008 no clinically significant abnormal-
ities in vital signs, ECG reports,
haematological, chemistry or uri-
nalysis values; no major hypogly-
caemia
E - Drucker 2008 nausea
(modestly greater weight loss in
people with nausea, but partic-
ipants without nausea also lost
weight)
34.5% 26.4%
E - Drucker 2008 diarrhoea 13.1% 13.5%
E - Drucker 2008 vomiting 18.6% 10.8%
E - Drucker 2008 constipation 6.2% 10.8%
E - Drucker 2008 injection site pruritus 1.4% 17.6%
E - Drucker 2008 injection site bruising 10.3% 4.7%
E - Drucker 2008 serious adverse events (none con-
sidered to be related to study treat-
ment)
3.4% 5.4%
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Adverse events (Continued)
E - Drucker 2008 anti-exenatide antibody levels significantly more anti-exenatide
antibodies with exenatide once
weekly, but mostly not detectable
or low titre
Analysis 20.9. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 9 Systolic blood pressure.
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 20 GLP-1 agonist versus GLP-1 agonist
Outcome: 9 Systolic blood pressure





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 versus Liraglutide
L - LEAD 6 Buse 2009 231 -2 (17.93) 233 -2.51 (17.55) 100.0 % 0.51 [ -2.72, 3.74 ]
Subtotal (95% CI) 231 233 100.0 % 0.51 [ -2.72, 3.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
2 versus Exenatide 2 mg once weekly
E - Blevins 2011 123 -1.2 (13.31) 129 -2.9 (12.49) 47.7 % 1.70 [ -1.49, 4.89 ]
E - Drucker 2008 147 -3.4 (13.3) 148 -4.7 (13.4) 52.3 % 1.30 [ -1.75, 4.35 ]
Subtotal (95% CI) 270 277 100.0 % 1.49 [ -0.71, 3.69 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.18)
-10 -5 0 5 10
Favours Exenatide 10 g Favours Other GLP1
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Analysis 20.10. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 10 Fasting plasma glucose
(mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 20 GLP-1 agonist versus GLP-1 agonist
Outcome: 10 Fasting plasma glucose (mmol/L)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 versus Liraglutide
L - LEAD 6 Buse 2009 231 -0.6 (3.04) 233 -1.61 (3.05) 100.0 % 1.01 [ 0.46, 1.56 ]
Subtotal (95% CI) 231 233 100.0 % 1.01 [ 0.46, 1.56 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.57 (P = 0.00035)
2 versus Exenatide 2 mg once weekly
E - Blevins 2011 123 -0.7 (0.3) 129 -1.9 (0.3) 92.6 % 1.20 [ 1.13, 1.27 ]
E - Drucker 2008 147 -1.4 (2.4) 148 -2.3 (2.4) 7.4 % 0.90 [ 0.35, 1.45 ]
Subtotal (95% CI) 270 277 100.0 % 1.18 [ 1.02, 1.33 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.13, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 14.99 (P < 0.00001)
-2 -1 0 1 2
Favours Exenatide 10 g Favours Other GLP1
Analysis 20.11. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 11 Post-prandial glucose
(mmol/L).
Post-prandial glucose (mmol/L)
Study Description Exenatide 10 µg BID Other GLP1 agonist Comments
versus Liraglutide
L - LEAD 6 Buse 2009 from self-monitored
7-point plasma glucose
measurements
after breakfast: 8.9 SE 0.
4 mmol/L
after dinner: 7.8 SE 0.4
mmol/L
after breakfast: 9.7 SE 0.
5 mmol/L









L - LEAD 6 Buse 2009
versus Exenatide 2 mg once weekly
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Post-prandial glucose (mmol/L) (Continued)
E - Drucker 2008 2 h post-prandial glu-
cose, meal tolerance test
(n = 51)
-6.9 mmol/L SE 0.5 -5.3 mmol/L SE 0.5 P = 0.0124
Analysis 20.12. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 12 Triglycerides (mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 20 GLP-1 agonist versus GLP-1 agonist
Outcome: 12 Triglycerides (mmol/L)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 versus Liraglutide
L - LEAD 6 Buse 2009 231 -0.23 (1.5) 233 -0.41 (1.53) 100.0 % 0.18 [ -0.10, 0.46 ]
Subtotal (95% CI) 231 233 100.0 % 0.18 [ -0.10, 0.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
2 versus Exenatide 2 mg once weekly
E - Blevins 2011 123 0.01 (0.01) 129 0.01 (0.04) 89.9 % 0.0 [ -0.01, 0.01 ]
E - Drucker 2008 148 -0.196 (0.64) 147 -0.28 (0.68) 10.1 % 0.09 [ -0.06, 0.24 ]
Subtotal (95% CI) 271 276 100.0 % 0.01 [ -0.04, 0.06 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.25, df = 1 (P = 0.26); I2 =20%
Test for overall effect: Z = 0.34 (P = 0.74)
-0.5 -0.25 0 0.25 0.5
Favours Exenatide 10 g Favours Other GLP1
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Analysis 20.13. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 13 Total cholesterol
(mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 20 GLP-1 agonist versus GLP-1 agonist
Outcome: 13 Total cholesterol (mmol/L)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 versus Liraglutide
L - LEAD 6 Buse 2009 231 -0.09 (1.1) 233 -0.2 (1.07) 100.0 % 0.11 [ -0.09, 0.31 ]
Subtotal (95% CI) 231 233 100.0 % 0.11 [ -0.09, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
2 versus Exenatide 2 mg once weekly
E - Blevins 2011 123 0.02 (0.78) 129 -0.4 (0.8) 47.0 % 0.42 [ 0.22, 0.62 ]
E - Drucker 2008 147 -0.1 (0.73) 148 -0.31 (0.73) 53.0 % 0.21 [ 0.04, 0.38 ]
Subtotal (95% CI) 270 277 100.0 % 0.31 [ 0.10, 0.51 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.57, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 2.94 (P = 0.0032)
-0.5 -0.25 0 0.25 0.5
Favours Exenatide 10 g Favours Other GLP1
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Analysis 20.14. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 14 HDL-cholesterol
(mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 20 GLP-1 agonist versus GLP-1 agonist
Outcome: 14 HDL-cholesterol (mmol/L)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 versus Liraglutide
L - LEAD 6 Buse 2009 231 -0.05 (0.3) 233 -0.04 (0.31) 100.0 % -0.01 [ -0.07, 0.05 ]
Subtotal (95% CI) 231 233 100.0 % -0.01 [ -0.07, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
2 versus Exenatide 2 mg once weekly
E - Blevins 2011 123 0.03 (0.22) 129 0 (0.23) 31.0 % 0.03 [ -0.03, 0.09 ]
E - Drucker 2008 147 -0.03 (0.12) 148 -0.02 (0.12) 69.0 % -0.01 [ -0.04, 0.02 ]
Subtotal (95% CI) 270 277 100.0 % 0.00 [ -0.03, 0.04 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.60, df = 1 (P = 0.21); I2 =38%
Test for overall effect: Z = 0.13 (P = 0.90)
-0.1 -0.05 0 0.05 0.1
Favours Exenatide 10 g Favours Other GLP1
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Analysis 20.15. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 15 LDL-cholesterol
(mmol/L).
Review: Glucagon-like peptide analogues for type 2 diabetes mellitus
Comparison: 20 GLP-1 agonist versus GLP-1 agonist
Outcome: 15 LDL-cholesterol (mmol/L)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 versus Liraglutide
L - LEAD 6 Buse 2009 231 -0.4 (0.9) 233 -0.44 (0.92) 100.0 % 0.04 [ -0.13, 0.21 ]
Subtotal (95% CI) 231 233 100.0 % 0.04 [ -0.13, 0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
2 versus Exenatide 2 mg once weekly
E - Blevins 2011 123 0.07 (0.67) 129 -0.17 (0.57) 45.0 % 0.24 [ 0.09, 0.39 ]
E - Drucker 2008 147 0.03 (0.61) 148 -0.13 (0.61) 55.0 % 0.16 [ 0.02, 0.30 ]
Subtotal (95% CI) 270 277 100.0 % 0.20 [ 0.09, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.72 (P = 0.00020)
-0.5 -0.25 0 0.25 0.5
Favours Exenatide 10 g Favours Other GLP1
Analysis 20.16. Comparison 20 GLP-1 agonist versus GLP-1 agonist, Outcome 16 Beta-cell function.
Beta-cell function
Study Description Exenatide 10 µg BID Liraglutide 1.8 mg daily
L - LEAD 6 Buse 2009 HOMA-B (%) +2.74% SD 103 +32.12% SD 103, P < 0.0001 versus exenatide 10
µg BID
L - LEAD 6 Buse 2009 proinsulin-to-insulin ratio -0.02 SD 0.46 0.00 SD 0.46, P = NS
A D D I T I O N A L T A B L E S
Table 1. Overview of study populations
Characteristic
GLP analogue
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Table 1. Overview of study populations (Continued)
LY2189265 ver-
sus placebo
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Table 1. Overview of study populations (Continued)












































“-” denotes not reported
C: control; GLP: glucagon-like peptide; I: intervention; ITT: intention-to-treat; T: Total
“*” indicate totals of the patients whose data were included in this review
‘#’ indicate that the total is missing for some data for both I and C group as they were not reported
‘##’ indicate that this is the actual total number of patients randomised. Please note ‘T’ for all trials were added to get this number
Table 2. Overview of comparisons
Characteristic
GLP analogue
Intervention Control Duration Quality (of 7)
EXENATIDE
Exenatide versus TZD
Bergenstal 2010 E QW+M+Placebo TZD+M+Placebo 26 weeks 7
Exenatide versus DPP-
4 inhibitors
Bergenstal 2010 E QW+M+Placebo DPP-4+M+Placebo 26 weeks 7
Exenatide versus in-
sulin glargine




LEAD 1 (Marre 2009) L+SU SU 26 weeks 5
LEAD 2 (Nauck 2009) L+M M 26 weeks 7
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Table 2. Overview of comparisons (Continued)
LEAD 5 (Russell-Jones
2008)
L+M+SU M+SU 26 weeks 6





L+M+SU GLAR+M+SU 26 weeks 6
Liraglutide versus SU
LEAD 2 (Nauck 2009) L+M M+SU 26 weeks 7
Yang 2010 L+M+Placebo SU+M+Placebo 16 weeks 5
Liraglutide versus TZD
LEAD 1 (Marre 2009) L+SU TZD+SU 26 weeks 5
Liraglutide versus
DPP-4 inhibitors








Umpierrez 2011 LY QW Placebo 16 weeks 6
TASPOGLUTIDE
Nauck 2009 T+M M 8 weeks 7
Ratner 2010 T+M Placebo+M 8 weeks 5
ALBIGLUTIDE
Rosenstock 2009 A+M M 16 weeks 5
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Table 2. Overview of comparisons (Continued)
GLP1 versus GLP1





Drucker 2008 E BID+M E QW+M 30 weeks 4
LEAD 6 (Buse 2009) L+M/SU E+M/SU 26 weeks 5
A:albiglutide;BID:twicedaily;DPP−4:dipeptidylpeptidase−4inhibitor;E:exenatide;GLAR:glargine;GLP :glucagon−likepeptide;L:liraglutide;LIXI :lixisenatide;LY :LY2189265;M:
A P P E N D I C E S
Appendix 1. Search strategies
Search terms
Unless otherwise stated, search terms are free text terms; MeSH = Medical subject heading (MEDLINE medical index term); exP =
exploded MeSH; the dollar sign ($) stands for any character(s); the question mark (?) substitutes one or no characters; tw = text word;
pt = publication type; sh = MeSH; adj = adjacent (i.e. number of words within range of search term)
MEDLINE
1. exp Glucagon-Like Peptides/
2. (glucagon like peptide* or GLP-1).tw.
3. (exenatide or liraglutide or albiglutide or taspoglutide or lixisenatide).tw
4. randomized controlled trial.pt.
5. random*.tw.
6. 1 or 3 or 2
7. 4 or 5
8. 6 and 7
Embase
1. exp Glucagon-Like Peptide 1/
2. (Glucagon-Like Peptide 1 or GLP-1).tw.
3. (exenatide or liraglutide or albiglutide or taspoglutide or lixisenatide).tw
4. randomized controlled trial/
5. (randomised or randomized).tw.
6. 1 or 3 or 2
7. 4 or 5
8. 6 and 7
The Cochrane Library
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(Continued)
(exenatide or liraglutide or albiglutide or taspoglutide or lixisenatide or glucagon like peptide or GLP-1):ti
Web of Science databases - Science Citation Index Expanded; Social Sciences Citation Index (SSCI); Conference Proceedings
Citation Index- Science
Title=(glucagon like peptide* or GLP-1 or exenatide or liraglutide or albiglutide or taspoglutide)
Refined by: Document Type=( MEETING ABSTRACT )
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BID:twicedaily;CI :conf idenceinterval;DPP−4:dipeptidylpeptidase−4inhibitor;FPG:f astingplasmaglucose;HbA1c:glycosylatedhaemoglobinA1c;HDL:highdensitylipoprotein;H
WH A T ’ S N E W
Last assessed as up-to-date: 28 February 2011.
Date Event Description
5 October 2011 Amended This review version is identical with the previously published one. The only correction that is being
made is in the authors contact details
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H I S T O R Y
Protocol first published: Issue 1, 2007
Review first published: Issue 10, 2011
C O N T R I B U T I O N S O F A U T H O R S
DEEPSON SHYANGDAN: Data extraction, quality assessment of studies, data summary and analysis, writing of main text
PAMELA ROYLE: Searching for studies, study selection, checking of data, data extraction, quality assessment of studies, writing of
main text
CHRISTINE CLAR:Data extraction, quality assessment of studies, data summary and analysis, writing of main text
PAWANA SHARMA: Data extraction, quality assessment of studies, writing of protocol
NORMANWAUGH: Study selection, general supervision of the review, writing of main text
AILSA SNAITH: Author of first version of the review (exenatide and liraglutide only) and of protocol
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• University of Aberdeen, Department of Public Health, UK.
• University of Warwick, Warwick Evidence, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• Authors have changed since publication of the protocol.
• Contact person has changed since publication of the protocol.
• Studies with a minimum duration of eight weeks were included.
• Outcome costs was deleted and blood pressure introduced.
• Number of glucagon-like peptide 1 (GLP-1) agonists increased from two to six. Exenatide twice daily rendered obsolete by once
weekly form so review focusses on latter.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Diabetes Mellitus, Type 2 [blood; ∗drug therapy]; Glucagon-Like Peptide 1 [∗analogs & derivatives]; Hemoglobin A, Glycosylated
[metabolism]; Hypoglycemic Agents [∗therapeutic use]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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